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The human gut microbiota is a diverse community of microbes residing in the 
intestine. Evidence from various animal models and human studies have highlighted 
its potential role in health, metabolic and immune-associated conditions such as 
osteoporosis, inflammatory arthritis, inflammatory bowel disease (IBD) and mult ip le 
sclerosis. This thesis provides further understanding of the changes in the gut 
microbiota dynamics in these disorders which is important for establishing a necessary 
knowledge base for potential microbiota-based diagnostic/therapeutic options. The 
studies undertaken in this thesis provides a baseline observation and identify the 
directionality of changes that occurs in the gut microbiota throughout disease 
progression and treatment. The thesis investigates alterations in the microbiota due to 
biologics treatment and differences associated with health and disease status. 
Amplicon and metagenomic whole genome shotgun (mWGS) sequencing were 
employed along with extensive meta-data analyses.  
Using robust and rigorous statistical approaches on the amplicon dataset, I 
identified a set of key taxa that are differentially abundant in osteoporosis. The 
microbiota diversity is associated with various covariates; however, the key taxa retain 
association with bone measures after accounting for the covariates. The gut microbio ta 
of different arthritis and IBD samples were profiled at different time-points using 
mWGS before and during biologics treatment. This demonstrated that the long- term 
biologics treated samples show the presence of taxa observed in healthy controls 
which are absent or reduced in treatment naive arthritic subjects. This signature is 
reflected in β-diversity and in the differentially abundant taxa. The strength of this 
signature varies in different arthritic diseases. In MS, I identified different taxonomic 




phenotype which is distinct from both young and elderly healthy population using 
mWGS profiles.  
For better inference of functional potential from amplicon data, I developed a 
novel methodology IPCO, a flexible R library. It outperforms other tools both in terms 
of sample and features profiles correlation by retaining most of the observed biologica l 
signal determined from paired mWGS and metabolites profile data.  
In conclusion, an altered microbiota composition was found to be associated 
with bone mineral density in osteoporosis, different phenotypes of MS as well as with 
biologics-mediated disease remission in different forms of arthritis. These noted 
alterations will contribute to a better understanding of the relationship between the gut 
microbiota and immune disorders. This can be useful to identify potential diagnost ic 
or therapeutic targets in at-risk individuals. Lastly, I demonstrated that IPCO 
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Chapter 1 Review of literature 
1. Microbiota 
The term microbiota refers to an ecological niche of various microbes cohabitating 
together in an environment (Lederberg and McCray, 2001). The term microbiome is 
often synonymously used with microbiota. However, the term microbiome refers to 
the cumulative genomes of the microorganisms present in a particular niche (Backhed 
et al., 2005). Studying the microbiota population involves understanding how the 
microbes thrive and function in an ecological niche (Knight et al., 2017). These 
microbial communities are found in environments such as soil and water or host-
associated environments and include plants and animals where they can reside on the 
surface (e.g. skin) or inside the host (e.g. gut). 
The evolution of microbiota and host is considered to be synergistic in nature 
and they are regarded a holobiont (Guerrero et al., 2013). However, the presence of 
host-specific microbiota does not imply co-evolution of the microbiota and its host 
hence the concept remains controversial (Moran and Sloan, 2015). The host-associated 
microbiota can have various types of relationship with the host: commensa l, 
mutualistic, symbiotic, or even pathogenic. A normal microbiota could be a 
community of microbes which do not harm the host. 
 
2. Human microbiota 
The human microbiota represents all living microorganisms on the surface or inside a 
human body (Human Microbiome Project, 2012). The microbiota can be acquired at 
birth from the mother and/or through interaction with various environmental factors  
(Rodriguez et al., 2015). Initially, the microbial cell count was estimated to exceed the 
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number of cells of the host by a ratio of 10:1 (Savage, 1977). However, this has been 
recently recalculated, and it was found that the ratio between microbial cell count and 
host cell count is closer to 1:1. Based on the current estimates, the microbial cell count 
per individual is expected to range from 103 in the stomach to 1011 in the colon, 
resulting in approximately 3.8*1013 total microbial cells (Sender et al., 2016). The gut 
microbiota is the most populated community of microbes in the human body. It is 
estimated that the number of unique species in the gut is between 500 – 1000 
(Turnbaugh et al., 2007) and harbours approximately 2 million bacterial genes (Gilbert 
et al., 2018). Despite the large population of microbiota in the gut, a single person is 
expected to have approximately 160 species on average (Qin et al., 2010). It is 
interesting to note that various taxa can carry out the same metabolic functions and 
therefore, despite considerable variations in taxonomic diversity across individua ls, 
the microbiota can have a level of functional redundancy. Hence, investigating the 
relationship between taxonomic and functional diversity can reveal insights into the 
mechanistic role of gut microbiota (Eng and Borenstein, 2018).  
Human microbiota research has documented that the microbiota carries out a 
variety of functions in the gut such as degradation of plant polysaccharides and 
production of vitamins, essential amino acids and SCFAs that are beneficial for the 
host (Rowland et al., 2018). The gut microbiota is also partly responsible for 
developing and maintaining immune homeostasis of the host by interacting with the 
host through the intestinal mucosal barrier (Belkaid and Hand, 2014). The mucosal 
barrier and the intestinal epithelial cells are the primary component of the intestina l 
mucosal barrier. It serves as the primary interface for interaction between the immune -
cells and the gut microbiota (Turner, 2009). 
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In 1900, Henry Tissier studied the gut microbiota in infants and this is the 
earliest known research on microbiota (Tissier, 1900). Later in 1958, Eiseman et al. 
showed that FMT treatment could be used to treat pseudomembranous enterocolit is 
(Eiseman et al., 1958). Subsequently, others have shown that probiotic treatment with 
Lactobacillus rhamnosus is effective against Clostridium difficile infection (Schwan 
et al., 1983). These early studies gave rise to future research on FMT and the role of 
microbiota in humans. Germ-free mice/rat models showed impaired development, 
physical and physiological alterations compared to normal mice/rat models which 
highlighted the role of microbiota in host development (Gordon and Bruckner-
Kardoss, 1961;Abrams et al., 1963;Sharma et al., 1995;Petersson et al., 2011). 
Research on acquisition and colonisation of microbiota in the early stage of life 
provided early insights into the host-microbiota relationship (Yoshioka et al., 
1983;Tamburini et al., 2016). It highlighted the immune-modulatory effect of 
microbiota in the host and the beneficial capability of the gut microbiota in immune 
homeostasis (Sudo et al., 1997;Rakoff-Nahoum et al., 2004;O'Mahony et al., 
2008;Smith et al., 2013). 
The gut microbiota community is primarily investigated by analysing faecal 
samples from the host. Microbiota communities have also been isolated and studied 
from other body sites such as oral, nasal, skin, and biopsy samples. The 16S rRNA 
gene is a molecular marker that is used for phylogenetic studies as it is conserved 
across bacteria and archaea. It is extensively used for identification and classificat ion 
of unculturable microbes. 
Characterising the microbiota composition from various body sites of mult ip le 
individuals has shown that the microbiota across the same body site is likely to have 
similar profiles whereas the microbial profile can be dissimilar between different sites 
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(Human Microbiome Project, 2012). This is within reasonable assumption that the 
individuals are representative of healthy population with similar dietary habits and 
other host factors like similar age range, no antibiotic medications etc. The microbio ta 
population changes throughout the lifespan with distinct patterns at different stages 
(Nagpal et al., 2018). Studies have reported that various immune-associa ted, 
metabolic, psychological, cancer and cardiovascular diseases are associated with 
undesirable changes in the microbiota community, potentially due to its role in 
degrading food materials, metabolite production and interaction with the immune 
system (Belizario and Faintuch, 2018). The last 10 years of microbiota research have 
explored the various roles of gut microbiota, their stability in the human host, 
individual differences across hosts, functional potential, environmental and dietary 
effects, and their role in regulation of the host immune system (Human Microbiome 
Project, 2012;Schnorr et al., 2014;O'Keefe et al., 2015;Falony et al., 2016;Zhernakova 
et al., 2016;Das et al., 2018). Based on large, multi-cohort studies of the microbio ta 
profiles, various factors like intra- and inter-individual differences, genetics, diet, 
medications, anthropometric measures, ethnicity, age, socio-economic factors and 
interactions with the environment have been identified as influencing the gut 
microbiota structure (Arumugam et al., 2011;Goodrich et al., 2014;Obregon-Tito et 
al., 2015;Falony et al., 2016;Zhernakova et al., 2016;Rothschild et al., 2018;Johnson 
et al., 2019;Pasolli et al., 2019). This chapter summarises the existing evidences on 
the interaction between the gut microbiota and some of the prominent factors like diet, 
medications, and environment. Furthermore, the pathogenesis of various immune 
disorders and the association with the gut microbiota is also presented. Finally, various 
bioinformatics approaches developed to study the gut microbiota are discussed. 
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2.1 Microbiota and the environment 
The colonisation by the gut microbial community in the host is considered to begin 
pre-birth but recently it has been shown that there is no placental microbiota and the 
detected species are likely to be pathogens or contaminants (de Goffau et al., 2019). 
However, rapid acquisition, development and stabilisation of the microbio ta 
community occurs after birth and continues for the first few years (Mackie et al., 
1999;Fanaro et al., 2003;Tamburini et al., 2016). Various key factors are considered 
to influence this acquisition and development of gut microbiota in the host. Among 
them, transmission from mother to infant is prominent as early microbial colonisat ion 
in the infants were found to be maternally derived e.g. milk, vaginal, mouth and skin. 
The acquisition and colonisation of the maternally derived microbiota occurs during 
the gestation period and birth through vertical transmission (Palmer et al., 
2007;Dominguez-Bello et al., 2010;Bokulich et al., 2016;Ferretti et al., 2018). The 
vaginally delivered infants had a similar microbiota as their own mother’s vagina l 
microbiota whereas the caesarean section infant’s microbiota resembled the mother’s 
skin microbiota. Interestingly the gut microbiota profiles in infants born through 
caesarean section had a decreased taxonomic diversity compared to vagina lly 
delivered babies (Bokulich et al., 2016).  
Interaction with pets alters the microbiota of infants with increased abundances 
of Ruminococcus and Oscillospira (Tun et al., 2017). These taxa are negatively linked 
with development of allergy and obesity and might be associated with decreased risk 
in infants. The abundance of family Streptococcaceae was lower upon exposure to 
pets that may result in reduced risk of Streptococcal infection. 
Exposure to a rural or urban environment also contributes to the acquisition of 
the gut microbial community. Urban dwellers were observed to have a reduced 
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microbiota diversity which were associated with changes in their lifestyle, antibiot ics 
usage, standard of hygiene and isolation from general flora and fauna (Popkin, 
1999;Turner et al., 2004;Sjogren et al., 2009). The hunter-gatherer’s population from 
Tanzania, rural healthy individuals from Papua New Guinea and Amerindians have a 
higher species richness compared to urban western population (Schnorr et al., 
2014;Clemente et al., 2015;Martinez et al., 2015). A recent study by Vangay et al. 
found that the diversity in the gut microbiota composition was reduced after a period 
of acclimatisation among the non-native people coming to USA (Vangay et al., 2018). 
The native microbial species that were observed in the non-USA population were lost. 
The group also observed that strains belonging to the genus Prevotella were replaced 
by Bacteroides strains. Social interactions with others and cohabitation have also been 
associated with increased richness and shared taxa among spouses (Dill-McFarland et 
al., 2019). 
The loss of diversity in the microbiota has been associated with decreased 
immune tolerance and various chronic inflammatory conditions in urban populations 
such as allergic reactions and asthma (Garn and Renz, 2007;Haahtela et al., 2013). The 
“hygiene hypothesis” is a concept which suggests that children exposed to various 
microbes in early childhood experience proper development of the immune system, 
which in turn results in effective immune tolerance (Strachan, 1989;Garn and Renz, 
2007). Studies comparing rural and urban children have shown that rural children have 
reduced incidences of asthma, which in part is attributed to the higher microbia l 
diversity in the rural environment (Ege et al., 2011). Exposure to an environment with 
high microbial diversity can be a source of various beneficial or commensal bacteria, 
which could reduce the risk of inflammatory diseases (Rook et al., 2013;Zhou et al., 
2016).  
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2.2 Microbiota and diet 
An infant’s diet is another major determinant of microbiota colonisation. A difference 
was observed in the taxonomic composition of the gut microbiota of breast-fed infants 
compared to formula-fed infants (Guaraldi and Salvatori, 2012). The microbia l 
population is more stable amongst the breast-fed babies compared to formula- fed 
infants, but the differences disappear after 1 year of life with introduction to solid 
foods (Stark and Lee, 1982;Mackie et al., 1999;Adlerberth and Wold, 2009). 
Bifidobacterium infantis, Staphylococcus epidermidis and Lactobacillus rhamnosus 
were identified to be dominant in breast-fed infants whereas Bifidobacterium fragilis, 
Clostridium and Streptococcus species were linked with formula-fed infants (Mackie 
et al., 1999;Penders et al., 2006;Adlerberth and Wold, 2009). Bacteroides, 
Clostridium, Enterococci and Streptococci genera emerged with introduction of solid 
food diet (Stark and Lee, 1982;Mackie et al., 1999;Adlerberth and Wold, 2009). 
The diet of an individual is the primary source of nutrients for the gut 
microbiota and a person’s diet reflects gut microbiota composition and community 
structure (Claesson et al., 2012;Zmora et al., 2019). One of the key roles of the 
microbiota is the breakdown of non-digestible food products such as complex 
polysaccharides, and biosynthesis of vitamins and essential amino acids (Salyers et 
al., 1978;Rowland et al., 2018). Various metabolites produced by the microbiota in 
the intestine can serve as necessary substrate for other microbes whereas other 
metabolites can have a direct or indirect impact on human health. Bacterial metabolites 
like SCFAs, secondary bile acids and TMA are known be associated with human 
health outcomes (Vinolo et al., 2011;Janeiro et al., 2018;Nguyen et al., 2018).  
SCFAs can modulate the immune system and can confer protective effects. An 
increased consumption of dietary fibre is linked with reduced inflammation due to 
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breakdown of dietary fibres into SCFAs by the gut microbiota (Bohmig et al., 
1997;Andoh et al., 1999). Butyrate, propionate, and acetate are the major SCFAs 
produced by the bacteria. SCFAs serve as a major source of energy for the epithelia l 
colonic cells and the bacterial population. Catabolism of SCFAs by the epithelial cells 
occurs through β-oxidation that also results in maintenance of anaerobic conditions in 
the intestine (Byndloss et al., 2017). Anti-carcinogenic activities of SCFAs have also 
been observed against colon cancer cells by inducing apoptosis and preventing 
proliferation of the cancer cells (Bindels et al., 2012). They also induce mucin 
production, which is necessary for maintaining the integrity of epithelial barrier  
function (Willemsen et al., 2003). Interaction of SCFAs with the liver is associated 
with regulation of lipogenesis, fatty acid synthesis, cholesterol metabolism, and 
appetite (Frost et al., 2014). Various species of bacteria are known to be producers of 
different types of SCFAs. Faecalibacterium prausnitzii, Ruminococcus bromii, 
Clostridium leptum, Eubacterium rectale and Roseburia species are known butyrate 
producers (Louis and Flint, 2017). Pathways necessary for propionate formation are 
found in Bacteroides fragilis, Megasphaera elsdenii, Clostridium neopropionicum, 
Propionibacteria species and Veillonella species (Hosseini et al., 2011). Known 
producers of acetate are Blautia hydrogenotrophica, Ruminococcus bromii, 
Bifidobacterium species and Akkermansia muciniphila, which can produce both 
acetate and propionate (Derrien et al., 2004).  
Primary bile acids produced by the liver and secreted into the small intestine  
are metabolised by the gut microbiota into secondary bile acids. These secondary bile 
acids serve as signalling molecules for various host-associated pathways that affect 
the host metabolism (Wahlstrom et al., 2016). Deconjugation of the primary bile acids 
is carried out by BSH enzymes and this enzyme is found in all major bacterial divis ions 
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(Wahlstrom et al., 2016). Formation of a diverse variety of secondary bile acids is 
carried out by species belonging to Bacteroides, Bifidobacteria, Clostridium, 
Eggerthella, Escherichia, Eubacterium, Lactobacillus, Peptostreptococcus and 
Ruminococcus genera (Staley et al., 2017). Secondary bile acids can also interact with 
immune associated host functions directly or indirectly thereby affecting the gut 
microbial composition. Various diseases such as IBD, metabolic syndrome, and CRC 
have been associated with an altered bile acid profile and composition (Jia et al., 2018). 
Individuals diagnosed with CRC who also consume diets containing high levels of 
saturated fats and red meat show elevated levels of secondary bile acids (Nagengast et 
al., 1995;Bernstein et al., 2005;Ridlon et al., 2014). Microbial metabolism of nutrients 
like choline and carnitine generates TMA, which is converted to TMAO in the liver. 
TMAO is associated with adverse cardiovascular conditions like atherosclerosis (Tang 
et al., 2013).   
The microbiota also produces various other nutrients such as certain vitamins 
and amino acids. Vitamin B and K are synthesised by species of Bacteroides and 
Bifidobacteria, Escherichia coli, Bacillus subtilis, and lactic acid bacteria (LeBlanc et 
al., 2013;Rowland et al., 2018). Lysine is produced by the gut microbiota and it can 
contribute up to 20% of the lysine measured in the circulatory system of the body 
(Metges, 2000). Other amino acids produced by the microbiota can also contribute to 
the maintenance of the amino acid pool in the host.  
The use of food additives and sweeteners can disrupt the composition of the 
gut microbiota. An increase in the abundance of pro-inflammatory bacteria was 
observed in mouse models consuming emulsifiers or sweeteners (Chassaing et al., 
2015;Nettleton et al., 2016;Bian et al., 2017). Other dietary habits like a gluten-free 
diet, vegan diet or a diet low in FODMAP have been linked with differences in the 
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microbial metabolite profiles and gut microbiota composition (McIntosh et al., 2017). 
An in-vitro study by Bevilacqua et al. found that gluten-free bread affected the gut 
microbiota from coeliac individuals in a positive manner by promoting Lactobacillus 
and Bifidobacterium species growth (Bevilacqua et al., 2016;Lebwohl et al., 2017). 
Consumption of dietary supplements like probiotics and prebiotics can promote the 
health of individuals. Probiotics include live microbes, such as species of 
Bifidobacterium or Lactobacillus, which can produce key bioactive metabolites or can 
interact with the immune system to confer benefits to the host. E.g. restoring immune 
homeostasis by regulating T-reg cells, increased gastrointestinal barrier function, and 
inhibiting pathogen growth (Azad et al., 2018). Prebiotics are dietary substrates 
consumed by an individual and metabolised by the gut microbiota providing health 
benefits like generation of SCFAs. Dietary fibres and MACs are considered as 
prebiotics. However, the definition of prebiotics is ill-defined and the concept is 
currently debated (Bindels et al., 2015).  
The microbiota is associated with obesity in a diet dependent manner. 
Introduction of microbiota from obese individuals into germ-free animals resulted in 
more weight gain compared to mice receiving microbiota from normal weight 
individuals (Goodrich et al., 2014). Introduction of taxa such as Christensenella into 
germ-free mice correlated with reduced body fat and lack of weight gain. Oscillospira 
and Akkermansia muciniphila were found to be negatively associated with fat and 
obesity in human studies (Everard et al., 2013;Goodrich et al., 2014;Le Roy et al., 
2018).  Evidence suggests that lower microbial diversity is linked with long- term 
weight gain and is also reflective of other inflammatory conditions like IBD and PSA 
(Manichanh et al., 2006;Scher et al., 2015;Menni et al., 2017). A study on the elderly 
Irish population has shown that habitual diet is associated with microbiota profile and 
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the microbiota community structure and habitation reflected the frailty and health 
status of the cohort (Claesson et al., 2012). This shows that a variety of inter-related 
mechanisms link diet, immune modulation, and microbiota composition within the 
host.  
 
2.3 Microbiota and medication  
Various drugs, medications and supplements consumed by an individual have an effect 
on the GIT and the gut microbiota. Consumption of antibiotics has a clear effect on 
the gut microbiota and is used extensively in animal studies to obtain microbiota free 
animals as opposed to working with germ-free animal models, which can be more 
expensive and laborious (Kennedy et al., 2018). Use of broad-spectrum antibiotics can 
wipe out mutualistic and commensal microbes thereby negatively affecting the health 
of the host due to depletion of SCFA producers, lack of immune modulation and 
opportunity for growth of pathobionts. Despite the depletion of the gut microbiota due 
to antibiotic usage, the composition of the gut microbiota tends to restore itself to the 
pre-treatment composition after completion of short-term use of antibiotics (Palleja et 
al., 2018). However, the loss of diversity due to repeated antibiotic use can result in 
an altered gut microbiota composition that promotes the growth of pathogens. 
Clostridium difficile infection, which is a hospital-acquired infection responsible for 
antibiotic-associated diarrhoea, is a common example of infection due to susceptibil ity 
caused by antibiotic treatment and a disrupted microbiota (Jernberg et al., 2010). 
Introduction of diverse group of bacteria (FMT) from healthy individuals into a CDI 
mouse model have been effective in reducing experimental C. difficile infect ion 
(Lawley et al., 2012). Overall, it is important to account for the use of antibiotics in 
human observational and clinical trial microbiota studies.  
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Two large European observational studies primarily comprised of people from 
the Netherlands and Belgium have shown the effect of various medications and other 
covariates (lifestyle, diet, heath, anthropometrics, blood parameters, bowel 
information and sex) on microbiota composition (Falony et al., 2016;Zhernakova et 
al., 2016). Individual factors like BMI, stool consistency, age, sex and diseases are 
associated with gut microbiota diversity but medication explained the most variation 
in the microbiota composition. Amongst various medications, the gut microbio ta 
composition is significantly associated with various over-the-counter-drugs and 
prescribed non-antibiotics drugs. These drugs include but are not limited to, PPIs, 
metformin, and psychotropic medications as well as NSAIDs and vitamin and minera l 
supplements, which are also reported by other groups (Jackson et al., 2016;de la 
Cuesta-Zuluaga et al., 2017;Otani et al., 2017;Skrypnik and Suliburska, 2018;Cussotto 
et al., 2019). The diversity of the microbiota correlated with comorbidity and 
polypharmacy in the elderly individuals also (Ticinesi et al., 2017). This highlights the 
necessity to understand the impact of multiple drug treatments and the presence of 
multiple disorders/conditions on the microbiota of patients. Drug-induced microbio ta 
alterations can result in higher susceptibility to infection. 
Various studies report that long-term use of PPIs is associated with creating a 
favourable environment for enteric pathogens like Helicobacter pylori and 
Clostridium difficile (Hagiwara et al., 2015;Trifan et al., 2017). Clooney et al. show a 
significant difference in the Firmicutes to Bacteroidetes ratio between PPI and non-
PPI users (Clooney et al., 2016). Jackson et al. observed increased abundance in 
Streptococcaceae and Micrococcaceae among PPI users in Twin UK samples (Jackson 
et al., 2018) which were also previously identified in other independent studies . 
Frequent use of NSAIDs causes ulcers and erodes the mucosal lining in the small 
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intestine. In germ-free and gnotobiotic rat models exposed to Escherichia coli or 
Eubacterium limosum, NSAIDs caused ulceration in the small intestine. However, the 
unexposed germ-free rat models were resistant to NSAID induced damage or if 
Bifidobacterium or Lactobacillus were present (Uejima et al., 1996). This suggests 
that certain bacteria may aggravate NSAID-induced damage while others may confer 
protection. Otani et al. reported that small intestinal bacterial overgrowth, which is a 
condition characterised by excessive bacterial population in the small intestine, is a 
risk factor in NSAID-induced damage to the small intestine (Otani et al., 2017). PPIs 
intensified NSAID-induced damage to the small intestine according to a study by 
Wallace et al. (Wallace et al., 2011). Studies have also revealed that metformin, which 
is a widely used medication for type II diabetes, can partially restore the altered gut 
microbiota composition and increase the abundance of SCFA-producing bacteria and 
mucin-degrading Akkermansia muciniphila in diseased individuals (Forslund et al., 
2015;de la Cuesta-Zuluaga et al., 2017). Vitamin D is a micronutrient commonly 
supplemented with calcium and is necessary for bone health. Vitamin D has an 
immunomodulatory role and decreased levels are associated with an increased 
inflammatory state (Cantorna, 2006). Deficiency of vitamin D and polymorphisms in 
the VDR are both associated with an altered gut microbial composition (Jin et al., 
2015;Luthold et al., 2017).  
Maier et al. did an extensive analysis on the effect of over 1000 non-antibiot ic 
drugs on 40 gut bacterial strains and observed antimicrobial properties in 24% of the 
drugs that inhibited the growth of at least one bacterial strain (Maier et al., 2018). 
Various antipsychotics represented the largest drug class. The molecular mechanism 
of interaction for most of these drugs remains unknown. Another recent study by 
Zimmermann et al. highlighted the metabolic capability of at least one strain from 76 
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gut bacteria on 65% of oral drugs out of 271 in mice models (Zimmermann et al., 
2019). Zimmermann et al. observed that the bacterial strains could metabolise between 
11 and 95 different drugs. Grouping these strains based on their drug-metabo lism 
capacity resembled their phylogenetic relationship at phylum-level. These highlight 
the effect of medications on gut microbiota and vice-versa which may explain varying 
drug responses, generation of functionally distinct or toxic metabolites or masking the 
disease signature associated with the gut microbiota.  
 
2.4 Microbiota and the immune system 
The various functions carried out by the gut microbiota result in direct or indirect 
interaction with the host immune system through the large intestine. Apart from 
absorbing minerals and water from undigested waste and excretion, the large intestine 
is also responsible for providing protection against harmful microbes, immune 
stressors and maintaining homeostasis for the native microbiota. This is achieve d 
through proper functioning of various mechanism in the large intestine. These 
mechanisms include presence of the mucosal layer, generation of antibodies and 
AMPs, and activation of immune cells. The epithelial layer is a single columnar cell 
type layer present in the inner lining of the intestinal cavity, which acts as a physica l 
barrier. Its purpose is absorption of nutrients and secretion of the mucous. Epithelia l 
cells connect and communicate with a rich population of immune cells from the lamina 
propria and lymphoid tissue regions (Goto and Kiyono, 2012)  
The stability of the gut microbiota and the integrity of the barrier is necessary 
for maintaining immune homeostasis. Disruption of the epithelial barrier due to 
erosion of the mucosal lining or other damage can alter the permeability and allow 
diffusion of antigens or bacteria into host tissues, resulting in inflammation (Yu, 
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2018). Pathobionts may also spread in an individual’s body harming the host by 
promoting inflammation, colitis, ulcer, or cancer (colon, gastric). The importance of 
gut microbiota is revealed in studies with germ-free animal models that show improper 
maturation of the immune system, nutritional deficiency, poor growth and 
development, increased intestinal permeability and an altered neurochemical profile 
(Wostmann, 1981). Functional immaturity of the immune system can be observed in 
infants where the gut microbiota is not established fully (Adlerberth and Wold, 2009).  
The immune system function decreases as age increases, which is also 
associated with persistent low levels of inflammation. This concept is called 
inflammaging due to increased levels of pro-inflammatory cytokines observed in the 
serum along with declining numbers of naive CD8+ T-cells and increased memory 
CD8+ T-cells (Franceschi et al., 2007;Czesnikiewicz-Guzik et al., 2008). Simila r 
effects have been observed in B-cells which shows a decline in B-cells generation and 
increased number of memory B-cells and intrinsic defects in B-cells (Scholz et al., 
2013).  
In the intestine, the T-reg cells are responsible for modulating inflammation 
due to microbiota- and dietary-mediated factors. In contrast, CD4+ effector T-cells 
contribute to increased intestinal inflammation (Lee and Kim, 2017;Whibley et al., 
2019). T-reg cells regulates Th cells and along with IgA is responsible for maintaining 
a stable and diverse gut microbiota, preserving commensal tolerance (Powrie et al., 
1993;Cong et al., 2009;Kim et al., 2016). Regulation and expression of Th17 RORγt 
transcription factor by T-reg cells is dependent on the gut microbiota whereas RORγt-  
T-reg cells are associated with dietary immune modulator molecules (Sefik et al., 
2015;Kim et al., 2016). T-reg cells expressing GATA3 confer protection against 
chronic inflammation and stimulate T-reg cell accumulation in the intestine. The T-
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reg cells are also known to be involved in tissue repair and epithelial stem cell renewal 
(Yu et al., 2015;Zhang et al., 2017;Biton et al., 2018). Studies on mice have shown 
that increased susceptibility to gut pathogens is associated with T-reg cell depletion 
(Wang et al., 2014).  
Various taxa from different genera namely Clostridium, Lactobacillus, 
Bifidobacterium, Bacteroides, Ruminococcus, Faecalibacterium, Roseburia and 
Helicobacter are associated with various cytokines and T-cells (Schirmer et al., 
2016;Chai et al., 2017). Evidence from mice and human studies have shown that 
SCFAs can promote T-reg cell numbers and are linked with a decrease in inflammation 
(Maslowski et al., 2009;Arpaia et al., 2013). Immunosuppressive activity of SCFAs 
have also been observed with APCs and DCs (Bohmig et al., 1997;Nastasi et al., 
2015;Park et al., 2019). In-vivo studies have shown a reduction in IgE-associated 
eczema in infants treated with probiotics and prebiotics (Abrahamsson et al., 2007). 
Similarly, other oligosaccharides can increase IgA and anti-inflammatory IL-13 levels 
and decrease pro-inflammatory cytokines like IL-1β. Metabolism of protein-based 
dietary products generates metabolites which are generally associated with stimulat ion 
of colonic inflammation (Lecerf et al., 2012). Dietary supplementation of amino acids 
to athletics and individuals performing intense exercises have been linked with 
decrease in levels of IFN-γ, IL-10, increase in levels of IL-1β, C-reactive proteins and 
other WBCs like lymphocytes and neutrophils (Murakami et al., 2009;Kraemer et al., 
2014). Metabolism of aromatic amino acids by the gut microbiota generates p-cresol 
and its derivative p-cresylsulphate which contributes to pro-inflammation and 
supresses activation of monocytes and lymphocytes (Schepers et al., 2007). Isomers 
of conjugated Linolenic acid influence T-cell activation and levels of IL-1β, IFN-γ, 
IL-10 and IL-5 in a dose dependent manner (Tricon et al., 2004;Song et al., 2005). 
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Interaction and association of various host cells in the large intestine with the gut 
microbiota is illustrated in Figure 1 (obtained with permission). 
 
Figure 1, which is obtained from Brown et al. (Brown et al., 2019), depicts the various 
microbiota-associated features, such as diversity, metabolites, diet, medication, other 
environmental factors and their interaction with the gut intestinal barrier cells and the 
immune cells. The activation and mechanism of cytokine-mediated immune 
homeostasis is also depicted. The depletion of the mucosal layer allows greater 
interaction between the microbes or microbial metabolites and the immune cells. 
 
 
2.5 Microbiota and diseases 
The various gut microbiota associated factors discussed until now highlight the 
complex interactions between the gut microbiota and the host. The modulation of any 
of these factors can induce changes in the community structure and the composition 
of the gut microbiota. Understanding the clinical implications of how the gut 
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microbiota influences human health is necessary to uncover their roles in various 
diseases. However, various confounding factors with the potential to affect the 
microbiota must be accounted for while investigating microbiota-disease association. 
This is necessary to reduce false positives and to ensure more robust observations. 
Although recent studies have identified various microbiota association with different 
types of diseases, human microbiota research is still at a very early stage. Studies 
across the world have identified alteration in microbial diversity and community 
profiles in various diseases including identification of potential specific marker taxa 
associated with health and/or disease (Kho and Lal, 2018). Certain key taxa identified 
were associated with more than one disease (Duvallet et al., 2017). These microbia l 
alterations are associated with changes in immune associated conditions like IBD, 
Coeliac disease, RA, AS, PSA, MS, allergy and Diabetes type I (Clemente et al., 
2018;Han et al., 2018;Pascal et al., 2018), metabolic and cardiovascular conditions  
like obesity, Diabetes type II, hypertension and atherosclerosis (Jie et al., 2017;Pascale 
et al., 2018), infectious diseases like CDI (Stecher and Hardt, 2008), 
neurodevelopmental conditions  which includes depression, ASD and Parkinson’s 
disease (Warner, 2019) and CRC (Wu et al., 2009). Many of these studies focus on 
correlations between the microbiota and the health and disease, lacking insight into 
defined functional mechanisms. Alternatively, studies with probiotics and FMT show 
some success in attenuating or achieving remission in certain diseases (Liu et al., 
2018;Mullish et al., 2018). However, these reports require further investigation and 
rigorous research. The evidence suggests a complex connection between microbio ta 
and development of various diseases as opposed to a unidirectional cause-and-effect 
association. This opens up the potential of gut microbiota not only as a diagnost ic 
measure but also for therapeutic purposes.  
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3. Immune-associated conditions and the microbiota 
The aetiology of various immune-associated disorders is multi- factor ia l. 
Epidemiologically various immune diseases are more prevalent in western countries 
compared to Asian and African demographics. The age of onset also varies for these 
diseases, though some of them can occur at a very young age. Table 1 summarises the 



















Europe America Africa Asia 
Osteoporosis 1-15 3-16 
No 
consensus 
4-38 8:5 ≥ 50 
1 in 5 men and 1 in 3 women is at risk. In 
men, hip fractures occur 10 years later than 
in women. Northern Europe has more 
fractures than southern Europe 
(Johnell and Kanis, 2006;Wade et al., 
2014;Eastell et al., 2016) 
Rheumatoid 
arthritis (RA) 
0.33-0.8 0.5 0.1-2.5 0.2-0.3 4:1 ≥ 25  
Highest in Native American (~5%). High 
in northern Europe compared to southern 
region. Elderly onset RA (EORA) ~65 
years 
(Peschken and Esdaile, 1999;Silman and 
Pearson, 2002;Sokka et al., 2009;Tobon et 




0.15-2.2 0.1-0.32 0.07 
0.009-
0.78 
1:3 ≥ 25 
Low prevalence in Finland. higher 
prevalence in Norway  
(Gran et al., 1985;Kaipiainen-Seppanen et 
al., 1997;Hukuda et al., 2001;Feldtkeller et 










0.7:1 – 2.1:1 ≥ 30 
Amongst psoriasis patients, prevalence of 
PSA is 6-42%. Reported in kids and elderly 
also 
(Torre Alonso et al., 1991;Gladman et al., 












on age and 
disease type 
≥ 10 
Reduced risk of Crohn in female in 
childhood. Increased thereafter. 
No difference in risk based on sex for 
Ulcerative colitis 







0.03-0.06 0.03 3:1   ≥ 20 
Prevalent in population with European 
ancestry. Can occur in childhood. Decline 
in life expectancy 
(Kingwell et al., 2013;Collaborators, 
2019;Wallin et al., 2019) 
Prevalence in Europe includes all regions of Europe, not only Western Europe. Prevalence in America includes both North and South America. 
Prevalence in Asia excludes the Middle East.  
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The primary basis for these disorders is the aberrant functioning of the immune 
system that results in increased production of pro-inflammatory cytokines and influx 
of active immune cells into various sites depending on the disease (Chen et al., 
2018;Clemente et al., 2018). Despite host genetic variation and heritability playing a 
major role in the pathogenesis of various immune diseases, there is growing evidence 
to suggest that external factors such as environment, diet, and the gut microbiota are 
also involved (Vojdani et al., 2014). It is established that the gut microbiota is 
necessary for proper functioning of the immune system and various studies have 
highlighted its potential role in the pathogenesis/onset of various conditions like 
arthritis, MS, IBD, and osteoporosis (Clemente et al., 2018;Jones et al., 2018). A 
recent study by Forbes et al. investigated IBD, MS and RA for a common microbio ta 
signature and observed that microbial diversity was lower in all cases compared to 
healthy individuals (Forbes et al., 2018). Species belonging to the genera Actinomyces, 
Eggerthella, Clostridium III, Streptococcus and Faecalibacterium were more 
abundant in all the disease samples. The study also identified various individual taxa 
unique to each disease and showed that the identified taxa were able to predict CD 
most accurately, followed by MS, RA, and UC. The microbial alterations were 
consistent with other studies carried out on individual immune associated disorders. 
Clemente et al. reviewed and summarised the current understanding of the relationship  
between microbiota, microbial metabolites, immune cells, cytokines and immune -
associated diseases (Clemente et al., 2018) which is highlighted in Figure 2 (obtained 
with permission). 
 




Figure 2 obtained from the review by Clemente et al. (Clemente et al., 2018) 
highlights the increase/decrease of various taxa, metabolites, immune cells, and 
cytokines in relation to different immune-associated diseases (IBD, RA, SpA, and 
MS). It also highlights the results from mice studies and human studies, includ ing 








Osteoporosis is a systemic skeletal disorder characterised by weakening of the bone 
due to deterioration of the bone tissue and low BMD that results in increased 
susceptibility to fractures and bone frailty (Hernlund et al., 2013). Most osteoporotic 
fractures occur in the hips, wrist, and spine. Osteoporosis is a commonly observed 
age-related condition in the elderly population and it is most common in post-
menopausal women. Osteoporosis does not manifest any symptoms and hence it is not 
usually detected until fractures occurs due to minor stress. However, not all fractures 
in old age are related to osteoporosis (Eastell et al., 2016). Osteopenia is the precursor 
state of osteoporosis where BMD is reduced but not as dramatically as in osteoporosis. 
The clinically determined BMD score determines the osteoporosis status. Osteoporotic 
individuals are defined as having BMD values below -2.5 standard deviations from 
the mean of peak/healthy bone mass of adult healthy individuals whereas people 
diagnosed with osteopenia have BMD values below -1.5 standard deviations. The 
standard deviation measures are defined as T-scores (Kanis et al., 1994;Kanis et al., 
2013). Genetics plays a major role in the aetiology of osteoporosis, however other 
factors such as smoking, exercise or manual labour have also been associated (Eastell 
et al., 2016). 
Currently, osteoporosis is detected by measuring BMD through DEXA scans 
and is a treatable condition if diagnosed early (Eastell, 1998). Untreated or 
undiagnosed cases can lead to high fracture rates, loss of mobility, and affect the 
quality of life. The diagnosis of osteoporosis is based on quantifying BMD determined 
by DEXA results, as it is considered as the best predictor for the risk of fracture. FRAX 
is another diagnostic measure that is used to evaluate the probability of risk of fracture 
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up to 10 years (Kanis et al., 2008). Serum levels of procollagen type I amino-termina l 
propetide and serum C-terminal telopeptide of type I collagen are two recommended 
markers for bone formation and resorption respectively which allow characterisat ion 
of the disease and the response towards treatment (Vasikaran et al., 2011;Diez-Perez 
et al., 2012). 
 The onset of osteoporosis is multifactorial but the primary contributors are 
genetics (heritability accounts for 50-70% of cases), and sex hormones, especially 
oestrogen levels in postmenopausal women (Szulc et al., 2006;Hernandez-de Sosa et 
al., 2014). In men, deficiency of androgen leads to sarcopenia, resulting in loss of body 
strength and increased probability of falling and fractures (Wiren et al., 2012). Bone 
mass is regulated by various key genes like vitamin D receptor, TGFβ, collagen type 
I-α, LRP5, LRP6, and other genes from the Wnt pathway. Variations in these key 
genes have been associated with alterations in bone mass (Ralston et al., 
2006;Uitterlinden et al., 2006;Langdahl et al., 2008;van Meurs et al., 2008). 
Assessment of individuals over the age of 50 should be carried out based on risk 
factors like smoking status, genetics, fractures, low BMI, sarcopenia, and frailty status. 
Despite having the same T-scores, without at least one risk factors, the risk of fractures 
in postmenopausal women is low compared to women with risk factors (Siris et al., 
2011). 
 Osteoblasts, osteoclasts, and osteocytes are the specialised cells responsible 
for maintaining the balance between bone resorption and bone formation. Although 
the immune system is involved in activation of osteoblast and osteoclast cells, the role 
of autoantibodies has been identified only when other autoimmune diseases are 
involved (Iseme et al., 2017). Osteoblasts, and osteoclasts have high affinity oestrogen 
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receptors and their interaction with various ligands triggers various effects like 
activation or inhibition of IL-1, IL-6, IGF1, TNF, and TGFβ (Weitzmann and Pacific i, 
2006). Activated T-cells are also the source of RANKL and TNF-α which are 
responsible for destruction of bone during inflammatory conditions. Studies with 
animal models lacking T-cells have shown normal or higher BMD. However, the exact 
links are not fully understood. The secretion of various cytokines by T-cells can direct 
or indirectly influence bone modulation (Hofbauer and Schoppet, 2004;Srivastava et 
al., 2018). 
 Supplementation of essential minerals and vitamins like calcium and vitamin 
D in the diet of people at risk is recommended as a preventive measure against the 
development of the disease. However, studies have shown that increased intake of 
calcium does not prevent development of the postmenopausal osteoporosis or fracture 
prevention but reduces age-associated BMD loss (Elders et al., 1994;Shea et al., 
2002;Avenell et al., 2014). Vitamin-D deficiency can also increase PTH secretion that 
can indirectly affect osteoclast cells and bone resorption as PTH is responsible for 
maintaining serum calcium levels (Khundmiri et al., 2016). Long-term use of 
bisphosphonate, one of the most widely used agent for treatment of osteoporosis 
(Lewiecki, 2010), has been reported to cause gastro-intestinal problems, renal failure, 
and osteonecrosis of the jaw (Vescovi and Nammour, 2010;Khosla et al., 2012). 
Denosumab is a monoclonal antibody developed to target RANKL inhibit ing 
osteoclast activity showing significant increase in BMD. Denosumab is given as 
subcutaneous injection every 6 months, however if injection is missed, a rapid relapse 
is observed (Miller et al., 2008).  
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 Proper maturation of the immune system is partly dependent on the host 
microbiota. Various studies have shown alteration in bone development in germ-free 
and antibiotic treated animal models. The lack of microbial community has been 
associated with an increase in bone mass and strength. In contrast, other animal studies 
have reported that lack of microbiota can negatively affect bone properties (Pytlik et 
al., 2004;Sjogren et al., 2012;Nobel et al., 2015;Guss et al., 2017;Guss et al., 2019). 
During inflammation, gut microbiota can influence the T-cells to produce cytokines 
responsible for bone mineral resorption (Hsu and Pacifici, 2018). Several studies have 
been carried out to identify probiotics that confer beneficial effects on bone health. 
These beneficial effects can include improvements in vitamin and mineral uptake, 
production of hormones or providing a protective effect against inflammation and 
bone resorption (Xu et al., 2017). 
Very few studies have been published with human cohorts exploring the role 
of the microbiota in bone homeostasis, especially concerning osteoporosis. Blanton et 
al. explored the gut microbiota in malnourished children and identified a microbio ta 
associated role in physical development and growth which also showed altered bone 
morphology in the malnourished groups (Blanton et al., 2016). Excluding this study, 
only two studies have been carried out on an adult human cohort. The first was carried 
out by Wang et al. where they observed significant alterations of α- and β-diversity 
measures between osteoporotic and healthy groups and identified various key 
discriminating taxa associated with osteopenia and osteoporosis (Wang et al., 2017). 
Despite this study being carried out on gender- and age-matched samples, the cohort 
size was very small and lacked information on other confounders. The study also did 
not control for false positives in their analysis. The second study was carried out on a 
larger cohort by Li et al. where they identified different taxa that were associated with 
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BMD measures (Li et al., 2019). In this study, the characterisation of the samples was 
done by separating the BMD measures into two categories based on the median BMD 
value: low BMD and high BMD. The study did not observe any significant alteration 
at both α- and β-diversity measures. Inferred pathways associated with LPS 
biosynthesis were more abundant in the low BMD group. However, this grouping may 
not be clinically relevant as the risk values may be different from segregation threshold 
which is an arbitrary cut-off. These two studies also observed contrasting results with 
respect to the microbiota diversity and its association with bone health. Interestingly, 
the LifeLines-DEEP cohort, which explored the gut microbiota profiles from a Dutch 
cohort, observed that osteoporosis showed a small but significant effect-size with a 
global microbiota profile (Zhernakova et al., 2016). Jackson et al. investigated the 
effect of different diseases and medications on gut microbiota profiles in a UK cohort 
and showed small but significant associations with fracture risk and calcium 
medication (Jackson et al., 2018). Bisphosphonate medication, which is routinely used 
for osteoporosis treatment, has been associated with increased abundance of 
Actinomyces species and bisphosphonate-associated jaw necrosis (Russmueller et al., 
2016). Vitamin-D, which is a supplement for promoting bone health, has immune-
modulatory properties (Luthold et al., 2017). 
These studies highlight the potential role that the gut microbiota plays in bone 
homeostasis through interactions with the immune system. 
 
3.2 Rheumatic diseases 
Rheumatism or rheumatic diseases are disorders of the joints and/or connective tissues 
characterised by chronic or irregular pain. It is an umbrella term for various disorders 
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which includes arthritic and non-arthritic conditions. Although the diseases share very 
little similarity in terms of their pathology and epidemiology, the common symptoms 
are often long-term pain and stiffness that are difficult to cure. The onset and progress 
of various arthritic conditions is due to aberrant immune responses resulting in 
autoimmunity and inflammation. This leads to destruction of the bone, cartilage, and 
tissues (in more advanced stages). Other symptoms of arthritic conditions include 
swelling, redness, tenderness, and limited joint movement. Undiagnosed or untreated 
conditions can severely disrupt quality of life and can result in loss of mobility . 
 
3.2.1 Rheumatoid arthritis 
Rheumatoid arthritis (RA) is a chronic, inflammatory disorder known to particular ly 
affect the joints. People with RA have swollen joints with stiffness, pain, and 
symmetrical inflammation. Common body sites affected include, but are not limited 
to, smaller joints like hands, feet, and cervical spine as well as knees, shoulders, and 
other larger joints (Heidari, 2011). It can also result in complications in other parts of 
the body like lungs, heart, skin, eyes, and degradation of the bone leading to 
irreversible disability (Scott, 2004;Cojocaru et al., 2010). Autoantibodies are 
antibodies produced by the immune cells which target and acts on an individual’s own 
proteins or tissues. RA is autoimmune in nature involving production of 
autoantibodies against citrullinated proteins and IgG. The autoantibodies produced by 
the human body are RF which target the Fc receptors present in IgG and also ACPAs 
that interacts with the citrullinated proteins (Malmstrom et al., 2017). However, RA is 
heterogeneous in nature, involving various genetic and environmental stressors that 
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can trigger pathogenesis in a variety of ways. Currently there is no established cure 
for RA, with remission being the most likely outcome from treatments. 
RA is classified by serological tests that are related to production levels of 
autoantibodies and acute-phase reactants (inflammation markers e.g. C-reactive 
proteins, haptoglobin, plasma fibrinogen) and by investigating the clinical progression 
of the disease. Currently, there are no diagnosis criteria and the diagnosis of RA is 
highly individualised. Clinical progression is monitored by studying the joint swelling, 
morning stiffness and tenderness (Egerer et al., 2009;Aletaha and Smolen, 2018). 
However, other types of arthritis may also show similar symptoms which makes 
diagnosis of RA difficult. RA is a systemic condition and is not exclusive to the joints. 
Manifestation and risk of cardiovascular diseases also increase with RA (Crowson et 
al., 2013). Currently, the classification criteria recommended by ACR and EULAR, 
which were defined in 2010, are followed (Aletaha et al., 2010). The three main 
indexes that are used to measure disease activity are CDAI, SDAI and/or DAS. The 
remission status of the disease and any improvement is calculated using Boolean 
remission criteria and ACR improvement criteria (Aletaha and Smolen, 2007;Felson 
et al., 2011;van Riel and Renskers, 2016). 
 Development of RA is strongly associated with genetics. However, other 
factors like sex, obesity, and other environmental factors such as smoking and 
exposure to silica have also been reported as key risk factors. Heritability of RA was 
estimated to be approximately 15% in an identical twin study by Silman et al. but 
another study by MacGregor et al. found it to be 60% (comprising of both identica l 
and fraternal twins) (Silman et al., 1993;MacGregor et al., 2000). ACPA-positive 
showed higher risk of RA compared to ACPA-negative individuals (Padyukov et al., 
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2011) which may indicate a bigger role of other factors. Human leucocyte antigen 
(HLA) class II is strongly linked with RA (Gregersen et al., 1987). Similarly, genetic 
variants of PRL and NFIA are reported in seronegative individuals while AFF3, CD28 
and TNFAIP3 gene variants are present in seropositive subjects. Irrespective of 
serostatus, variation in HLA-DRB1, PTPN22, BLK, ANKRD55 and IL-6ST genes 
have been associated with RA (Viatte et al., 2016). Smoking and RA are strongly 
associated, and this association is possibly limited to ACPA-positive patients (Meng 
et al., 2017). Smoking is linked with increased pro-inflammatory cytokines levels and 
RA disease activity (Sokolove et al., 2016). Individuals with RA have also shown 
higher risk of prevalence of cardiovascular conditions which are the most common 
cause of death among those individuals (Radner et al., 2017). 
The onset of RA occurs much earlier than it is clinically detected or classified. 
Various factors can act independently to contribute to its development by trigger ing 
changes like citrullination or other modifications in proteins which can serve as target 
for generation of autoimmunity but it can also be considered as a part of the normal 
immune response (Makrygiannakis et al., 2008;van der Woude et al., 2010). The 
presence of RF and APCAs can be detected a decade before being clinically classified 
as RA. These markers are also associated with more aggressive disease progression 
(Houssien et al., 1997;Toes and van der Woude, 2011;Arend and Firestein, 2012).  
The synovium is a lining of specialised soft connective tissue in the inner 
surface of the joint. The synovium serves as the main site for pathogenesis. The 
synovial barrier is not highly selective and allows leakage of cells and proteins into 
the synovial fluid. Inflammation in the synovium due to infiltration and presence of 
CD4+ T-cells, macrophages, and fibroblasts is necessary for disease onset and 
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progression (Kinne et al., 2000;Klarenbeek et al., 2012;Lefevre et al., 2015). These 
cells types are also involved in production of pro-inflammatory cytokines and 
proteases. The influx of various cells into the synovium including mast cells, 
macrophages, and neutrophils along with FLS results in production of MMPs and 
collagenases which damage the extracellular matrix proteins, collagens and cartilage  
(Keyszer et al., 1998;Bluml et al., 2014). Osteoclasts are responsible for breakdown 
of the bone due to nuclear factor κB produced by T-cells. In the absence of 
autoantibodies, TNF was shown to increase osteoclast activation resulting in joint 
damage (Redlich et al., 2002;Schett and Gravallese, 2012). Other studies have 
highlighted the roles of other cytokines like IL-6, IL-8, IL-1, IL-15, IL-7, IL-17 and 
interferons that can interact with various receptors (Magyari et al., 2014).  
Treatment strategies recommend the use of DMARDs along with short-term 
dosage of glucocorticoids (Aletaha and Smolen, 2018). Glucocorticoids are a class of 
steroidal hormones with disease-modifying activity but are not recommended for long-
term use due to possible adverse effects (del Rincon et al., 2014). DMARDs block 
inflammatory processes through both known and unknown targets. Methotrexate is a 
commonly used synthetic DMARD (Smolen et al., 2017). Other types of DMARDs 
are targeted synthetic DMARDs that target JAK signalling and biologics (also known 
as biological DMARDs) which are monoclonal antibodies produced to target specific 
cell receptors and proteins namely TNF, IL-6 and its receptors, CD80, CD86 and 
CD20 (Fleischmann et al., 2017;Nam et al., 2017). Combination of both biologics and 
other synthetic DMARDs can be more effective compared either treatment alone 
(Smolen et al., 2014) but biologics are costlier and hence, their use as first line of 
treatment is still debated.  
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Many studies have explored possible links between RA and the microbio ta 
given that the microbiota plays a key role in immune modulation. In this regard, 
various animal studies have been carried out with knock-out models of different 
immune genes to elucidate the role of microbiota in the development of the disease. 
Rogier et al. reported that the microbiota stimulates IL-17 and TLR receptor dependent 
arthritis in IL-1 receptor negative mice. The IL-1 negative mice also had lower 
microbiota diversity (Rogier et al., 2017). The same group observed that 
Ruminococcus, Parasutterella, Xylanibacter, Barnesiella, and Prevotella were 
depleted whereas Helicobacter, Butyricimonas, Rikenella, and Streptococcus were 
abundant in the IL-1 negative mice. This highlights the role of IL-1 in modulating the 
microbiota. Germ-free mice show a lack of development of the arthritis phenotype. 
The development of arthritis was observed in germ-free animals with the introduction 
of Lactobacillus bifidus, other filamentous bacteria or recolonization of microbia l 
flora from collagen induced arthritis susceptible mice (Abdollahi-Roodsaz et al., 
2008;Wu et al., 2010;Liu et al., 2016). The SCFAs have an opposite impact on disease 
severity depending on the knockout mouse type (Mizuno et al., 2017). Investigat ing 
the probiotic effect of different bacteria uncovered that Lactobacillus casei confers a 
beneficial effect and suppresses pro-inflammatory cytokine expressions in RA animal 
models (Mizuno et al., 2017;Pan et al., 2019). Treatment with Lactobacillus casei also 
resulted in increased abundances of Lactobacillus hominis, Lactobacillus reuteri, and 
Lactobacillus vaginalis that were decreased in diseased animals before treatment. 
A large human study by Zhang et al. on a Chinese cohort (212 samples) 
highlighted the alteration in the gut and oral microbiota profiles of RA patients (Zhang 
et al., 2015). The study observed that microbiota alteration in the disease state partially 
reverted back towards normal after treatment of MTX and/or glycosides of the 
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traditional Chinese medicinal component Tripterygium wilfordii. This study also 
observed that the oral and gut microbiota showed concordance between them and had 
distinct profiles compared to healthy samples. Haemophilus species were found to be 
depleted in RA patients and negatively correlated with autoantibodies. In patients with 
onset of RA, increased abundance of Prevotella copri was found as well as a decrease 
in species belonging to Bacteroides. Chen et al. noted that taxa from the 
Actinobacteria were more abundant in RA and showed that Collinsella, a taxon from 
the phylum Actinobacteria was associated with increased IL-17A mediated 
inflammation, gut permeability, and disease severity in humanised mice and human 
epithelial cell line (Chen et al., 2016). The group also observed that MTX treatment 
was associated with increased α-diversity suggesting a potential restoration of the gut 
microbiota. Jeong et al. investigated the microbiota profiles of female subjects with 
RA, which included mainly preclinical and early stages of RA showed that the β-
diversity was significantly different compared to healthy cases but not α-diversity 
(Jeong et al., 2019). The phylum Bacteroidetes was enriched whereas phylum 
Actinobacteria was decreased in people with RA. Functionality associated with LPS 
was positively associated with established RA patients and DAS-28 metric. The 
decrease in Actinobacteria by Jeong et al. is in contrast to the findings in the Chen et 
al. study and may be due to difference in patient characteristics, clinical features, and 
mediation usage. Recently Sultan et al. reported that the use of antibiotics increases 
the risk of RA (Sultan et al., 2019).  
A meta-analysis study by Armour et al. investigated the microbial functiona l 
signature of various disorders that included RA, IBD, colorectal cancer, diabetes II, 
liver cirrhosis and obesity, and compared these diseases against healthy controls 
(Armour et al., 2019). The group observed that the functional (protein) richness and 
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diversity from RA samples was not significantly different from the healthy controls. 
Only a few functional modules were linked with RA. Modules related to acetate and 
methane production were increased in RA. The lack of strong association with 
functionality resulted in lack of sensitivity and specificity for RA classification based 
on KEGG modules. These human studies consistently reported that both taxonomic 
and functional richness were very similar to the healthy controls. This may suggest 
that specific taxonomic alterations may play a prominent role in driving pathogenes is 
of RA as opposed to reduced/altered diversity which is normally associated with 
inflammation. 
Investigation into the effects of probiotics on RA disease activity have been 
carried out in small clinical trials. Lactobacillus casei was found to attenuate disease 
activity and increase anti-inflammatory cytokines (Alipour et al., 2014). Zamani et al. 
studied the effect of administering a consortium of bacteria (Lactobacillus 
acidophilus, Lactobacillus casei and Bifidobacterium bifidum) and observed an 
improvement in the DAS-28, and reduced levels of CRPs (Zamani et al., 2016). 
Prevotella copri was enriched in new-onset RA individuals who had not undergone 
any treatment compared to healthy controls. The abundance of Prevotella correlated 
with the decrease in Bacteroides and other beneficial microbes suggesting a potential 
role in development of RA (Scher et al., 2013).  
 
3.2.2 Ankylosing spondylitis 
Ankylosing spondylitis (AS) is an asymmetrical, inflammatory disease that affects the 
axial skeleton. In AS, the bone-tendon interface serves as the site where inflammation 
originates, leading to both erosion and proliferation of the bone resulting in fusion of 
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bones (Zhu et al., 2019). AS is a subtype of spondylarthritis (SpA) which is an 
umbrella term that includes reactive arthritis, spondylitis, and enteritis (Sieper et al., 
2015). In 1990s, the ESSG and Amor et al. proposed defining the group of SpA as one 
disease (Amor et al., 1990;Dougados et al., 1991). Based on ESSG criteria, SpA is 
categorised as axial SpA (axSpA) characterised predominantly by back pain and 
peripheral SpA characterised by inflammation in the peripheral joints. Later, with 
inclusion of MRI results, the ASAS developed new criteria. Based on these, axSpA 
was split into AS (radiographic disease) that show structural damage and bony bridges 
in the sacroiliac (SI) joints and non-radiographic axial SpA (nr-axSpA) that shows no 
damage in SI joints (Rudwaleit et al., 2011;Sieper and van der Heijde, 2013). AS is a 
seronegative condition as there is no RF autoantibodies like those observed in RA. AS 
has long been associated with the HLA-B27 allele, however the genes IL-17A, IL-23 
and ERAP-1 have also been linked with AS (Brewerton et al., 1973;Evans et al., 
2011;Taams et al., 2018). 
 Initially AS was detected based on radiographic evidences, which was 
essential as it was possible to observe visible sacroiliitis. However, as the disease 
developed with inflammation, it was not detected in early cases where there was no 
visible structural damage (Sieper et al., 2002). Currently based on ASAS criteria, 
classification of AS includes MRI results and a test for HLA-B27 (Rudwaleit et al., 
2009b). The patients must also have chronic back pain for at least 3 months at an age 
of less than 45 years. The sensitivity and specificity of classification is at 82.9% and 
84.4% respectively when testing for clinical or laboratory measures like HLA-B27 
along with imaging. There are no diagnostic criteria established for AS, hence 
classification criteria are used commonly for diagnosis (Rudwaleit et al., 2005). The 
classification criteria reflect the standardised definitions from well-defined cohort of 
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patients whereas diagnostic criteria require identifying the cause and nature of the 
disease determined by supportive tests, signs, and symptoms. Diagnosis is carried out 
by investigating the x-ray reports, investigating inflammation in at least two different 
sites using MRI, measuring C-reactive proteins levels, testing for HLA-B27, 
accounting for family history of SpA and response to NSAIDs (van den Berg et al., 
2013). A flexible approach is necessary depending on the condition of the patients. 
 Genetics has been established as the primary risk factor for development for 
AS. HLA-B27 has the strongest link with AS (Schlosstein et al., 1973;Bowness, 
2015). In cases of advanced axSpA, the prevalence of HLA-B27 is estimated to be 
approximately 80% (Rudwaleit et al., 2009a). The concordance of the risk in 
monozygotic twins is 63% and in cases of first-degree relatives it is 8.2% (Brown et 
al., 2000). Genetic variants of ERAP-1 have been associated with increased risk of AS 
for it is responsible for trimming HLA class 1 peptides, affecting HLA-B27 
interactions(Evans et al., 2011). IL-17A and IL-23 are also recognised as important 
for AS because IL-23 signalling through CD4+ T helper cells causes differentiation of 
T helper 17 cells that produce IL-17A cytokines (McGeachy et al., 2009;Jethwa and 
Bowness, 2016). Excluding genetic factors, smoking and hypertension are also 
recognised as risk factors for AS (Videm et al., 2014). 
Onset of AS involves autoinflammation at the specific site due to immune and 
mechanical stress. The SNPs at IL-23 receptors were also found to be responsible for 
the promotion of cytokines IL-17F, interferon-γ and TNF (Coffre et al., 2013). The 
increased expression of IL-17 is related to other cells like neutrophils, mast cells and 
myeloperoxidase cells (Appel et al., 2011;Noordenbos et al., 2012;Appel et al., 2013). 
However, their roles in driving AS pathogenesis remain unclear. The overexpression 
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of IL-23 in experimental models has shown induction of an inflammatory state that 
resembles that of axSpA and RA (Sherlock et al., 2012). Genetic studies have 
identified SNPs on the TNF receptor 1 gene that are associated with AS samples 
(International Genetics of Ankylosing Spondylitis et al., 2013) but the exact role of 
TNF remains unclear (Braun et al., 1995). In axSpA, both TNF and IL-17 play a major 
role in cartilage destruction but AS is uniquely distinguished with bone proliferat ion 
also (Francois et al., 2000;Herman et al., 2008). Until now, there is no evidence to 
support the relationship between osteo-proliferation and the inflammation observed in 
this disease as anti-inflammatory therapy targeting TNF does not inhibit bone 
formation (Baraliakos et al., 2014). However, it has been suggested that the effect of 
targeting TNF would take years to show any measurable effect on osteo-proliferat ion 
(Haroon et al., 2013).  
Use of DMARDs can prevent radiographic damage, but there is limited 
research showing disease-modifying activity and efficacy on axSpA (van der Horst-
Bruinsma et al., 2002;Braun et al., 2006). Use of glucocorticoids is effective at high 
dosage (Haibel et al., 2014). Primarily, TNF-specific therapy have shown to reduce 
inflammation, C-reactive protein levels, and improve mobility and functionality of the 
spine, hence overall improvement in health (Braun et al., 2003;Haroon et al., 2013). 
Other biologics treatments have been developed that target IL-17, IL-12 and IL-23 
which have shown improvements in patients (Baeten et al., 2013;Poddubnyy et al., 
2014). Treatment of AS with NSAIDs was effective with partial remission in 
approximately 10-35% of patients (van der Heijde et al., 2005).  Early diagnos is 
followed by continuous treatment can reduce radiographic progression compared to 
on-demand treatment (medication only if necessary); however, this still requires 
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extensive investigation due to risk of side-effects from long-term medicat ions 
(Wanders et al., 2005). 
The role of the microbiota as an environment trigger for disease pathogenes is 
is being studied in various arthritic conditions. In germ-free conditions, HLA-B27 
transgenic rats models do not develop AS but when commensal gut microbiota are 
introduced, these rats developed AS symptoms and inflammation (Rath et al., 
1996;Lin et al., 2014). Studies with germ-free mice also report similar results 
(Rehakova et al., 2000;Sinkorova et al., 2008). Studies with rat models have identified 
alterations in bacterial species, namely decreases in Firmicutes and Rikenellaceae. 
Taxa that are observed to be enriched in rat models are Proteobacteria, Paraprevotella, 
Prevotella, Bacteroides vulgatus and Akkermensia municiphila (Lin et al., 
2014;Asquith et al., 2016). These alterations have been associated with colonic Th cell 
expansion and increased expression of Th cell cytokines and IgA antibodies. Asquith 
et al. found that bacterial metabolites like propionate are associated with attenuation 
of disease (Asquith et al., 2017). The expression of HLA-B27 in AS rat models have 
been reported to effect microbial metabolites. A very recent study by Gill et al. 
observed that the gut microbiota signature was distinct in different rat models and yet 
the association with pro-inflammatory cytokines remained. The group identified 
metabolic pathways related to SCFAs, LPS and steroids that were associated with 
immune modulation. However, the identified microbial markers did not show any 
significant difference when compared to wild-type controls (Gill et al., 2019). 
Human studies have also shown that up to 30% of IBD patients can develop 
symptoms of AS (Orchard et al., 2000). The role of gut microbiota in AS pathogenes is 
is suspected as 61% of AS patients have shown varying degrees of gut inflammation 
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(De Vos et al., 1989). Analysis of biopsy samples by Costello et al. from a small cohort 
of AS patients and healthy controls revealed that the families Veillonellaceae and 
Prevotellaceae were depleted in the diseased subjects, whereas Lachnospiraceae, 
Ruminococcaceae, Rikenellaceae, Porphyromonadaceae and Bacteroidaceae were 
more abundant (Costello et al., 2015). Studies on other SpA types have identified 
Faecalibacterium prausnitzii to be decreased in diseased groups (Stoll et al., 2014).  
The identified taxa may serve as markers because species from these taxa are known 
to degrade mucin and produce SCFAs. These markers can be potentially associated 
with AS susceptibility as these taxa may influence barrier integrity and inflammation 
mediated through Th17 and IL-23 immune signalling (Yang et al., 2016b). A probiotic 
study on AS patients have been carried out with Streptococcus salivarius, 
Bifidobacterium lactis, and Lactobacillus acidophilus acting as a consortium of 
bacteria, which reported no significant clinical improvement (Highton et al., 2012). 
However, Bacteroides fragilis has been reported to benefit AS patients (Stebbings et 
al., 2009). 
 
3.2.3 Psoriatic arthritis 
Psoriatic arthritis (PSA) is a chronic inflammatory arthritic condition that affects the 
synovial tissue, skin, and the skeletal system along with other clinical conditions like 
enthesitis, dactylitis and other comorbidities (Veale and Fearon, 2018). PSA is 
considered a part of the SpA group of conditions and is seronegative (Kruithof et al., 
2005;Ritchlin et al., 2017). Onset of PSA in different individuals have varied tissue 
origin, heterogeneous presentations, different disease routes and outcomes. Studies on 
PSA have primarily focussed on skin, joints, and entheses (Veale and Fearon, 2018). 
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PSA is characterised by influx of immune cells and inflammation due to production 
of pro-inflammatory cytokines in the synovium and damage to bone and other tissues  
(Veale et al., 1993;Kruithof et al., 2005). The osteoclast cells are also activated which 
leads to resorption of bone resulting in bone erosion (Sucur et al., 2017). Inflammation 
at the entheses is the most common characteristic of PSA (McGonagle et al., 1998). 
The inflammation observed in the DIP joints through MRI and clinical results shows 
a marked difference in the pattern of inflammation and damage compared to RA. PSA 
is underdiagnosed in patients with psoriasis due to lack of effective screening methods 
and lack of proper identification of PSA symptoms. However, early diagnosis and 
treatment can lead to remission of PSA symptoms (Liu et al., 2014). 
The ClASsification criteria for Psoriatic ARthritis (CASPAR) were developed 
by Taylor et al.  in 2006 and are the most commonly used criteria, with a sensitivity 
and specificity of 0.91 and 0.98 respectively (Taylor et al., 2006). This scheme 
includes the history of psoriasis from the patient or closely related relatives, psoriatic 
nail dystrophy, swelling of digits and evidence of seronegative and radiographic 
changes of hands and feet. Various clinical features like axial skeleton disorder, 
inflammation of the peripheral joints, entheses and dactylitis are indicative of PSA 
onset and development (Gladman et al., 1987). These conditions can be observed 
individually or in combination with other factors. Spondylitis, inflammation in the 
neck and sacroiliitis are the primary features and most commonly identified 
manifestation in patients with PSA (Helliwell, 2004;Feld et al., 2018). Diagnosis is 
carried out by radiography which is used to detect bone turnover, asymmetr ica l 
distribution and DIP involvement with deformity (Mease and Goffe, 2005). 
Ultrasonography is an important and widely used tool to evaluate PSA status and 
efficacy of treatment (Sankowski et al., 2013). MRI is used to identify and monitor 
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synovial inflammation in PSA and is more sensitive in detecting small damages to 
bone (Schwenzer et al., 2010). 
Like other types of arthritis discussed earlier, various genetic and 
environmental factors have been identified with the onset and development of PSA 
(Stuart et al., 2015). Heritability studies have identified strong genetic components 
with PSA (Myers et al., 2005). Studies with HLA alleles have identified specific HLA 
susceptibility with subtypes of PSA (Haroon et al., 2016). Excluding the HLA loci, 
IL-12B, IL-13, IL-23R and TNFAIP3 are also implicated in the pathogenesis of PSA 
amongst which IL-23R has shown the strongest association (Huffmeier et al., 
2010;Eder et al., 2011;Sherlock et al., 2012;O'Rielly and Rahman, 2014;Stuart et al., 
2015). High levels of antibodies against Streptococcal infection have also been 
observed in PSA patients along with evidence of Streptococcus genetic material in 
blood and synovial fluid (Muto et al., 1996). In HIV-positive patients, a depletion of 
CD4+ T-cells is observed which triggered exacerbation of PSA (Mijiyawa et al., 
2000). Amongst various environmental factors, smoking, infection, trauma, and stress 
have been associated with PSA onset (Mease and Goffe, 2005;Duffin et al., 2009). 
Smoking is shown to be a risk factor for onset of PSA in people without psoriasis and 
is considered to be protective in cases of psoriasis which has been associated with 
polymorphisms in IL-13 (Duffin et al., 2009).  
Inflammation at the synovium by various immune cells drives the pathogenes is 
in PSA. Formation of pannus (abnormal fibrovascular tissue layer) including increased 
fibroblast- like synoviocytes and activation leads to destruction of the bone and 
cartilage in the joints (Veale and Fearon, 2018). The lining of the synovium develops 
increased blood vessels in PSA, whereas RA is characterised by a thick, avascular 
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lining in the synovium (Ceponis et al., 1998). The synovium of PSA patients also 
shows an increased expression of growth factors in early stages in contrast to RA that 
suggests distinct vascular morphology regulation (Fraser et al., 2001;Fearon et al., 
2003). The environment of the synovium allows immune cell invasion, proliferat ion 
and production of pro-inflammatory cytokines resulting in destruction of the joints and 
increased risk of associated comorbidities (Ceponis et al., 1998;Biniecka et al., 
2010;Biniecka et al., 2016;Hotamisligil, 2017). Secretion of IL-22 induces 
osteoclastogenesis and activates fibroblast- like synoviocytes, which can increase 
invasion, contributes to osteoclastogenesis, produce pro-inflammatory cytokines, and 
produce matrix-degrading enzymes (Mitra et al., 2012). Remission of PSA is achieved 
by depletion or absence of T-cells by targeting CD4+ and CD8+ through therapeutics. 
Studies have shown that PSA pathogenesis is marked by increased CD8+ cells 
compared to CD4+ cells (Veale et al., 2005). The DCs can activate T-cells and in PSA, 
immature dendritic cells can induce T helper cells to produce TNFα, interferon γ and 
IL-12 (Candia et al., 2007) and also increase the population of CD8+ T-cells in the 
synovium (Ramos et al., 2016). Macrophages are also responsible for pro-
inflammation and damage to the bone as they secrete large amounts of pro-
inflammatory cytokines and matrix metalloproteases as well as induce bone resorption 
and antigen presentation of T-cells and B-cells (Kurowska-Stolarska and Alivernini, 
2017). All these inflammatory reactions result in degradation of cartilage and bone, 
which have been noted to be architecturally distinct from RA. 
Treatment of PSA is aimed at alleviating suffering, preserving the joints, and 
achieving remission status. Use of glucocorticoids is effective in mild forms of the 
disease, however long-term use is not advised due to lack of information regarding 
long-term efficacy, risk of adverse side effects and relapse after discontinuing. 
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Similarly, NSAIDs are also initially prescribed to patients for short-term treatment of 
symptoms (Nash and Clegg, 2005). DMARDs are used for treatment of moderate to 
severe forms of PSA, sometimes in combination with NSAIDs. Conventiona l 
DMARDs reduce levels of pro-inflammatory cytokines and inhibit T-cell activity 
(Cuchacovich et al., 2012). The use of biologics have been suggested as the first line 
of therapy despite being expensive. Antibodies have been designed to target specific 
ILs (IL-17A, IL-12 and IL-23), TNF or their respective receptors (Carneiro et al., 
2013;Coates et al., 2013;Palfreeman et al., 2013;Cantini et al., 2016). Several anti-
TNF drugs are effective in managing PSA but their association with increased risk of 
infection and tumour formation are highlighted as an adverse effect (Glintborg et al., 
2011;Ash et al., 2012;Ali et al., 2013;Minozzi et al., 2016). 
Several studies have investigated the link between microbiota, inflammation, 
and various arthritic conditions. However, extensive investigation with PSA is limited. 
Scher et al. reported microbiota-associated changes in PSA patients for the first time 
(Scher et al., 2015). Species belonging to Akkermansia, Ruminococcus, and 
Pseudobutyribrio were less abundant in abundance amongst PSA patients (Scher et 
al., 2015;Codoner et al., 2018). Taxa identified with PSA patients are involved in 
mucin metabolism and SCFA production, which are necessary for immune 
homeostasis. This study observed increased levels of bacterial specific IgA antibodies 
and decreased concentration of TNF super family 11 in the faecal supernatants. The 
levels of medium chain fatty acids (hexanoate and heptanoate) were also reported to 
be lower in diseased groups. These alterations may be associated with microbia l 
immune modulation. The group noted that the microbiota alterations resembled those 
of IBD patients despite the unique changes in immune proteins. A recent study by 
Shapiro et al. investigated a cohort of psoriatic patients that included both PSA and 
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psoriasis patients and observed a significant difference in the global gut microbio ta 
profile compared to healthy controls but no difference in α-diversity (Shapiro et al., 
2019). Shapiro et al. identified 8 genera with increased abundance in the diseased 
group: Ruminococcus, Coprococcus, Blautia, Dorea, Collinsella, Actinomyces, 
Christensenella and Faecalibacterium. At species level, Ruminoccocus gnavus, 
Dorea formicigenerans and Collinsella aerofaciens were more abundant in the 
diseased group. Key functionality associated with butyrate kinase and phosphate 
butyryltransferase were depleted while LPS biosynthesis pathways were enriched in 
the disease subjects (Shapiro et al., 2019). It is interesting to note that the time-period 
since diagnosis or type of treatment had no association with the gut microbiota profile.  
The study by Shapiro et al.  and Scher et al. shows certain contrasting results. 
The latter observed a decrease in α-diversity amongst the PSA compared to healthy 
controls, which was not observed in the former study. Species of Ruminococcus are 
important taxa with immune-modulatory properties. Both of these studies report 
contrasting observations in the abundance of this genus. This may be partly due to 
unclear distinction between psoriasis and psoriatic arthritis samples in the work by 
Shapiro et al. It may also be due to presence of different species of Ruminococcus in 
the samples that contributed to the cumulative genus level abundance. Ruminococcus 
bromii is commonly observed to be enriched in healthy whereas Ruminococcus gnavus 
is increased in diseased individuals with gut inflammation (Kang et al., 2010;Henke 
et al., 2019). 
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3.3 Inflammatory bowel disease 
Inflammatory bowel disease (IBD) is a group of chronic inflammatory disorders of the 
GIT. It is a complex multi- factorial condition characterised by chronic inflammation 
in the intestine. The two principal types of IBD are Crohn’s disease (CD) and 
ulcerative colitis (UC). CD is known to affect any part of the GIT i.e. from mouth to 
anus, whereas UC results in inflammation and ulceration in the large intestine (colon) 
and the rectum (Ordas et al., 2012). Despite being different diseases, CD and UC share 
certain similar symptoms like abdominal pain, diarrhoea, loss of appetite, weight loss, 
rectal bleeding, and feverishness. Aetiology of IBD is still unknown; however 
interaction of various genetic, dietary, and other environmental factors with the 
immune system is associated with the onset and development of IBD (Xavier and 
Podolsky, 2007;Wilkins et al., 2011). IBD is an autoimmune disorder but no specific 
blood markers have been identified that distinguishes CD and UC (Bennike et al., 
2014). IBD goes through both active and remission phase and treatment is aimed at 
achieving remission without relapsing to active form.  
Primary diagnostic criteria for IBD are visualisation of the intestine using 
colonoscopy and by obtaining biopsy samples. Measuring the levels of faecal 
calprotein is also carried out for intestinal inflammation due to its sensitivity but this 
technique is not unique to IBD (Henderson et al., 2014). To visualise the features of 
small intestinal walls, magnetic resonance (MR) enterography is also carried out 
(Yoon et al., 2017). Currently the Montreal classification system is the most 
commonly used measure for classifying IBD into either CD or UC (Satsangi et al., 
2006). As there is no known marker to distinguish disease type, classification into CD 
or UC is done by noting the location and nature of the inflammation. Inflammation of 
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the mucosal layer is characteristic of UC whereas CD is known to affect the whole 
thickness of the intestinal wall.  
Onset and development of IBD is due to complex interaction between genetics, 
epigenetics, environment, immune system, microbiota and diet (Zhang and Li, 2014). 
Increased incidences of IBD has been observed amongst relatives and 5-23% of 
patients had first degree relatives with IBD (Ek et al., 2014). Studies have shown 20-
25% of heritability of the risk loci. However, the number of susceptible loci is 
increasing with ongoing research (Loddo and Romano, 2015). The IBD-associated 
risk variants were reported in patients with European ancestry (Inoue et al., 
2002;Leong et al., 2003). The majority of identified loci are shared by UC and CD, 
whereas a small number were unique to either disease (Jostins et al., 2012). The first 
risk allele to be identified was NOD2 (Hugot et al., 2001;Ogura et al., 2001). This 
gene is needed in the NFB pathway, a pro-inflammatory pathway that is necessary 
for proper bacterial recognition (Inohara et al., 2003). A variant of NOD2 associated 
with CD has been reported to supress anti-inflammatory cytokine IL-10 (Noguchi et 
al., 2009). Polymorphic variants IL genes; IL-23R, IL-12B, IL-10 and IL-1R2 have 
also been reported along with STAT3 and JAK2 of which the IL-23 pathway is well 
established in the pathogenesis of IBD (Tremelling et al., 2007;Anderson et al., 2011). 
Amongst the various environmental factors associated with IBD, risk 
associated with smoking has been the most replicated in IBD studies. Other factors 
include socio-economic status, stress, diet, and medications. Interestingly, heavy 
smoking is a risk factor for CD development but confers a protective effect against the 
development of UC (Lakatos et al., 2007). Vitamin D has immune modulatory 
properties and low levels of vitamin D were observed in patients diagnosed with IBD 
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(Leslie et al., 2008). Both high and prolonged dosage of NSAIDs have also been 
reported to increase the risk of IBD (Ananthakrishnan et al., 2012). Diet is considered 
to play an important role in the management of IBD (Rajendran and Kumar, 2010;Hou 
et al., 2011). Increased consumption of fat and meat has been linked with increased 
risk of IBD, whereas increased fruit and vegetable consumption was related to a 
decreased risk.  
Although the pathogenesis is unknown, various studies have highlighted the 
role of pro-inflammatory cytokines and dysfunction of the immune system in IBD by 
investigating the T cell associated mucosal immunity. It is hypothesised that Th1 
response is associated with CD whereas Th2 response has been associated with UC 
(Breese et al., 1993;Fuss et al., 2004;Heller et al., 2005). IBD studies have been carried 
out to understand immune response in relation to barrier integrity, autophagy, UPR 
and microbial detection (Wehkamp et al., 2003;Rioux et al., 2007;Kaser and 
Blumberg, 2011;Salim and Soderholm, 2011). The expression of TLRs and NOD are 
significantly altered in IBD patients. These receptors play a key role in antigen 
recognition, immune tolerance, and autophagy. Malfunctioning of TLR2 and NOD2 
activate and increase Th1 response (Watanabe et al., 2004;Abreu et al., 2005). IBD 
has also been associated with UPR-induced stress response from the ER, trigger ing 
apoptosis (Kaser and Blumberg, 2011). Various IL families of cytokines produced by 
the immune cells have been linked with CD and UC or both. These cytokines play a 
central role in accumulation of other immune cells, triggering response against 
microbes and a cascade of other inflammatory pathways. Th1 cells produce increased 
levels of IL-2 and IL-12 that induce IFN-γ in CD (Breese et al., 1993;Peluso et al., 
2006). IL-23 plays a key role in Th17 activation and has been observed in both UC 
and CD (Kobayashi et al., 2008). IL-1β and IL-8 are expressed in UC whereas CD 
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showed a reduced expression level due to traumatic exposure (Marks et al., 2006). Th2 
responses in UC produces elevated levels of IL-4, IL-5 and IL-13 (Nemeth et al., 
2017;Imam et al., 2018). In-vitro studies have shown that IL-13 may have anti-
inflammatory effects and have increased levels of IL-6 when IL-13 is not expressed in 
UC biopsy samples (Bernardo et al., 2012). Despite the evidence, there is debate 
regarding the Th1/Th2 drivers (Di Sabatino et al., 2012;Globig et al., 2014;Li et al.,  
2016). Th17 is highly expressed in both UC and CD, producing IL-17A, IL-17F, IL-
21 and IL-22 cytokines through IL-6, TFGβ and IL-23 signalling (Zhou et al., 
2007;Guglani and Khader, 2010;Zhang, 2018). However, its role in pathogenesis of 
IBD is being extensively investigated (Ueno et al., 2018). 
IBD is treated using immunosuppressant drugs, dietary alterations and lifestyle 
changes (Carter et al., 2004). However, surgery is the most common option for 
management and is carried out least 70-75% of CD patients and over 25-30% of UC 
patients according to World Gastroenterology Organisation Global Guidelines on 
IBD. Surgery is required if the patient does not respond to medications. Nutritiona l 
therapy is implemented in mild to moderate cases of IBD to rest the bowel and reduce 
bowel movement. This is achieved by cutting down on fibre, dairy products, digestib le 
carbohydrate, and by adhering to an anti-inflammatory diet resulting in less volume of 
food passing through the GIT but can also result in nutritional deficiencies (Lee et al., 
2015). Nevertheless, nutritional modulation achieves between 50% to 90% remission 
rates in CD amongst children (Afzal et al., 2005). Remission is also achieved using 
immunomodulatory drugs like azathioprine, methotrexate, biologics and TNF 
inhibitors (Louis et al., 2014;Herfarth et al., 2016;Adegbola et al., 2018;Rawla et al., 
2018). These are often used to treat severe forms of the disease. Corticosteroids are 
also prescribed for immune-suppressive effects and antibiotics are used to reduce 
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microbial load in combination with other treatments but has been linked with high risk 
of CDI and relapse of the disease (Prantera and Scribano, 2009;Waljee et al., 2016). 
Because IBD is an inflammatory condition associated with the GI tract, the 
role of gut microbiota in its pathogenesis is considered important. Research link ing 
inflammation, IBD and gut microbiota is carried out widely across the world. It has 
been suggested that the microbiota profiles from IBD subjects may have diagnost ic 
potential. The role of microbiota in IBD has been recognised as early as in 1961 by 
Weinstein et al. and Vince et al.  in 1972 (Weinstein, 1961;Vince et al., 1972). Two 
large international cohorts MetaHIT and iHMP have been setup to investigate the role 
of microbiota in diseases, with one of the key diseases being IBD (Qin et al., 
2010;Integrative, 2014). iHMP consists of longitudinal sampling from patients over a 
one-year period. It contains extensive sampling and meta-data from the subjects 
accounting for biopsies, metabolites, proteomics, transcriptomics, virome, genetics, 
serological and dietary information. 
Germ-free and antibiotic-treated animal models show absence or attenuation 
of IBD highlighting the important role of gut microbiota in IBD pathogenes is. 
Development of IBD conditions has been observed when microbiota from IBD 
patients were introduced into germ-free mice models. It was observed that germ-free 
wild type mice colonised with donor microbiota did not develop IBD or inflammation, 
which may be an indicator of genetic susceptibility (Schaubeck et al., 2016). Overall, 
various taxa have been identified to be enriched in IBD animal models. These include 
Bacteroides, Porphyromonas, Enterobacteriaceae, Akkermansia muciniphila and 
Clostridium ramosum (Gkouskou et al., 2014). Certain species belonging to these taxa 
are pathobionts, mucin metabolisers and can have pro-inflammatory effects.  
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A lower taxonomic and functional diversity is observed in the microbiome of 
IBD patients compared to healthy subjects. A reduction in the abundance of Firmicutes 
and Bacteriodetes and an increase in Proteobacteria (mainly species of 
Enterobacteriaceae and Pasteurellacaea) is seen in IBD patients (Ott et al., 2004;Frank 
et al., 2007;Kang et al., 2010). However, species of Enterococcus, Clostridium and 
Listeria were also observed to be more abundant in IBD (Kang et al., 2010). A loss of 
commensal bacteria primarily known for SCFA production is also observed (Machiels 
et al., 2014). Prominent among them are the butyrate-producing obligate anaerobes 
Faecalibacterium prausnitzii and Roseburia hominis. These taxa have been linked 
with reduction in disease activity and gut inflammation and their depletion is linked 
with relapse of IBD. Other known SCFA producers that are depleted in IBD are 
Phascolarctobacterium and Paraprevotella (Watanabe et al., 2012). 
Leuconostocaceae and Odoribacter are also reduced in IBD patients (Morgan et al., 
2012). Lactobacillus and Bifidobacterium are reported to confer a protective effect by 
reducing disease activity with no observed side effects (Kato et al., 2004;Sood et al., 
2009). Biopsy studies have identified Enterobacteriaceae, Bacteroidales, 
Clostridiales, Pasteurellaceae, Veillonellaceae, Neisseriaceae and Fusobacteriaceae to 
be enriched in disease samples while Bacteroides, Faecalibacterium, Roseburia, 
Blautia, Ruminococcus and Coprococcus were depleted (Gevers et al., 2014). Bacteria 
coated with IgA modulate Th17-dependent inflammation and higher concentrations of 
IgA-coated bacteria induced severe colitis (Palm et al., 2014;Viladomiu et al., 2017). 
Large-scale comprehensive longitudinal analysis of microbial gene expression and 
other “omics” data have not been carried out until recently.  
A recent publication by Schirmer et al. investigating the faecal 
metatranscriptomics profiles of IBD patients has shown that the both microbia l 
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functional potential and the observed gene expression correlated well with the disease 
activity across timepoints and samples (Schirmer et al., 2018). Taxa such as 
Faecalibacterium prusnitzii showed shifts in gene expression but not in their 
taxonomic abundance suggesting that taxonomic abundance are not predictive of their 
activity. Pathways associated with various sugar metabolism (rhamnose, glucurona te, 
galacturonate) were associated with difference in gene expression from 
Faecalibacterium prusnitzii but did not correlated with the taxonomic abundance 
across samples. This shows that the gene expression and functionality of taxa can play 
a greater role than their taxonomic abundance. Different patient-specific Bacteroides 
species were also reported which may indicate certain similar functionality by 
different species. However, this does not account for unique genes and their expression 
found in different species of the same genus. Significant IBD-specific transcriptiona l 
alterations were observed for Alistipes putredinis and Bacteroides vulgatus, 
Ruminococcus gnavus and Roseburia intestinalis, showing taxonomic variability 
between patients and over time. Ruminococcus gnavus also exhibited variability in 
expression suggesting a greater role of this taxa in disease-specific changes in IBD. 
Functions associated with oxidative stress have consistently been reported as increased 
in IBD while carbohydrate metabolism and amino acid biosynthesis were decreased. 
Another recent publication by Lloyd-Price et al. highlighted IBD-associated 
alterations related to microbial, serological, biochemical and host factors (Lloyd-Price 
et al., 2019). Consistent with other research, a decrease in SCFAs and other known 
taxa were also observed.  The study identified a decrease in stability of gut microbio ta 
composition characterised by frequent and extreme shifts in the microbiota throughout 
the duration of the disease. Network analysis identified various interactions between 
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taxonomy, functionality and metabolic profiles with host transcription and serologica l 
features.  
 
3.4 Multiple Sclerosis 
Multiple sclerosis (MS) is an immune-associated neurodegenerative condition of the 
CNS. It forms demyelinating lesions in the white matter, grey matter, and the optic 
nerves. Onset of MS is heterogeneous in nature and includes various complex host and 
environmental interactions. Various subtypes of MS exist which are considered at an 
active or inactive stage depending on assessment (Compston and Coles, 2008). The 
initial onset of the disease is considered a CIS. MS can show reversible relapse of the 
lesion manifestations also known as RRMS. Once the lesions become more developed, 
causing permanent neurological deficits, the disease is called SPMS. In a small subset 
of patients, the disease progression continues from the initial onset without remission 
and in such cases, it is considered as PPMS (Lublin et al., 2014). The assessment of 
disease progression and lesion activity is determined using MRI. The diagnosis of MS 
is based on analysing different regions of the CNS over different periods of time. 
Diagnosing MS depends on the clinical manifestation of the disease, as it is 
heterogeneous in nature with demyelination occurring at different locations. The onset 
(CIS) is typically characterised by dysregulation of the neural cells, which results in 
unpredictable loss of functionality, depending on the site of occurrence (optic nerve, 
spinal cord, cerebrum or cerebellum) in 85% of patients (Miller et al., 2012). EDSS is 
the most widely used measuring criterion for disability that scores the clinica l 
manifestation from 0 – 10 (0 is a completely normal neurological test and 10 is 
mortality due to MS) (Kurtzke, 1983). Diagnosis of MS is based on McDonald’s 2017 
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revised criteria (Thompson et al., 2018). In summary, it involves monitoring the 
disease, disability progression, at least one to two clinical relapses, and evidence for 
two or more lesions in distinct locations based on neurological examination. Diagnos is 
also include counting the number of lesions in different areas over time. MRI is also 
recommended, as it is highly sensitive in detecting defects in the brain and spinal cord  
(Rovira et al., 2015). 
The primary cause of MS is still unknown; however, various genetic and 
environmental risk factors have been associated with susceptibility to MS. In 
monozygotic twins, the heritability risk is 35%, whereas dizygotic twins and siblings 
show 6% and 3% respectively (Compston and Coles, 2002). Amongst the various 
genes identified as risk factors, polymorphism of HLA class I and II genes are the 
most prominent (Brynedal et al., 2007;Moutsianas et al., 2015). Polymorphism in T-
cell and other immune cell associated genes (IL-2RA, IL-7R and TNF) are also 
identified as important risk factors for MS (Gregory et al., 2007;International Multip le 
Sclerosis Genetics et al., 2007;De Jager et al., 2009). It is hypothesised that 
pathogenesis of MS is also associated with infectious diseases due to involvement of 
the immune system. EBV infection is the most well established risk factor as 
epidemiological studies show biomarkers for EBV in 100% of MS patients (Haahr et 
al., 2004;Olsson et al., 2017). Other factors identified include low vitamin D levels, 
adolescent obesity, and smoking. However, the exact mechanism of actions is not clear 
for any of these risk factors (Olsson et al., 2017). 
 Demyelination which results in lesions is the primary features for all types of 
MS. This breakdown of the BBB results in influx of active immune cells like 
macrophages, T-cells and B-cells which escalate the inflammation leading to neuro-
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axonal degeneration (Ortiz et al., 2014). Lesions are found throughout the CNS and 
can affect both white matter and grey matter (Gilmore et al., 2009). The immune cells 
interact with microglia and astrocytes secreting a variety of pro-inflammato ry 
cytokines that not only induce demyelination causing neural damage but also signal 
the influx of other immune cells into the area (Li et al., 2018). Insufficient functioning 
of the T-reg cells results in aberrant T-cell modulation, thus mediating demyelinat ion 
(Viglietta et al., 2004;Venken et al., 2008;Kitz et al., 2018). Various pro-inflammato ry 
cytokines identified to be involved in MS are IL-17, TNF, IL-12, IL-6, IL-1β and IL-
23 (Palle et al., 2017).  
MS patients are prescribed DMTs as the first line of therapy as soon as they 
are diagnosed. Commonly used DMTs are Rituximab, IFN-β or glatiramer (Tintore et 
al., 2019). In non-responsive patients, transplantation of haematopoietic stem cells is 
recommended which have proven to be effective (Muraro et al., 2017). More recently, 
newer biologics have been developed to reduce inflammation rapidly by targeting the 
T-cells and other immune cells (Buc, 2018). It is interesting to note that the older 
DMTs have a lower risk profile compared to the newer line of therapy. These newer 
DMTs are associated with an increased risk of infection (Comi et al., 2017).  
Investigating the role of the microbiota in MS pathogenesis in mouse models 
(EAE) has shown promotion of Th1 and Th17 responses when bacterial adjuvant with 
myelin protein is introduced (Berer et al., 2011;Mirza and Mao-Draayer, 2017). EAE 
mice did not develop MS when maintained under germ-free conditions. Under germ-
free conditions, animals showed low levels of inflammatory cytokines and increased 
population of T-reg cells (Lee et al., 2011). The progression and severity of the disease 
was also reported to be reduced during early treatment with antibiotics. However, in 
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later stages of MS, there was no effect of the same antibiotics on the mice (Yokote et 
al., 2008). Th17-mediated development of EAE was observed upon introduction of 
commensal gut microbiota into the animals (Berer et al., 2011;Lee et al., 2011). 
Disease susceptibility was also reported when gut microbiota from MS patients were 
introduced into germ-free mice (Berer et al., 2017). Studies have highlighted that the 
gut microbiota may be involved in gene expression related to CNS functionality like 
activating microglia, myelination  and BBB permeability (Mirza and Mao-Draayer, 
2017). The levels of neurometabolites can be inferred based on certain gut microbia l 
populations according to a study on young pigs (Mudd et al., 2017). Certain lipids and 
polysaccharides produced by species of Bacteroidetes such as Bacteroides fragilis can 
induce TLR2 tolerance, T-reg cell promotion, suppress CNS inflammation and prevent 
demyelination in EAE models (Ochoa-Reparaz et al., 2010;Anstadt et al., 2016). 
Treatment with SCFAs attenuates EAE through T-reg cells and anti-inflammato ry 
cytokine upregulation (Haghikia et al., 2015). Colonisation by Bifidobacterium  
animalis, Prevotella histicola and Pediococcus acidilactici as well as species of 
Lactococcus also reduce disease severity (Chu et al., 2018). 
Human studies have highlighted gut microbiota taxa depleted in MS that are 
also associated with decreased SCFAs production, T-reg cell population and microglia 
maturation (Mirza and Mao-Draayer, 2017). Taxa that were increased in MS patients 
were associated with mucin metabolism and were known to promote environment-
gene immune response. Bacteriodes, Butyricimonas, Collinsella, Faecalibacterium 
and Prevotella were reduced while Bifidobacterium, Streptococcus, Akkermansia 
muciniphila and the archaeal genus Methanobrevibacter were enriched in MS patients 
(Shahi et al., 2017). An increase in the abundance of Prevotella and Sutterella with a 
decrease in abundance of Sarcina was observed between DMT-treated patients and 
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untreated patients (Jangi et al., 2016). Probiotic treatment with strains of 
Lactobacillus, Bifidobacterium and Streptococcus have shown an increase in anti-
inflammatory cytokines in human trials (Tankou et al., 2018). A recent study on a 
Chinese cohort by Zeng et al. showed an increased abundance of Streptococcus and a 
decreased abundance of Prevotella in MS patients. Th17 cell population were 
positively associated with Streptococcus and negatively associated with Prevotella. 
The study also observed a positive association between SCFAs and T-reg cells (Zeng 
et al., 2019). Bang et al. built different models using different taxonomic levels and 
different classification methods for predicting various diseases including MS. The 
group observed that the MS samples consistently had a high false negative rate (32.18-
77.01% depending on classification method) and were misclassified as CRC (Bang et 
al., 2019). The microbiota signature associated with MS may be complex and may 
have shared certain similarity with other disorders. This would be make disentangling 
the role of microbiota in MS more complicated. 
 
4. Sequencing and Bioinformatics - a historical perspective 
Sequencing is the process of determining the order of nucleotide or amino acids from 
a given sample of genetic material or protein. It is a continuous linear representation 
of the sequence, which is also considered as the primary structure and summarises the 
monomeric units present in a sequence. 
The term “bioinformatics” was given by Paulien Hogeweg and Ben Hesper in 
1970 where they defined it as the study of information from a biotic system (Hesper 
and Hogeweg, 1970). The application of computers became essential in Biology when 
sequences of amino acids became available and the manual comparison of mult ip le 
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sequences was found to be impractical. The field of Bioinformatics not only involves 
the analysis of biological data combining concepts from mathematics, statistics, and 
engineering, but also requires computer programming for development of 
tools/methods suitable for biological studies. Bioinformatics expanded rapidly due to 
advances in sequencing technologies, generation of sequence data and the Human 
Genome project in the mid-1990s (Venter et al., 2001). Computers became essential 
for scientific studies as they allowed researchers to compute complex interactions, 
discern patterns and explore large amounts of biological data. 
 
4.1 First-generation sequencing 
As the study of DNA, RNA and proteins continued, methods to sequence these 
biomolecules developed. In the year 1955, Frederick Sanger reported the complete 
amino acid sequence of the insulin protein (Ryle et al., 1955). Nucleic acids are a 
sequence of four nucleotide molecules and also a sugar-phosphate backbone known 
as adenine (A), cytosine (C), guanine (G) and thymine (T). A sequence of these 
molecules forms a linear strand of DNA which results in the double helix structure of 
DNA. In case of RNA, thymine is replaced by uracil (U), which is the demethyla ted 
form of thymine. Together, they are also known as nucleobases or bases. Walter Fiers 
and his colleagues successfully published the earliest form of nucleotide sequencing 
by sequencing RNA to get the first complete gene of the coat protein in 1972 and the 
complete genome of bacteriophage MS2 in 1976 (Min Jou et al., 1972). In sequencing, 
the complex 3-D structure of DNA/RNA is represented by a linear sequence of bases 
like rows of letters on a page, but without any spaces. In the year 1977, Sanger had 
developed the methodology commonly known as Sanger sequencing for DNA by 
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adapting the idea from Ray Wu’s work (Sanger et al., 1977). In parallel to Sanger’s 
work, Allan Maxam and Walter Gilbert also published a sequencing method in 1977 
known as Maxam and Gilbert sequencing (Maxam and Gilbert, 1977). Despite, being 
initially more popular than Sanger’s method, its use declined due to technica l 
difficulties and improvement in other methods. 
 Sanger’s method remained popular for decades. Sanger’s method relies on a 
chain-termination step. This was achieved by adding ddNTPs of A, T, G, C bases into 
the reaction pool containing the DNA molecule to be sequenced that acts as the 
template while bases are added sequentially. Initially the ddNTPs were radioactive ly 
labelled however in later version, fluorescent tags were used. Using this method, 
Sanger and his colleagues successfully sequenced the human mitochondrial DNA of 
length 16,569 base pairs (bp) in 1981 and the genome of bacteriophage λ of length 
48,502 bp in 1982 (Sanger et al., 1982). Subsequently, other groups successfully 
sequenced the complete DNA of various species of bacteria and other organisms, like 
yeast. With increased complexity and size of genomes being sequenced, various 
modifications were implemented into Sanger sequencing to make it more cost 
effective and faster in order to generate larger sequences. This method was used to 
sequence the human genome (Venter et al., 2001). The demand for faster, cost-
effective methods that could sequence large biological data led to the development of 
a new generation of techniques, which came to be known as NGS techniques. 
 
4.2 Second-generation sequencing 
The second generation of techniques that facilitated sequencing of large biologica l 
data on a routine basis was termed as NGS or HTS methods. They had the capability 
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to sequence multiple individual genomes at the same time. There are four main 
methods of NGS, namely 1) pyrosequencing, 2) sequencing by synthesis, 3) 
sequencing by ligation and 4) ion semiconductor sequencing.  
In pyrosequencing, at each nucleotide incorporation, light is emitted from a 
released pyrophosphate (Ronaghi et al., 1996). The type of nucleotide incorporated is 
identified by the emitted intensity of light. The released pyrophosphate binds to 
ammonium persulfate releasing an ATP molecule which in turn binds to luciferin. In 
the presence of the enzyme luciferase, oxyluciferin is produced that generates light of 
different intensities which is read by a detector. Pyrosequencing can sequence long 
strands of DNA by adding one base at a time, detecting the light emission, and 
removing the unincorporated bases, followed by addition of another base and 
repeating the steps. However, it tends to have a high error rate when strings of 
homopolymers (~6-mers) are present (Ivady et al., 2018).  
Illumina, which is one of the most famous NGS platforms, uses sequencing by 
synthesis. It makes use of a fluorescent dye and terminated nucleotides as bases 
(Bentley et al., 2008). All four bases are added at the same time and once a nucleotide 
is incorporated, the remaining bases are washed off. The fluorescence of the 
incorporated base is recorded following which the fluorescent molecule and the 
terminator group are removed. The bases are added again and the whole process is 
repeated. By repeatedly washing away unincorporated bases after each addition of 
nucleotide, it is able to overcome the issue with homopolymers encountered by 
Pyrosequencing. However, it has a high error rate when sequencing long reads because 
the fluorescent molecules are incompletely washed resulting in a noisier background 
signal.  
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The third method is sequencing by ligation, which does not require DNA 
polymerase to be added with the nucleotides. This technique was developed by 
Applied Bioscience. In this method, 16-octamer oligonucleotide probes are used that 
have four different fluorescent dyes at the 5’ end of the probes. The octamers contain 
two probe-specific bases at the 3’ end and six degenerate bases. The sequencing starts 
by hybridisation of the appropriate probe by annealing. The two probe-specific bases 
guide hybridisation. Unbound oligonucleotides are washed away, followed by 
recording of the signal given by the fluorescent dye. The dye and the last three bases 
of the octamer are cleaved, and the next cycle begins. After multiple cycles, the DNA 
strand is denatured. Another primer is then added to the template strand at one 
nucleotide upstream position from the previous primer and the steps are repeated. This 
repetition is done by using five different primers offsetting by 1 each time. This 
method is limited by its generation of short sequencing reads (Metzker, 2010).  
The sequencing process of ion semiconductor sequencing is similar to 
pyrosequencing; however, instead of pyrophosphate, it detects hydrogen ions released 
during sequencing to identify the sequences, which is located above a semiconducto r 
transistor (Rusk, 2011). This transistor detects changes in pH due to release of H+ into 
the solution. This method is much cheaper and faster than pyrosequencing. However, 
it cannot generate high coverage of large genomes compared to sequencing by 
synthesis or ligation but is used in clinical setting as it generates sufficient output in a 
much shorter time period. 
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4.3 Third-generation sequencing 
The third generation of sequencing approaches were first described in 2009 when 
newer sequencing methods different from second-generation technologies were 
developed. These methods are still being developed currently. These methods read 
nucleotide sequences at single molecule level and can generate longer reads compared 
to second-generation methods (Schadt et al., 2010). These methods can not only 
generate reads at a much faster rate but can also be used for epigenetic studies  
(Simpson et al., 2017). They require minimal sample processing and smaller 
equipment making these technologies portable, which was not possible previous ly. 
This allows real time sample collection and data generation, especially in a hospital 
setting which requires results in a very short time or from extreme places where it is 
difficult to travel and bring samples back.  
Among these third-sequencing methodologies, two of the widely used tools 
are SMRT from Pacific Biosciences and Oxford Nanopore technologies (Levene et 
al., 2003;Branton et al., 2008). SMRT utilises ZMW which is a structure that converts 
electromagnetic waves into light spectra. This method requires a polymerase enzyme, 
which is attached to the end of a ZMW object. Nucleotide bases are attached with 
different fluorescent dyes. The ZMW object allows only one nucleotide to be accessed 
by DNA polymerase and once the complementary base is added to this accessible 
nucleotide, the fluorescent dye attached to this base is cleaved off. The detector detects 
the single fluorescence molecule at the time of base incorporation and records it by 
base calling based on the type of dye. 
Alternatively, Oxford nanopore sequencing is dependent on changes in the 
electrical field inside a nanopore structure when a nucleotide molecule passes through 
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it. The system contains an electrolytic solution with a constant electric current. When 
different bases in a sequence pass through the nanopore structure, the magnitude of 
electric current density changes depending on the type of nucleotide, causing a 
characteristic electric current density flux (Branton et al., 2008). 
 
5. Processing and analysis of microbiome data 
The quality of the sequencing data generated is dependent on various factors like 
sample processing, amplification, number of samples processed, sequencing depth, 
base calling and the technology used. Different types of sequencing data are processed 
in different ways; however, the primary principles remain the same. It involves 
removing low quality sequences, denoising (correcting errors), removing 
contamination and identifying taxa and their functional capacity. 
 
5.1 Amplicon sequence data 
Certain regions in the genomes of different microbes (bacteria, archaea, or fungi) have 
been identified to be present across different phyla. These regions are considered as 
conserved sequences and share homology across species. rRNA and tmRNA are 
examples of highly conserved sequences. Based on these conserved sequences, 
microbes can be studied using molecular methods that provides information on the 
phylogenetic relationship between species. Species with highly similar conserved 
sequences are assumed to be closely related while distant species would have less 
homology between them in these sequences. Information on unknown or unannotated 
taxa can be obtained by reconstructing the phylogenetic relationship based on its 
sequence homology to known reference species. 
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In the case of bacteria and archaea, this region is the 16S rRNA gene and the 
ITS region for fungi (Woese et al., 1990;Baldwin et al., 1995). The 16S rRNA gene 
codes for the small subunit of the ribosome and is named for the sedimentat ion 
coefficient of the product in Svedberg units. The 16S rRNA gene is approximate ly 
1500 bases long. It contains nine hypervariable regions namely V1-V9. The secondary 
structure of rRNA is composed of helices and loops resulting in both conserved and 
variable regions (Figure 3A, obtained with permission). The length of the different 
variable and conserved regions and the most commonly used primers and sequencing 
technologies are also highlighted in Figure 3B.  
 









































Figure 3A) shows the secondary structure of the 16S rRNA gene, highlighting the 
hypervariable and conserved regions which form the helices and loops. This figure is 
obtained from Yarza et al. (Yarza et al., 2014) Figure 3B) shows the variation in the 
length of conserved and variable regions along with the most commonly used primers 
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The 16S rRNA gene is used for phylogenetic reconstruction because it has a 
slow rate of evolution and is conserved in all species of bacteria and archaea. The use 
of the 16S rRNA gene for phylogenetic study was pioneered by Carl Woese and 
George E. Fox in 1977 (Woese and Fox, 1977). The 16S rRNA gene can be used to 
classify bacteria based on taxonomic specific signature where the 16S sequence is 
aligned to a reference database. The extent of variability/conservation differs greatly 
in the hypervariable region as it shows higher conservation at lower taxonomic levels 
(genus or species) and greater variations at higher taxonomic levels such as phylum or 
class (Yarza et al., 2014;Yang et al., 2016a). 16S rRNA gene is not only used for 
identification of bacteria, but it has been used to reclassify bacteria from old 
phenotypic-based annotation methods and also to classify uncultured bacteria. 
Although full- length 16S sequences (Sanger sequenced) can be used for greater 
taxonomic resolution i.e. phylum (low resolution) to species level (high resolution) 
from a diverse community, it is often not feasible to use due to high sequencing cost. 
The presence of conserved regions between the hypervariable regions is used to design 
universal primers that can be used to amplify only a portion of the 16S rRNA gene. 
By amplifying certain hypervariable regions, it is possible to attain certain levels of 
taxonomic resolution. Chakravorty et al. in 2007 presented the different levels of 
resolution attainable by the different hypervariable regions and showed that the ability 
to distinguish different genera or species would depend on the taxa under investigat ion 
(Chakravorty et al., 2007).  
In microbiota studies, the amplification and sequencing of 16S rRNA gene 
represents the community-wide population of microbes colonising the sample. As the 
field of microbiota analysis expanded, numerous studies explored the microbio ta 
community structure, its association with health and disease, and its relationship with 
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diet and host-associated factors. Large-scale microbiota consortia such as the HMP 
and the EMP used 16S rRNA gene sequencing and analysis to study microbio ta 
communities (Turnbaugh et al., 2007;Gilbert et al., 2014).  
 
5.1.1 Processing 16S microbiota sequence data 
Analysis of microbiota based on 16S rRNA gene sequencing data has its own 
computational challenges. During the early phases of 16S rRNA-based microbio ta 
studies, Riesenfeld et al. in 2004 reported that Genbank had 21,466 and 54,655 16S 
rRNA gene sequences from cultured and uncultured prokaryotes respective ly 
(Riesenfeld et al., 2004). Based on 16S rRNA analysis only, many candidate phyla 
were proposed; however, many of these phyla had no cultured representatives. Over 
the years, various pipelines have been developed for processing and analysing 16S 
rRNA microbiota data. Some of the most popular and widely used pipelines and tools 
are QIIME1 and QIIME2, mothur and USEARCH suite of tools (Schloss et al., 
2009;Caporaso et al., 2010;Edgar, 2010;Bolyen et al., 2019). These pipelines/too ls 
incorporate various steps required to generate a taxonomic abundance table and 
various diversity measures.  
 Sequence data generated from 16S rRNA genes can be several GB in size. 
Processing the 16S sequencing data to obtain the taxonomic abundance data requires 
multiple steps that involve removal of adapters and primer sequences, quality filter ing 
of the sequence data, merging forward and reverse paired reads to obtain the full length 
of the hypervariable region and generation of a taxonomic abundance table. The 
removal of primers is necessary because primers contain ambiguous characters which 
allow matching to multiple nucleotides in the templates. Primer inclusion can allow 
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mismatches to occur thus introducing artificial variations in the hybridised region. 
Removal of these sequences can be carried out primarily in two ways. Software such 
as cutadapt (Martin, 2011), split_libraries.py (QIIME) or truncate_reverse_primer.py 
(QIIME) can be used to trim the sequences by using adapter/primer sequences as 
references. The software identifies adapter and primer regions allowing a user-defined 
number of expected nucleotide differences. The advantage of this method is that you 
can trim the adapter/primer region of interest accounting for the differences in length 
and nucleotide sequence due to errors. Alternatively, one can also trim by length which 
removes bases of a specified length, ideally the length of adapters/primers from the 
beginning of the sequenced reads. Quality filtering of the reads is done by examining 
the phred scores (a measure that defines the quality and accuracy of bases calling) of 
the reads and removing those that fall below a certain threshold. A sliding window 
approach is often used to calculate the average read quality over a number of bases 
and trimmed if the average quality drops below the threshold. Trimmometric can be 
used for both primer removal and trimming purposes (Bolger et al., 2014). Quality 
filtering ensures that low quality reads are removed, thus retaining a filtered set of 
reads, whose nucleotides can be attributed to high quality base calling.  
In paired-end sequencing, forward and reverse 16S reads must be merged to 
obtain the full- length hypervariable region of interest. Hence, it is recommended that 
the overlap between the paired reads should be large (e.g. over 10 bases for V3/V4 
region) (Schirmer et al., 2015). The length of overlapping regions is dependent on the 
length of amplicon sequenced and the read length obtained from the sequencing 
technology used. Large overlapping regions are also particularly helpful as quality 
filtering normally trims few a bases at the beginning and at the end of reads due to 
poor quality which can reduce the region of overlap between forward and reverse 
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reads. Large overlaps also ensure correct length of the merged sequences. The success 
of overlap is also dependent on the quality of base calling. Merging of paired end-
reads can be done using tools like Flash, PANDAseq and PEAR that effectively merge 
reads over a relatively short period of time (Magoc and Salzberg, 2011;Masella et al., 
2012;Zhang et al., 2014). Flash can calculate the length of overlap based on the input 
reads. The proportion of reads merged can be tuned by adjusting different parameters 
such as the acceptable range of expected nucleotide errors, the length of sequence 
overlap and expected length of the merged sequences (including standard deviation in 
length).  
The quality-filtered, merged reads are processed/clustered to determine OTUs 
i.e. representative sequences which can be assumed to be similar enough to be 
considered as OTUs (Blaxter et al., 2005;Schmidt et al., 2014). A representative 
sequence is chosen from among the reads within each OTU by one of several methods 
(e.g. most common, or centroid). The idea behind clustering is to reduce the effect of 
errors due to incorrect base calling that can result in nucleotide polymorphisms. This 
exaggerates the number of unique sequences, resulting in a greater number of false 
positive and thus a higher measure of community diversity. Two different approaches 
were developed to address this concern. Closed reference clustering and de novo 
clustering. 
In closed reference clustering, the reads obtained from sequence data are 
mapped to a reference prokaryotic database (Greengenes) (DeSantis et al., 
2006;Rideout et al., 2014). Here, each reference sequence in the database takes the 
place of an OTU and all reads mapping on to that sequence above a user-defined 
threshold (i.e. 97% sequence identity) are placed in the same taxon group. This 
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allowed reads to be successfully mapped to a set of known representative taxa and 
provided a curated set of representative bacterial taxa. However, by using this method, 
identification of novel or phylogenetically distant taxa is not possible. This may result 
in discarding a large volume of sequenced reads as “unknown” and is not convenient 
for analysing samples from sites/environments that do not contain well-
studied/representative taxonomic diversity.  
To overcome the limitation of a lack of representative sequences, the de novo 
method was developed (Rideout et al., 2014). In the de novo method, the reads from 
the sequencing run are clustered based on a similarity threshold (e.g.  97%) i.e. all 
sequences, which are similar by at least 97% or more, are clustered together and 
represented by one representative sequence (considered the centroid). As reads are not 
aligned to an external database, potentially all the reads in the samples can be used 
thus ensuring detection of novel or rare taxa. However, given the fact that the reads 
are not mapped to a reference database, it is possible that representative sequences 
which are not biological in nature but are formed as a result of amplification error 
would remain. This may result in generating false OTUs e.g. chimeric sequences or 
chimeras.  
Chimeras are hybrid sequences that arise due to incomplete amplification of 
the template DNA during a PCR cycle (Haas et al., 2011). Such sequences can get 
amplified in the next cycle by merging with another sequence which is not its origina l 
template. These hybrid sequences thus are a result of two different templates that 
proceed with further amplification as the PCR cycles continue. Factors that mainly 
influence generation of chimeric sequences are enzymes used, PCR cycles and level 
of sequence identity between 16S rRNA sequences. It has been estimated that 
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chimeras can represent 15% of the total reads in a study or even higher (Gohl et al., 
2016). Chimeric sequences pose a greater problem during de novo methodology due 
to lack of a reference database which can also be used to distinguish biologica l 
sequences from chimeric ones. To detect and remove chimeras, two different methods 
have been proposed. The first method utilises a curated chimera-free reference 
database to which the representative OTUs are mapped using a tool, ChimeraSlayer 
(Haas et al., 2011). It compares all sequences and searches for potential hybrid 
sequences that may have formed from multiple sequences to the database and removes 
those sequences which are considered chimeras. Alternatively, de novo methods were 
also developed to detect chimeras. UCHIME is an algorithm that implements a de 
novo-based chimera detection method by investigating the representative sequences in 
decreasing order of their abundance (Edgar et al., 2011). The references sequences 
(parent OTU) must be 2 times abundant than the query sequences (sequence 
investigated). The query sequences are fragmented and aligned against the various 
parent OTUs to identify if the query sequences belong to different parent sequences 
or not. Recently Edger showed that UCHIME has a lower error rate than reference-
based methods, which is likely to remove false positive predictions (Edgar et al., 
2011). He also showed that no method in principle can distinguish all chimeras 
accurately from true biological sequences (Edgar, 2016). 
A hybrid method of both closed and de novo OTU generation known as open-
reference OTU clustering can also be implemented (Rideout et al., 2014). In this 
method, the filtered reads are first processed using a reference-based methodology and 
reads excluded from this step are subsequently clustered with de novo method. This 
strategy may be preferred over the previous methods as it not only allows maximum 
utilisation of the reads but also generates a set of reference based OTUs with known 
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taxonomy. Once the representative OTUs are identified then all the reads from the 
sequencing data are mapped to these OTUs. The number of reads mapped to each OTU 
is tabulated which results in an OTU count table.  
One of the key concerns with representative OTU sequences is that they may 
be underrepresenting certain taxa which could be similar by more than 97% percent 
e.g. species from the Enterobacteriaceae family (Jovel et al., 2016). With 
improvements in sequencing methods and generation of high-quality sequencing data, 
alternate methods have been developed that do not rely on clustering. Examples of 
these methods are oligotyping, DADA2 and Deblur (Callahan et al., 2016;Amir et al., 
2017). These methods can identify variants in sequences down to a single nucleotide 
polymorphism. In oligotyping, site-specific nucleotide polymorphisms can be 
detected which can then be referenced and would allow discrimination of closely 
related species and strains (Eren et al., 2013;Eren et al., 2015). DADA2 resolves 
unique sequences, which are also termed as SVs, at high resolution by calculating the 
transition and transversion rates between the nucleotides and also considering the 
observed and expected frequency of nucleotides at each position from the given 
sequence data. This is done in order to distinguish true sequence variants from 
sequencing errors and thereby correct the errors (Callahan et al., 2016). This method 
does not rely on reference databases so reference-based chimera detection is not an 
option, but can be included as a later step in the 16S processing pipeline. 
OTUs and SVs generated through clustering approaches (uclust), DADA2 or 
Deblur lacks taxonomic annotation. Taxonomic annotation would allow classificat ion 
of the OTUs and SVs at phylum, class, order, family, genus and/or species levels. 
Various methodologies have been developed over the years for classification of 
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amplicon sequences. The most popular of these are the Ribosomal Database Project 
(RDP)-classifier, UTAX, SortMeRNA, UCLUST and nucleotide BLAST 
(Edger;Wang et al., 2007;Kopylova et al., 2012). These tools allow reliable 
classification of sequences down to genus level. RDP-classifier, UTAX, and 
SortMeRNA use k-mers to compare query sequences to a reference database. K-mers 
are substrings of length k obtained from a representative OTU sequence or SV that are 
then compared with k-mers from a reference sequence – the more k-mers two 
sequences share, the higher the confidence/similarity score. BLAST locates exact 
matches of length k (8 by default) and extends these in both directions (5’ and 3’) 
based on a substitution matrix until the score drops below a user-defined (or default) 
threshold. This heuristic approach is similar to the Smith-Waterman algorithm but is 
magnitude faster at the expense of accuracy. However, species-level classification of 
16S data is difficult due to the very high levels of similarity between species of the 
same genus. New tools have been developed in recent years that allow classificat ion 
at species level: SPINGO, BLCA and IDTAXA (Allard et al., 2015;Gao et al., 
2017;Murali et al., 2018). SPINGO also utilises a k-mer approach and a curated RDP 
reference database annotated to species level. IDTAXA also uses a k-mer approach 
but provides multiple databases from which to choose. BLCA assigns taxonomy based 
on Bayesian posterior probability and calculates the likelihood of taxonomic 
assignment. This likelihood is defined first by BLAST alignment of query sequences 
to reference databases, followed by multiple alignment using muscle. Bootstrapping 
of the alignment is then performed 100 times to calculate the posterior probability of 
each hit and to obtain a confidence score for each best hit. 
All these taxonomic assignment methods are dependent on various databases. 
The databases commonly used are RDP database, GreenGenes and SILVA (DeSantis 
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et al., 2006;Quast et al., 2013;Cole et al., 2014). The RDP database consists of 16S 
rRNA gene sequences obtained from INSDC and the current version (11.5) has 
3,356,809 16S rRNA gene sequences. The GreenGenes database is smaller than the 
RDP database; however, sequences present in this database are filtered to remove 
chimeras. It provides representative sequences of clusters of 16S rRNA genes at a 
different identity threshold - the latest version, 13_5, contains 203,452 representative 
sequences at 99% identity. The taxonomic annotations of the 16S rRNA gene 
sequences in the SILVA database are obtained from Bergey’s Taxonomic Outlines  
and the List of Prokaryotic Names with Standing in Nomenclature (Parte, 2018). All 
assignments are manually curated. The latest update version, 132, contains 617,630 
non-redundant 16S rRNA gene representative sequences (also taken from 16S gene 
clusters at 99% identity). 
 
5.1.2 Downstream data analysis 
The OTU/taxonomic data generated are analysed using various techniques some of 
which are adopted from macro-ecological or RNA-Seq studies. However, prior to 
applying any methodology, it is important to ensure that the data from all the samples 
are scaled/normalised to an even level to make them comparable. This is necessary as 
a sequencing run usually results in an uneven distribution of read depth across samples 
due to the stochastic nature of the sequencing process. Rarefaction is a commonly used 
normalisation technique in which the reads from each sample are randomly 
subsampled (without replacement) to a uniform sequencing depth (Hughes and 
Hellmann, 2005). However, this results in discarding valid data from samples with 
greater sequencing depth which has led to criticism about rarefaction being 
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statistically unacceptable (McMurdie and Holmes, 2014). Aside from rarefaction, 
other approaches have also been found to be applicable for microbiota data. These 
methods are CSS, proportional normalisation, UQ scaling, DESeq-VS, regularised log 
and log transformation on proportional or rarefied data (Bullard et al., 2010;Robinson 
et al., 2010;Paulson et al., 2013;Love et al., 2014;Weiss et al., 2017;McKnight et al., 
2019).  
One of the primary and key types of analysis of microbiota data is investigat ion 
of diversity. Diversity analysis involves within-sample diversity or α-diversity and 
between-sample diversity or β-diversity. The α-diversity of a microbial community is 
a measure of taxonomic diversity and is determined using various indices includ ing 
species richness, Chao1, Shannon index, Simpson index and phylogenetic diversity 
(Simpson, 1949;Whittaker, 1972;Faith, 1992;Spellerberg and Fedor, 2003;Chao et al., 
2006). Species richness is a measure of the number of unique species-level taxa (often 
the OTU count) detected. Chao1 is an extrapolation of detected species to estimated 
total species giving more importance to low-abundant OTUs such as singletons and 
doubletons in each sample. Shannon and Simpson indices calculate diversity by 
accounting for the richness and taxon abundance in each sample (species evenness). 
Shannon gives more weight to richness whereas Simpson gives more importance to 
species evenness. Phylogenetic diversity calculates the total branch length for all 
OTUs in each sample from a pre-generated tree built from all representative OTU 
sequences.  
The β-diversity of a microbial community is a measure of 
dissimilarity/distance between samples calculated from the taxonomic abundances of 
samples (Whittaker, 1960). Dissimilarity measures range from 0 to 1. A value of zero 
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denotes identical representation of taxa between two samples and a value of 1 denotes 
complete dissimilarity of taxonomic profiles between two samples. This can be used 
to define the microbiota community structure of the samples in a dataset. BC, Jaccard, 
Weighted and Unweighted UniFrac distance are some of the metrics used to calculate 
the β-diversity between samples in microbiota studies (Jaccard, 1901;Bray and Curtis, 
1957;Lozupone and Knight, 2005). BC distance is measured by 1 – BC similarity. BC 
similarity is defined as the sum of the abundance of taxa/OTUs shared by two samples 
divided by the number of taxa/OTUs detected in both samples. Bray-Curtis considers 
both richness and evenness in its calculations. Similarly, Jaccard distance is calculated 
by 1 – Jaccard similarity. Jaccard similarity is defined as the number of common 
taxa/OTUs detected between two samples divided by the total number of taxa/OTUs 
detected. Jaccard does not consider the abundance of taxa/OTUs in its calculat ion. 
UniFrac distance is a more modern metric and was developed for microbiota analys is 
- it is one of the most commonly used β-diversity metrics. UniFrac distance calculates 
the shared branch lengths between two samples and expresses this as a fraction of total 
branch length. Two variations of this method are Weighted UniFrac in which 
taxonomic abundance is considered and Unweighted UniFrac which only accounts for 
the presence or absence of taxa. The β-diversity measures are commonly visualised 
using dimension reduction methods such as PCoA or dbRDA. The effect size of 
metadata groups (e.g. healthy vs diseased) and other factors and their significance at 
explaining the variation in the global community profiles can be calculated using 
permutational-based approaches such as PERMANOVA or randomisation using 
Monte-Carlo permutation. 
Another key analysis of microbiota data is identifying differences in taxonomic 
composition that are associated with changes in diversity and groups. These 
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differentially abundant taxa serve as key markers that are associated with different 
groups/conditions. Identification of the differentially abundant taxa is done using 
various statistical methods. Due to the non-normal distribution of the microbiota data, 
non-parametric methods are commonly used to identify significant taxa where raw 
values are converted into relative ranks. Some of the simplest approaches include 
Wilcoxon Signed-Rank test, Mann–Whitney U test, Kruskal-Wallis test, and Dunn’s 
test. Given that the detection of differential taxonomic abundance can be inaccurate 
due to the influence of uneven sequencing depth across samples, it is necessary to 
normalise the data as discussed before. The datasets are also zero-inflated due to a 
spare distribution of most taxa; hence filtering of the dataset to remove very low-
abundant taxa with a majority of zeros is also carried out before identifying the 
differentially abundant taxa. Presences of zero can represent the absence of a taxon in 
a sample or its presence below the limits of detection. They are removed because they 
break all the assumptions of statistical tests, although this depends on the test. 
Identification of significant taxa is dependent on the sensitivity of the method 
implemented. Non-parametric statistics are usually less sensitive than their parametric 
counterparts. To capture the biological signal accurately, various methods have been 
designed or adapted from RNA-Seq studies. These methods rely on various 
normalisation procedures. DESeq2 uses Wald’s test and uses a negative binomia l 
distribution for the data, modelling taxa count with fitted mean and feature-specific 
dispersion parameter (Love et al., 2014). DESeq2 also handles outliers using Cook’s 
diagnostic test and replaces them with the trimmed mean over all groups if at least 
seven samples are present in a group. MetagenomeSeq is another methodology 
designed specifically to deal with sparseness in microbiota datasets (Paulson et al., 
2013). This methodology uses CSS normalisation, which calculates a scaling factor 
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by dividing the sum of the read counts up to a particular quartile for a sample and 
applies a mixed model with zero-inflated Gaussian distribution that can account for 
varying sequencing depth and under sampling. It also applies Fisher’s exact test to 
presence-absence data and odd’s ratios. ALDEx2 is another recently published robust 
methodology for analysing high throughput sequencing data (Fernandes et al., 2013). 
It uses Bayesian approaches to account for technical variations and implements a clr 
transformation. 
Due to the compositional nature of microbiota data, the use of different 
normalisation and abundance testing strategies have been debated. McKnight et al. 
have shown that proportional transformation can be utilised for investigat ing 
community structures and agrees better with actual data compared to other 
transformations (McKnight et al., 2019). Weiss et al. have compared different 
normalisation techniques highlighting the different levels of sensitivity for various 
methods when analysing differential abundance (Weiss et al., 2017). The group 
reported that rarefaction showed better segregation of the samples based on microbia l 
community structure. DESeq2 showed high sensitivity with smaller datasets however 
was affected by large difference in library size.  
Amplicon sequencing is extensively used for microbiota studies due to cheaper 
cost, smaller data size and less computation time. It is also very informative when 
analysed properly. Despite these advantages, it has certain limitations. Currently, 
sequencing of the full-length 16S rRNA gene with sufficient coverage to capture all 
microbial species from a large number of samples is usually not possible from 16S 
based microbiota data. In terms of amplification and sequencing, most commonly used 
primers cannot effectively target archaea (Acinas et al., 2005). Presence of mult ip le 
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copy number of 16S rRNA gene in a genome, low amplification from microbes from 
low biomass samples and sequencing bias can affect can affect the accurate estimation 
of the microbial population (Kembel et al., 2012;Karstens et al., 2019). Variation in 
genomic copy number of 16S gene will affect the estimation of relative abundance of 
species. Contamination during sample collection and processing are amplified during 
PCR and gets sequenced to a greater sequencing depth dominating low microbia l 
biomass. This results in false inflation of diversity and abundances. To control for 
contamination, negative controls are processed alongside, and any microbial load 
observed in the negative controls are removed from all other samples from the same 
run. Multiple sequencing runs can also result in run-to-run cross-contamination, thus 
effecting accurate estimation of the microbiota population. The taxonomic resolution 
of the representative sequences is down to genus level only with high confidence in 
many cases. Hypervariable regions vary in their ability to detect taxa at different 
taxonomic levels. This resulted in different recommendations (Chakravorty et al., 
2007;Mizrahi-Man et al., 2013). These differences are due to various factors includ ing 
use of different primers, sampling environment and classification approaches. It is also 
not possible to determine directly the functional potential of the microbial community 
from 16S data only (Langille et al., 2013). 
Methods for indirect functional prediction from 16S rRNA data have been 
developed in which representative sequences/taxa are mapped to the closest 
functionally annotated genome and the functional abundance is determined based on 
the taxonomic abundances. PICRUSt is the earliest method to attempt this (Langille 
et al., 2013). PICRUSt generates a phylogenetic tree of the reference sequences 
obtained from Greengenes. From the functionally annotated references in the tree, 
ancestral gene content is inferred from the ancestral branches. This inferred gene 
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content is then added to the reference sequences with unknown functions. This step 
ensures that all reference sequences represented by tips on the phylogenetic tree have 
either known or predicted gene content. This information is precalculated and is not 
required to be computed every time. To infer functional potential of the queried data, 
representative OTU sequences are aligned against the Greengenes database, and the 
OTU identifiers are matched to the reference tree. Functional abundance is calculated 
by multiplying the gene content of the matched reference sequences with the OTU 
abundance from the table. One of the limitations of this approach is that 
phylogenetically distant sequences may have very distinct functionality from their 
most closely matched reference genomes, thereby making functional predictions for 
these sequences inaccurate. To overcome this issue, Tax4Fun and Piphillin are two 
other tools that were developed (Asshauer et al., 2015;Iwai et al., 2016). Tax4Fun 
utilises the SILVA database as a reference and sequences are processed into KEGG 
annotated taxonomic profiles using BLAST against KEGG prokaryotic genomes. It 
uses Taxy-Pro to obtain reference organism-specific profiles (Klingenberg et al., 
2013). Using UProC and PAUDA, it computes functional KOs for the annotated OTU 
table (Huson and Xie, 2014;Meinicke, 2015). Piphillin is a web-based functiona l 
prediction (KOs) tool from the start-up company SecondGenome. Unlike PICRUSt, 
which requires OTUs to be mapped to Greengenes, or Tax4Fun that requires mapping 
to SILVA, Piphillin does not require any such processing. The representative 
sequences and OTU table are uploaded to the webserver. The representative sequences 
are aligned using global alignment against 16S rRNA gene sequences of known 
genomes. The OTU table is adjusted to the mapped genomes and subsequently 
normalised for copy numbers variation, followed by functional profiling using the 
gene content of the reference genomes. While all these tools boast high predictability, 
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they are still limited to calculating the functional potential for only those 
OTUs/representative sequences which can be successfully mapped to the functiona lly 
annotated reference genomes. 
 
5.2 Shotgun sequence data 
Metagenomic whole genome shotgun (mWGS) sequencing is a method of sequencing 
the total genetic material of a sample. It is a massively high-throughput sequencing 
process, where the DNA obtained from the samples is sheared into random fragments 
of smaller read lengths and sequenced (Claesson et al., 2017). It is designed to capture 
the fragmented whole genomes of the microbial communities. There is no 
amplification of a specific marker gene; only sequencing adapters and indexing 
primers are added. It is an expensive method but can generate hundreds of GB to TB 
of sequencing data, which is magnitudes larger than 16S data depending on the 
sequencing technology. Hillmann et al. showed that sequencing depth of as low as 0.5 
million reads can provide similar information as ultra-deep shotgun sequencing 
(Hillmann et al., 2018). This allows consideration for reduced cost and generation of 
lower volumes of sequencing data while still capturing the dominant taxa. With a 
reduction in cost and advancing computational capacity, mWGS is becoming a 
preferred method for current and upcoming projects. Using shotgun metagenomics, a 
community-wide functional profile can also be determined, although this is not 
necessarily indicative of the full functional capacity of the microbiota as it only 
identifies genes/pathways present in the metagenomic data and not their expression 
levels (Franzosa et al., 2014;Schirmer et al., 2018). 
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5.2.1 Processing mWGS sequence data 
Due to the large volume of data generated, processing mWGS sequence data is 
computationally intensive and takes longer than 16S data. Quality trimming of 
sequence data can be processed in a similar manner as discussed earlier for 16S data. 
In mWGS sequence data, host genome contamination is a major concern. As mWGS 
data are processed from the total DNA extracted, and the protocol uses no 
amplification steps, all DNA fragments including host genomic content are indexed 
and sequenced. To remove host contamination, reads from the samples are mapped to 
the host reference genome and all the mapped reads are considered as contamination 
and removed. This is particularly important when processing samples with low 
biomass, which includes samples obtained from the host like biopsy samples or skin 
samples (Eisenhofer et al., 2019). These samples must be processed carefully to avoid 
contaminated reads during downstream processing which could result in presence of 
host genes and pathways. 
Primarily there are two approaches to analyse mWGS data, assembly-based 
and reference-based. In assembly-based methods, the whole genomes of the organisms 
in a community are potentially reconstructed by assembling the sequenced reads into 
longer continuous sequences known as contigs which are further assembled into 
scaffolds. The subsequent joining of the reads into continuous longer reads is done 
using the de Bruijn graph algorithm. This approach is also considered to be a de-novo 
assembly method as no reference genomes are involved. Tools like IDBA (Peng et al., 
2010) and Velvet (Zerbino and Birney, 2008) were initially developed to assemble 
single genomes; however, different variations of these tools (Meta-IDBA, IDBA-UD, 
MetaVelvet-SL) were developed for metagenomic sequence data which contains 
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many genomes from a diverse array of microorganisms (Peng et al., 
2011;2012;Afiahayati et al., 2015). Other commonly used tools are SOAPdenovo2 
and SPAdes (Bankevich et al., 2012;Luo et al., 2012). IDBA-UD applies a depth 
threshold to eliminate contigs with low depth. MetaVelvet-SL implements a Support 
Vector machine learning algorithm to identify chimeric nodes (k-mer sequences 
shared between genomes of similar species). Once contigs and scaffolds have been 
built, these sequences can be annotated taxonomically and functionally. Binning is a 
strategy that categorises sequences into groups that are likely to belong to the same 
genome and is carried out based on nucleotide compositions or coverage. Binning 
accuracy is partly affected by the length of sequences and reads. CONCOCT, 
MetaBAT, Maxbin and Maxbin2.0 are amongst the commonly used binning 
approaches and these tools utilise nucleotide frequency and coverage to obtain 
different bins where each bin contains sequences from potentially similar genomes 
(Alneberg et al., 2014;Wu et al., 2014;Kang et al., 2015;Wu et al., 2016). Given that 
scaffolds and contigs are representative of a full length or partial genome, the 
functional potential of these sequences can be determined by predicting the genes. 
Genes can be predicted by a variety of tools like MetaGeneMark, PRODIGAL and 
GLIMMER (Salzberg et al., 1998;Zhu et al., 2010;Hyatt et al., 2012). The reliability 
of predicted genes is dependent on the quality of the assembled sequences. Low 
coverage or a large number of smaller contigs results in incomplete genes that are 
truncated at either their 5’ or 3’ ends (or both) by contig boundaries. Predicted genes 
can be annotated using methods like BLAST against functional databases such as 
KEGG, UniRef, COG, TIGRFAMs or InterPro (Kanehisa and Goto, 2000;Tatusov et 
al., 2000;Haft et al., 2001;Suzek et al., 2015;Mitchell et al., 2019). Using assembly-
based methods, it is possible to assemble genomes of unknown or novel taxa. 
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However, as mWGS sequencing data is represented by various taxa and can have 
various closely related strains, building contigs and scaffolds may collapse such strains 
into a single representative genome thus preventing strain-level resolution 
(Breitwieser et al., 2017).  
To overcome the limitations of an assembly-based approach, reference-based 
methods were developed. The reads are mapped to a database directly which would 
contain taxonomic marker sequences or functionally annotated genes. Various tools 
have been developed using different approaches for fast and accurate classificat ion 
using composition-based or alignment-based approaches. Amongst composition-
based tools, Kraken and K-SLAM compare the k-mers of queried reads against a 
reference database (Wood and Salzberg, 2014;Ainsworth et al., 2017). The reference 
database consists of prokaryotic genomes from the NCBI RefReq database from which 
the LCA taxa is determined for the k-mers of reads mapped. K-SLAM validates the 
alignment using local alignment and pseudo assemblies of genomes from simila r 
species. K-SLAM reports both taxonomic and gene information. Kaiju implements the 
BWT algorithm on 6-frame translated sequences against the NCBI RefSeq database 
of microbial and viral protein sequences (Li and Durbin, 2009;Menzel et al., 2016). 
Amongst the alignment-based tools, MetaPhlAn and MetaPhlAn2 map the reads 
against a clade-specific marker database to obtain bacterial and archaeal taxonomic 
information (Segata et al., 2012;Truong et al., 2015). MetaPhlAn initia lly 
implemented BLASTn as a default but it can also use other tools like MBLASTX 
(Davis et al., 2015). MetaPhlAn2 is the enhanced version consisting of a larger 
reference database expanding into viral and eukaryotic markers and also allows strain-
level analysis also using StrainPhlAn (Truong et al., 2017). MetaPhlAn2 uses Bowtie2 
to reduce its computation time (Langmead and Salzberg, 2012). As reads are mapped 
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only to known clade specific genes, MetaPhlAn2 can introduce false negatives when 
generating taxonomic profiles as only known annotated reference taxa are identified. 
To obtain functional information from reads, tools like DIAMOND can be 
implemented which aligns short reads to protein databases (Buchfink et al., 2015). The 
sensitivity of DIAMOND is similar to BLASTX (up to 94%) and it is a magnitude 
faster than BLASTX. 
Due to the availability of a variety of tools and databases, various pipelines 
have been developed to automate the process of obtaining taxonomic and functiona l 
profiles. For assembly-based approaches, MOCAT2 and MG-RAST pipelines have 
been developed (Meyer et al., 2008;Kultima et al., 2016). These pipelines implement 
a variety of tools, some of which were discussed earlier, in an automated manner to 
generate taxonomic and functional profiles. In summary, MOCAT2 uses FastX, 
SolexaQA and an internal script for quality filtering and trimming (Hannon, 2010). 
Assembly of quality- filtered reads is carried out using SOAPdenovo. Prediction of 
genes is carried out by MetaGeneMark and Prodigal. Taxonomic and functiona l 
annotation is carried out using SOAPaligner and DIAMOND, respectively (Gu et al., 
2013).  Amongst reference-based pipelines, HUMAnN and its next-generat ion 
HUMAnN2 pipeline has been developed (Abubucker et al., 2012;Franzosa et al., 
2018). In HUMAnN2, a taxonomic profile is obtained using MetaPhlAn2. 
Subsequently a functional profile is obtained using a nucleotide and a 6-frame 
translated search. It initially maps the reads to a pangenome database of functiona lly 
annotated species using Bowtie2. Unmapped reads are processed using DIAMOND 
as default against the UniRef database to obtain protein profiles from unknown taxa. 
MetaCyc Pathway profiles are then generated from protein profiles using Minpath (Ye 
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and Doak, 2009). KEGG orthologs, modules and pathways can also be obtained from 
the UniRef profiles by using the legacy database of HUMAnN1. 
Downstream analysis of the taxonomic and functional profiles can be carried 
out in the similar manner as discussed earlier, including calculation of α- and β-
diversity, and the use of statistical tests/methodology to detect significantly different 
compositions of taxa and functions.  
 




In summary, there is an increasing number of studies on both animals and humans that 
highlights the relationship between the microbiota and its host. Limitations in culture -
based methods underlines the importance of culture-independent and HTS approaches 
using computational tools. Secretion of antibodies (IgA) and AMPs by immune cells 
into the mucosa of the gut, SCFA-associated regulation of T-reg cells, production of 
bacterial polysaccharides which triggers T-helper cells, availability of nutrients and 
the integrity of the mucosal layer can influence the microbiota and vice-versa. These 
prominent phenomena suggest a role for the gut microbiota in immune homeostasis 
and inflammation as highlighted by various germ-free animal models. It is promising 
to explore these relationships in different immune-mediated disorders. It is also 
necessary to identify the effect on the microbiota population and their functiona lity 
associated with changes in host metabolism, medication, diet, and other factors. 
However, as various covariates are associated with microbiota, it is necessary to 
account for these confounders and adjust for their influences. This can be achieved by 
carrying out both observational and longitudinal studies. Studying immune-media ted 
disorders will uncover shared and unique microbiota signatures associated with these 
disorders. Uncovering host-microbe/microbe-microbe interactions and their effects in 
disease and health will also facilitate development of effective in-vitro and in-vivo 
experiments for validation. This is essential for generating a knowledge base necessary 
for potential personalised diagnostic and therapeutic implementation.  
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7. Aims and objectives 
This chapter summaries the evidences highlighting the impact of the gut microbio ta 
on human physiology. It establishes the gut microbiota as a modifiable component 
with major implications on the health of human. Despite the progress in microbio ta 
research associated with immune homeostasis, there a tremendous knowledge gap 
regarding exploiting the malleable nature of microbiota for potential 
diagnostic/therapeutic purposes in various immune-mediated diseases. For this, it is 
necessary to understand and establish the microbiota- immune interaction in the 
aetiology of various immune disorders. The research carried out in this thesis is 
focused on exploring and establishing the microbiota profiles associated with the 
disease activity (onset, progression, and remission) in immune-associated conditions 
which could potentially lead to development of live biotherapeutics. 
Hence, the objectives of this research thesis are: 
1) Characterisation of the gut microbiota dynamics in various disorders and their 
subtypes (arthritis, osteoporosis, and multiple sclerosis) 
2) To investigate the changes in the microbiota associated with the progression of 
various arthritic diseases and biologics treatment 
3) Development of a novel approach for improved functional inference from 16S 
microbiota profiles to reflect the bacterial metabolic potential better  
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Chapter 2 Gut Microbiota Alterations associated with reduced Bone Mineral 
Density in Older Adults 
2.1 Abstract 
Objective To investigate compositional differences in the gut microbiota associated 
with bone homeostasis and fractures in a cohort of older adults.  
Methods Faecal microbiota profiles were determined from 181 individuals with 
osteopenia (n=61), osteoporosis (n=60) and an age- and gender-matched group with 
normal bone mineral density (n=60). Analysis of the 16S (V3-V4 region) amplicon 
dataset classified to the Genus level was used to identify significantly differentia lly 
abundant taxa. Adjustments were made for potential confounding variables identified 
from the literature using several statistical models. 
Results We identified six genera that were significantly altered in abundance in 
osteoporosis or osteopenic goups compared to age- and gender-matched controls. A 
detailed study of microbiota associations with meta-data variables which included 
BMI, health status, diet and medication, revealed that these meta-data explained 15-
19% of the variance within the microbiota dataset. Bone mineral density 
measurements were significantly associated with alterations in the microbiota. After 
controlling for known biological confounders, five of the six taxa remained 
significant. Overall microbiota alpha diversity did not correlate to bone minera l 
density in this study. 
Conclusion Reduced bone mineral density in osteopenia and osteoporosis is 
associated with an altered microbiota. These alterations may be useful as biomarkers 
or therapeutic targets in individuals at high risk of reductions in bone mineral density. 
These observations will lead to a better understanding of the relationship between the 
microbiota and bone homeostasis. 
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Keywords  
Osteoporosis, Gut microbiota, Bone mineral density, Elderly, Osteopenia 
Key messages  
Reduced bone mineral density is associated with taxon-specific signatures in the gut 
microbiota. 
Medication, anthropometric measures, nutrition, and gender are associated with gut 
microbiota composition. 
Confounders do not explain the microbiota-bone density interactions observed here.  
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2.2 Introduction 
Osteoporosis, characterized by reduced bone mineral density and degradation of the 
micro-architectural structure of bone, affects over 27.5 million people in Europe  
(Hernlund et al., 2013). Over the age of 50, 1 in 3 women and 1 in 5 men, worldwide, 
will experience an osteoporotic fracture in their lifetime, representing a significant 
burden for patients and health care providers (Sozen et al., 2017). The aetiology of 
osteoporosis and its precursor, osteopenia, is multi- factorial. Contributing factors 
include oestrogen and vitamin D deficiency, and genetic modification in regulatory 
genes such as vitamin D receptors and transforming growth factor-β (Eastell et al., 
2016). Osteoporosis occurrence is accelerated in patients with immune-media ted 
inflammatory conditions where excessive production of pro-inflammatory cytokines 
leads to increased osteoclastic bone resorption (e.g. inflammatory bowel disease, 
rheumatoid arthritis, and ankylosing spondylitis) (Donnelly et al., 1994;Sambrook et 
al., 1995;Ali et al., 2009). The gut microbiome is known to modulate immune cell 
activities and alterations in the microbiome have previously been associated with these 
inflammatory conditions (Clemente et al., 2018).  
The gut microbiome shares a complex relationship with the host. Development 
and maturation of the innate and adaptive immunity in the host is dependent on 
appropriate exposure to the gut microbiota (Peterson et al., 2015). Alterations in the 
microbiota may result in immune system modulation or activation. Circulat ing 
osteoclastogenic cytokines may be increased in a T cell-dependent mechanism by the 
microbiota which can drive bone resorption in inflammatory conditions (Hsu and 
Pacifici, 2018). Several investigations have identified microbes that regulate the 
production of hormones or improve uptake of vitamins that are integral to bone health 
(Jones et al., 2013;Baker et al., 2017).  
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Studies with germ-free and antibiotic-treated animals have indicated the 
possibility of gut microbial influence on both bone mass accumulation and turnover. 
These animals have shown a reduction in osteoclastic precursor cell number (Sjogren 
et al., 2012), an increase in bone mass (Nobel et al., 2015) and improvement in bone 
strength and material properties (Pytlik et al., 2004). 
We have previously identified significant microbiota alterations associated 
with inflamm-aging and frailty in an elderly cohort (Claesson et al., 2012). Other 
studies have demonstrated that the absence of gut microbiota leads to a reduction in 
bone mechanical strength (Guss et al., 2017) and inversely, long term colonisation of 
pathogen-free gut microbiota increases bone formation (Yan et al., 2016). In contrast 
another recent study suggested that microbiota restoration in germ-free mice does not 
affect bone loss (Quach et al., 2018). These conflicting findings may, in part, be due 
to different animal genotypes, the anti-microbials administered and the absence or 
presence of particular taxa in their baseline microbiota. 
Our aim in the present study was to determine whether gut microbiota features 
are associated with bone mineral density in a cohort of individuals at high risk of 
reduced bone mineral density and fractures. In addition to this, any genus-level taxa 
associated with altered bone mineral density would be identified by comparing the gut 
microbiota composition of osteopenic and osteoporotic patients with those of age- and 
gender-matched controls with normal bone mineral density. Our hypothesis was that 
intestinal microbiota composition was different in the osteoporotic subjects. 
Furthermore, we developed and applied a rigorous statistical regime to remove the 
effect of potentially confounding variables.  
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2.3 Methods 
2.3.1 Subject recruitments and clinical information 
Ethical approval was granted by the Clinical Research Ethics Committee of the Cork 
Teaching Hospitals (CREC) before recruitment. Adult female and male subjects, aged 
55 to 75 years, were recruited from the bone densitometry unit at Cork Univers ity 
Hospital, Cork City, Ireland. The indications for referral for bone mineral density 
(BMD) assessment by Dual-energy X-ray absorptiometry (DEXA) were varied with 
referrals from primary, secondary and tertiary care. No single specific referral criterion 
was used, and request for assessment was at the discretion of the attending clinic ian 
and not the study investigators. Written informed consent was obtained from the 
participants. Individuals with a known history of alcohol abuse, participation in an 
investigational drug trial in the 30 days before enrolment, use of antibiotics in the 3 
months prior to bone density measurement, and previous partial or total colectomy 
were excluded. No measure was taken to exclude participants with co-existing 
osteoarthritis, aortic calcification or fractures. Altogether from 193 participants, stool 
samples were collected. Due to lack of vitamin D information from 12 samples, they 
were excluded from the analysis, resulting in the final dataset comprising of 181 
participants. 
Patients underwent DEXA assessment of Bone mineral density (BMD) (g/cm2) 
at the femoral neck, and antero-posterior lumbar spine (L1-L4) with a GE Healthcare 
Lunar iDXA machine (GE Healthcare, Madison, WI) and enCORE software (V.13.4, 
2010) using standardized methodology (Hind et al., 2010). T-score threshold was used 
to define 3 groups based on their BMD. These were normal BMD (n = 60) with a T-
score of  -1, patients with osteopenia (n = 61) with a T-score between -1 and -2.5, 
and patients with osteoporosis (n = 60) were defined as having a T-score of  -2.5 
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(Kanis et al., 1994;Kanis et al., 2013). The detailed procedure of recording 
anthropometric, clinical, dietary and medications information is recorded in the 
supplementary text. 
 
2.3.2 Molecular methods and bioinformatics 
Genomic DNA was extracted from 0.25g of each of the faecal samples based on a 
modified Yu and Morrison protocol (Yu and Morrison, 2004). The V3-V4 region of 
the 16S rRNA gene was amplified and sequenced (Klindworth et al., 2013) on the 
Illumina MiSeq platform at Moorepark Teagasc Food Research Centre, Fermoy, 
Ireland. The reads were merged using flash (v1.2.8) (Magoc and Salzberg, 2011). The 
forward adapters were removed using cutadapt (v1.8.3). The quality filtering of reads 
and removal of reverse primers were carried out using the QIIME (v1.9.1) (Caporaso 
et al., 2010) pipeline with default settings. The removal of chimeric sequences and 
generation of operational taxonomic units (OTUs) at 97% identity threshold was done 
using USEARCH (v8.1) (Edgar, 2010). Representative OTUs were classified using 
the Ribosomal Database Project (RDP) database (v11.4) (Cole et al., 2014) 
implemented in mothur (v1.34.4) (Schloss et al., 2009). α- and β-diversity measures 
were produced from a rarefied dataset (10,613 reads per sample). 
 
2.3.3 Statistical analysis 
All statistical analyses were carried out in the R statistical software (v3.4.0) (Team, 
2017). Significance was determined by a cut-off p-value  0.05 and p-adjusted  0.05 
(Benjamini-Hochberg procedure) unless stated otherwise. P-adjusted for pairwise 
comparison is based on the p-values obtained from all the pairwise comparisons for 
each variable.  
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2.3.4 Analysis of meta-data 
Kruskal-Wallis, Dunn’s test (v1.3.4) (Dinno, 2017) and/or chi-square tests were 
carried out to identify anthropometric, clinical, dietary and medications significantly 
different between the groups. For chi-square testing, at least 7 participants were 
present across the whole dataset for that factor. 
 
2.3.5 Analysis of microbiota data 
Kruskal-Wallis test was used to determine significant difference in α-diversity 
measures between the groups. Co-inertia analysis was used to explore the covariance 
between the dietary dataset and microbiota dataset. DESeq2 (v1.16.1) (Love et al., 
2014) was used to identify differentially abundant taxa from the microbiota dataset. 
The dataset was filtered to retain only those taxa which were present in at least 20% 
of the samples across the whole dataset. A DESeq2 model adjusted for Body Mass 
Index (BMI) and gender was used to identify genera that were significantly 
differentially abundant. 
 
2.3.6 Identification of meta-data variables associated with beta-diversity 
Meta-data variables significantly associated with variations in global microbio ta 
profiles were identified using permutational multivariate analysis of variance 
(PERMANOVA). A nominal p-value of ≤ 0.05 was used as the analysis was a 
confirmation of previously established associations. Subjects with diseases such as 
coeliac disease, diverticulitis and inflammatory arthritis conditions were present 
within the dataset and tested separately. Inflammatory and non-inflammatory diseases 
can alter the microbiota with a common dysbiosis signature (Duvallet et al., 2017). To 
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investigate the common signature of microbiota-associated inflammatory diseases, we 
created an inflammatory disease index, where the presence of any one of the 
microbiota-associated conditions (Coeliac, Diverticulitis, Arthritis, IBD and Multip le 
Sclerosis) was considered. Nominally significant meta-data variables were added to a 
single PERMANOVA model to identify overall effect sizes. The cumulative effect 
was calculated based on these pre-defined groups of variables. 
 
2.3.7 Analysis of confounding variables 
Clinical variables which have been reported to interact with the microbiota were 
identified from the literature (Supplementary table 1). These included diet (Healthy 
food diversity (HFD) index) (Drescher et al., 2007), Barthel score (Mahoney and 
Barthel, 1965), Godin leisure time activity score (Godin and Shephard, 1985), Mini-
Mental State Examination (MMSE) scores (Molloy et al., 1991), Mini Nutritiona l 
Assessment (MNA) (Guigoz and Vellas, 1999) and Carlson co-morbidity index 
(Charlson et al., 1987). Secondly, the meta-data identified as significantly different 
between the subject groups were confirmed by a literature search (Table 1, 
Supplementary table 2, p-adjusted ≤ 0.05) and were added to the analysis as potential 
confounders.  
Confounding factors were modelled using a general linear mixed-effect 
model (GLMM) using the negative binomial distribution and the sequencing depth 
was controlled for by categorising the number of reads into four quartiles and adding 
this information as a random effect to the model. Firstly, univariate GLMMs were 
generated with individual confounding factors as the predictor and the significant taxa 
as the response. The confounders identified as significant for individual taxa were 
controlled for in a bivariate model. To maximise the number of known confounders 
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identified, a nominal p-value was regarded as significant. In this model, the effect of 
group category was evaluated after adjusted for the individual significant confounders. 
Summary reports were generated for both the univariate and bivariate GLMM models 
to explain the contribution of the predictors. 
An expanded methodology is available in the supplementary notes. 
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2.4 Results 
2.4.1 Descriptive statistics of the study population 
In the present study, samples and clinical information for 181 individuals were 
analysed. These patients were evenly divided between those with normal BMD (60), 
osteopenia (61) and osteoporosis (60) groups. Clinical, physiological, biomedical and 
dietary measures were investigated and significant differences between normal BMD, 
osteopenia and osteoporosis participants were detected. Differences in bone density 
measurements (T-score and BMD of the anterior-posterior spine and neck of femur) 
were confirmed and differences in BMI, weight, circumference measures, vitamin D 
levels, and the use of calcium and bisphosphonate supplements were noted (Table 1, 
Supplementary Table 2, Supplementary Figure 1, 2A-B). Due to the recruitment 
by clinical referral of this high risk cohort, there was a high rate of fractures in all 
groupings with percentages for one or more fractures being 40% (24/60), 59% (36/61) 
and 42% (25/60) for normal BMD, osteopenia and osteoporosis groups respective ly 
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Table 1 Significant characteristics of the participants in the final dataset 




Gender (Male/Female) 13/47 7/54 11/49 NS 
Age (Years) 63.57±5.73 64.84±5.28 65.07±5.58 NS 
BMI  29.09±4.57 27.20±4.80 23.96±3.31 ***  
Weight (kg) 78.86±13.60 70.96±14.44 61.65±9.44 ***  
Waist circumference (cm) 95.71±11.95 (13/46) 89.81±12.40 (6/54) 81.81±9.36 ***  
Hip circumference (cm) 106.71±9.83 (13/46) 103.63±10.45 (6/53) 96.66±7.26 ***  
Waist-Hip ratio 0.90±0.08 (13/46) 0.87±0.06 (6/53) 0.85±0.07 **  
Mid arm circumference (cm) 30.98±3.62 (12/47) 28.85±3.97 26.80±2.91 ***  
Calf circumference (cm) 37.69±3.73 (11/47) 35.76±4.28 33.93±2.76 ***  
AP spine T-score 0.28±1.02 -1.16±0.87 -2.86±0.74 ***  
AP spine BMD (g/cm
2
) 1.22±0.13 1.04±0.11 0.84±0.09 ***  
Neck-femur T-score -0.54±0.35 -1.27±0.53 -1.95±0.80 ***  
Neck-femur BMD (g/cm
2
) 0.98±0.09 0.84±0.07 0.84±0.68 ***  
Vitamin D3 [25(OH)D3] (nmol/L) 60.49±20.84 69.98±25.27 75.96±26.43 **  
Total Vitamin D [25(OH)D)] 
(nmol/L) 
63.68±20.57 72.40±25.36 79.18±26.07 **  
Calcium supplements (Yes/No) 10/50 31/30 35/25 ***  
Bisphosphonate medication 
(Yes/No) 
4/56 6/55 17/43 *** 
Group-wise comparisons of the clinical variables. Kruskal-Wallis or chi-square statistic was used to 
determine significance. The values represent mean and standard deviation: Mean±SD or number of 
samples per group. 
BMI, body mass index; BMD, bone mineral density; 25(OH)D3, vitamin D3, Total 25(OH)D, total 
vitamin D. 
Significance: p-adjusted *** ≤ 0.0005, ** ≤ 0.005, NS Not significant  
Values in brackets for circumference measures and waist-hip ratio represents different sample size. The 
complete list of sample characteristics along with pairwise comparisons is available in supplementary 
table 2. 
Indicators of BMD measures: AP spine T-score, AP spine BMD (g/cm2), Neck-femur T-score, Neck-
femur BMD (g/cm2) 
Indicators of obesity: BMI, Weight (kg), Waist circumference (cm), Hip circumference (cm), Waist-
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2.4.2 Microbiota characterisation 
The microbiota composition of the samples analysed was dominated by phylum 
Firmicutes with a mean abundance of 78.9% across the whole dataset followed in rank 
abundance order by Bacteroidetes accounting for 14.9%. Other phyla accounted for 
5.8%, while 0.4% were unclassified (Supplementary figure 3A).  The core 
microbiota consisted of 23 genera that were found in at least 90% of the samples. The 
top five genera with mean relative abundance in the whole dataset were 
Faecalibacterium (11.7%), Bacteroides (9.4%), Roseburia (7.9%), Blautia (7.6%), 
and Coprococcus (3.2%) (Supplementary figure 3B). Based on PCoA (Principa l 
Coordinate analysis) on different β-diversity measures, Axes 1 and 2 explained 11-
17% and 8-13% of variance respectively (Supplementary figure 4A, Supplementary 
Table 3). The relationship of BMD measures with global microbiota profile was 
visualised using dbRDA (distance-based redundancy analysis), testing AP spine BMD 
measure with Bray-Curtis distance (Supplementary figure 4B). With regard to α-
diversity, an average richness of 308.7±84.2 was observed and extrapolated richness 
(chao1) was estimated at 406.8±122 (Figure 1D, Supplementary figure 4C) No 
significant difference was observed in any of the alpha diversity indices among the 
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Figure 1 Effect size of covariates significantly associated with global microbiota 
profiles 
Significance was defined as a p-value of 0.05. A) A total of 20 factors were identified 
to be nominally significantly associated with β–diversity. The bar plot shows the 
variation explained by each factor individually on microbiota composition (Weighted 
and Unweighted UniFrac). The factors are sorted based on their mean cumulat ive 
(grouped into predefined categories) and individual effect size from both distance 
measures. B) shows the combined variance explained by the predefined categories.  
C) The donut plot shows the portion of combined variance explained by the nomina lly 
significant factors on weighted and unweighted UniFrac measures respectively. D) 
and E) shows the lack of significant difference in observed species diversity measure 
and Shannon index respectively. 
PPIs, Proton Pump Inhibitors; BMI, Body Mass Index; BMD, Bone mineral density; 
MNA, Mini Nutritional Assessment; HFD, Healthy Food Diversity; MMSE, Mini-
Mental State Examination   
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2.4.3 Association of gut microbiota with covariates 
Both sets of bone density measurements and one of the T-scores tested explained a 
significant amount of microbiota variance (p-value ≤ 0.05), verifying the origina l 
hypothesis that BMD is associated with alterations in the microbiota (Figure 1, 
Supplementary Table 4). We extended this beta-diversity analysis to known 
microbiota-associated putative meta-data variables to measure their effect on the 
microbiota (Supplementary table 4). This analysis identified 20 meta-data variables 
to be associated with the global microbiota profile (Figure 1A), with BMI having the 
largest effect size individually (2.1%). An inflammatory disease index was created 
indicating the presence or absence of a disease, disorder or condition. This index 
showed a significant association with the β-diversity (Bray-Curtis p-value: 0.042, R2: 
0.009). 
Amongst the significant variables, the combined effect-size of the different 
medications explained the most variance (4.8%) followed by anthropometric measures 
(3.5%). Chronic diseases explained 3.5% and BMD measurement was the fourth 
largest contributor to effect-size (2%) Nutritional information (HFD and MNA), 
cognitive measures (MMSE) and gender explained 1.4%, 1% and 0.6% of variance 
respectively (Figure 1B). Overall, a cumulative total range of 15-17% of the variance 
in our dataset was explained which indicates that stochastic factors explain the 
majority of the variance in global microbiota composition (Figure 1C). Analysis of 
the Food Frequency Questionnaire (FFQ) data and diet quality as measured by the 
HFD index revealed no significant difference in diet composition or HFD across the 
three groups. Co-inertia analysis of the FFQ dataset with the microbiota dataset 
(Figure 2A) graphically confirmed a significant co-variation between the two datasets 
which was independent of the defined bone health groups.  
 
156 | P a g e  
 
 
Figure 2 Global food profile is significantly associated with the microbiota profile  
based on the co-inertia analysis (CIA) which investigates the relationship between 
the two datasets 
A) shows the CIA of the FFQ PCA and microbiota PCA where the arrows relate the 
position of the samples in the FFQ dataset in relation to the microbiota dataset. B) 
shows the FFQ item category associated with the visualised trends. Green dots 
represent fruits and vegetables, orange represents grains, cereals and bread, brown 
represents meats, cyan represents fish, yellow represents dairy products, blue 
represents sweets, cakes and alcohol and grey represents vitamins, minerals and tea. 
The food items on the most extreme ends are labelled. C) shows the microbial taxa at 
family level associated with visualised trends. The taxa present at the extreme ends 
are labelled. 
FFQ, Food frequency questionnaire; PCA, Principal component analysis 
 
2.4.4 Identification of significantly differentially abundant taxa in patients with 
osteopenia and osteoporosis 
DESeq2 statistical analysis was used to identify genera that were differentia lly 
abundant across the groups with adjustment for BMI and gender (Figure 3A-B, 
Supplementary table 5). In summary, we found that Escherichia/Shigella and 
Veillonella were more abundant in subjects with osteopenia compared to those with 
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osteoporosis. Actinomyces, Eggerthella, Clostridium Cluster XlVa and Lactobacillus 
were more abundant in subjects with osteoporosis compared to the normal BMD 
group. We did not identify any taxa significantly differentially abundant in osteopenia 
compared to the normal BMD group. The relative abundance of these taxa are shown 
in Figure 3C. 
 
Figure 3 Taxa with differential abundance across the BMD groups  
Plot of the Log2 fold difference from the significantly differentially abundant genera 
in pairwise analysis between the groups from the DESeq2 analysis when the model is 
adjusted for BMI and gender. Based on the log2 fold difference A) shows the genera 
which are significantly higher in osteoporosis compared to normal BMD. B) 
represents the genera which are significantly more abundant in osteoporosis compared 
to osteopenia. C) represents the relative abundance of the significant genera in the 
three groups identified in DESeq2. 
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2.4.5 Alterations at taxonomic levels are not associated with confounding 
factors 
It is well established that many confounding factors may affect the intestina l 
microbiota (Zhernakova et al., 2016). Therefore, it is important to account for 
confounders potentially affecting the significant taxa identified. We implemented an 
in-depth statistical analysis to control for potential cofounders based on a combination 
of previously published approaches (Jeffery et al., 2016;Zhernakova et al., 2016). Each 
significant taxon was tested against the confounding meta-data factors as outlined in 
the Methods section. A total of 29 factors and the inflammatory disease index were 
analysed and based on the results of the univariate models (Supplementary Table 6), 
the bivariate models explaining the associations with each significant genus were 
generated (Supplementary Table 7).  
Significant associations with the different significantly differentially abundant 
genera were explained by a range of factors including diet, frailty variables, levels of 
physical activity, medications, weight, BMI, gender, and bone density measurements 
including the osteopenic and osteoporotic groups (Supplementary table 6) based on 
the univariate models. Based on the bivariate models, five of the six previous ly 
identified genera remained significantly differentially abundant after adjustment for 
known confounding factors (Supplementary table 7). The inflammatory disease 
index did not show any significant association with these significant taxa in the 
bivariate models. Lactobacillus abundance was not significantly associated with any 
of the bone density measurements in the univariate and bivariate models unless BMI 
was included in the model and therefore was no longer considered.  
Our analysis shows that BMI is significantly associated with AP spine BMD 
measures but not with lowest neck of femur BMD values (Supplementary table 8a, 
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Supplementary table 9a). The removal of the effect of BMI, medications and vitamin 
D levels (Supplementary table 8b-e, Supplementary table 9b-e) retained all but two 
of the results with Clostridium XlVa and Veillonella losing significance 
(Supplementary table 8f, Supplementary table 9f).   
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2.5 Discussion 
This is the largest study to-date to investigate associations between the microbiota and 
reduced bone density in a human cohort including individuals suffering from 
osteopenia and osteoporosis. We have identified significant associations between 
different gut microbial genera and reduced bone density in this well-character ised 
cohort. Extensive investigation by considering the potential influence of various 
confounders clearly established that the taxonomic differences observed are not 
explained by the confounders.  
It has been observed that the microbiome field suffers from a prolifera t ion 
of small datasets that show associations of the microbiome with particular diseases or 
states, without the ability to adequately control for confounding variables. Here we 
show that global alterations in the gut microbiota are associated with BMD measures, 
and these interactions explain a similar amount of variance compared to other known 
microbiota associated diseases and disorders. This confirms our hypothesis of the 
association of the gut microbiota alterations with a reduction in BMD in the elderly. 
Diseases, disorders and medical conditions are associated with smaller effect 
sizes compared to medications (Falony et al., 2016;Zhernakova et al., 2016). In-depth 
analysis of confounding variables revealed that bisphosphonate and calcium 
supplements show no significant association with the global microbiota profile. This 
is consistent with previous reports that bisphosphonates are not significantly 
associated with gut microbiota markers and the evidence for microbiota alteration in 
association with calcium intake is weak (Jackson et al., 2018). We identified six 
individual gut microbial taxa that may affect bone metabolism. This modest result 
contrasts with a small cohort study which identified a large number of alterations 
associated osteoporosis and osteopenia patients in the microbiota at the global and 
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genus level (Wang et al., 2017) The lack of replication of these global alterations in 
this cohort shows the importance of adequate sample sizes and controlling for mult ip le 
testing when investigating possible new associations. 
A loss of microbiota diversity is associated with a wide range of disease 
states and it is widely considered as an important indicator of health associated 
microbiota. Within this context, the lack of significant differences in the within-
sample diversity measures is interesting. However, it has been observed previous ly 
that despite loss of commensal population with the elderly microbiota and noticeable 
differences in microbiome composition and other host associated factors (e.g. 
inflammation, dietary patterns), there was no significant observable difference in 
overall diversity in ageing individuals (Bian et al., 2017)  and between frail and non-
frail elderly individuals(Jeffery et al., 2016). 
The taxa identified resonate well with the bone density-microb iome 
literature. Actinomyces abundance in the osteoporosis group here concords find ings 
that Actinomyces is involved in the development of bisphosphonate-rela ted 
osteonecrosis of the jaw (Arranz Caso et al., 2012) and it has been proposed that 
prolonged courses of anti-microbial therapy targeting this organism may lead to better 
clinical outcomes (De Ceulaer et al., 2014). The increase in Clostridium XlVa in the 
osteoporotic group represents a means by which the gut microbiota may influence 
bone state acting through several differentiating mechanisms (Lopetuso et al., 2013). 
Clostridium XlVa induces accumulation and differentiation of T-reg cells, which in 
turn are responsible for bone homeostasis (Bozec and Zaiss, 2017). Clostridium XlVa 
is an important producer of butyrate, a short chain fatty acid (SCFA) known to 
stimulate bone formation (Lucas et al., 2018). Further functional analysis of this group 
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of microorganisms may provide insight into how the gut microbiota affects BMD 
through modulation of the host’s immune system and metabolism. 
Vitamin D receptor polymorphisms are associated with increased 
osteoporotic fracture risk (Wu et al., 2016). The increase in Eggerthella abundance in 
the osteoporotic group is of interest, as absence of the vitamin D receptor leads to 
increased Eggerthella abundance and other unfavourable alterations in the intestina l 
microbiota in murine models (Jin et al., 2015). The current investigation also found 
that vitamin D concentration is associated with a decrease in the relative abundance of 
Escherichia/Shigella (Supplementary Table 6 and 7) mirroring other find ings 
looking at vitamin D supplementation (Bashir et al., 2016). The high relative 
abundance of this genus in osteopenic but not in osteoporotic patients may be partially 
due to the greater use of oral vitamin D supplementation among the patients with 
osteoporosis. 
A number of microbes belonging to the phylum Firmicutes are known 
metabolizers of isoflavone diadzin to equol which is an oestrogen analogue (Rafii, 
2015). This includes species from the genus Veillonella, which we have observed to 
be decreased in osteoporotic patients. This suggests that a reduction in Veillonella 
would lead to lower production of equol which in turn leads to a lack of inhibition of 
bone resorption. 
An analysis of the meta-data revealed that diet and BMI were large 
contributors to variance in the dataset, with BMI being the largest single contributor 
in line with numerous reports linking gut microbiota with obesity (Falony et al., 2016). 
Our study investigated and confirmed the effect of these variables that can alter the 
microbiota as reported by previous studies. These included various medications that 
have a profound effect on the microbiota profiles such as proton pump inhibitors and 
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the general term of polypharmacy (Ticinesi et al., 2017;Jackson et al., 2018). Thus the 
current study corroborates previous reports which show that cumulative medication 
use has the largest effect size on global microbiota profiles (Falony et al., 
2016;Zhernakova et al., 2016). However, neither these alterations nor chronic diseases 
(Falony et al., 2016;Wang et al., 2018) or anthropometric measures explained the 
observed microbiota alterations.  
The relationships between BMI and BMD and the microbiota is complex. 
Although, lower BMI has been associated with a higher fracture rate (De Laet et al., 
2005), a high amount of fat mass may provide no beneficial effect on bone health 
(Zhao et al., 2007). Within this study, individuals with a higher BMI tended to have 
higher BMD which is consistent with the literature (Beck et al., 2009). BMI is known 
to be associated with microbiota alterations. Our analysis has considered both of these 
BMI associations. Of the taxa related to BMD, Lactobacillus and Veillonella were 
significantly related (p-value <0.05) to both obese category and BMD, whilst 
Clostridium XlVa showed trends of associations with the obese category (p-value 
<0.1). However, the Lactobacillus correlation was not significant without adjustment 
for BMI and so was considered a false positive. Further analysis showed that with 
removal of variance associated with BMI and medications from the BMD measures 
results in Veillonella and Clostridium XlVa losing significance. Other results were 
unaffected showing that the associations are independent of BMI. Therefore, the 
association of Clostridium XlVa and Veillonella with BMD should be interpreted with 
caution.  
This is the first investigation of the intestinal microbiota in a large well-
characterised human adult cohort with respect to BMD, with one previous study 
having a limited sample size (Wang et al., 2017).  Nevertheless, the current study has 
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certain limitations. Due to the recruitment of individuals through consultant referral, 
the normal BMD cohort are not truly representative of the general population as 
highlighted by the high fracture rate in this group. However, a history of fractures was 
not associated with a detectable alteration in the microbiota and controlling for this 
variable confirmed the BMD results but did not improve the analysis. Due to the 
incomplete information of the standalone vitamin supplements, we included serum 
vitamin D levels to use directly measured concentrations to account for vitamin D. 
The number of variables that can be tested in the identification of confounding factors 
through statistical analyses is limited by the sample size. However, this analysis was 
not dependant on the statistical identification of confounding variables, with the 
majority of the variables being identified from the literature before the commencement 
of the analysis with all additional variables being supported by the literature. The 
reported study is also observational and the association with BMD does not imply 
direct causation. However, the literature supports the notation that these taxa may have 
functional links to bone health and this microbial contribution to bone health may 
represent a modifiable environmental factor in the prevention and treatment of 
osteoporosis. Despite the limitations discussed, changes in gut bacterial composition 
with respect to bone health suggest further exploration and mechanistic studies are 
warranted. 
In conclusion, we identified taxa-specific differences in the gut microbiota 
profiles associated with normal bone mineral density, osteopenic and osteoporotic 
subjects. These genera could be potential biomarkers and therapeutic targets in high 
risk cohorts. These differences support the concept that specific genera within the gut 
exert influence on bone metabolism in the host, subsequently affecting bone health in 
adulthood.  
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2.8 Supplementary Information 
2.8.1 Supplementary Methods 
Subject recruitments 
Patients were screened by telephone and if eligible for study participation, a 
measurement visit was arranged in the Department of Medicine, Cork Univers ity 
Hospital. All subjects were recruited through referral and stratified post screening. 
This also allowed for the minimisation of differences in environmental confound ing 
factors between the normal bone density group and the osteoporosis and osteopenia 
groups compared to if a control group would have been recruited separately through a 
different methodology.  
 
Bone densitometry assessment 
Quality control analysis was performed on the iDXA machine before use on each 
measurement day. T-score threshold was used to define 3 groups based on their BMD.  
 
Clinical and demographical information 
A number of clinical measurements were taken including weight, height, blood 
pressure, and heart rate using standardized method. Serum blood samples were taken 
and concentrations of 25-hydroxyvitamin D (25(OH)D) were measured at the Cork 
Centre for Vitamin D and Nutrition Research using a LC-MS/MS method as described 
by Cashman et al. (2013) (Cashman et al., 2013). Muscle mass was assessed by 
standard tape measurement of mid-calf and mid-arm circumferences and muscle 
strength assessed by handheld dynamometer (Jamar, Illinois, USA). A full medical, 
surgical, and medications history was recorded from each patient including a previous 
fracture history. Co-morbidities were quantified using the Charlson co-morbidity 
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index (Charlson et al., 1987). Functional status was assessed using the Barthel index 
(Mahoney and Barthel, 1965) and mini-mental state examination (MMSE) (Molloy et 
al., 1991). Patients’ physical activity levels were estimated using the Godin-Shepard 
leisure time physical activity questionnaire (Godin and Shephard, 1985).  
 
Dietary data collection 
Dietary habits were assessed by means of a 146-item food frequency questionna ire 
(FFQ). Participants were asked to record their usual pattern of dietary intake over the 
previous 3 months. The FFQ was an adapted version of the questionnaire used in the 
UK arm of the European Prospective Investigation into Cancer (EPIC) study 
(McKeown et al., 2001), which was based on the original Willet FFQ (Willett et al., 
1985). Quality of nutritional intake was assessed using the mini-nutritional assessment 
(MNA) (Guigoz and Vellas, 1999). Diet quality was represented by the Healthy Food 
Diversity (HFD) index which was determined from the food frequency of the FFQ 
dataset based on the publication by Drescher et al. (2007) (Drescher et al., 2007). 
 
Molecular methods and bioinformatics 
The faecal samples obtained from the participants were stored at -80 C until 
processed. Mock communities were not utilized as positive controls in the current 
study. All samples were processed with the same method and sequenced in a single 
run. Extraction of genomic DNA from the faecal samples stored in the storage tube 
was carried out based on modified Yu and Morrison protocol (Yu and Morrison, 
2004). The homogenising step was reduced to 60 seconds followed by cooling on ice 
for 30-60 seconds. The steps were repeated twice more. All other subsequent steps 
remained same as described in the original protocol. Nuclease free water was used as 
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a negative control which was processed along with other samples for PCR. As no 
amplicons were observed in the electrophoresis gel after the amplification step, 
negative samples were not sent for sequencing. Because faecal samples contain 
considerably greater microbial biomass than the negative controls, possible reagent 
contaminant DNA cannot easily outcompete with the amplification template in a 
faecal DNA preparation (Eisenhofer et al., 2019). It has also been shown that the 
extraction protocol has a much greater impact on faecal microbiota composition than 
reagent choices and read counts from negative controls are negligible (Velasquez-
Mejia et al., 2018). The V3-V4 region of the 16S ribosomal RNA (rRNA) gene was 
amplified and sequenced using the following primers: 
16S Amplicon PCR Forward Primer (S-D-Bact-0341-b-S-17) = 5' 
TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCCTACGGGNGGCWGCA
G 
16S Amplicon PCR Reverse Primer (S-D-Bact-0785-a-A-21) = 5' 
GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGACTACHVGGGTATC
TAATCC(Klindworth et al., 2013) 
The 2 x 250 paired reads obtained were merged using flash (v1.2.8) (Magoc 
and Salzberg, 2011) using the following parameters: The average read length is 250. 
The expected length of merged reads is 460. The standard deviation of length of 
merged reads is 46. All other parameters were set to default. 
The quality filtering of reads and removal of reverse primers were carried out 
using the QIIME (v 1.9.1) (Caporaso et al., 2010b) pipeline. The 
split_libraries_fastq.py was set to filter with minimum average quality score set to 20 
and truncate_reverse_primer.py with default settings was used to trim. All other 
settings were set to default. The OTU table was generated as follows using USEARCH 
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(v8.1) (Edgar, 2010): The unique sequences of length 360-460 were filtered and sorted 
by length. The sequences were then clustered at 97% (cluster_otus) and chimeras were 
removed using (uchime_ref) the ChimeraSlayer reference database (microbiomeutil-
r20110519)(Haas et al., 2011) to generate representative OTUs. All the reads were 
mapped against the representative OTUs (usearch_global) and the mapped reads were 
tabulated in R (v3.4.0)(Team, 2017) to obtain the OTU table. All reported taxa were 
classified with at least 80% confidence at all levels. Multiple sequence alignment of 
the representative OTUs were carried out using PyNAST (Caporaso et al., 2010a), and 
the phylogenetic tree was constructed using FastTree (Price et al., 2009). Calculat ion 
of alpha diversity and beta diversity measures were carried out using R and QIIME as 
follows: using the vegan library (Oksanen et al., 2017)(v2.4.3), a rarefied OTU table 
was computed by rarefying to the minimum sequencing depth (10613 reads) among 
the samples. Beta diversity measures (Bray-Curtis) and alpha diversity indexes (chao1, 
number of unique OTUs (observed richness) and Shannon) were calculated using the 
rarefied table using the same library. Using the rarefied OTU table and the 
phylogenetic tree, weighted and unweighted UniFrac distance measure and 
phylogenetic diversity index were obtained in QIIME. 
 
Analysis of meta-data 
Missing values in FFQ dataset were replaced by the median value of that particula r 
food item. Violin plots and stacked bar plots were created using 
ggplot2(v2.2.1)(Wickham, 2009), RColorBrewer(v1.1.2) (Neuwirth, 2014) and 
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Analysis of microbiota data 
Bar plots of relative abundance of taxa at phylum level and the top 20 genera based 
on average abundance across the whole dataset were generated.  
To explore the covariance between the FFQ dataset and the microbiota dataset, 
co-inertia analysis using the ade4 library (v1.7.6) (Dray and Dufour, 2007), was 
carried out on the Principle Component Analysis (PCA) of log to the base 10 
transformed values of the FFQ dataset and microbiota dataset. The first five PCA axes 
of the microbiota and FFQ dataset were considered for co-inertia analysis. The 
minimum non-zero value (1e-05) was added to the matrix to remove all zeros before 
log transformation. Significance of the analysis was determined by Monte-Carlo test 
with 1000 permutations. 
PCoA (Principal Coordinates Analysis) was done for visualising the global 
microbiota profiles in general as explained by any variable and distance dbRDA 
(distance-based redundancy analysis) was carried out to explore the global profile as 
explained by the BMD measures. Both PCoA and dbRDA was done using ade4 library 
on Bray-Curtis distance. Significance of dbRDA was determined by anova. 
Body Mass Index (BMI) was categorised into underweight (≤18), normal (>18 
and <25), overweight (≥25 and <30) and obese (≥30) for all further analyses. 
DESeq2 (v1.16.1) (Love et al., 2014) was used to identify differentia lly 
abundant taxa from the microbiota composition table. For the OTU level dataset, 
DESeq2 analysis was carried out with only group variable. Log2 fold difference of the 
significant genera based on pairwise comparisons were shown as bar plots created 
using ggplot2. By default, DESeq2 generates adjusted p-values for only the two groups 
analysed. As a 3-way comparison was carried out, all of the DESeq2 p-values were 
adjusted separately using Benjamini-Hochberg method and only those taxa were 
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selected that passed both DESeq2 adjusted p-values and independently adjusted 
values. 
 
Identification of meta-data variables associated with beta-diversity 
All nominally significant meta-data were analysed to identify their effect size. The 
effect size was evaluated individually to identify their individual contribution in 
explaining variance in the global microbiota profiles. Bar-plots and donut plots were 
made showing the individual effect size, the combined effect size based on pre-defined 
groups and the overall cumulative effect size. For reproducibility of simulations and 
permutations, set.seed() function in R was set to 100 for all cases. 
 
Analysis of confounding variables 
Analysis of confounding variables was carried out using a univariate general linear 
mixed model (GLMM) regression with a negative binomial distribution from the 
library glmmADMB(v0.9.35) (Fournier et al., 2012). Given that R-squared cannot be 
exactly calculated for mixed models easily. Various methods have been designed 
recently to approximately obtain a similar value. A pseudo R-squared value is 
determined for the general linear mixed models in this study using the first formula 
described by Ben Bolker (https://bbolker.github.io/mixedmode ls-
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Analysis of association of taxa after removal of the effect of BMI, medications  
and vitamin D levels on BMD measures 
A multi-step analysis was carried out to remove the effect of BMI, medications and 
vitamin D on the BMD measures. At first, we investigated the effect of BMI on the 
BMD measures by linear regression of BMD to BMI values and determined the 
associated coefficients and significance using summary. To remove the effect of BMI, 
medications and vitamin D levels on BMD measures, we generated two mult ip le 
regression model one for AP spine BMD and another for Neck of Femur BMD scores. 
In both these models, the effect of medications (Calcium, Bisphosphonate and 
Denosumab) and vitamin D levels were investigated. BMI was included in these 
multiple regression models if it showed significant association with BMD measures in 
the linear regressions. The residuals were then calculated by removing the effect of 
the medications investigated and vitamin D levels. Given that the group variable is 
necessary to show that effect of the medications on BMD measures in the disease 
groups, the residuals obtained now also had the group effect removed. This effect was 
added back to the residuals obtained to restore the association with groups and BMD 
measures excluding BMI, medications and vitamin D levels. To validate this, the 
values obtained after restoring the effect was modelled against BMI, medications, 
vitamin D levels and the BMD measures in individual linear regression models and 
compared against the variations observed between BMD measures to groups. This can 
be described as follows 
Model 1 BMD ~ BMI (If BMI is significant, it is added to the next multiple regression 
model) 
Model 2 BMD ~ BMI + Groups + medication 1 + medication 2 + medication n + 
vitamin D levels (multiple regression model) 
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Model 3 BMD ~ Groups (Difference of residuals to BMD from this model is added to 
residuals of model 2 to restore the effect of groups lost in model 2) 
Model 4 Modified residuals ~ Groups (The associated coefficients from model 4 
should be similar to model 3) 
Model 5 Modified residuals ~ BMD (this result should be near exact fit (coeffic ient 
closer to one)) 
Model 6 Modified residuals ~ BMI/medications/vitamin D levels + Groups (All 
associations should be with model 4 only and no significance with the other 
confounders) 
Once verified, these residuals without the effect of BMI, medications and vitamin D 
levels were investigated using univariate GLMMs against the significant taxa 
identified to determine whether the association of taxa to the disease status were 
retained or not after removing the effect of BMI, medications and vitamin D levels.   
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2.8.2 Supplementary Results 
Descriptive statistics of the study population 
Across all groups, 83% of the participants were women with a mean age of 64.64±5.5 
and mean age of male is 63.77±5.76. The BMI of 1% of the participants were 
underweight while 41% of them were within the normal range, 36% of the participants 
were overweight and 22% of them were in the obese category. Analysis of the food 
frequency questionnaire did not reveal any food items to be significantly differentia lly 
consumed across the groups. The percentage of missing values in the FFQ dataset was 
0.6%. There was no significant difference in diet quality across the groups as defined 
the HFD metric (Supplementary table 2). Diet is controlled for in all microbio ta 
related results using the HFD metric. 
 
Microbiota characterization 
Microbiota profiling and analysis was carried out using 16S rRNA gene amplicon 
sequencing of V3-V4 region which generated 12,821,961 reads in total from 181 
samples. After quality filtering and removal of chimeras, we obtained a table 
comprising of 4835 OTUs. From 181 participants, a total of 6,512,978 reads were 
mapped to 4835 OTUs. The average number of reads were 35983±9725. 
 
Identification of significantly differentially abundant taxa in patients with 
osteopenia and osteoporosis 
At the OTU level, significant differences (p-adjusted ≤ 0.05) were observed in the 
abundance of certain OTUs between the three groups (Supplementary table 5). 
Blautia was more abundant in osteopenia and osteoporosis compared to normal BMD 
however it was significantly higher in osteopenia compared to osteoporosis also. 
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Clostridium IV and Eggerthella was higher only in the case of osteoporosis compared 
to normal BMD whereas Bacteroides was significantly abundant in normal BMD 
compared to osteopenia and osteoporosis. Escherichia/Shigella was significantly 
higher in normal BMD and osteopenia compared to osteoporosis but was highest in 
osteopenia. The results of this analysis were not considered for further analysis due to 
the sparseness of the dataset. 
We applied a DESeq2 model in which we adjusted for fractures; this analys is 
returned the same results as the above-mentioned model. Two additional taxa, 
Akkermansia and Klebsiella, were identified as being more abundant in osteopenia 
compared to normal BMD subjects but because they were not identified in the earlier 
model, they were not investigated further. 
 
Alterations at taxonomic levels are not associated with confounding factors 
Abundance of Actinomyces was positively associated with osteoporosis group and all 
measures of bone in the univariate model. Bisphosphonate use was not significantly 
associated when groups category was present, however Coeliac Disease, a prior 
history of cholecystectomy and total vitamin D levels remained significantly 
positively associated in the bivariate models. For Clostridium Cluster XlVa, an 
increased abundance was observed with the diseased status. Bisphosphonate and 
anticoagulant medication and HFD index showed positive significant associated along 
with the groups variable while Godin score was negatively associated in the bivariate 
models. Three measures of bone - Groups, AP spine T-score and BMD, were 
associated with increased abundance of Eggerthella. Gender, vitamin D levels, opiod 
use and previous cholecystectomy were also significantly associated with this genus 
in the univariate models but only gender and previous cholecystectomy remained 
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significant in presence of the group category. Escherichia/Shigella abundance showed 
negative associations with vitamin D levels and positively associated with hip 
circumference measure and appendicectomy. Abundance of this taxon was observed 
to be lower in osteoporosis and increased in osteopenia. Hip, calf, mid-arm 
circumference measures and MNA were significantly negatively associated in the 
bivariate model for Veillonella and presence of these confounders showed a non-
significant association with disease status. However, after adjustment for calcium and 
bisphosphonate supplements, BMI, MMSE, medications (anti-epileptics, analges ia 
(opiods), inhalers and proton pump inhibitors), Veillonella was still significantly 
associated with decreased abundance in osteoporosis and increased in osteopenia. 
Appendicectomy was also significantly associated after adjustment. 
 
Adjustment for BMI, medications and vitamin D levels 
To control for the effect of BMI, medications and vitamin D levels on the bone minera l 
density, the relationship between these variables and the BMD values were modelled 
and the residual BMD values generated from the multiple regression models were 
recorded. These residual BMD values represent the BMD values after adjusting for 
the effect of BMI, medications (Calcium, Bisphosphonate and Denosumab) and 
vitamin D levels on the BMD measures (Supplementary table 8b-9b). The validat ion 
of this removal of effect is described in supplementary table 8c-e and 9c-e. 
Supplementary table 8c and 9c shows the association of BMD measures to groups 
categorisation. It can be observed that the Groups categorisation explained 66% of 
variation with AP spine BMD and 3% variations with neck femur BMD values 
individuals. The BMD residuals obtained from model 2 and restoring group effect 
from model 3 shows similar results (Supplementary table 8d.1, 9d.1) compared to 
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supplementary table 8c and 9c. We also observed that the modified BMD residuals 
explain 97% of variation with BMD measures (Supplementary table 8d.2, 9d.2), thus 
proving that residuals obtained accurately represents the groups and BMD 
information. To further, validate the removal of confounder effects, we regress this 
modified residual values against BMI, medications and vitamin D level and show that 
the variations in the BMD residuals values is not associated at all with BMI, 
medications or vitamin D levels and any variation explained is attributed the groups 
status only (Supplementary table 8e,9e). After validation of BMD residuals, we used 
the GLMM regression to show that significant associations are observed with the 
significant taxa. We observe that the association of the taxa identified to be significant 
with BMD measures are retained, except for Clostridium XlVa, and Veillonella where 
the significance is lost after this adjustment (p-value > 0.05) (Supplementary table  
8f-9f) and Lactobacillus which is not significant in this analysis except for the lowest 
neck femur residuals. 
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2.8.3 Supplementary Figures 
 
Supplementary figure 1 Variables associated with BMD subject groups  
Pairwise comparison of the clinical and BMI data across groups identifies significant 
alterations in clinical measures in osteoporosis and osteopenia groups compared to the 
normal BMD group. The violin plots show the distribution of the significant meta-data 
within each group. Total Vitamin D and Vitamin D3 levels are increased in 
osteoporosis and osteopenia groups compared to normal BMD, whilst bone minera l 
density related measurements, BMI and other anthropometric measures are reduced. 
BMI, body mass index; BMD, bone mineral density; AP spine, antero-posterior spine; 
Total 25(OH)D, total vitamin D; 25(OH)D3, vitamin D3 













Supplementary figure 2 Medications associated with different BMD subject groups  
(A) Consumption of Calcium supplements and (B) Bisphosphonate medication in the normal BMD controls, osteopenia and osteoporosis 
individuals.
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Supplementary figure 3 Relative abundance of the gut microbiota across 
different BMD groups 
(A) Composition of bacteria at phylum level and (B) the 20 most abundant genera in 


































Supplementary figure 4 Microbiota α- and β-diversity across the different BMD subject groups  
 A) Global microbiota profile as observed by unconstrained ordination (PCoA) on Bray-Curtis distance measure. B) Constrained ordination i.e. 
distance-based redundancy analysis (dbRDA) on Bray-Curtis shows global profile best explained by BMD measures. Significant difference in α-












2.8.4 Supplementary Tables 
Supplementary table 1 Literature citation for all the confounding variables analysed in the dataset 
Confounding variables Literature 
Bisphosphonate 
Caso et al. 2012. Bisphosphonate related osteonecrosis of the jaw and infection with Actinomyces. Smruti et 
al. 2014. Oral microbiota and host innate immune response in bisphosphonate-related osteonecrosis of the 
jaw 
Body Mass Index (BMI) 
Yun et al. 2017. Comparative analysis of gut microbiota associated with body mass index in a large Korean 
cohort.  
Calcium supplements 
Chaplin eta al. 2015. Calcium supplementation modulates gut microbiota in a prebiotic manner in dietary 
obese mice 
Charlson co morbidity Claesson et. al. 2012. Gut microbiota composition correlates with diet and health in the elderly 
Diet (HFD and MNA) Claesson et. al. 2012. Gut microbiota composition correlates with diet and health in the elderly 
Frailty (Barthel Score) 
Jackson et. al. 2016. Signatures of early frailty in the gut microbiota. Claesson et. al. 2012. Gut microbiota 
composition correlates with diet and health in the elderly 
Godin Score Mach and Fuster-Botella 2017. Endurance exercise and gut microbiota: A review 
Mini mental score exam (MMSE) Jeffery et. al. 2015. Composition and temporal stability of the gut microbiota in older persons 
vitamin-D 
Barbáchano et. al. 2017. The endocrine vitamin D system in the gut. Luthold et al. 2017. Gut microbiota 
interactions with the immunomodulatory role of vitamin D in normal individuals 
Weight 
Ley et al. 2006. Microbial ecology: Human gut microbes associated with obesity. Seganfredo et al. 2017. 














Supplementary table 2 Meta-data analysed in the final dataset. P-value adjustment is based on Benjamini-Hochberg method 
Significance: P-adjusted ≤ 0.05 
Values mentioned within brackets for the circumference and hand grip measures represents a different sample size from the original 
  



















  Gender (Male/Female) 13/47 7/54 11/49 
3.2E-
01 
5.7E-01       
  Age (Years) 63.57±5.73 64.84±5.28 65.07±5.58 
2.1E-
01 
4.5E-01       
  Weight (kg) 78.86±13.60 70.96±14.44 61.65±9.44 
4.4E-
11 
6.1E-10 6.4E-04 7.8E-12 1.6E-04 
  Height (cm) 164.68±8.66 161.25±7.75 160.40±7.56 
1.3E-
02 
5.4E-02       
  AP spine T-score 0.28±1.02 -1.16±0.87 -2.86±0.74 
1.8E-
30 
1.3E-28 1.1E-07 2.5E-31 4.4E-11 
  AP spine BMD (g/cm2) 1.22±0.13 1.04±0.11 0.84±0.09 
8.7E-
30 
3.0E-28 8.7E-08 1.1E-30 1.4E-10 
  Neck of femur T-score -0.54±0.35 -1.27±0.53 -1.95±0.80 
1.7E-
21 
2.9E-20 1.2E-09 5.2E-22 1.1E-04 
  Neck of femur BMD (g/cm2) 0.98±0.09 0.84±0.07 0.84±0.68 
5.8E-
23 
1.3E-21 4.7E-11 3.3E-23 2.6E-04 








2.7E-08 5.9E-03 6.6E-10 1.4E-04 








2.8E-07 4.3E-02 1.8E-08 5.3E-05 








9.1E-03 5.0E-02 6.3E-04 4.6E-02 






1.5E-07 1.1E-03 3.5E-09 2.4E-03 

























3.7E-01       
  25(OH)D2 (nmol/L) 3.19±2.54 2.42±1.63 3.22±3.59 
5.4E-
01 
7.6E-01       
  3-epi-25(OH)D3 (nmol/L) 2.97±1.58 3.45±1.97 3.52±2.06 
3.0E-
01 
5.7E-01       
  25(OH)D3 (nmol/L) 60.49±20.84 69.98±25.27 75.96±26.43 
1.7E-
03 
8.4E-03 2.7E-02 5.8E-04 7.1E-02 
  25(OH)D (nmol/L) 63.68±20.57 72.40±25.36 79.18±26.07 
1.2E-
03 
7.0E-03 3.2E-02 3.8E-04 5.0E-02 
  BMI 29.09±4.57 27.20±4.80 23.96±3.31 
6.2E-
10 
7.1E-09 6.9E-03 1.7E-10 4.5E-05 
  BMI Categories (number of people)                
  Underweight (BMI < 18.5) 1 0 1 
         
  Normal (BMI 18.5 - 24.9) 10 23 41 
  Overweight (BMI 25 - 29.9) 27 24 15 
  Obese (BMI ≥ 30) 22 14 3 
  HFD 0.38±0.10 0.42±0.13 0.41±0.12 
1.6E-
01 
3.8E-01       
  MNA (/30) 26.89±2.13 26.86±2.10 26.43±2.47 
6.1E-
01 
8.3E-01       
  Systolic BP 137.77±18.05 142.51±18.43 134.37±17.71 
5.7E-
02 
1.9E-01       
  Diastolic BP 80.08±9.73 79.87±10.08 76.65±10.30 
7.7E-
02 
2.4E-01       






1.0E+00       
  Barthel score 19.68±0.50 19.48±0.87 19.58±0.79 
4.2E-
01 
6.6E-01       
  Mini mental score exam 28.48±2.08 28.98±1.57 28.40±2.01 
3.1E-
01 
5.7E-01       
  
Mini mental score exam ≤ 24 (number 
of people) 












  Godin Leisure time activity score 23.65±22.58 25.56±23.37 24.12±17.71 
7.5E-
01 
       
  
insufficiently active (number of 
people) ≤ 13 
20 20 16 
  
       
  
moderately active (number of 
people)14-23 
15 13 15 9.0E-01       
  active (number of people) ≥ 24 25 28 29        
  Exercises (Number of people)                




      
  Mild 16 16 15       
  Moderate 20 18 21       
  Mild+Moderate 12 11 13       
  Strenuous 0 1 2       
  Moderate+Strenuous 2 3 1       
  Mild+Moderate+Strenuous 2 5 2       
  
Charlson co morbidity (number of 
people) 
               




      
  1 13 10 9       
  2 8 13 11       
  ≥3 2 2 5       
  Smoking Status (number of people)                




      
  Former smoker 25 25 26       
  Current smoker 10 7 9       
  Drinking Status (number of people)                




      
  Former drinker 5 1 3       


















   
medications Calcium supplements (Yes/No) 10/50 31/30 35/25 
5.2E-
06 
3.3E-05 2.40E-04 1.80E-05 5.17E-01 
medications Bisphosphonate (Yes/No) 4/56 6/55 17/43 
1.5E-
03 
8.1E-03 7.62E-01 1.20E-02 2.70E-02 
medications Analgesia Non-opiod (Yes/No) 8/52 8/53 8/52 
1.0E+
00 
1.0E+00       
medications Analgesia Opiod (Yes/No) 8/52 7/54 6/54 
8.5E-
01 
9.8E-01       
medications Anticoagulants (Yes/No) 1/59 6/55 1/59 
4.1E-
02 
1.5E-01       
medications Antihistamines (Yes/No) 3/57 2/59 4/56 
6.9E-
01 
8.8E-01       
medications Antiplatelets (Yes/No) 11/49 11/50 9/51 
8.7E-
01 
9.8E-01       
medications ARBs ACEi (Yes/No) 19/41 11/50 11/49 
1.2E-
01 




13/47 7/54 6/54 
1.4E-
01 
3.6E-01       
medications Cholesterol medications (Yes/No) 28/32 30/31 17/43 
4.0E-
02 
1.5E-01       
medications Denosumab (Yes/No) 1/59 3/58 9/51 
1.3E-
02 
5.4E-02       
medications Diuretics (Yes/No) 8/52 4/57 4/56 
3.2E-
01 
5.8E-01       
medications Epilepsy medications (Yes/No) 6/54 3/58 7/53 
3.9E-
01 
6.4E-01       
medications Immunosuppressants (Yes/No) 3/57 3/58 2/58 
8.8E-
01 
9.8E-01       
medications Inhalers (Yes/No) 7/53 9/52 12/48 
4.4E-
01 
6.6E-01       
medications Iron supplementation (Yes/No) 1/59 3/58 4/56 
4.0E-
01 












medications Laxatives (Yes/No) 2/58 1/60 4/56 
3.5E-
01 
6.0E-01       
medications Minerals (Yes/No) 2/58 4/57 1/59 
3.7E-
01 
6.1E-01       
medications Mood Disorders (Yes/No) 8/52 7/54 10/50 
7.0E-
01 
8.8E-01       
medications NSAIDs (Yes/No) 3/57 3/58 6/54 
4.4E-
01 
6.6E-01       
medications Nutritional Supplements (Yes/No) 5/55 7/54 7/53 
8.0E-
01 
9.5E-01       
medications Omega supplementation (Yes/No) 6/54 2/59 1/59 
8.3E-
02 
2.5E-01       
medications Other GIT (Yes/No) 6/54 7/54 7/53 
9.5E-
01 
1.0E+00       
medications PPIs (Yes/No) 14/46 14/47 21/39 
2.4E-
01 
5.0E-01       
medications Sedatives (Yes/No) 2/58 4/57 4/56 
6.6E-
01 
8.7E-01       
medications Steroids (Yes/No) 4/56 6/55 3/57 
5.8E-
01 
8.0E-01       
medications Thyroid Hormones (Yes/No) 11/49 14/47 12/48 
8.2E-
01 
9.5E-01       
medications Vitamins (Yes/No) 8/52 10/51 7/53 
7.5E-
01 
9.0E-01       
medications β-blockers (Yes/No) 9/51 10/51 2/58 
4.9E-
02 
1.7E-01       
Chronic 
diseases 
Appendicectomy (Yes/No) 13/47 13/48 12/48 
9.7E-
01 
1.0E+00       
Chronic 
diseases 
Bout of depression (Yes/No) 8/52 3/58 3/57 
1.4E-
01 
1.0E+00       
Chronic 
diseases 
cholecystectomy (Yes/No) 6/54 5/56 12/48 
1.1E-
01 
3.6E-01       
Chronic 
diseases 
Coeliac (Yes/No) 9/51 5/56 7/53 
5.1E-
01 














Diverticulitis (Yes/No) 5/55 1/60 2/58 
1.8E-
01 
7.3E-01       
Chronic 
diseases 
Inflammatory arthritis (Yes/No) 3/57 3/58 3/57 
1.0E+
00 
3.9E-01       
Chronic 
diseases 
Reflux (Yes/No) 3/57 3/58 7/53 
2.6E-
01 
5.2E-01       
 
Inflammatory Bowel Disease 
(Yes/No) 2/60 2/59 2/58 
     
 Multiple Sclerosis (Yes/No) 1/59 1/60 1/59      
 Diabetes Type I (Yes/No) 1/59 0/61 0/60      
 Diabetes Type II (Yes/No) 1/59 4/57 1/59      
BMD, Bone Mineral Density; 25(OH)D2, Vitamin D2; 3-epi-25(OH)D3, epimer of vitamin D3; 25(OH)D3, Vitamin D3; 25(OH)D, Total Vitamin 
D; BMI, Body Mass Index; HFD, Healthy Food Diversity; MNA, Mini Nutritional Assessment; ARBs/ACEi, angiotensin-recepto r 



















Supplementary table 4 PERMANOVA analysis of various meta-data 
for its influence on global microbiota profile 
  
  
Unweighted  Weighted Bray-Curtis   
  R2 P-value   R2 P-value   R2 P-value   
  25(OH)D (nmol/L) 0.005 4.7E-01   0.006 3.4E-01   0.006 3.1E-01   
  25(OH)D3 (nmol/L) 0.005 4.3E-01   0.007 2.6E-01   0.006 2.4E-01   
  Age 0.007 1.1E-01   0.007 2.4E-01   0.006 3.5E-01   
  AP spine BMD (g/cm2) 0.006 3.8E-01   0.010 4.0E-02   0.009 2.1E-02   
  AP spine T.score 0.006 3.5E-01   0.010 5.0E-02   0.009 2.5E-02   
  Barthel Score 0.008 6.2E-02   0.010 5.5E-02   0.007 1.5E-01   
  BMI category 0.018 1.9E-01   0.026 3.0E-02   0.020 8.5E-02   
  Calf circumference (cm) 0.005 6.5E-01   0.004 7.3E-01   0.005 5.8E-01   
  Carlson Co-morbidity 0.006 3.1E-01   0.010 5.4E-02   0.007 2.2E-01   
  Gender 0.005 5.1E-01   0.010 4.2E-02   0.009 3.0E-02   
  Godin Leisure time activity score 0.007 8.9E-02   0.007 2.2E-01   0.006 2.8E-01   
  Groups 0.010 7.9E-01   0.015 1.0E-01   0.012 3.5E-01   
  Hand Grip 0.006 2.5E-01   0.008 1.3E-01   0.008 5.3E-02   
  Height (cm) 0.007 1.4E-01   0.006 3.4E-01   0.006 2.3E-01   
Β-diversity measure Axis 1 Axis 2 
Bray-Curtis 11.77 % 08.33 % 
Unweighted UniFrac 14.62 % 04.55 % 












  HFD 0.008 4.7E-02   0.008 1.4E-01   0.009 3.0E-02   
  Hip circumference (cm) 0.006 3.1E-01   0.007 2.7E-01   0.009 5.1E-02   
  Lowest Neck of femur BMD (g/cm2) 0.006 3.8E-01   0.011 2.8E-02   0.007 1.5E-01   
  Lowest Neck of femur T.score 0.006 1.9E-01   0.007 1.8E-01   0.006 3.0E-01   
  Mid-arm circumference (cm) 0.005 5.7E-01   0.005 5.0E-01   0.007 1.5E-01   
  MMSE 0.007 9.1E-02   0.011 3.8E-02   0.008 4.4E-02   
  MNA 0.011 8.0E-03   0.009 8.6E-02   0.009 2.5E-02   
  Waist circumference (cm) 0.009 2.6E-02   0.011 3.4E-02   0.011 7.0E-03   
  Waist-Hip ratio 0.010 1.6E-02   0.012 1.7E-02   0.010 1.5E-02   
  Weight (kg) 0.006 3.7E-01   0.005 4.8E-01   0.007 1.1E-01   
Chronic disease Appendicectomy (38) 0.008 3.9E-02   0.007 2.1E-01   0.006 2.1E-01   
Chronic disease cholecystectomy (23) 0.008 5.1E-02   0.011 3.9E-02   0.009 3.7E-02   
Chronic disease Coeliac (21) 0.008 7.4E-02   0.013 2.3E-02   0.011 6.0E-03   
Chronic disease Depression (14) 0.006 3.4E-01   0.006 3.6E-01   0.007 1.6E-01   
Chronic disease Diverticulitis (8) 0.006 2.4E-01   0.006 3.5E-01   0.006 3.5E-01   
Chronic disease Inflammatory arthritis (9) 0.008 6.2E-02   0.005 5.0E-01   0.007 1.3E-01   
Chronic disease Reflux (13) 0.007 1.7E-01   0.011 3.0E-02   0.008 6.2E-02   
medications Analgesia Non-opiod (24) 0.006 1.9E-01   0.007 2.3E-01   0.007 1.2E-01   
medications Analgesia Opiod (21) 0.009 1.6E-02   0.007 2.4E-01   0.008 6.9E-02   
medications Anticoagulants (8) 0.013 2.0E-03   0.014 1.4E-02   0.011 1.0E-02   
medications Antihistamines (9) 0.006 1.8E-01   0.005 4.9E-01   0.005 6.4E-01   
medications Antiplatelets (31) 0.005 7.5E-01   0.006 2.9E-01   0.007 1.9E-01   
medications ARBs/ACEi (41) 0.005 5.1E-01   0.010 6.7E-02   0.007 1.0E-01   
medications β-blockers (21) 0.005 5.4E-01   0.004 6.9E-01   0.005 5.0E-01   
medications Bisphosphonate (27) 0.005 4.1E-01   0.004 6.0E-01   0.005 4.5E-01   
medications Calcium supplements (76) 0.005 6.0E-01   0.010 5.4E-02   0.007 1.9E-01   












medications Cholesterol medications (75) 0.005 8.3E-01   0.004 7.1E-01   0.004 8.2E-01   
medications Denosumab (13) 0.005 4.2E-01   0.003 8.4E-01   0.004 8.5E-01   
medications Diuretics (16) 0.005 4.6E-01   0.005 5.3E-01   0.004 9.1E-01   
medications Epilepsy medications (16) 0.007 1.7E-01   0.011 3.6E-02   0.008 7.6E-02   
medications Immunosuppressants (8) 0.005 4.6E-01   0.009 9.4E-02   0.009 3.3E-02   
medications Inhalers (28) 0.009 1.9E-02   0.004 7.7E-01   0.004 7.9E-01   
medications Iron supplement (8) 0.006 2.8E-01   0.007 2.6E-01   0.007 2.1E-01   
medications Laxatives (7) 0.007 1.5E-01   0.004 6.7E-01   0.006 2.7E-01   
medications Minerals (7) 0.004 9.2E-01   0.003 8.3E-01   0.004 9.3E-01   
medications Mood Disorders (25) 0.005 4.9E-01   0.006 3.4E-01   0.007 2.1E-01   
medications NSAIDs (12) 0.007 8.5E-02   0.006 3.1E-01   0.005 5.6E-01   
medications Number of medications 0.011 1.0E-02   0.011 2.8E-02   0.010 1.5E-02   
medications Nutritional Supplements (19) 0.005 7.3E-01   0.004 7.0E-01   0.005 5.9E-01   
medications Omega supplement (9) 0.005 6.3E-01   0.002 9.5E-01   0.003 9.9E-01   
medications Other GIT (20) 0.006 3.5E-01   0.005 6.0E-01   0.006 2.4E-01   
medications PPIs (49) 0.009 2.1E-02   0.008 1.6E-01   0.008 5.6E-02   
medications Sedatives (10) 0.006 3.5E-01   0.003 9.0E-01   0.003 9.8E-01   
medications Steroids (13) 0.005 5.1E-01   0.005 5.1E-01   0.006 3.2E-01   
medications Thyroid Hormones (37) 0.006 3.7E-01   0.002 9.6E-01   0.003 9.8E-01   
medications Vitamins (25) 0.005 4.5E-01   0.005 4.6E-01   0.004 8.1E-01   













Supplementary table 5 DESeq2 analysis on the OTU dataset and the genus level dataset. The genus level dataset is adjusted for BMI 
and/or Gender  
DESeq2 OTU level                  
              Relative abundance  
Osteopenia vs Normal BMD            Normal BMD  Osteopenia  
  log2FoldChange lfcSE pvalue padj Family Genus Mean SD SE Mean SD SE 
OTU_1226 2.778 0.581 1.7E-06 1.0E-03 Lachnospiraceae Blautia 0.023 0.072 0.009 0.482 2.729 0.349 
OTU_945 2.019 0.465 1.4E-05 4.1E-03 Lachnospiraceae unclassified 0.140 0.782 0.101 0.140 1.382 0.177 
             Normal BMD  Osteoporosis  
Osteoporosis vs Normal BMD            Mean SD SE Mean SD SE 
OTU_115 -3.314 0.976 6.9E-04 2.2E-02 Bacteroidaceae Bacteroides 0.009 0.025 0.003 0.144 1.103 0.142 
OTU_1866 -1.248 0.322 1.0E-04 1.3E-02 Lachnospiraceae unclassified 0.099 0.148 0.019 0.078 0.095 0.012 
OTU_205 1.075 0.295 2.7E-04 1.6E-02 Lachnospiraceae unclassified 0.037 0.038 0.005 0.076 0.107 0.014 
OTU_208 1.984 0.550 3.1E-04 1.6E-02 Ruminococcaceae Clostridium_IV 0.018 0.029 0.004 0.046 0.144 0.019 
OTU_214 -3.029 0.846 3.4E-04 1.6E-02 Coriobacteriaceae unclassified 0.017 0.042 0.005 0.004 0.016 0.002 
OTU_220 2.532 0.607 3.0E-05 5.8E-03 Coriobacteriaceae Eggerthella 0.010 0.015 0.002 0.034 0.077 0.010 
OTU_253 1.606 0.435 2.2E-04 1.6E-02 unclassified unclassified 0.009 0.010 0.001 0.020 0.027 0.004 
OTU_54 1.344 0.410 1.1E-03 3.1E-02 Ruminococcaceae unclassified 0.148 0.138 0.018 0.251 0.437 0.056 
OTU_570 1.834 0.527 5.0E-04 1.8E-02 Lachnospiraceae unclassified 0.046 0.069 0.009 0.135 0.313 0.040 
OTU_650 2.709 0.643 2.5E-05 5.8E-03 Lachnospiraceae Blautia 0.003 0.006 0.001 0.021 0.055 0.007 
OTU_700 -2.407 0.683 4.2E-04 1.8E-02 Lachnospiraceae unclassified 0.009 0.031 0.004 0.013 0.038 0.005 
OTU_732 -3.322 0.959 5.3E-04 1.8E-02 Bacteroidaceae Bacteroides 0.039 0.154 0.020 0.005 0.020 0.003 
OTU_8 -2.293 0.623 2.4E-04 1.6E-02 Enterobacteriaceae Escherichia/Shigella 0.840 3.432 0.443 0.138 0.370 0.048 
             Osteopenia  Osteoporosis  
Osteoporosis vs Osteopenia            Mean SD SE Mean SD SE 
OTU_1226 -2.626 0.580 6.0E-06 3.5E-03 Lachnospiraceae Blautia 0.482 2.729 0.349 0.084 0.365 0.047 

















              
DESeq2 Gender BMI Genus level                  
             Normal BMD  Osteopenia  
Osteopenia vs Normal BMD log2FoldChange lfcSE pvalue padj     Mean SD SE Mean SD SE 
 No significant taxa                  
             Normal BMD  Osteoporosis  
Osteoporosis vs Normal BMD            Mean SD SE Mean SD SE 
Actinomyces 1.329 0.396 7.9E-04 1.8E-02     0.010 0.011 0.001 0.026 0.041 0.005 
Clostridium_XlVa 0.687 0.221 1.9E-03 2.6E-02     0.445 0.392 0.051 0.580 0.525 0.068 
Eggerthella 2.282 0.614 2.0E-04 6.9E-03     0.010 0.015 0.002 0.034 0.077 0.010 
Lactobacillus 3.355 0.872 1.2E-04 6.9E-03     0.076 0.344 0.044 0.238 0.800 0.103 
Veillonella -1.867 0.592 1.6E-03 2.6E-02     0.057 0.189 0.024 0.039 0.133 0.017 
              Osteopenia  Osteoporosis  
Osteoporosis vs Osteopenia             Mean SD SE Mean SD SE 
Escherichia/Shigella -2.963 0.611 1.2E-06 4.2E-05     1.563 4.786 0.613 0.138 0.370 0.048 
Veillonella -2.849 0.551 2.3E-07 1.6E-05     0.120 0.430 0.024 0.039 0.133 0.017 













Supplementary table 6 Univariate analysis of the confounding variables against the significant genera 
Significant nominal p-values are highlighted in red and bold        




1024.3 1040.3 -507.2 
0.352 1.3E-01 
181 
Osteoporosis 0.843 2.3E-04 
  AP spine BMD (g/cm2) 1023.5 1036.3 -507.7 -1.653 3.5E-04 181 
  AP spine T.score 1023.7 1036.5 -507.8 -0.200 3.9E-04 181 
  Neck of femur T-score 1019.1 1031.9 -505.5 -0.490 7.0E-05 181 
  Neck of femur BMD (g/cm2) 1019.8 1032.6 -505.9 -2.699 2.0E-04 181 
BMI category 
Obese 
1038.9 1058.1 -513.5 
0.043 8.7E-01 
181 Overweight 0.075 7.3E-01 
Underweight -0.799 4.2E-01 
  Calf circumference (cm) 1026.1 1038.8 -509.0 -0.034 1.9E-01 179 
  Hip circumference (cm) 1023.4 1036.1 -507.7 -0.003 8.0E-01 178 
  Mid arm circumference (cm) 1032.0 1044.8 -512.0 -0.016 5.5E-01 180 
  Waist-Hip circumference ratio 1021.8 1034.6 -506.9 1.648 2.1E-01 178 
  Waist circumference (cm) 1026.9 1039.7 -509.5 0.005 5.2E-01 179 
  Weight (kg) 1035.3 1048.1 -513.6 -0.004 5.4E-01 181 
  Gender Male 1035.6 1048.4 -513.8 -0.058 8.2E-01 181 
  25(OH)D (nmol/L) 1027.1 1039.9 -509.5 0.011 3.9E-03 181 
  25(OH)D3 (nmol/L) 1027.9 1040.7 -510.0 0.010 5.7E-03 181 
  Calcium supplements 1035.4 1048.2 -513.7 0.108 5.8E-01 181 












  Anticoagulants 1035.0 1047.8 -513.5 -0.426 3.9E-01 181 
  Number of medications 1033.9 1046.7 -512.9 0.052 1.8E-01 181 
  Epilepsy medications 1034.5 1047.3 -513.3 -0.384 2.7E-01 181 
  PPIs 1032.3 1045.1 -512.1 0.397 6.9E-02 181 
  Analgesia (Opiod) 1034.7 1047.5 -513.4 -0.301 3.2E-01 181 
  Coeliac 1030.2 1043.0 -511.1 -0.818 1.4E-02 181 
  Cholecystectomy 1022.8 1035.6 -507.4 0.922 7.8E-04 181 
  Reflux 1033.4 1046.2 -512.7 0.510 1.6E-01 181 
  Appendicectomy 1035.5 1048.3 -513.8 -0.092 7.0E-01 181 
  Inhalers 1034.8 1047.6 -513.4 0.245 3.7E-01 181 
  Barthel score 1035.1 1047.8 -513.5 0.106 4.2E-01 181 
  Co morbidity 1035.3 1048.1 -513.6 0.066 5.3E-01 181 
  Godin 1035.6 1048.4 -513.8 -0.001 8.3E-01 181 
  MMSE 1035.6 1048.4 -513.8 -0.008 8.8E-01 181 
  MNA 1033.4 1046.2 -512.7 -0.066 1.3E-01 181 
  HFD 1034.8 1047.6 -513.4 0.781 3.5E-01 181 




2213.8 2229.8 -1101.9 
0.343 6.3E-03 
181 
Osteoporosis 0.297 1.8E-02 
  AP spine BMD (g/cm2) 2219.9 2232.7 -1105.9 -0.140 6.2E-01 181 
  AP spine T.score 2220.0 2232.8 -1106.0 -0.010 7.8E-01 181 












  Neck of femur T-score 2214.9 2227.7 -1103.4 -0.144 2.3E-02 181 
BMI category 
Obese 
2218.7 2237.9 -1103.4 
0.264 5.5E-02 
181 Overweight -0.034 7.7E-01 
Underweight -0.257 6.1E-01 
  Calf circumference (cm) 2197.4 2210.1 -1094.7 -0.004 7.3E-01 179 
  Hip circumference (cm) 2184.5 2197.3 -1088.3 0.007 1.3E-01 178 
  Mid arm circumference (cm) 2208.3 2221.0 -1100.1 0.006 6.3E-01 180 
  Waist-Hip circumference ratio 2185.8 2198.6 -1088.9 0.769 3.1E-01 178 
  Waist circumference (cm) 2195.1 2207.9 -1093.6 0.007 8.3E-02 179 
  Weight (kg) 2220.1 2232.9 -1106.0 0.001 8.3E-01 181 
  Gender Male 2215.7 2228.5 -1103.9 -0.304 2.9E-02 181 
  25(OH)D (nmol/L) 2219.9 2232.7 -1106.0 0.001 6.6E-01 181 
  25(OH)D3 (nmol/L) 2220.1 2232.9 -1106.1 0.000 8.5E-01 181 
  Calcium supplements 2220.1 2232.9 -1106.0 0.028 8.0E-01 181 
  Bisphosphonate supplements 2213.5 2226.3 -1102.7 0.368 1.2E-02 181 
  Anticoagulants 2210.9 2223.7 -1101.4 0.694 5.4E-03 181 
  Number of medications 2216.6 2229.4 -1104.3 0.039 6.2E-02 181 
  Epilepsy medications 2220.0 2232.8 -1106.0 -0.056 7.7E-01 181 
  PPIs 2218.1 2230.9 -1105.1 0.165 1.6E-01 181 
  Analgesia (Opiod) 2219.9 2232.7 -1105.9 0.084 6.1E-01 181 
  Coeliac 2217.3 2230.1 -1104.6 -0.289 8.0E-02 181 












  Reflux 2220.1 2232.9 -1106.1 -0.037 8.5E-01 181 
  Appendicectomy 2219.4 2232.2 -1105.7 -0.113 3.8E-01 181 
  Inhalers 2219.8 2232.6 -1105.9 0.085 5.6E-01 181 
  Barthel score 2220.0 2232.8 -1106.0 0.029 6.8E-01 181 
  Co morbidity 2219.6 2232.4 -1105.8 -0.041 4.7E-01 181 
  Godin 2215.7 2228.5 -1103.9 -0.005 2.9E-02 181 
  MMSE 2219.9 2232.7 -1105.9 -0.014 6.1E-01 181 
  MNA 2216.2 2229.0 -1104.1 -0.047 4.8E-02 181 
  HFD 2211.4 2224.2 -1101.7 1.228 3.4E-03 181 




970.2 986.2 -480.1 
0.964 8.8E-03 
181 
Osteoporosis 1.179 1.4E-03 
  AP spine BMD (g/cm2) 972.1 984.9 -482.1 -2.245 1.4E-02 181 
  AP spine T.score 973.6 986.4 -482.8 -0.231 3.5E-02 181 
  Neck of femur BMD (g/cm2) 977.1 989.9 -484.5 0.205 4.0E-01 181 
  Neck of femur T-score 974.2 987.0 -483.1 -0.403 6.1E-02 181 
BMI category 
Obese 
978.1 997.3 -483.0 
-0.104 8.0E-01 
181 Overweight 0.187 5.9E-01 
Underweight -72.936 1.0E+00 
  Calf circumference  (cm) 968.1 980.8 -480.0 -0.039 2.7E-01 179 
  Hip circumference (cm) 961.7 974.4 -476.9 -0.001 9.7E-01 178 












  Waist-Hip circumference ratio 960.5 973.2 -476.2 2.652 2.7E-01 178 
  Waist circumference (cm) 968.9 981.7 -480.5 0.007 6.0E-01 179 
  Weight (kg) 976.1 988.9 -484.1 -0.016 1.4E-01 181 
  Gender Male 974.0 986.8 -483.0 -0.912 2.6E-02 181 
  25(OH)D (nmol/L) 973.9 986.7 -482.9 0.014 4.7E-02 181 
  25(OH)D3 (nmol/L) 973.3 986.1 -482.6 0.015 3.4E-02 181 
  Calcium supplements 976.2 989.0 -484.1 0.419 1.8E-01 181 
  Bisphosphonate supplements 977.9 990.7 -484.9 -0.192 6.6E-01 181 
  Anticoagulants 977.8 990.6 -484.9 0.343 6.5E-01 181 
  Number of medications 976.3 989.1 -484.1 0.073 1.9E-01 181 
  Epilepsy medications 977.5 990.3 -484.7 0.388 4.7E-01 181 
  PPIs 978.0 990.8 -485.0 -0.075 8.3E-01 181 
  Analgesia (Opiod) 972.4 985.2 -482.2 0.997 3.4E-02 181 
  Coeliac 977.4 990.2 -484.7 -0.421 3.8E-01 181 
  Cholecystectomy 968.5 981.3 -480.2 1.220 6.0E-03 181 
  Reflux 977.8 990.6 -484.9 -0.308 6.1E-01 181 
  Appendicectomy 978.1 990.9 -485.0 0.035 9.3E-01 181 
  Inhalers 975.4 988.1 -483.7 0.650 1.2E-01 181 
  Barthel score 977.2 990.0 -484.6 -0.188 3.7E-01 181 
  Co morbidity 976.4 989.2 -484.2 -0.225 1.9E-01 181 
  Godin 977.3 990.1 -484.6 -0.008 3.5E-01 181 












  MNA 976.0 988.8 -484.0 -0.106 1.6E-01 181 
  HFD 976.7 989.5 -484.4 1.519 2.5E-01 181 




1675.1 1691.1 -832.6 
1.765 2.7E-03 
181 
Osteoporosis -1.090 4.0E-02 
  AP spine BMD (g/cm2) 1698.7 1711.5 -845.3 2.268 3.8E-02 181 
  AP spine T.score 1698.4 1711.2 -845.2 0.289 3.5E-02 181 
  Neck of femur BMD (g/cm2) 1702.4 1715.2 -847.2 -0.216 7.9E-01 181 
  Neck of femur T-score 1697.8 1710.6 -844.9 0.737 1.5E-02 181 
BMI category 
Obese 
NULL NULL NULL NULL NULL 181 Overweight 
Underweight 
  Calf circumference  (cm) 1678.5 1691.3 -835.3 0.076 2.4E-01 179 
  Hip circumference (cm) 1674.6 1687.3 -833.3 0.051 3.2E-02 178 
  Mid arm circumference (cm) 1685.6 1698.4 -838.8 0.085 1.3E-01 180 
  Waist-Hip circumference ratio 1676.9 1689.6 -834.5 -5.494 1.7E-01 178 
  Waist circumference (cm) 1684.1 1696.8 -838.0 0.022 3.8E-01 179 
  Weight (kg) 1702.1 1714.9 -847.1 0.014 5.3E-01 181 
  Gender Male 1701.5 1714.3 -846.7 -0.627 2.9E-01 181 
  25(OH)D (nmol/L) 1691.8 1704.6 -841.9 -0.025 2.1E-04 181 
  25(OH)D3 (nmol/L) 1693.0 1705.8 -842.5 -0.024 5.9E-04 181 












  Bisphosphonate supplements 1702.0 1714.8 -847.0 -0.469 4.6E-01 181 
  Anticoagulants 1702.5 1715.3 -847.2 0.079 9.4E-01 181 
  Number of medications 1702.2 1715.0 -847.1 -0.037 5.7E-01 181 
  Epilepsy medications 1699.5 1712.3 -845.8 -1.408 4.1E-02 181 
  PPIs 1701.9 1714.7 -847.0 0.364 4.8E-01 181 
  Analgesia (Opiod) 1702.5 1715.3 -847.2 0.044 9.5E-01 181 
  Coeliac 1698.5 1711.3 -845.3 -1.454 2.0E-02 181 
  Cholecystectomy 1701.6 1714.4 -846.8 0.647 3.7E-01 181 
  Reflux 1692.6 1705.4 -842.3 -3.497 2.6E-06 181 
  Appendicectomy 1695.4 1708.2 -843.7 1.474 2.8E-02 181 
  Inhalers 1698.4 1711.2 -845.2 -1.297 2.0E-02 181 
  Barthel score 1701.8 1714.6 -846.9 -0.275 4.2E-01 181 
  Co morbidity 1702.3 1715.1 -847.2 0.089 7.1E-01 181 
  Godin 1698.1 1710.9 -845.0 0.017 5.1E-02 181 
  MMSE 1702.4 1715.2 -847.2 0.029 7.5E-01 181 
  MNA 1700.1 1712.9 -846.0 -0.151 1.4E-01 181 
  HFD 1697.8 1710.6 -844.9 3.714 3.7E-02 181 




1183.3 1199.3 -586.6 
0.836 1.9E-01 
181 
Osteoporosis 0.319 6.1E-01 
  AP spine BMD (g/cm2) 1182.3 1195.1 -587.1 -1.319 3.4E-01 181 












  Neck of femur BMD (g/cm2) 1182.3 1195.1 -587.2 -0.643 1.8E-01 181 
  Neck of femur T-score 1183.2 1196.0 -587.6 0.008 9.7E-01 181 
BMI category 
Obese 
1180.0 1199.2 -584.0 
1.347 3.1E-02 
181 Overweight 0.654 1.8E-01 
Underweight -15.388 9.8E-01 
  Calf circumference (cm) 1164.1 1176.8 -578.0 0.039 6.6E-01 179 
  Hip circumference (cm) 1147.5 1160.3 -569.8 0.039 7.1E-02 178 
  Mid arm circumference (cm) 1169.2 1182.0 -580.6 -0.040 6.0E-01 180 
  Waist-Hip circumference ratio 1149.4 1162.1 -570.7 3.883 2.8E-01 178 
  Waist circumference (cm) 1164.8 1177.6 -578.4 0.040 4.6E-02 179 
  Weight (kg) 1182.9 1195.7 -587.4 -0.011 5.7E-01 181 
  Gender Male 1183.0 1195.8 -587.5 -0.300 6.0E-01 181 
  25(OH)D (nmol/L) 1182.9 1195.7 -587.4 0.007 5.6E-01 181 
  25(OH)D3 (nmol/L) 1182.7 1195.5 -587.4 0.008 4.8E-01 181 
  Calcium supplements 1180.8 1193.6 -586.4 0.751 1.2E-01 181 
  Bisphosphonate supplements 1172.4 1185.2 -582.2 1.748 3.4E-03 181 
  Anticoagulants 1183.0 1195.8 -587.5 -0.539 6.2E-01 181 
  Number of medications 1169.0 1181.8 -580.5 0.296 1.2E-04 181 
  Epilepsy medications 1182.6 1195.4 -587.3 -0.608 4.1E-01 181 
  PPIs 1183.1 1195.9 -587.6 -0.128 7.9E-01 181 
  Analgesia (Opiod) 1182.4 1195.2 -587.2 -0.661 3.2E-01 181 












  Cholecystectomy 1182.6 1195.4 -587.3 0.479 4.5E-01 181 
  Reflux 1182.6 1195.4 -587.3 -0.694 4.1E-01 181 
  Appendicectomy 1179.0 1191.8 -585.5 1.116 5.0E-02 181 
  Inhalers 1177.5 1190.3 -584.8 1.435 2.5E-02 181 
  Barthel score 1168.8 1181.6 -580.4 -0.640 1.9E-03 181 
  Co morbidity 1175.1 1187.9 -583.6 0.574 5.2E-03 181 
  Godin 1183.0 1195.8 -587.5 0.004 6.4E-01 181 
  MMSE 1182.9 1195.7 -587.5 -0.061 6.1E-01 181 
  MNA 1183.2 1196.0 -587.6 -0.009 9.2E-01 181 
  HFD 1177.8 1190.6 -584.9 -5.372 2.0E-02 181 




1249.8 1265.8 -619.9 
1.126 2.0E-03 
181 
Osteoporosis -0.196 5.9E-01 
  AP spine BMD (g/cm2) 1262.4 1275.2 -627.2 1.113 3.0E-01 181 
  AP spine T.score 1262.8 1275.6 -627.4 0.106 4.2E-01 181 
  Neck of femur BMD (g/cm2) 1251.0 1263.8 -621.5 -3.804 7.2E-04 181 
  Neck of femur T-score 1244.8 1257.6 -618.4 -0.858 5.3E-05 181 
BMI category 
Obese 
1256.3 1275.5 -622.1 
-1.447 3.3E-04 
181 Overweight -0.486 1.6E-01 
Underweight -1.838 2.1E-01 
  Calf circumference (cm) 1246.3 1259.1 -619.2 -0.096 3.0E-03 179 












  Mid arm circumference (cm) 1252.1 1264.9 -622.0 -0.107 2.1E-03 180 
  Waist-Hip circumference ratio 1230.6 1243.3 -611.3 1.150 6.8E-01 178 
  Waist circumference (cm) 1243.2 1255.9 -617.6 -0.026 7.2E-02 179 
  Weight (kg) 1260.8 1273.5 -626.4 -0.018 8.4E-02 181 
  Gender Male 1259.6 1272.4 -625.8 0.902 5.0E-02 181 
  25(OH)D (nmol/L) 1263.4 1276.2 -627.7 0.002 8.1E-01 181 
  25(OH)D3 (nmol/L) 1263.4 1276.2 -627.7 0.002 7.4E-01 181 
  Calcium supplements 1257.1 1269.9 -624.6 -0.818 8.2E-03 181 
  Bisphosphonate supplements 1257.5 1270.3 -624.7 -1.231 4.4E-03 181 
  Anticoagulants 1262.7 1275.5 -627.4 0.615 4.2E-01 181 
  Number of medications 1263.5 1276.3 -627.7 0.009 8.9E-01 181 
  Epilepsy medications 1254.3 1267.1 -623.1 -2.164 8.1E-05 181 
  PPIs 1245.4 1258.2 -618.7 1.352 4.8E-05 181 
  Analgesia (Opiod) 1259.9 1272.6 -625.9 -1.058 2.9E-02 181 
  Coeliac 1259.5 1272.3 -625.8 0.954 6.5E-02 181 
  Cholecystectomy 1262.2 1275.0 -627.1 -0.575 2.2E-01 181 
  Reflux 1240.9 1253.7 -616.5 2.073 2.4E-04 181 
  Appendicectomy 1243.3 1256.1 -617.7 1.520 1.1E-04 181 
  Inhalers 1259.2 1272.0 -625.6 -0.997 1.9E-02 181 
  Barthel score 1259.8 1272.6 -625.9 -0.548 6.6E-02 181 
  Co morbidity 1262.0 1274.8 -627.0 0.249 2.2E-01 181 












  MMSE 1257.3 1270.1 -624.6 0.246 6.4E-03 181 
  MNA 1249.7 1262.5 -620.8 -0.194 4.4E-04 181 
  HFD 1261.7 1274.5 -626.9 -1.571 1.8E-01 181 
The intercept represents normal BMI, normal BMD, females and No. 
AIC, Akaike Information criterion; BIC, Bayesian information criterion          
 
Supplementary table 7: Bivariate analysis of the groups category controlling for significant confounding variables identified from 
supplementary table 5 against the significant genera 
Taxa     AIC BIC logLik estimate p-value Number of samples 
Actinomyces 
  Bisphosphonate supplements 




Osteopenia 0.336 1.4E-01 
Osteoporosis 0.700 3.1E-03 
  Coeliac 




Osteopenia 0.293 2.1E-01 
Osteoporosis 0.777 7.5E-04 
  Cholecystectomy 




Osteopenia 0.335 1.4E-01 
Osteoporosis 0.639 6.6E-03 
  25(OH)D (nmol/L) 




Osteopenia 0.262 2.6E-01 
Osteoporosis 0.698 3.0E-03 
  25(OH)D3 (nmol/L) 




Osteopenia 0.260 2.6E-01 
Osteoporosis 0.707 2.7E-03 
                 
Clostridium XlVa 
  Bisphosphonate supplements 




Osteopenia 0.310 1.3E-02 
Osteoporosis 0.222 8.3E-02 
  Anticoagulants 




Osteopenia 0.250 4.9E-02 












  Gender 




Osteopenia 0.315 1.2E-02 
Osteoporosis 0.289 2.0E-02 
  Godin 




Osteopenia 0.345 5.6E-03 
Osteoporosis 0.294 1.7E-02 
  HFD 




Osteopenia 0.248 5.7E-02 
Osteoporosis 0.264 3.3E-02 
  MNA 




Osteopenia 0.322 1.0E-02 
Osteoporosis 0.272 3.0E-02 
                 
Eggerthella 
  Gender 




Osteopenia 0.934 1.0E-02 
Osteoporosis 1.270 5.4E-04 
  Analgesia (Opiod) 




Osteopenia 0.800 3.0E-02 
Osteoporosis 1.096 2.7E-03 
  Cholecystectomy 




Osteopenia 0.939 9.1E-03 
Osteoporosis 0.783 4.0E-02 
  25(OH)D (nmol/L) 




Osteopenia 0.843 2.8E-02 
Osteoporosis 1.029 1.0E-02 
  25(OH)D3 (nmol/L) 




Osteopenia 0.823 3.4E-02 
Osteoporosis 1.004 1.3E-02 
                 
Escherichia/Shigella 
  HFD 




Osteopenia 1.719 5.5E-03 
Osteoporosis -1.080 4.2E-02 
  Epilepsy medications 
1676.5 1695.7 -832.2 
0.548 4.5E-01 
181 












Osteoporosis -1.156 2.8E-02 
  Coeliac 




Osteopenia 1.510 1.8E-02 
Osteoporosis -1.257 2.1E-02 
  Reflux 




Osteopenia 1.662 6.1E-03 
Osteoporosis -0.971 8.0E-02 
  Appendicectomy 




Osteopenia 1.898 8.1E-04 
Osteoporosis -0.672 2.1E-01 
  Inhalers 




Osteopenia 1.576 6.8E-03 
Osteoporosis -1.213 1.8E-02 
  Hip circumference (cm) 




Osteopenia 2.023 6.0E-04 
Osteoporosis -0.784 1.4E-01 
  25(OH)D (nmol/L) 




Osteopenia 1.795 7.6E-04 
Osteoporosis -0.585 2.9E-01 
  25(OH)D3 (nmol/L) 




Osteopenia 1.781 1.0E-03 
Osteoporosis -0.646 2.5E-01 
                 
Lactobacillus 
  Barthel score 




Osteopenia -0.058 9.2E-01 
Osteoporosis 0.205 7.2E-01 
  Bisphosphonate supplements 




Osteopenia 0.042 9.4E-01 
Osteoporosis -0.073 9.1E-01 
BMI category  
Obese 
1179.2 1204.8 -581.6 
1.913 7.8E-03 
181 
Overweight 1.561 1.9E-02 
Underweight -15.371 9.8E-01 
Groups 
Osteopenia 1.226 6.3E-02 












  Number of medications 




Osteopenia 0.727 1.8E-01 
Osteoporosis 0.635 2.8E-01 
  Co morbidity 




Osteopenia 0.507 3.9E-01 
Osteoporosis 0.521 3.9E-01 
  HFD 




Osteopenia 1.095 5.6E-02 
Osteoporosis 0.743 2.5E-01 
  Waist circumference (cm) 




Osteopenia 0.551 3.9E-01 
Osteoporosis 0.666 3.2E-01 
                  
Veillonella 
  Bisphosphonate supplements 




Osteopenia 1.101 2.4E-03 
Osteoporosis -0.015 9.7E-01 
BMI category  
Obese 
1247.2 1272.8 -615.6 
-1.297 2.6E-03 
181 
Overweight -0.246 5.4E-01 
Underweight -1.069 4.6E-01 
Groups 
Osteopenia 0.844 4.5E-02 
Osteoporosis -0.474 2.6E-01 
  Calcium supplements 




Osteopenia 1.171 1.3E-03 
Osteoporosis 0.210 6.4E-01 
  Epilepsy medications 




Osteopenia 1.101 2.1E-03 
Osteoporosis -0.134 7.1E-01 
  PPIs 




Osteopenia 0.601 9.6E-02 
Osteoporosis -0.805 3.0E-02 
  Analgesia (Opiods) 




Osteopenia 1.078 2.9E-03 
Osteoporosis -0.283 4.4E-01 













Osteopenia 0.737 3.9E-02 
Osteoporosis -0.164 6.4E-01 
  Appendicectomy 




Osteopenia 1.243 3.1E-04 
Osteoporosis -0.003 9.9E-01 
  Inhalers 




Osteopenia 1.140 1.6E-03 
Osteoporosis -0.117 7.5E-01 
  Calf circumference (cm) 




Osteopenia 0.760 4.1E-02 
Osteoporosis -0.615 1.2E-01 
  Hip circumference (cm) 




Osteopenia 0.703 6.9E-02 
Osteoporosis -0.625 1.2E-01 
  Mid arm circumference (cm) 




Osteopenia 0.646 1.2E-01 
Osteoporosis -0.565 1.6E-01 
  MMSE 




Osteopenia 1.049 7.1E-03 
Osteoporosis -0.152 6.9E-01 
  MNA 




Osteopenia 0.572 1.4E-01 
Osteoporosis -0.687 7.3E-02 












Supplementary table 8: BMI, medications and vitamin D adjustment on AP spine BMD and association with significant genera  
a) Identifying association between BMD and BMI (AP spine BMD ~ BMI) 
  Estimate Std. Error P-values R2 
BMI 0.018 0.003 1.9E-10 0.20 
 
b) Investigating the effect of BMI, medications and vitamin D levels on BMD measures  
AP spine BMD ~ BMI + Groups + Calcium supplements + Bisphosphonate + Denosumab 
+ vitamin D total + Calcium supplements * Denosumab * vitamin D total 
  Estimate Std. Error 
(Intercept) 0.994 0.074 
BMI 0.005 0.002 
Osteopenia -0.158 0.021 
Osteoporosis -0.353 0.024 
Calcium supplementsYes 0.037 0.062 
BisphosphonateYes 0.014 0.024 
DenosumabYes 0.099 0.423 
Vitamin D Total 0.001 0.001 
The intercept represents normal BMD and No 
 
c) Association of AP spine BMD on Groups (AP spine BMD ~ Groups) 
  Estimate Std. Error P-values R2 
Osteopenia -0.17 0.02 2.6E-15 
0.66 
Osteoporosis -0.38 0.02 < 2E-16 















d) Validating the association of residuals from b) on Groups and BMD measure 
d.1) Residual obtained from b) and restoring only AP spine variations ~ Groups 
 Estimate  Std. Error P-values R2 
Osteopenia -0.17 0.02 2.5E-16 
0.68 
Osteoporosis -0.38 0.02 < 2E-16 
The values of estimate, standard error, p-values and R2(variance explained) in linear regression of restored residuals from model 2 on Groups 
d.2) Residual obtained from b) and restoring only AP spine BMD ~ actual AP spine BMD 
 Estimate  Std. Error P-values R2 
AP spine BMD 0.97 0.01 <2E-16 0.97 
The values of estimate, standard error, p-values and R2(variance explained) in linear regression of restored residuals from model 2 on AP spine 
BMD 
 
e) Residual obtained from b) and restoring only BMD variations ~ medications and BMI 
 Estimate  Std. Error P-values  R2 
BMI 1.2E-17 1.9E-03 1.0E+00 
0.68 Osteopenia -1.7E-01 2.0E-02 7.4E-16 
Osteoporosis -3.8E-01 2.2E-02 2.9E-40 
Osteopenia -1.7E-01 2.0E-02 3.3E-15 
0.68 Osteoporosis -3.8E-01 2.1E-02 1.8E-42 
Calcium supplementsYes 1.7E-17 1.7E-02 1.0E+00 
Osteopenia -1.7E-01 2.0E-02 5.5E-16 
0.68 Osteoporosis -3.8E-01 2.0E-02 5.1E-44 
Vitamin D Total -1.4E-18 3.3E-04 1.0E+00 
Osteopenia -1.7E-01 1.9E-02 3.2E-16 
0.68 Osteoporosis -3.8E-01 2.0E-02 1.4E-44 












Osteopenia -1.7E-01 1.9E-02 3.1E-16 
0.68 Osteoporosis -3.8E-01 2.0E-02 4.2E-44 
BisphosphonateYes 9.0E-18 2.3E-02 1.0E+00 
The results of linear regression obtained from modelling the restored residuals of model 2 against BMI, medications and vitamin D levels  
 
f) GLMM with residuals obtained from b) and restoring only AP spine BMD variations to taxa 
GLMMs Estimate Std. Error P-values pseudo-R2 
Actinomyces -1.88 0.46 5.1E-05 0.09 
Clostridium_XlVa -0.34 0.29 2.4E-01 0.05 
Eggerthella -2.51 0.92 6.4E-03 0.03 
Escherichia/Shigella 2.96 1.20 1.3E-02 0.02 
Lactobacillus -2.22 1.44 1.2E-01 0.08 
Veillonella 0.95 1.12 4.0E-01 0.001 
Significant nominal p-values are highlighted in red and bold  
 
Supplementary table 9: BMI, medications and vitamin D adjustment on lowest neck-femur BMD and association with significant genera 
a) Identifying association between BMD and BMI (Lowest neck femur BMD ~ BMI) 
  Estimate Std. Error P-values R2 
BMI -0.001 0.006 8.2E-01 0.0003 
 
b) Investigating the effect of BMI, medications and vitamin D levels on BMD measures  
Lowest neck femur BMD ~ Groups + Calcium supplements + Bisphosphonate + Denosumab 
+ vitamin D total + Calcium supplements * Denosumab * vitamin D total 
  Estimate Std. Error   
(Intercept) 1.008 0.129   
BMI -0.164 0.078   












Osteoporosis 0.011 0.228   
Calcium supplementsYes 0.163 0.090   
BisphosphonateYes 0.329 1.563   
DenosumabYes -0.001 0.002   
Vitamin D Total 1.008 0.129   
The intercept represents normal BMD and No 
 
c) Association of lowest neck-femur BMD on Groups (Lowest neck-femur BMD ~ Groups) 
  Estimate Std. Error P-values R2 
Osteopenia -0.137 0.072 6.0E-02 
0.03 
Osteoporosis -0.136 0.073 6.3E-02 
The values of estimate, standard error, p-values and R2(variance explained) in linear regression of Groups variable on lowest neck femur BMD 
 
d) Validating the association of residuals from b) on Groups and BMD measure 
d.1) Residual obtained from b) and restoring only Lowest neck-femur variations ~ Groups  
 Estimate  Std. Error P-values R2 
Osteopenia -0.137 0.071 5.7E-02 
0.03 
Osteoporosis -0.136 0.072 5.9E-02 
The values of estimate, standard error, p-values and R2(variance explained) in linear regression of restored residuals from model 2 on Group 
 
 
d.2) Residual obtained from b) and restoring only lowest neck-femur BMD ~ actual lowest neck-femur BMD  
 Estimate  Std. Error P-values R2 
Lowest neck femur BMD 0.971 0.013 <2E-16 0.97 














e) Residual obtained from b) and restoring only lowest neck-femur BMD variations ~ medications and BMI 
 Estimate  Std. Error P-values R2 
Osteopenia -0.137 0.075 6.9E-02 
0.03 Osteoporosis -0.136 0.077 7.7E-02 
Calcium supplementsYes 0.000 0.064 1.0E+00 
Osteopenia -0.137 0.072 6.0E-02 
0.03 Osteoporosis -0.136 0.074 6.8E-02 
Vitamin D Total 0.000 0.001 1.0E+00 
Osteopenia -0.137 0.072 5.8E-02 
0.03 Osteoporosis -0.136 0.074 6.5E-02 
DenosumabYes 0.000 0.116 1.0E+00 
Osteopenia -0.137 0.072 5.7E-02 
0.03 Osteoporosis -0.136 0.074 6.8E-02 
BisphosphonateYes 0.000 0.085 1.0E+00 
The results of linear regression obtained from modelling the restored residuals of model 2 against BMI, medications and vitamin D levels  
 
f) GLMM with residuals obtained from b) and restoring only lowest neck-femur BMD variations to taxa 
GLMMs Estimate Std. Error P-values pseudo-R2 
Actinomyces -2.552 0.638 6.4E-05 0.08 
Clostridium_XlVa 0.154 0.099 1.2E-01 0.08 
Eggerthella 0.246 0.270 3.6E-01 0.04 
Escherichia/Shigella -0.374 0.598 5.3E-01 0.02 
Lactobacillus -0.851 0.360 1.8E-02 0.06 
Veillonella -2.030 1.314 1.2E-01 0.001 
Significant nominal p-values are highlighted in red and bold, trends of associations are highlighted in green and bold 
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Chapter 3 Investigating the Potential of Biologic Treatment to Alter the Gut 
Microbiota in Rheumatic Inflammatory Disorders 
3.1 Abstract 
Gut microbiota plays an important role in the maintenance of human health and 
modulates and is modulated by the immune system. The microbiota has been 
implicated as a potential risk factor in immune-mediated diseases. The literature 
suggests that immunosuppressive drugs are associated with microbiota alterations and 
that these alterations may be a partial restoration of the gut microbiota towards 
healthy- like structure. No study to date has investigated the effects of biologics on 
microbiota composition.  This pilot study aims to establish if there are changes in gut 
microbiota associated with biologics treatment and if such changes are observed, if 
these changes are disease specific or a general property of biologic associated 
microbiota-recovery.  
Metagenomic sequencing was used to compare the gut microbiota profiles of biologics 
treatment naive subjects undergoing de-novo treatment and long-term biologics 
treated subjects with established diseases (Rheumatoid arthritis (RA), Psoriatic 
arthritis (PSA), Ankylosing Spondylitis (AS)) compared with healthy controls. This 
consisted of a multi-timepoint analysis of treatment naive subjects consisting of 132 
samples from 24 subjects representing 9 RA, 7 PSA, 4 AS, 4 Inflammatory Bowel 
diseases (IBD) subjects before and after biologics treatment with sampling pre-
treatment and at 3 and 6 months post-treatment. The established group comprises of 
10 AS, 18 PSA and 16 RA samples. Healthy samples included 16 subjects sampled 
across time-points. These subjects were extensively phenotyped with clinical, dietary 
and anthropometric information investigated. 
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Our analysis shows that the immunomodulatory medication may partially restore the 
microbiome to a health-associated state with the β-diversity of the established 
treatment groups showing no significant differences from the controls. The treatment 
naive samples showed increased abundances of distinct taxa that were lower in the 
controls. The microbiota associated with established diseased groups with long- term 
biologics treatment has an intermediate structure with both control and disease 
associated taxa being evident. Key taxonomic markers as identified in other studies 
were also observed and showed significant correlation with clinica l variables. Overall, 
the results indicate that biologics treatment shifts the microbiota signature towards that 
of healthy controls like. This study provides incentive for the recruitment and analys is 
of larger cohorts that will allow for the identification of key taxonomic predictors of 
treatment responsiveness and remission. 
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3.2 Introduction 
Immune associated conditions such as different types of arthritis and Inflammato ry 
Bowel Diseases (IBD) are associated with an inflammatory state across body sites 
(Baumgart and Sandborn, 2007;Ledingham et al., 2017). The aetiology of these 
conditions are multi- factorial and can affect anyone from a very young age (Baumgart 
and Carding, 2007;Mezoff and Dykes, 2015;Simone et al., 2018;Smolen et al., 
2018;Veale and Fearon, 2018). Arthritis has been reported to affect approximate ly 
0.001-1.4% of populations worldwide (Dean et al., 2014;Liu et al., 2014;Smolen et 
al., 2018). Epidemiological studies have shown that rheumatoid arthritis (RA) is 
increasing in prevalence in women whereas ankylosing spondylitis (AS) is more 
prevalent in men (Landi et al., 2016;Smolen et al., 2018). Occurrence of psoriatic 
arthritis (PSA) is known to occur at a very young age (Southwood et al., 1989). The 
detection of these conditions is dependent on development of symptoms and further 
aggravation of the disease pathogenesis. Amongst these conditions only RA has been 
identified to be seropositive which allows early patient’s evaluation for autoimmune 
conditions susceptibility (Smolen et al., 2018). Other diseases (AS or PSA) can remain 
undetected for long time. Factors known to contribute to the onset of these conditions 
include immunological factors such as HLA-B27, Th17, Th12, Th23 as well as 
improper protein folding, smoking and stress (Khor et al., 2011;Simone et al., 
2018;Smolen et al., 2018;Veale and Fearon, 2018). These conditions are also 
associated with various co-morbidities and may be associated with other inflammato ry 
conditions such as Inflammatory Bowel disease (IBD), where a subset of patients 
develop arthritis (Arvikar and Fisher, 2011). The role of gut microbiota in these 
conditions has not been fully elucidated but animal models have shown the importance 
of the microbiota, with a lack of disease development in a germ-free (GF) animals. 
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The subsequent introduction of gut microbiota into these GF animals resulted in the 
onset of disease symptoms (Peloquin and Nguyen, 2013;Rogier et al., 2017). 
 The relationship between the gut microbiota in health and disease is well 
characterised but represents a highly complex relationship (Clemente et al., 2018). 
One of the prominent roles of the gut microbiota is the proper development, 
maturation, and maintenance of the immune system (Adlerberth and Wold, 2009). 
Alterations in the microbiota profiles, community structure or introduction of certain 
taxa have been related to T-cell mediated modulation of inflammation (Kho and Lal, 
2018;Brown et al., 2019). Production of certain bacterial metabolites, degradation of 
the intestinal mucin layer, or leakage of pathobionts into the host system can also 
influence the immune system to trigger an inflammatory response (Chow et al., 
2011;Kho and Lal, 2018).  
Various non-antibiotic medications have also been associated with alterations 
in the gut microbiota profiles (Maier et al., 2018). Prominent among them are 
psychotherapeutics, metformin, supplements like vitamin-D, non-steroidal anti-
inflammatory drugs (NSAIDs) and proton-pump inhibitors (PPIs) (Zhernakova et al., 
2016;Jackson et al., 2018). Anti-Tumour Necrosis Factor (TNF) biologics used for 
treating immune associated inflammatory conditions have been identified to increase 
risk of infection (Atzeni et al., 2012).  
Medications like Methotrexate, other Disease modifying anti-rheumatic drugs 
(DMARDs), and biologics that have strong immune-suppressive properties are used 
extensively to treat arthritis and IBD. However, only a limited number of studies have 
highlighted potential changes in the gut microbiota dynamics in patients due to 
immunosuppressive medications.  
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 The aim of the present pilot study was to investigate whether biologics-trea ted 
patients with arthritis and IBD show different microbiota profile dynamics over the 
course of treatment and recovery. In addition, we aim to uncover the directionality of 
any such change in the gut microbiota profiles, and key marker features associated 
with different disease and recovery stages. We hypothesise that the disease-associated 
gut microbiota profiles demonstrate dysbiosis in the treatment-naive stage which is 
restored towards the healthy like microbiota with treatment.  
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3.3 Methods 
3.3.1 Subject recruitment and clinical information 
Samples were recruited from Cork University Hospital and Irish Centre for Arthrit is 
Research and Education (iCARE). Patients diagnosed with rheumatoid arthritis (RA), 
psoriatic arthritis (PSA), ankylosing spondylitis (AS) and Inflammatory Bowel 
Diseases (IBD) were considered for the study. Two different groups of participants 
were considered. The patients from the first groups were diagnosed with the disease 
but were not treated with biologics. Samples from this group of patients were collected 
over three time-points of three-month intervals where the first sample is collected 
before biologics treatment and the subsequent samples were collected during biologics 
treatment. The second group of patients recruited were an established disease group 
that had been on biologics for over a year. Control participants were obtained from the 
ControlMet cohort of APC Microbiome Ireland, Cork City and were similar ly 
collected over three time-points. All participants provided written consent. Exclus ion 
criteria included known history of alcohol abuse, participation in an investigationa l 
drug trial in the 30 days before enrolment, use of antibiotics in the 3 months prior 
recruitment. 
Clinical information included age, sex, anthropometric measures, smoking 
status, alcohol status, medication, surgery, and other medical history. Effectiveness of 
therapy was also recorded. It is defined by Bath Ankylosing Spondylitis Disease 
Activity Index (BADSAI) for AS (Garrett et al., 1994), Disease Activity in Psoriatic 
Arthritis (DAPSA) for PSA (Schoels et al., 2010), Disease Activity Score of 28 joints 
(DAS28) for RA (Prevoo et al., 1995), Harvey-Bradshaw index for Crohn’s disease 
(CD) (Harvey and Bradshaw, 1980) and Powell-Tuck index for ulcerative colitis (UC) 
(Powell-Tuck et al., 1978). Morisky score was used to determine adherence to 
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medications (Morisky et al., 1986). Population of various immune-cells (WBCs, 
Monocytes, Neutrophils, Lymphocytes, Basophils and Eosinophils) and levels of C-
reactive protein (CRP) were obtained from the blood of the diseased samples. Venous 
blood samples were collected from the antecubital fossa, where possible. One Greiner 
Bio-One VACUETTE® K3EDTA and one VACUETTE® Z Serum Sep Clot 
Activator tube was filled from each participant and centrifuged as per manufacturer’s 
specifications to produce a plasma and serum sample. All haematological (includ ing 
total and differential white cell count) and biochemical (high sensitivity CRP) analys is 
was performed in an accredited University Hospital laboratory compliant with 
international best standards of quality and competence (ISO 15189:2012). The control 
samples lacked serum information. International Physical Activity Questionna ires 
(IPAQ) was used to calculate the health-related physical activity of the individua ls 
(Hagstromer et al., 2006). Dietary information was recorded using food frequency 
questionnaires adapted from the European Prospective Investigation into Cancer 
(EPIC) study (UK arm) (McKeown et al., 2001). Any missing dietary information for 
samples was inferred from the same subjects at subsequent time-points by considering 
the recorded values from these time-points. Any other missing values in the samples 
were replaced by the median value of that particular food item observed for that group 
of samples. Healthy Food Diversity (HFD) index was calculated to determine diet 
quality (Drescher et al., 2007). 
 
3.3.2 Sample collection and DNA extraction 
Faecal and blood samples were collected from the subjects. Faecal samples were 
stored in -80 until further processing. DNA extraction was carried out using modified 
Yu and Morrison protocol (Yu and Morrison, 2004). Homogenisation was carried out 
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for 60 seconds followed by 30-60 seconds of cooling on ice. These modified steps 
were repeated twice more. All other steps remained unchanged.  
 
3.3.3 Sample processing  
Preparation of faecal samples for metagenomics whole genome shotgun (mWGS) 
sequencing was carried out using standard Illumina protocol for paired 150 X 2 MiSeq 
run. Paired reads obtained were trimmed and quality filtered using Trimmomatic 
(v.0.38) (Bolger et al., 2014) with the following parameters. The leading and trailing 
end were trimmed up to 10 bases. Sliding window of 4 bases and average quality of 
20 was set. Reads were retained if the trimmed length were at least 75 bases long. 
Quality filtered reads were then processed with bowtie2 (v.2.2.3) (Langmead and 
Salzberg, 2012) and mapped against the human genome (GRCh 38) to remove host 
contamination.  
Taxonomic profile was obtained using MetaPhlAn2 (Truong et al., 2015) at 
default setting. Using HUMAnN2 (v.0.7.1) (Franzosa et al., 2018) with UniRef90 
protein database and larger structured MetaCyc pathways mapping file, functiona l 
profile was obtained. The datasets were normalised to relative abundance. Eukaryotes, 
viruses, and archaea were removed from the taxonomic dataset, whereas all 
UMAPPED, UniRef_unknown and UNINTEGRATED were removed from 
functional datasets after normalisation to relative abundances. 
From the taxonomic dataset, α-diversity indices (Observed species and 
Shannon) were calculated using the vegan library (v.2.5.4) (Oksanen et al., 2017) in 
R (v.3.6.0) (Team, 2019). Β-diversity defined by Spearman dissimilarity measure was 
calculated from the taxonomic profiles. Functional diversity index (observed gene 
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count) was obtained from UniRef gene dataset. Spearman dissimilarity measure was 
also calculated from the relative abundance of pathways profiles. 
 
3.3.4 Statistical analysis 
All statistical analyses described below were carried out in R. Statistical significance 
is determined by P-adjusted ≤ 0.05 (Benjamini-Hochberg method) or nominal P-value 
≤ 0.05 cut-off unless stated otherwise. Species level taxonomic data and non-stratified 
pathway abundance data were used for all analysis.  
 
3.3.5 Analysis of meta-data 
 All meta-data values were compared between time-points using paired Wilcox 
test for any significant changes throughout the duration. To compare disease groups 
to control, disease samples from timeseries and established groups were compared 
with Control T0 using Mann-Whitney test. Diseased samples from timeseries groups 
were compared against the respective disease established groups using Mann-Whitney 
test to identify alterations associated with disease and treatment progression.  
 
3.3.6 Analysis of global microbiota composition 
Alterations in the global composition defined by various dissimilarity measures were 
analysed using bca (between-class analysis) from ade4 library (v.1.7.13) (Dray and 
Dufour, 2007) on datasets containing only a particular disease type along with the 
control samples. Significance and effect size were determined using Monte-Carlo 
algorithm for bca.  
Differences between timepoints were investigated using the beta diversity 
dissimilarity values as modelled by a linear regression model with adjustment for 
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observed species. This was done because reduced α-diversity is associated with 
increased variability in β-diversity (Jeffery et al., 2016). The model is as follows: 
Distance between timepoints ~ observed species + Groups 
Absolute dissimilarity measures from T2 to T0 and T3 to T0 was calculated 
for the different disease groups.  
An independent dataset by Zhang et al. (Zhang et al., 2015) comprising of RA 
samples was also included in the β-diversity analysis. The Zhang et al. dataset was 
filtered to remove control relatives, as they could not be related back to the clinica l 
data. Amongst the samples in the Posttreatment group’s stratification, those groups 
that were represented by less than 3 biological samples were also excluded from the 
analysis.  
Using paired Wilcox test on α-diversity indices and observed gene count 
identified significant differences between time-points. These indices from different 
disease groups were compared against controls (T0) using Mann-Whitney test. The 
indices from different diseases were also compared between time-points and 
established groups. 
 
3.3.7 Identification of discriminating taxonomic features  
Investigation of the taxonomic profiles from the individual disease groups was carried 
by comparing against the control T0 samples. The taxonomic datasets from each 
disease groups were filtered to remove species present below 0.001% abundance and 
detected in less than 10% of the samples. Identification of differentially abundant taxa 
was carried out using DESeq2 library (v.1.24.0) (Love et al., 2014). To generate count 
data. relative abundance data was multiplied by the number of reads mapped to clade-
specific genes. This is adapted from the tutorial provided in curatedMetagenomicData 
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(Pasolli et al., 2017) for analysing MetaPhlAn2 profiles. Each disease group was 
investigated individually, and significant species were identified based on p-adjusted 
≤ 0.05 in each pairwise analysis. Significant taxonomic features identified more than 
once across all pairwise comparisons were reported. This was done to remove 
spuriously detected taxa that were not reproduced in any pairwise comparisons. These 
were visualised using the heatmap.2 functionality from gplots (v.3.0.1.1) using the 
transformed values derived from the DESeq2 analysis. Heatmap dendrogram was 
generated using Kendall distance with ward clustering on the transformed values of 
the reported taxa.  
Differential abundance of pathways was carried out using Kruskal-Wallis test 
between diseased samples and control T0 samples adjusted for multiple testing across 
pathways. Significant p-adjusted (≤ 0.05) pathways were further investigated using 
dunn’s test (Dinno, 2017). 
 
3.3.8 Association between meta-data and significant taxa 
Key meta-data were correlated against significant taxa using Kendall correlation to 
identify significant association between meta-data and significant taxonomic markers 
and significance of Kendall’s correlation were defined by nominal p-value (≤ 0.05). 
Correlations between meta-data and significant taxa was visualised using heatmaps. 
Dendrogram for meta-data and significant taxa was obtained using Euclidean distance 
on the correlation values using ward.D2 clustering.   
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3.4 Results 
3.4.1 Description of the study population 
The present study comprised of 132 samples stratified into their respective groups as 
detailed in Supplementary tables 1-2. The samples comprised of established disease 
patients and a time-point of biologic treatment that consisted of pre-treatment 
(biologic naive), and 3 and 6 post-treatment samples. All biologics naive samples were 
deemed to have active disease by a physician despite being on methotrexate (MTX) 
and/or non-steroidal anti-inflammatory drugs (NSAIDs). The established samples are 
represented by their abbreviated disease names whereas the timeseries samples are 
labelled as abbreviated disease with their respective time-point. IBD samples 
comprised of 3 CD and 1 UC subjects. 
Subjects in both the established and timeseries disease groups were older 
compared to controls. They had a reduced dietary index (HFD), a smaller stature and 
a higher BMI than the control group (Supplementary table 2, Figure 1). A total of 
53% of patients were currently or previously ex-smokers whereas only 31% of the 
control subjects had a history of smoking. Among the disease subjects 57% of them 
reported a history of immune disorder in their family. 
Statistical analysis of the time-series meta-data showed that the majority of 
patient characteristics were stable over the timeseries (Supplementary table 3) with 
noticeable exceptions being an increase in HFD and the Morisky score for the RA 
timeseries and CRP levels between T2 compared to T1 mentioned above. 
Levels of CRP were significantly higher between pre-treatment RA (T0) and 
established RA (Supplementary table 4, Figure 1B) but dropped at the T2 timepoint 
as expected but was not significant at the T3 timepoint. 
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Immune cells population in blood was observed to be higher in biologic naive 
RA (T0) than biologic treated established RA with ssignificant differences observed 
between T0 vs T2 for white blood cells, Neutrophils, Lymphocytes and Monocytes. 
No immune cell differences reached significance in the other disease states. This may 
be due to lack of statistical power due to insufficient sample size (Supplementary 
table 1).  
  
 






















Figure 1 Significantly different meta-data characteristics of the disease 
populations compared to healthy controls   
Meta-data observed to be significantly different between the controls and the disease 
samples as shown in Figure 1A. Figure 1B shows the significant differences in C-
reactive protein (CRP) levels as observed in the different diseased groups. AS, PSA 
and RA represents established samples with long-term biologics treatment. T0 
represents timepoint before the biologics treatment and T2 and T3 represents 3 months 
and 6 months after T0.  
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3.4.2 Microbiota characterisation 
The MISeq mWGS sequencing run generated a total of 341.87 gigabases of quality 
filtered, contaminant removed sequence data comprising of 9,240,682±1,857,340 
reads per sample. Mapping these reads to reference databases using the HUMAnN2 
pipeline provided information on 348 bacterial species and 1,216,060 UniRef 
genefamilies resulting in 740 MetaCyc annotated pathways.  
 
3.4.3 Taxonomic diversity is partially associated with Biologic treatment 
The α-diversity for the control samples was stable over the timeseries 
(Supplementary table 5, Supplementary table 6A). The IBD biologic naive samples 
(T0) showed a reduced number of observed species compared to control T0 and AS 
(T0) and RA (T0, T2 and T3) samples showed a higher number of observed species 
compared to control T0. This increase in richness was retained in the unrelated 
samples in the established RA group (Supplementary table 6B, Figure 2). Other 
established arthritic diseases did not present with an altered richness compared to 
controls. IBD was also associated with a reduced gene count and Shannon index 
compared to controls (Supplementary table 6B, Figure 2D,E). No significant 
alterations in α-diversity were observed for PSA in the treatment naive or established 













Figure 2 Significant within-sample taxonomic and functional diversity associated with various immune disorders   
Differences in α-diversity was observed between the controls and various diseased samples. In plot A), B) and C) the number of unique species 
shows prominent differences in Rheumatoid arthritis, Ankylosing spondylitis but no significant difference in Psoriatic arthritis compared to 
controls. In plot D) Shannon index reflects significant within-sample variations in IBD against controls. Plot E) highlights significant difference 
in functional diversity as defined by gene count in IBD. Significance is defined by P-adjusted values. * ≤ 0.05, ** ≤ 0.005  
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3.4.4 Distinct β-diversity is observed with established and de-novo disease groups  
The control timeseries samples showed a stable β-diversity with taxonomic datasets 
as no significant alterations were observed with BCA analysis on Spearman 
dissimilarity (Supplementary table 7). The IBD and AS timeseries samples showed 
an altered β-diversity when compared against the control samples which was not 
observed with RA and PSA timeseries samples (Supplementary table 7, Figure 3). 
Comparison of established disease groups against the controls identified no 
differences in β-diversity (Supplementary table 7). The BCA ordination analys is 
showed that the established disease samples were closer to the controls than the 
timeseries samples in all cases (Figure 3). β-diversity was different between all 
disease groups except between PSA and AS samples (Supplementary table 7). 
The Zhang et al. RA cohort showed a significant difference in β-diversity 
(Spearman distance) based on the group stratifications (Supplementary table 7). 
Integrating the Zhang et al. RA taxonomic dataset with the current RA dataset revealed 
that the primary separation (X-axis) observed was between cohorts (Supplementary 
table 7, Figure 4A). However, along the Y-axis, RA (T3) and established samples 
from our dataset moved away from RA (T0) and towards controls. This was also 
observed in Zhang et al. cohort where the treated samples were observed to be between 
control and naive RA samples. This suggests a potential restoration of the microbio ta 
towards control-like following treatment. 
The functional datasets reflected the results observed in the taxonomic datasets 
in the IBD samples which showed statistically significant separation where IBD (T3) 
samples were closer to controls compared to IBD (T0) treatment naive samples 
(Supplementary table 8, Figure 5). 
 




Figure 3 Global gut microbiota β-diversity in various immune disorders  
The ordination represents between-class analysis (bca) using Spearman distance on 
taxonomic composition, stratified by groups and time-points. A) represents 
Rheumatoid arthritis (RA) B) represents Ankylosing spondylitis (AS), C) represents 
Psoriatic arthritis (PSA) and D) represents Inflammatory Bowel diseases (IBD) 
samples. Significant associations were observed only in AS and IBD with group plus 
time-point stratification. Established groups are represented by RA, AS, PSA and 
time-point samples are suffixed by T0, T2 and T3.   
 





Figure 4 Comparison of RA microbiota profiles from this study with an 
independent RA dataset 
Separation based on cohort is observed in both datasets. Axis 1 represents the primary 
split between the two rheumatoid arthritis cohorts. A trend is observed in both RA 
cohort showing movement away from treatment partly towards controls.   
 





Figure 5 Functional β-diversity of the gut microbiota in various immune  
disorders  
The ordination represents between-class analysis (bca) using Spearman distance on 
pathway abundance, stratified by groups and time-points. A) represents Rheumato id 
arthritis (RA) B) represents Ankylosing spondylitis (AS), C) represents Psoriatic 
arthritis (PSA) and D) represents Inflammatory Bowel diseases (IBD) samples. 
Significant associations were observed only in IBD with group plus time-point 
stratification. Established groups are represented by RA, AS, PSA and time-point 
samples are suffixed by T0, T2 and T3.   
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The difference from T0 to T2 or T3 is an indicator of the degree of alterations 
in the β-diversity profiles based on taxonomic datasets across the timeseries (Figure  
6). Dissimilarity did not achieve statistical significance between T2-T0 in any disease 
groups against control (Figure 6A). However, RA and IBD groups showed significant 




Figure 6 Increased dissimilarity between timepoints observed in treated disease 
states  
Dissimilarity was defined as absolute distance as calculated by Spearman between 
subjects at T2 and T3 with T0 from different diseases. Plot A) highlights the distance 
observed for a subject between T2 and T0. Plot B) represents the distance observed 
between T3 and T0 for each subject. The subjects are coloured by Group category. 
Rheumatoid arthritis (RA), Ankylosing spondylitis (AS), Psoriatic arthritis (PSA) and 
Inflammatory Bowel diseases (IBD). Significance is defined by P-adjusted values. * 
≤ 0.05, ** ≤ 0.005  
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3.4.5 Unique and shared taxonomic markers associated with disease groups 
The analysis of abundant taxonomies identified various shared and unique bacterial 
species associated with different disease groups. Overall, 37 differentially abundant 
species, belonging to 23 different genera were shared between at least two disease 
groups. These included species belonging to known genera associated with potential 
immune modulation like Alistipes, Bacteroides, Bifidobacterium, Clostridium, 
Collinsella, Desulfovibrio, Lactococcus, Paraprevotella, Rumminococcus and 
Streptococcus (Figure 7A-D) (Liu et al., 2016;Clemente et al., 2018).  
In the RA dataset, 23 species were differentially abundant between disease 
groups and controls (Figure 7A, Supplementary table 9A). Amongst them, 
Streptococcus gordonii, Streptococcus anginosus, Streptococcus infantis, 
Streptococcus mutans, Rothia dentocariosa, Collinsella intestinalis, Lactobacillus 
casei paracasei and Anaerotruncus colihominis were prevalent only in the disease 
group. Blautia hydrogenotrophica, Bacteroides salyeriae, Lactococcus lactis, 
Bacteroides clarus were depleted in the disease samples. The established RA samples 
showed the presence of species from Streptococcus, Collinsella and Veillonella that 
were significantly associated with disease groups and Bacteroides salyeriae, Blautia 
hydrogenotrophica, Lacococcus lactis that were associated with control samples.  
The AS dataset identified 43 different species belonging to 26 genera that were 
significantly differentially abundant between the groups from the pairwise 
comparisons (Figure 7B, Supplementary table 9B). Collinsella intestinalis, 
Clostridium hathewayi, Anaerotruncus colihominis, Clostridium symbiosum and 
Clostridium nexile were identified in the AS timeseries samples and missing in the 
control and AS established samples. In the control group, Lactococcus lactis, 
Bacteroides coprocola, Bacteroides stercoris Baceroides massiliensis, Bacteroides 
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finegoldii, Desulfovibrio desulfuricans and Bacteroides salyersiae were more 
abundant. Certain taxa such as Ruminococcus bromii, Bifidobacterium bifidum, 
Bacteroides stercoris, Bacteroides coprocola, Bacteroides massiliensis, and 
Eubacterium biforme were observed across both established disease and control 
samples while they were depleted in the timeseries samples. The established AS 
disease group showed the presence of disease associated (Anaerotruncus colihominis, 
Clostridium nexile) and control associated taxa (Desulfovibrio desulfuricans, species 
of Clostridium and Bacteroides). Eubacterium ventriosum and Bacteroides 
cellulosilyticus were detected across all groups. 
 In the PSA dataset, 34 distinct species were identified to be significantly 
different between at least two pairwise comparisons (Figure 7C, Supplementary 
table 9C). In the diseased timeseries samples, Bacteroides faecis, Bacteroides 
finegoldii, Veillonella dispar and Lactococcus lactis were distinctively depleted but 
were observed in established PSA and controls. Species such as Roseburia intestinalis 
and Bacteroides fraigilis were observed PSA T0 samples but were depleted in T2 and 
T3. Roseburia intestinalis was observed in both established PSA and control samples 
also. In the control samples, Mitsuokella multacida and Bacteroides clarus were 
prominent and reduced in all disease samples (established and timepoint). 
Prominent group-specific signatures with 66 different species from 32 genera 
were seen in the IBD dataset. The differentially abundant species identified are well 
established with inflammation and IBD (Figure 7D, Supplementary table 9D). In 
the disease group, Blautia hansenii, Blautia producta, Lachnospiraceae bacterium 
species, Clostridiales bacterium species, Dorea, Clostridium nexile, Bacteroides 
fragilis, Enterococcus faecalis and Streptococcus gordonii were dominant and 
completely absent in control group. Ruminococcus gnavus was observed in low 
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abundant in few control samples but was prominent in disease. Similar ly, 
Ruminococcus bromii and Bacteroides dorei were observed in few IBD samples but 
were more abundant in controls. In the controls, Roseburia hominis, Alistipes 
indistintus, Eubacterium rectale, Coprococcus species, Clostridium leptum, 
Bacteroides finegoldii, Bacteroides faecis, Paraprevotella species, Prevotella copri to 
name a few were abundant and not detected in IBD samples. 
A comparison of the common disease associated species across different 
disease types highlighted that the RA dataset shared the smallest number of 
differentially abundant species with other conditions whereas AS and IBD shared the 
most.   
 









































Figure 7 Heatmap of differentially abundant species in different diseases   
Heatmap of the differentially abundant species between all pairwise comparisons 
identified by DESeq2 analysis in A) rheumatoid arthritis (RA) and B) Ankylos ing 
spondylitis (AS). All pairwise comparisons were carried out within the disease 
samples and against control T0 samples. DESeq2 normalised values are plotted in the 
heatmap and the dendrogram represents Kendall distance based on the significant 
species.  
 
























Figure 7 Heatmap of differentially abundant species in different diseases   
Differentially abundant species between all pairwise comparisons identified by 
DESeq2 analysis in C) Psoriatic arthritis (PSA) and D) Inflammatory Bowel diseases 
(IBD). All pairwise comparisons were carried out within the disease samples and 
against control T0 samples. DESeq2 normalised values are plotted in the heatmap and 
the dendrogram represents Kendall distance based on the significant species.  
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3.4.6 Only IBD groups showed significantly different functional features  
Investigation of the functional profiles determined by pathway abundances did not 
identify any significantly differentially abundant pathway in the arthritic groups. 
Pathways were observed to be significantly differentially abundant in the pairwise 
comparison between IBD timeseries samples vs controls (T0) (Supplementary table  
10). Amongst these, two pathways were guanosine and adenosine biosynthes is 
pathways, which are part of DNA replication. Arginine dependent acid resistance and 
asparagine degradation pathways was found to be significantly different in multi-
group comparisons but did not pass the statistical threshold during the pairwise 
analysis. Only Arginine degradation and putrescine biosynthesis pathways were 
significantly different in their abundance between IBD timeseries and controls.  
 
3.4.7 Nominally significant associations were observed between key meta-data 
and significant species 
Key meta-data such as immune cells populations, CRP levels, diet (HFD index), BMI, 
weight, physical activity, and medical information such as adherence to medication 
and years since diagnosis were correlated with the identified differentially abundant 
species in different diseases. Significance of correlations observed between various 
meta-data and the species was defined by nominal p-value (≤0.05) (Figure 8A-D).  
 In the RA dataset, different immune cells showed significant correlation with 
different species (Figure 8A). Blautia hydrogenotrophica negatively correlated with 
white blood cells (WBCs) and neutrophils, whereas monocytes and basophils 
population positively correlated with Streptococcus anginosus and Streptococcus 
infantis respectively. CRP levels showed significant negative correlation with 
Bacteroides clarus and Collinsella intestinalis. Morisky score did not show any 
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significant correlation with any taxa, while unclassified Holdemania species showed 
positive association with disease duration. 
Different species of Clostridium were significantly negatively correlated with 
disease duration in the AS dataset (Figure 8B). Different immune cells population 
excluding lymphocytes were negatively correlated with different species of 
Bacteroides. Physical activity negatively correlated with Bacteroides finegoldii, 
Paraprevotella species, Eubacterium ventriosum and positively correlated with 
Clostridium nexile and Collinsella intestinalis.  
Correlation between the meta-data and the species significantly different in the 
PSA dataset highlighted significant positive association between Basophils, 
Lymphocytes, WBCs and Neutrophils with Streptococcus vestibularis, Flavonifractor 
plautii, Clostridium asparagiforme and Lachnospiraceae bacterium (Figure 8C). 
HFD and physical activity did not show any significant correlation with significant 
species observed in PSA. Disease duration was significantly positively correlated with 
Turicibacter species and negatively correlated with Desulfovibrio piger and 
Clostridium asparagriforms. CRP levels were also significantly positively correlated 
with Flavonifractor plautii, Lactococcus lactis, Actinomyces graevenitzii and 
negatively correlated with Bacteroides corprophilus. 
 As the IBD dataset had various species depleted in the diseased state, those 
species could not be correlated with various meta-data that were available only for the 
diseased samples (Figure 8D). Overall, BMI showed significant negative correlation 
with Clostridium leptum, Bacteroides dorei, Alistipes finegoldii, Bacteroides 
Massilliensis, Ordibacter species and Eubacterium retale. Species belonging to 
Roseburia, Alistipes, Eubacterium, Bacteroides, Akkermansia, Rumminococcus and 
Clostridium were significantly positively associated with physical activity while 
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Streptococcus, Enterococcus and Bacteroides fragilis were negatively correlated. Diet 
also correlated positively with Ruminococcus, Lachnospiraceae bacterium, Dorea and 
showed negative correlation with Streptococcus gordonii and Bacteroides fragilis. 
Significant negative correlation was observed between immune cells (WBCs, 
Monocytes and Neutrophils) and species of Bacteroides, Dorea, Ruminococcus 
gnavus, Lachnospiraceae and positively correlated with Eubacterium and Alistipes 
species. Bacteroides dorei and Ruminococcus bromii negatively correlated with CRP 
levels. 
Similar disease associated species from different diseases showed simila r 
correlation with immune cells, diet, and physical activity. However, these correlations 
were nominally significant and many of the known association were non-significant 
after p-value adjustment.   
 













































Figure 8 Correlation between significantly different species and clinical factors   
Heatmap of Kendall correlation between clinical meta-data and the abundances of 
significant taxa from Control T0 and the diseased samples per disease. Dendrogram is 
based on Euclidean distance on Kendall correlation. Plot A) represents correlation 
observed in RA dataset. B) shows correlation in AS dataset. Significance is based on 
nominal P-values. * ≤ 0.05, ** ≤ 0.005. Grey cells represent no correlation due to 
zero abundance of species in disease groups.  
 















Figure 8 Correlation between significantly different species and clinical factors  
Heatmap of Kendall correlation between clinical meta-data and the abundances of 
significant taxa from Control T0 and the diseased samples per disease. Dendrogram is 
based on Euclidean distance on Kendall correlation. Plot C) represents correlation 
observed in PSA dataset. D) shows correlation in IBD dataset. Significance is based 
on nominal P-values. * ≤ 0.05, ** ≤ 0.005, *** ≤ 0.0005. Grey cells represent no 
correlation due to zero abundance of species in disease groups.  
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3.5 Discussion 
This study investigated the dynamics of the gut microbiota populations associated with 
immunosuppressive biologic drugs. The study allowed for the analysis of α-  and β-
diversity of microbiome populations in disease states where we observe that biologics 
at least partially restore healthy-control associated taxa after long-term use of 
immunosuppressive drugs in two of the three arthritic diseases studied and in IBD. 
Extensive analysis of the clinical profile has highlighted some nominally significant 
associations with disease-associated taxa.  
Diversity defined by within-sample variation and between sample dissimilar ity 
showed a trend of movement of the gut microbiota populations towards the control 
subjects however, the dataset lacked the required statistical power. Despite the 
diversity being a key indicator of the stability of the gut microbiota population, 
previous cohort studies required large sample sizes to detect small alterations 
associated with the global microbiota composition (Zhang et al., 2015;Jackson et al., 
2018), however similar to Zhang et al 2015, we were able to use timeseries to detect 
these treatment-associated alterations, and control for various inter-individua l 
confounders. Previous studies have also noted that there was no observable association 
with alpha-diversity despite alterations in taxa-specific signatures (Zhang et al., 
2015;Picchianti-Diamanti et al., 2018;Shapiro et al., 2019).  
This is reflected in our study where we have identified taxonomic signature 
associated with the biologics treatment naive arthritic groups and noticeable difference 
from the biologics treated established groups, which partially resembled the control 
samples. Due to MTX treatment in the biologics naive groups, except for AS, the 
degree of restoration cannot be fully determined from a complete treatment naive 
status. The MTX treatment may be associated with partial restoration as highlighted 
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in two studies on RA by Zhang et al. and Picchianti-Diamanti et al. (Zhang et al., 
2015;Picchianti-Diamanti et al., 2018). These two studies have also shown that 
treatment with Etanercept and glycosides of the traditional Chinese medicina l 
component Tripterygium wilfordii are also associated with changes in the gut 
microbiota towards healthy- like. Brazin et al. also observed that response to anti-TNF 
treatment was associated with alteration in the microbiota profile in Spondyloarthr it is 
patients but not duration of treatment (Bazin et al., 2018).  
The significantly differentially abundant taxa identified to be associated with 
different disease groups in this study or with the controls have also been evidenced in 
other independent studies (Clemente et al., 2018). This is indicative that despite the 
low sample size, the signature of the key markers is detectable. Different species of 
Streptococcus were observed to be more abundant in RA samples, which could be an 
indicator for molecular mimicry as Streptococcal antibodies have been linked with 
inflammation and autoimmunity (Cunningham, 2014). Similarly, Rothia is associated 
with infection in immunocompromised host and usually found in oral cavity 
(Ramanan et al., 2014). Its presence in our study could be allochthonous in nature and 
due to MTX medications. Collinsella is known to be associated with RA (Chen et al., 
2016).  
The AS disease group showed a dominance of Clostridium and Collinsella 
species. Different species of Clostridium are associated with immune homeostasis in 
the gut (Lopetuso et al., 2013). Interestingly taxa such as Eubacterium that are 
associated with anti-inflammatory properties in IBD were observed across established 
AS samples (Kanauchi et al., 2006). 
The presence of species belonging to genus Blautia, Lachnospiraceae,  
Clostridiales, Dorea and Bacteroides in the disease subjects is interesting as these taxa 
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are observed to be depleted in other studies (Loh and Blaut, 2012;Sokol et al., 2017). 
This could potentially be a technical artefact, as these species were not observed in the 
controls. Enriched abundance of Enterococcus faecalis, Ruminococcus gnavus and 
Streptococcus species in IBD samples shows concordance with other studies (Liu et 
al., 1995;Zhou et al., 2016;Hall et al., 2017). On the other hand, taxa associated with 
healthy diet or healthy people such as Roseburia, Eubacterium rectale, Ruminococcus 
bromii, Coprococcus and Bacteroides were not found in IBD samples (Kang et al., 
2010;Zhernakova et al., 2016). 
PSA samples did not show prominent enriched taxa that were supported by 
literature. However, known taxa that are associated with healthy like certain species 
of Bacteroides, Roseburia, Lactococccus lactis were reduced in PSA (Kimoto et al., 
2004;Tamanai-Shacoori et al., 2017). A recent study observed that treatment was not 
associated with any changes in the microbiota diversity or profiles in psoriatic patients 
(Shapiro et al., 2019).  
The detection of different species of Bacteroides genus in both disease and 
control groups across various diseases is interesting as the responses from the immune 
system differs based on different species (Berezow et al., 2009). A recent study 
investigated the taxonomic profiles of different immune disorders and also observed 
increased Streptococcus abundance across all disease groups, and decreased 
abundance of Corprococcus and Roseburia in CD and RA, which was replicated in 
this study (Forbes et al., 2018). The prevalence of control associated taxa in the 
established groups of various diseases highlights restoration of gut microbiota towards 
normal-like.  
The relationships between microbiota and various confounders are complex. 
Significant correlation between the significant taxa in various diseases and vario us 
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meta-data reflects established roles. This includes the relationship between immune 
cells and Streptococcal species (Guyre et al., 1990;Ellis et al., 2015), Ruminococcus 
species with inflammation as determined by immune cell population and CRP levels 
(Henke et al., 2019). Species from Ruminococcus genus is also linked with healthy 
diet (Ze et al., 2012). The positive correlation observed between physical activity and  
Roseburia, Alistipes, Eubacterium and Akkermansia is also documented in literature 
(Chen et al., 2018). These relationships are observed in parts across different diseases 
in this study highlighting the complex interactions of the gut-host axis. The 
identification of these signatures is an indicator of their biological significance in 
maintaining host health.  
This study is a pilot investigation of the changes in gut microbiota dynamics 
due to biologics treatment. Despite uncovering key and established signature, the 
study is limited by its sample size. Other associated factors include a younger control 
samples compared to diseased groups, lack of representation of complete treatment 
naive disease cohort which could reflect the initial microbiota configuration at the 
onset or in early cases. The lack of serum profiles in the controls also limits the 
analysis to only disease samples without proper representation of those features in the 
general population. This study is an observational study and any association observed 
with the different disease groups or clinical factors does not imply any causation. 
Despite these limitations, the study highlights potential association of biologics and 
other immunosuppressants as supported by literature with the gut microbio ta 
population and prevalence of different taxa. 
In conclusion, we have highlighted that there are microbiota taxonomic 
associations related to treatment and remission status of the disease when treated with 
biologics, even if the subjects were previously treated with methotrexate. These 
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taxonomic alterations have the potential to influence microbiota-associa ted 
inflammation, remission status, effectiveness of therapy and may be important in 
maintaining remission.   
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3.8 Supplementary Tables 
Supplementary table 1 Sample characteristics of the treatment naive subjects 
A) Sample count, mean and standards deviation of different meta-data variables observed in the controls and time-point samples 
Groups control AS PSA RA IBD 
Time point T0 T2 T3 T0 T2 T3 T0 T2 T3 T0 T2 T3 T0 T2 T3 
Sample size 16 9 7 4 3 2 7 4 3 9 6 6 4 4 3 
Sex(Male/Female) 9/7 5/4 3/4 2/2 2/1 2/0 3/4 2/4 2/1 5/4 3/3 3/3 1/3 1/3 1/2 
Smoking 
(Yes/No/Previous) 
1/11/4 0/7/2 0/7/0 0/3/1 0/2/1 0/1/1 3/4/0 1/3/0 1/2/0 3/3/3 2/2/2 2/2/2 0/3/1 0/3/1 0/2/1 
Alcohol 
(Yes/No/Previous) 
16/0/0 9/0/0 7/0/0 2/2/0 1/2/0 1/1/0 5/2/0 3/1/0 2/1/0 8/1/0 5/1/0 5/1/0 4/0/0 4/0/0 3/0/0 
Abdominal 
Surgery (Yes/No) 
NA NA NA 3/1 2/1 1/1 2/5 1/3 1/2 7/2 5/1 5/1 3/1 3/1 2/1 
History of immune 
disorders (Yes/No) 








































































































































































































Disease activity NA NA NA 
Only performed on one sample 



















The number of samples per time-point in different disease groups for various meta-data variables. For immune disorder history, deviation from the total number represents lack of complete 












B) Serum profile, medication, and disease activity of the samples in different disease groups 
Groups AS PSA RA IBD 
Time-point T0 T2 T3 T0 T2 T3 T0 T2 T3 T0 T2 T3 
MTX treatments 
(Yes/No) 
0/4 0/3 0/2 6/1 4/0 3/0 9/0 6/0 6/0 2/2 1/3 1/2 

















































































































































































0.05 ± 0 
1.44 ± 
1.25 
















Only performed on one 


















Observed serum profiles, medication and disease activity for all the time-point diseased samples Disease activity score for different disease is defined by (AS: 
BADSAI; PSA: DAPSA; RA: DAS28; IBD: Harvey Bradshaw Index Score for Crohn’s & Powell Tuck Score for UC). CRP, C-Reactive protein.  
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Supplementary table 2 Sample characteristics of Established disease samples 
    P-adjusted 





T0 - PSA 
control_
T0 - RA 
Sample size 10 18 16    
Sex(Male/Female) 9/1 7/11 9/7    
Smoking 
(Yes/No/Previous) 
3/4/3 4/9/5 2/6/8    
Alcohol 
(Yes/No/Previous) 
8/2/0 13/5/0 12/4/0    
Abdominal Surgery 
(Yes/No) 
0/10 4/2 7/0    
History of immune 
disorders (Yes/No) 
6/3 8/9 11/5    
MTX treatments 
(Yes/No) 
0/7 6/12 6/4    
NSAIDs (Yes/No) 9/1 16/2 13/3    






































4.9E-01 8.8E-01 2.4E-01 
HFD 0.38 ± 0.09 0.38 ± 0.1 0.37 ± 0.12 1.7E-03 1.7E-03 3.9E-03 
Morisky_score 6.42 ± 1.31 6.61 ± 1.6 6.92 ± 1.54    
White_blood_cells 6.13 ± 1.86 
7.25 ± 
3.15 
6.75 ± 2.16    
Neutrophils 3.23 ± 1.27 4.5 ± 3 4.1 ± 1.79    
Lymphocytes 2.14 ± 0.72 
2.02 ± 
0.78 
1.87 ± 0.47    
Monocytes 0.34 ± 0.11 
0.41 ± 
0.17 
0.41 ± 0.2    
Eosinophils 0.23 ± 0.11 
0.18 ± 
0.11 
0.22 ± 0.09    
Basophils 0.04 ± 0.02 
0.04 ± 
0.02 
0.03 ± 0.01    
CRP 3.92 ± 5.86 
3.48 ± 
4.38 
3.17 ± 2.44    
 
In the established samples, reported values are based on group wise stratificat ion, 
mean ± standard deviation for various meta-data, including serum profiles, dietary, 
anthropometric measures, medication and medical history. Pairwise comparison with 
Dunn’s test with adjustment is reported. Significance is defined by P-adjusted ≤ 0.05 
CRP, C-Reactive protein. HFD, Healthy Food Diversity.  
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Supplementary table 3 Paired comparison of sample characteristics between time-
points 








Group 1 Group 2 
Age 
Control 
T0 - T2 36.56 ± 9.88 36.89 ± 9.97 1.5E-01 
T0 - T3 38.14 ± 10.56 38.71 ± 10.8 7.2E-02 




T0 - T2 57 ± 7.21 57.17 ± 7.44 
1.0E+0
0 
T0 - T3 57 ± 7.21 57.67 ± 7.31 7.2E-02 
T3 - T2 57.67 ± 7.31 57.17 ± 7.44 1.5E-01 
PSA 
T0 - T2 48.75 ± 14.77 49.25 ± 14.75 3.5E-01 
T0 - T3 48 ± 18 48.67 ± 18.01 3.5E-01 
T3 - T2 48.67 ± 18.01 48.67 ± 18.01 NA 
AS 
T0 - T2 47.67 ± 5.51 48 ± 6 
1.0E+0
0 
T0 - T3 45 ± 4.24 45 ± 4.24 NA 
T3 - T2 45 ± 4.24 45 ± 4.24 NA 
IBD 
T0 - T2 39.5 ± 11.96 40.25 ± 12.34 1.5E-01 
T0 - T3 35.67 ± 11.24 36.67 ± 11.24 1.5E-01 





T0 - T2 26.49 ± 6.68 26.61 ± 6.72 2.7E-01 
T0 - T3 27.3 ± 7.47 27.86 ± 8.05 2.9E-01 
T3 - T2 27.86 ± 8.05 27.31 ± 7.57 3.4E-02 
RA 
T0 - T2 27.53 ± 4.11 28.03 ± 3.92 6.9E-01 
T0 - T3 27.53 ± 4.11 27.63 ± 3.36 
1.0E+0
0 
T3 - T2 27.63 ± 3.36 28.03 ± 3.92 2.9E-01 
PSA 
T0 - T2 25.02 ± 7.17 25.12 ± 7.67 
1.0E+0
0 
T0 - T3 22.23 ± 5.51 21.87 ± 5.16 2.5E-01 
T3 - T2 21.87 ± 5.16 21.97 ± 5.34 7.5E-01 
AS 
T0 - T2 27.43 ± 3.33 28.1 ± 3.57 2.5E-01 
T0 - T3 26.9 ± 4.53 26.85 ± 4.45 
1.0E+0
0 
T3 - T2 26.85 ± 4.45 27.25 ± 4.6 5.0E-01 
IBD 
T0 - T2 27.83 ± 5.38 29.4 ± 3.21 2.5E-01 
T0 - T3 25.87 ± 4.52 28.4 ± 2.48 2.5E-01 





T0 - T2 1.73 ± 0.13 1.73 ± 0.13 NA 
T0 - T3 1.71 ± 0.14 1.7 ± 0.13 1.7E-01 
T3 - T2 1.7 ± 0.13 1.71 ± 0.14 1.7E-01 
RA 
T0 - T2 1.68 ± 0.10 1.68 ± 0.10 NA 
T0 - T3 1.68 ± 0.10 1.68 ± 0.10 NA 
T3 - T2 1.68 ± 0.10 1.68 ± 0.10 NA 
PSA 
T0 - T2 1.73 ± 0.08 1.74 ± 0.08 
1.0E+0
0 
T0 - T3 1.76 ± 0.06 1.77 ± 0.06 
1.0E+0
0 
T3 - T2 1.77 ± 0.06 1.77 ± 0.06 NA 
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AS 
T0 - T2 1.70 ± 0.01 1.70 ± 0.01 NA 
T0 - T3 1.76 ± 0.09 1.76 ± 0.09 NA 
T3 - T2 1.76 ± 0.09 1.76 ± 0.09 NA 
IBD 
T0 - T2 1.64 ± 0.10 1.64 ± 0.10 NA 
T0 - T3 1.65 ± 0.11 1.65 ± 0.11 NA 
T3 - T2 1.65 ± 0.11 1.65 ± 0.11 NA 
HFD 
Control 
T0 - T2 0.51 ± 0.04 0.49 ± 0.04 6.5E-01 
T0 - T3 0.5 ± 0.05 0.52 ± 0.03 9.4E-01 
T3 - T2 0.52 ± 0.03 0.51 ± 0.03 5.8E-01 
RA 
T0 - T2 0.31 ± 0.04 0.33 ± 0.07 3.1E-01 
T0 - T3 0.31 ± 0.04 0.37 ± 0.08 3.1E-02 
T3 - T2 0.37 ± 0.08 0.33 ± 0.07 3.1E-02 
PSA 
T0 - T2 0.42 ± 0.06 0.43 ± 0.07 
1.0E+0
0 
T0 - T3 0.39 ± 0.04 0.41 ± 0.07 
1.0E+0
0 




T0 - T2 0.29 ± 0.01 0.31 ± 0.05 
1.0E+0
0 
T0 - T3 0.3 ± 0 0.39 ± 0.02 5.0E-01 




T0 - T2 0.29 ± 0.13 0.31 ± 0.13 1.8E-01 
T0 - T3 0.29 ± 0.16 0.35 ± 0.13 3.7E-01 
T3 - T2 0.35 ± 0.13 0.3 ± 0.16 3.7E-01 
Weight (Kg) 
Control 
T0 - T2 79 ± 19.43 78.46 ± 17.32 6.8E-01 
T0 - T3 80.54 ± 22.05 80.46 ± 21.11 9.3E-01 
T3 - T2 80.46 ± 21.11 79.41 ± 19.74 9.4E-01 
RA 
T0 - T2 78.73 ± 19.32 80.07 ± 18.93 4.0E-01 
T0 - T3 78.73 ± 19.32 78.82 ± 17.45 
1.0E+0
0 
T3 - T2 78.82 ± 17.45 80.07 ± 18.93 1.6E-01 
PSA 
T0 - T2 74.5 ± 18.16 75.08 ± 19.35 8.8E-01 
T0 - T3 69.43 ± 18.46 67.8 ± 17.66 2.5E-01 
T3 - T2 67.8 ± 17.66 69.1 ± 18.63 2.5E-01 
AS 
T0 - T2 79.5 ± 17.51 80.73 ± 18.6 2.5E-01 
T0 - T3 84.15 ± 21.99 84.45 ± 22.7 
1.0E+0
0 
T3 - T2 84.45 ± 22.7 85.8 ± 23.19 5.0E-01 
IBD 
T0 - T2 73.53 ± 8.3 78.35 ± 5.36 2.5E-01 
T0 - T3 69.63 ± 3.51 77.13 ± 3.54 2.5E-01 
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T0 - T2 
12645.38 ± 
19685.45 
3759 ± 3123.53 2.5E-01 
T0 - T3 16394 ± 22292.66 7531 ± 1975.51 
1.0E+0
0 




T0 - T2 6029 ± 3816.71 16424 ± 14126.85 5.0E-01 
T0 - T3 7744.5 ± 3387.75 28434 ± 17768.18 5.0E-01 




T0 - T2 372.67 ± 189.13 3270 ± 4951.75 5.0E-01 




T3 - T2 1006.67 ± 1036.38 4100 ± 5713.7 2.5E-01 
Morisky_score 
RA 
T0 - T2 5.88 ± 1.01 7.17 ± 1.17 5.9E-02 
T0 - T3 5.88 ± 1.01 8 ± 0 3.5E-02 
T3 - T2 8 ± 0 7.17 ± 1.17 1.7E-01 
PSA 
T0 - T2 6.62 ± 1.16 6.44 ± 1.94 
1.0E+0
0 
T0 - T3 7.17 ± 0.52 7 ± 1.32 
1.0E+0
0 
T3 - T2 7 ± 1.32 7.25 ± 1.3 3.7E-01 
AS 
T0 - T2 6.92 ± 1.13 8 ± 0 3.7E-01 
T0 - T3 6.88 ± 1.59 7.5 ± 0.71 
1.0E+0
0 




T0 - T2 5.38 ± 2.29 7.19 ± 0.55 1.8E-01 
T0 - T3 6.33 ± 1.53 7.67 ± 0.58 3.5E-01 






T0 - T2 9.86 ± 2.4 7.4 ± 2.82 6.3E-02 
T0 - T3 9.86 ± 2.4 7.9 ± 2.99 6.3E-02 
T3 - T2 7.9 ± 2.99 7.4 ± 2.82 1.4E-01 
PSA 
T0 - T2 6.25 ± 0.85 6 ± 1.93 8.8E-01 
T0 - T3 5.93 ± 0.7 6.77 ± 1.9 7.5E-01 
T3 - T2 6.77 ± 1.9 5.07 ± 0.61 2.5E-01 
AS 
T0 - T2 7.63 ± 2.1 5.63 ± 0.84 2.5E-01 
T0 - T3 8.45 ± 2.19 5.6 ± 0.99 5.0E-01 
T3 - T2 5.6 ± 0.99 5.9 ± 0.99 3.5E-01 
IBD 
T0 - T2 8.72 ± 2.19 7.2 ± 2.82 3.8E-01 
T0 - T3 9.6 ± 1.61 10.17 ± 4.05 7.5E-01 
T3 - T2 10.17 ± 4.05 7.23 ± 3.46 2.5E-01 
Neutrophils 
RA 
T0 - T2 7 ± 2.07 4.35 ± 2.59 6.3E-02 
T0 - T3 7 ± 2.07 4.85 ± 2.86 6.3E-02 
T3 - T2 4.85 ± 2.86 4.35 ± 2.59 5.9E-02 
PSA 
T0 - T2 3.87 ± 0.5 3.21 ± 1.31 3.8E-01 
T0 - T3 3.69 ± 0.44 4.29 ± 2.44 7.5E-01 
T3 - T2 4.29 ± 2.44 2.62 ± 0.65 2.5E-01 
AS 
T0 - T2 5.27 ± 1.99 2.97 ± 0.55 2.5E-01 
T0 - T3 6.05 ± 2.05 2.9 ± 0.99 5.0E-01 
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IBD 
T0 - T2 5.81 ± 1.63 4.3 ± 1.97 2.5E-01 
T0 - T3 6.48 ± 1.14 6.99 ± 3.78 7.5E-01 
T3 - T2 6.99 ± 3.78 4.44 ± 2.39 2.5E-01 
Lymphocytes 
RA 
T0 - T2 1.78 ± 0.58 3.9 ± 4.52 6.3E-02 
T0 - T3 1.78 ± 0.58 2.05 ± 0.54 5.9E-01 
T3 - T2 2.05 ± 0.54 3.9 ± 4.52 8.3E-01 
PSA 
T0 - T2 1.69 ± 0.39 1.98 ± 0.66 2.5E-01 
T0 - T3 1.55 ± 0.33 1.66 ± 0.39 
1.0E+0
0 




T0 - T2 1.6 ± 0.1 1.93 ± 0.23 2.5E-01 
T0 - T3 1.6 ± 0.14 1.95 ± 0.07 5.0E-01 




T0 - T2 1.84 ± 0.6 1.98 ± 0.9 6.3E-01 
T0 - T3 1.89 ± 0.72 1.79 ± 0.45 
1.0E+0
0 





T0 - T2 0.74 ± 0.11 0.5 ± 0.15 1.0E-01 
T0 - T3 0.74 ± 0.11 0.48 ± 0.18 1.0E-01 
T3 - T2 0.48 ± 0.18 0.5 ± 0.15 7.9E-01 
PSA 
T0 - T2 0.39 ± 0.02 0.44 ± 0.12 4.2E-01 
T0 - T3 0.39 ± 0.02 0.49 ± 0.05 2.5E-01 
T3 - T2 0.49 ± 0.05 0.42 ± 0.14 3.7E-01 
AS 
T0 - T2 0.5 ± 0.2 0.33 ± 0.06 3.7E-01 
T0 - T3 0.5 ± 0.28 0.4 ± 0.14 
1.0E+0
0 




T0 - T2 0.59 ± 0.13 0.43 ± 0.09 1.8E-01 
T0 - T3 0.63 ± 0.11 0.59 ± 0.11 
1.0E+0
0 
T3 - T2 0.59 ± 0.11 0.44 ± 0.1 2.5E-01 
Eosinophils 
RA 
T0 - T2 0.29 ± 0.29 16.63 ± 39.86 4.2E-01 
T0 - T3 0.29 ± 0.29 0.37 ± 0.22 3.7E-01 
T3 - T2 0.37 ± 0.22 16.63 ± 39.86 3.6E-01 
PSA 
T0 - T2 0.17 ± 0.08 0.16 ± 0.05 7.9E-01 
T0 - T3 0.19 ± 0.08 0.17 ± 0.11 
1.0E+0
0 




T0 - T2 0.13 ± 0.06 0.19 ± 0.08 2.5E-01 
T0 - T3 0.15 ± 0.07 0.18 ± 0.13 
1.0E+0
0 
T3 - T2 0.18 ± 0.13 0.2 ± 0.11 5.0E-01 
IBD 
T0 - T2 0.42 ± 0.47 0.37 ± 0.18 8.8E-01 
T0 - T3 0.52 ± 0.51 0.64 ± 0.4 3.7E-01 
T3 - T2 0.64 ± 0.4 0.39 ± 0.21 3.7E-01 
Basophils RA 
T0 - T2 0.04 ± 0.05 5.52 ± 13.46 
1.0E+0
0 
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T0 - T2 0.03 ± 0.03 0.02 ± 0.02 7.9E-01 
T0 - T3 0.04 ± 0.03 0.05 ± 0.05 
1.0E+0
0 




T0 - T2 0.05 ± 0.05 0.06 ± 0.01 7.5E-01 
T0 - T3 0.05 ± 0.07 0.06 ± 0.02 
1.0E+0
0 




T0 - T2 0.04 ± 0.04 0.04 ± 0.05 3.5E-01 
T0 - T3 0.05 ± 0.04 0.09 ± 0.01 3.7E-01 
T3 - T2 0.09 ± 0.01 0.05 ± 0.05 3.7E-01 
CRP 
RA 
T0 - T2 18.4 ± 14.61 6.18 ± 9.25 3.1E-02 
T0 - T3 18.4 ± 14.61 11.84 ± 15.86 3.1E-01 
T3 - T2 11.84 ± 15.86 6.18 ± 9.25 2.5E-01 
PSA 
T0 - T2 2.01 ± 1.39 1.03 ± 1.7 
1.0E+0
0 
T0 - T3 1.68 ± 1.5 2.02 ± 1.98 
1.0E+0
0 




T0 - T2 4.67 ± 2.08 0.7 ± 1.13 2.5E-01 
T0 - T3 3.5 ± 0.71 0.05 ± 0 5.0E-01 
T3 - T2 0.05 ± 0 0.05 ± 0 NaN 
IBD 
T0 - T2 13.7 ± 17.51 2.73 ± 1.74 1.8E-01 
T0 - T3 16.57 ± 20.26 11.9 ± 19.14 7.5E-01 





T0 - T2 5.3 ± 0.25 4.24 ± 0.86 1.3E-01 
T0 - T3 5.3 ± 0.25 4.08 ± 1.08 1.3E-01 
T3 - T2 4.08 ± 1.08 4.24 ± 0.86 6.3E-01 
PSA 
T0 - T2 18.82 ± 8.75 19.75 ± 16.44 
1.0E+0
0 
T0 - T3 15.83 ± 7.82 9 ± 4.36 2.5E-01 
T3 - T2 9 ± 4.36 13.33 ± 12.58 5.9E-01 
AS 
T0 - T2 
Not performed T0 - T3 
T3 - T2 
IBD 
T0 - T2 5 ± 4.32 2.67 ± 2.31 7.5E-01 
T0 - T3 6.33 ± 4.16 0.5 ± 0.71 5.0E-01 




Paired Wilcoxon test between the time-point values of different meta-data values in 
different disease and control groups to identify variation in time-point within the 
groups. Significance is defined by nominal p-values ≤ 0.05. 
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Supplementary table 4 Significance of comparison of sample characteristics of 
Time-point disease samples with controls and Established samples 
A) Result of comparison of time-point samples of each disease group against controls 




Control_T0 - AS_T0 1.9E-01 8.2E-01 8.7E-03 9.2E-01 1.5E-01 2.9E-02 
Control_T0 - AS_T2 1.9E-01 8.2E-01 1.3E-02 9.2E-01 4.2E-01 6.2E-03 
Control_T0 - AS_T3 2.3E-01 8.2E-01 2.9E-02 9.2E-01 7.8E-02 2.0E-02 
Control_T0 - PSA_T0 5.2E-02 7.5E-01 6.2E-04 8.1E-01 8.0E-01 2.3E-03 
Control_T0 - PSA_T2 1.8E-01 1.0E+00 4.3E-03 1.0E+00 1.0E+00 6.4E-02 
Control_T0 - PSA_T3 2.2E-01 8.4E-01 8.5E-03 8.1E-01 1.9E-01 6.4E-02 
Control_T0 - RA_T0 1.8E-03 3.4E-01 1.5E-04 8.5E-01 9.3E-01 4.4E-05 
Control_T0 - RA_T2 2.2E-03 3.0E-01 4.6E-04 8.5E-01 9.3E-01 4.4E-05 
Control_T0 - RA_T3 2.2E-03 3.0E-01 4.6E-04 8.5E-01 9.3E-01 3.4E-03 
Control_T0 - IBD_T0 9.0E-01 4.8E-01 4.3E-03 1.0E+00 6.2E-03 1.7E-02 
Control_T0 - IBD_T2 9.0E-01 4.4E-01 4.3E-03 1.0E+00 1.2E-01 1.7E-02 
Control_T0 - IBD_T3 9.1E-01 4.8E-01 8.5E-03 1.0E+00 7.1E-02 4.7E-02 
 
B) Comparison between Time-point disease samples and Established samples 



















































































































































































































































































































Supplementary table 4A) represents P-adjusted values from the pairwise comparison 
between the meta-data values of the disease at particular time-point against Control 
samples at T0. Supplementary table 4B) represents comparison of various time-point 
diseased samples against the established treated group for the same disease. 
Significance is defined by P-adjusted ≤ 0.05  
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Supplementary table 5 Within sample taxonomic and functional indices 
 
Groups Gene count Unique_species Shannon_diversity 
control_T0 200673.8 ± 25193.01 73.31 ± 9.25 2.98 ± 0.23 
control_T2 195856.4 ± 41917.72 72.11 ± 12.52 2.84 ± 0.48 
control_T3 191205.9 ± 48288.58 70.29 ± 16.95 2.82 ± 0.35 
RA 204749.8 ± 27963.77 82.81 ± 10.23 3.00 ± 0.23 
RA_T0 217989.9 ± 33998.53 87.78 ± 21.28 3.00 ± 0.21 
RA_T2 203455.3 ± 25000.44 81.67 ± 7.89 2.74 ± 0.26 
RA_T3 206872 ± 34865.97 87.33 ± 12.69 3.06 ± 0.35 
AS 183013.6 ± 48421.07 69.80 ± 17.94 2.64 ± 0.60 
AS_T0 215356.5 ± 18421.81 86.00 ± 7.87 3.07 ± 0.12 
AS_T2 212473 ± 28490.29 80.50 ± 8.54 3.02 ± 0.08 
AS_T3 199550 ± 4690.95 87.50 ± 13.44 3.02 ± 0.12 
PSA 206789.9 ± 26726.11 75.78 ± 11.20 3.07 ± 0.29 
PSA_T0 199940.7 ± 15200.11 77.00 ± 6.32 2.90 ± 0.33 
PSA_T2 194479.8 ± 10286.26 73.75 ± 4.79 2.87 ± 0.02 
PSA_T3 176107 ± 50960.77 64.33 ± 13.32 2.91 ± 0.24 
IBD_T0 115160.8 ± 31350.50 56.75 ± 13.18 2.16 ± 0.28 
IBD_T2 126724 ± 48964.62 57.75 ± 28.93 2.32 ± 0.31 
IBD_T3 149461.7 ± 62444.76 63.33 ± 30.24 2.52 ± 0.43 
 
Mean and standard deviation of different within-sample indices observed across 
different groups including time-points and established samples.  
 
Supplementary table 6 Comparison of within sample diversity within time-points, 
against controls and established groups 
A) Significance of paired comparison between time-point of within sample indices 
 P-values 
 Unique species Shannon gene count 
control_T2 vs T0 1.0E+00 8.2E-01 9.1E-01 
control_T3 vs T0 8.3E-01 1.1E-01 5.8E-01 
control_T3 vs T2 7.3E-01 6.9E-01 6.9E-01 
RA_T2 vs T0 4.2E-01 6.3E-02 3.1E-01 
RA_T3 vs T0 4.4E-01 8.4E-01 8.4E-01 
RA_T3 vs T2 5.6E-01 9.4E-02 6.9E-01 
PSA_T2 vs T0 4.2E-01 2.5E-01 1.0E+00 
PSA_T3 vs T0 3.7E-01 5.0E-01 7.5E-01 
PSA_T3 vs T2 7.5E-01 7.5E-01 1.0E+00 
AS_T2 vs T0 1.3E-01 6.3E-01 8.8E-01 
AS_T3 vs T0 1.0E+00 1.0E+00 1.0E+00 
AS_T3 vs T2 5.0E-01 1.0E+00 5.0E-01 
IBD_T2 vs T0 8.8E-01 6.3E-01 1.0E+00 
IBD_T3 vs T0 5.0E-01 2.5E-01 5.0E-01 
IBD_T3 vs T2 1.0E+00 7.5E-01 5.0E-01 
P-adjusted values is based on all pairwise comparison between time-point for a 
particular group. Within-sample diversity was not significant within different time-
point of each disease and healthy groups. Significance is defined by P-adjusted values 
(≤ 0.05) of all pairwise comparisons with each group. Trends of association is defined 
as P-adjusted values ≤ 0.1 
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B) Significance of within sample diversity between disease time-point against 
control T0 samples 
 Unique species Shannon gene count 
Control_T0 vs AS_T0 1.8E-02 6.8E-01 4.4E-01 
Control_T0 vs AS_T2 2.2E-01 9.6E-01 4.4E-01 
Control_T0 vs AS_T3 1.6E-01 1.0E+00 8.4E-01 
Control_T0 vs IBD_T0 1.6E-02 4.1E-04 8.3E-04 
Control_T0 vs IBD_T2 4.2E-01 2.9E-03 2.9E-03 
Control_T0 vs IBD_T3 7.8E-01 6.4E-02 1.1E-01 
Control_T0 vs PSA_T0 4.4E-01 7.7E-01 7.7E-01 
Control_T0 vs PSA_T2 7.4E-01 1.5E-01 6.2E-01 
Control_T0 vs PSA_T3 2.2E-01 5.6E-01 5.6E-01 
Control_T0 vs RA_T0 7.9E-02 8.0E-01 2.3E-01 
Control_T0 vs RA_T2 3.2E-02 1.1E-01 8.6E-01 
Control_T0 vs RA_T3 2.2E-02 4.9E-01 5.9E-01 
Control_T0 vs AS 4.3E-01 8.7E-02 4.8E-01 
Control_T0 vs PSA 1.7E-01 2.2E-01 4.8E-01 
Control_T0 vs RA 1.6E-02 8.7E-01 7.2E-01 
Pairwise comparison of different time-point and established samples from diseased 
groups against controls. Significance is defined by P-adjusted values (≤ 0.05) between 
all pairwise comparisons of all time-points from a disease group against Control T0. 
Trends of association is defined as P-adjusted values ≤ 0.1 
 
 
Supplementary table 7 Comparison of taxonomic β-diversity between various 
groups 
   Spearman Distance 
    Observed estimate P-value 




AS 0.06 1.6E-01 
PSA 0.04 2.5E-01 




AS 0.16 4.3E-02 
PSA 0.10 7.8E-01 
RA 0.10 4.6E-01 




RA 0.09 4.0E-01 
AS 0.15 4.0E-02 




RA & IBD 0.25 1.0E-03 
RA & AS 0.04 3.0E-03 
RA & PSA 0.03 6.0E-03 
PSA & IBD 0.29 1.0E-03 
PSA & AS 0.03 1.3E-01 
AS & IBD 0.29 1.0E-03 
Independent 
dataset 
Zhang only 0.05 1.0E-03 
Zhang & RA Biologics  0.12 1.0E-03 
Significance based on Monte-Carlo permutations test from the BCA analysis of 
individually compared time-point groups against controls, established samples against 
controls, timeseries and established together against controls, comparison of the 
different disease samples amongst themselves and validating the significance in the 
public datasets. Significance is defined by nominal p-value ≤ 0.05  
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Supplementary table 8 Comparison of β-diversity between timepoints observed in 
timeseries groups  
A) summary and analysis of variance (ANOVA) from the linear model of dissimilar ity 
values as explained by group stratification adjusted for observed species  
      Summary ANOVA 
      Estimate Std. Error R-squared P-value 
Spearman 
T2-T0 
Intercept 0.22 0.09 
0.40 1.3E-01 
Observed species 0.00 0.00 
control 0.00 0.04 
IBD 0.09 0.05 
PSA -0.05 0.05 
RA 0.02 0.05 
T3-T0 
Intercept 0.34 0.05 
0.78 4.1E-04 
Observed species 0.00 0.00 
control -0.06 0.03 
IBD 0.03 0.03 
PSA -0.09 0.03 
RA 0.05 0.03 
The model investigated here is:  
The distance between paired time-points samples ~ observed species + Groups 
Significance as defined by nominal P-values (≤ 0.05) are highlighted in red and bold. 
 
B) Pairwise comparison of Spearman dissimilarity based on significance as defined 














control-AS -0.01 -0.13 0.11 1.0E+00 -0.04 -0.13 0.05 6.4E-01 
IBD-AS 0.07 -0.07 0.22 5.8E-01 0.05 -0.05 0.16 4.9E-01 
PSA-AS -0.05 -0.20 0.09 8.2E-01 -0.07 -0.17 0.04 3.1E-01 
RA-AS 0.02 -0.11 0.15 9.9E-01 0.05 -0.04 0.14 5.3E-01 
IBD-control 0.08 -0.04 0.21 3.0E-01 0.09 0.02 0.17 1.3E-02 
PSA-control -0.04 -0.17 0.08 8.4E-01 -0.03 -0.10 0.05 8.4E-01 
RA-control 0.03 -0.08 0.14 9.1E-01 0.09 0.02 0.15 4.6E-03 
PSA-IBD -0.13 -0.27 0.02 1.2E-01 -0.12 -0.21 -0.03 7.4E-03 
RA-IBD -0.05 -0.19 0.08 7.7E-01 -0.01 -0.09 0.07 1.0E+00 
RA-PSA 0.07 -0.06 0.21 4.9E-01 0.11 0.03 0.19 4.0E-03 
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Supplementary table 9 Cumulative comparison of functional β-diversity by 
including established and time-point samples of each disease type and controls 
FUNCTIONAL Spearman 
  Observed estimate P-value 
RA time-point, Establish & Control 0.10 2.1E-01 
AS time-point, Establish & Control 0.13 2.2E-01 
PSA time-point, Establish & Control 0.10 2.7E-01 
IBD time-point & Control 0.37 1.0e-03 
 
 
Supplementary table 10 Pairwise results of taxonomic differential abundance 
analysis 
A) Significant pairwise comparisons of rheumatoid arthritis (RA) time-point, 
established samples and controls T0 
RA T0 & Control T0 log2FoldChange lfcSE pvalue padj 
Bacteroides_salyersiae -30.00 3.58 5.5E-17 3.4E-15 
Dialister_invisus -30.00 4.43 1.3E-11 3.8E-10 
Slackia_piriformis -26.34 4.40 2.2E-09 2.7E-08 
Blautia_hydrogenotrophica -25.71 4.43 6.4E-09 6.5E-08 
Bacteroides_clarus -23.73 4.43 8.4E-08 7.9E-07 
Streptococcus_infantis  23.17 4.41 1.5E-07 1.3E-06 
Lactobacillus_casei_paracasei 25.82 4.40 4.3E-09 4.7E-08 
Actinomyces_viscosus 27.09 4.41 7.8E-10 1.1E-08 
Veillonella_dispar 27.59 4.41 3.8E-10 5.8E-09 
Streptococcus_gordonii 27.80 4.38 2.2E-10 3.9E-09 
Rothia_dentocariosa 28.50 4.41 9.9E-11 2.0E-09 
Collinsella_intestinalis  28.78 4.29 2.0E-11 5.0E-10 
Acidaminococcus_intestini 29.95 4.41 1.1E-11 3.8E-10 
Streptococcus_anginosus 30.00 2.99 1.1E-23 1.4E-21 
     
RA T2 & Control T0     
Bacteroides_salyersiae -30.00 4.13 3.5E-13 1.4E-11 
Dialister_invisus -30.00 5.10 3.9E-09 6.9E-08 
Holdemania_unclassified -28.65 3.16 1.3E-19 1.6E-17 
Erysipelotrichaceae_bacterium_6_1_45 -26.86 3.81 1.7E-12 5.2E-11 
Anaerotruncus_unclassified -26.35 5.10 2.3E-07 2.4E-06 
Slackia_piriformis -24.75 5.07 1.0E-06 8.4E-06 
Actinomyces_odontolyticus  -24.54 3.83 1.4E-10 3.5E-09 
Anaerotruncus_colihominis  -23.79 4.52 1.4E-07 1.7E-06 
Bacteroides_clarus -23.25 5.10 5.1E-06 3.7E-05 
Blautia_hydrogenotrophica -23.23 5.10 5.2E-06 3.7E-05 
Lactobacillus_casei_paracasei 20.65 5.04 4.3E-05 2.9E-04 
Acidaminococcus_intestini 24.87 5.05 8.6E-07 7.5E-06 
Streptococcus_gordonii 25.24 5.03 5.1E-07 4.8E-06 
Actinomyces_viscosus 26.44 5.05 1.7E-07 1.9E-06 
Streptococcus_infantis  26.92 5.05 1.0E-07 1.4E-06 
Streptococcus_mutans 27.31 5.05 6.5E-08 9.9E-07 
Streptococcus_anginosus 28.83 3.42 3.8E-17 2.3E-15 
Collinsella_intestinalis  30.00 4.92 1.1E-09 2.3E-08 
     
RA T3 & Control T0     
Bacteroides_salyersiae -30.00 4.13 3.5E-13 1.4E-11 
Holdemania_unclassified -29.40 3.16 1.4E-20 1.8E-18 
Lactococcus_lactis  -28.89 4.52 1.6E-10 3.8E-09 
Actinomyces_odontolyticus  -25.51 3.83 2.6E-11 8.1E-10 
Pseudoflavonifractor_capillosus  -24.82 4.77 2.0E-07 1.9E-06 
Blautia_hydrogenotrophica -24.09 5.10 2.3E-06 1.9E-05 
Bacteroides_clarus -23.98 5.10 2.5E-06 1.9E-05 
Streptococcus_gordonii 23.36 5.03 3.4E-06 2.4E-05 
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Acidaminococcus_intestini 25.64 5.05 3.9E-07 3.4E-06 
Streptococcus_infantis  26.87 5.05 1.1E-07 1.1E-06 
Veillonella_dispar 27.21 5.05 7.3E-08 8.1E-07 
Streptococcus_mutans 27.62 5.05 4.6E-08 5.6E-07 
Rothia_dentocariosa 28.64 5.05 1.4E-08 2.0E-07 
Collinsella_intestinalis  28.98 4.92 4.0E-09 8.1E-08 
Actinomyces_viscosus 29.13 5.05 8.2E-09 1.3E-07 
Streptococcus_anginosus 29.23 3.42 1.4E-17 8.5E-16 
Lactobacillus_casei_paracasei 29.52 5.04 4.8E-09 8.4E-08 
     
RA & Control T0     
Lachnospiraceae_bacterium_1_4_56FAA 7.36 2.50 3.2E-03 2.8E-02 
Actinomyces_viscosus 23.43 3.75 4.1E-10 4.5E-09 
Rothia_dentocariosa 26.12 3.75 3.2E-12 3.9E-11 
Acidaminococcus_intestini 26.21 3.75 2.7E-12 3.7E-11 
Streptococcus_infantis  26.59 3.75 1.3E-12 2.0E-11 
Streptococcus_mutans 27.13 3.75 4.5E-13 7.9E-12 
Veillonella_dispar 27.15 3.75 4.4E-13 7.9E-12 
Streptococcus_anginosus 28.15 2.55 2.8E-28 3.4E-26 
Streptococcus_gordonii 28.26 3.73 3.4E-14 8.4E-13 
Collinsella_intestinalis  29.40 3.65 8.5E-16 3.7E-14 
Alistipes_sp_AP11 30.00 3.75 1.2E-15 3.7E-14 
Lactobacillus_casei_paracasei 30.00 3.74 1.0E-15 3.7E-14 
     
RA T3 & RA T0 log2FoldChange lfcSE pvalue padj 
Actinomyces_odontolyticus  -29.78 4.20 1.3E-12 7.8E-11 
Pseudoflavonifractor_capillosus  -29.12 5.24 2.7E-08 5.5E-07 
Lactococcus_lactis  -28.89 4.96 5.6E-09 1.4E-07 
Holdemania_unclassified -24.92 3.46 6.0E-13 7.3E-11 
Dialister_invisus 25.01 5.58 7.3E-06 1.3E-04 
Slackia_piriformis 32.30 5.54 5.7E-09 1.4E-07 
Streptococcus_mutans 36.71 5.58 4.6E-11 1.9E-09 
     
RA T2 & RA T0     
Rothia_dentocariosa -37.76 5.60 1.5E-11 6.2E-10 
Actinomyces_odontolyticus  -28.81 4.20 6.6E-12 4.0E-10 
Anaerotruncus_unclassified -28.67 5.60 3.0E-07 5.3E-06 
Veillonella_dispar -28.30 5.60 4.3E-07 6.6E-06 
Anaerotruncus_colihominis  -28.19 4.96 1.3E-08 2.7E-07 
Erysipelotrichaceae_bacterium_6_1_45 -27.91 4.17 2.3E-11 6.9E-10 
Holdemania_unclassified -24.17 3.46 2.9E-12 3.5E-10 
Streptococcus_mutans 36.40 5.58 6.7E-11 1.6E-09 
     
RA T3 & RA T2     
Lactococcus_lactis  -28.99 5.42 8.7E-08 3.6E-06 
Pseudoflavonifractor_capillosus  -28.64 5.73 5.7E-07 1.2E-05 
Dialister_invisus 25.01 6.12 4.4E-05 6.0E-04 
Erysipelotrichaceae_bacterium_6_1_45 25.66 4.56 1.8E-08 1.1E-06 
Anaerotruncus_colihominis  27.31 5.42 4.7E-07 1.2E-05 
Veillonella_dispar 27.92 6.12 5.1E-06 7.7E-05 
Anaerotruncus_unclassified 29.28 6.12 1.7E-06 3.0E-05 
Slackia_piriformis 30.72 6.08 4.5E-07 1.2E-05 
Rothia_dentocariosa 37.90 6.12 5.9E-10 7.2E-08 
     
RA T0 & RA log2FoldChange lfcSE pvalue padj 
Streptococcus_mutans -36.22 4.43 2.9E-16 1.8E-14 
Alistipes_sp_AP11 -33.96 4.43 1.8E-14 7.1E-13 
Slackia_piriformis -32.83 4.40 8.9E-14 2.7E-12 
Bacteroides_salyersiae -29.34 3.58 2.6E-16 1.8E-14 
Blautia_hydrogenotrophica -28.73 4.43 8.7E-11 2.1E-09 
 
280 | P a g e  
 
Dialister_invisus -26.50 4.43 2.2E-09 4.5E-08 
Bacteroides_clarus -24.81 4.43 2.1E-08 3.7E-07 
     
RA T2 & RA     
Rothia_dentocariosa -35.39 5.10 3.8E-12 9.3E-11 
Alistipes_sp_AP11 -33.47 5.10 5.1E-11 1.0E-09 
Slackia_piriformis -31.24 5.07 7.0E-10 1.1E-08 
Bacteroides_salyersiae -29.34 4.13 1.1E-12 3.5E-11 
Erysipelotrichaceae_bacterium_6_1_45 -28.13 3.81 1.5E-13 8.9E-12 
Anaerotruncus_colihominis  -28.05 4.52 5.5E-10 9.6E-09 
Actinomyces_odontolyticus  -28.01 3.83 2.5E-13 1.0E-11 
Veillonella_dispar -27.86 5.10 4.6E-08 6.2E-07 
Holdemania_unclassified -27.06 3.16 1.2E-17 1.4E-15 
Dialister_invisus -26.50 5.10 2.0E-07 2.4E-06 
Anaerotruncus_unclassified -26.33 5.10 2.4E-07 2.6E-06 
Blautia_hydrogenotrophica -26.25 5.10 2.6E-07 2.6E-06 
Bacteroides_clarus -24.32 5.10 1.8E-06 1.7E-05 
Lachnospiraceae_bacterium_5_1_63FAA 3.65 1.16 1.7E-03 1.5E-02 
     
RA T3 & RA     
Alistipes_sp_AP11 -34.40 5.10 1.5E-11 4.5E-10 
Bacteroides_salyersiae -29.34 4.13 1.1E-12 4.7E-11 
Lactococcus_lactis  -29.21 4.52 9.9E-11 2.4E-09 
Actinomyces_odontolyticus  -28.98 3.83 3.7E-14 2.3E-12 
Holdemania_unclassified -27.81 3.16 1.5E-18 1.8E-16 
Blautia_hydrogenotrophica -27.11 5.10 1.0E-07 1.8E-06 
Pseudoflavonifractor_capillosus  -26.61 4.77 2.5E-08 5.0E-07 
Bacteroides_clarus -25.06 5.10 8.8E-07 1.3E-05 
Significance is defined by P-adjusted ≤ 0.05. Red colour indicates species with 
reduced abundance while green represents species with increased abundance in that 
pairwise comparison. 
 
B) Significant pairwise comparisons of ankylosing spondylitis (AS) time-point, 
established samples and controls T0 
AS T0 & Control T0 log2FoldChange lfcSE pvalue padj 
Desulfovibrio_piger -36.28 4.65 6.1E-15 3.6E-13 
Bacteroides_finegoldii -34.46 4.91 2.2E-12 6.7E-11 
Bacteroides_massiliensis  -30.94 4.03 1.7E-14 6.6E-13 
Desulfovibrio_desulfuricans  -30.88 4.91 3.2E-10 5.4E-09 
Acidaminococcus_unclassified -30.78 4.91 3.6E-10 5.4E-09 
Coprobacter_fastidiosus -30.52 4.91 5.1E-10 6.8E-09 
Mitsuokella_unclassified -30.41 4.91 5.9E-10 7.0E-09 
Bacteroides_salyersiae -30.32 4.91 6.6E-10 7.2E-09 
Bacteroides_coprocola -30.02 4.91 9.7E-10 9.6E-09 
Mitsuokella_multacida -29.53 4.91 1.8E-09 1.6E-08 
Eubacterium_biforme -29.40 4.61 1.9E-10 3.7E-09 
Bacteroides_clarus -28.69 4.91 5.1E-09 4.3E-08 
Olsenella_unclassified -28.47 4.91 6.7E-09 4.7E-08 
Bifidobacterium_bifidum -28.34 4.88 6.4E-09 4.7E-08 
Bacteroides_faecis -28.21 4.91 9.2E-09 5.8E-08 
Lactococcus_lactis  -28.14 4.86 7.2E-09 4.7E-08 
Megasphaera_unclassified -26.76 4.91 5.1E-08 3.0E-07 
Bacteroides_stercoris  -10.53 3.78 5.3E-03 3.0E-02 
Clostridium_hathewayi 8.34 3.01 5.6E-03 3.1E-02 
Anaerotruncus_colihominis  28.00 4.83 6.9E-09 4.7E-08 
Clostridium_nexile 32.73 4.83 1.3E-11 3.0E-10 
Collinsella_intestinalis  43.59 4.30 3.7E-24 4.4E-22 
     
AS T2 & Control T0     
 
281 | P a g e  
 
Desulfovibrio_piger -36.04 4.65 9.2E-15 5.5E-13 
Bacteroides_finegoldii -34.53 4.91 2.0E-12 6.0E-11 
Bacteroides_massiliensis  -30.94 4.03 1.7E-14 6.6E-13 
Desulfovibrio_desulfuricans  -30.87 4.91 3.2E-10 7.1E-09 
Odoribacter_unclassified -30.79 4.91 3.6E-10 7.1E-09 
Acidaminococcus_unclassified -30.59 4.91 4.6E-10 7.7E-09 
Bacteroides_salyersiae -30.51 4.91 5.2E-10 7.7E-09 
Mitsuokella_unclassified -30.26 4.91 7.1E-10 9.4E-09 
Bacteroides_coprocola -30.02 4.91 9.7E-10 1.2E-08 
Mitsuokella_multacida -29.70 4.91 1.5E-09 1.6E-08 
Olsenella_unclassified -28.42 4.91 7.1E-09 5.6E-08 
Bifidobacterium_bifidum -28.34 4.88 6.4E-09 5.6E-08 
Bacteroides_clarus -28.33 4.91 7.9E-09 5.9E-08 
Lactococcus_lactis  -28.28 4.86 6.0E-09 5.6E-08 
Bacteroides_faecis -28.16 4.91 9.8E-09 6.8E-08 
Ruminococcaceae_bacterium_D16 -27.56 4.91 2.0E-08 1.2E-07 
Megasphaera_unclassified -26.76 4.91 5.1E-08 3.0E-07 
Bifidobacterium_animalis  -26.51 4.72 2.0E-08 1.2E-07 
Clostridium_hathewayi 10.35 3.01 5.9E-04 3.2E-03 
Clostridium_nexile 23.50 4.83 1.2E-06 6.6E-06 
Anaerotruncus_colihominis  27.98 4.83 7.0E-09 5.6E-08 
Collinsella_intestinalis  38.44 4.30 3.9E-19 4.6E-17 
     
AS T3 & Control T0     
Bacteroides_stercoris  -32.61 5.25 5.4E-10 1.1E-08 
Bacteroides_salyersiae -32.39 6.58 8.7E-07 6.9E-06 
Desulfovibrio_piger -31.69 6.24 3.8E-07 3.5E-06 
Bacteroides_finegoldii -31.14 6.58 2.3E-06 1.6E-05 
Bacteroides_massiliensis  -30.94 5.41 1.1E-08 1.9E-07 
Odoribacter_splanchnicus  -30.69 6.58 3.2E-06 2.1E-05 
Mitsuokella_multacida -30.58 6.58 3.4E-06 2.1E-05 
Alistipes_indistinctus  -30.48 4.34 2.2E-12 6.5E-11 
Bacteroides_coprocola -30.02 6.58 5.1E-06 3.0E-05 
Odoribacter_unclassified -29.90 6.58 5.6E-06 3.2E-05 
Paraprevotella_clara -29.88 5.78 2.3E-07 2.3E-06 
Paraprevotella_unclassified -29.82 5.32 2.0E-08 2.8E-07 
Bacteroides_cellulosilyticus  -29.75 5.31 2.1E-08 2.8E-07 
Eubacterium_ventriosum -29.69 3.07 3.6E-22 4.3E-20 
Ruminococcus_bromii -29.55 4.26 3.9E-12 9.2E-11 
Eubacterium_biforme -29.40 6.19 2.1E-06 1.5E-05 
Lachnospiraceae_bacterium_2_1_58FAA -29.16 5.46 9.1E-08 1.1E-06 
Alistipes_unclassified -28.92 6.58 1.1E-05 5.8E-05 
Bilophila_wadsworthia -28.88 3.55 3.8E-16 2.2E-14 
Bifidobacterium_bifidum -28.34 6.54 1.5E-05 7.4E-05 
Burkholderiales_bacterium_1_1_47 -28.13 6.56 1.8E-05 8.7E-05 
Acidaminococcus_unclassified -27.91 6.58 2.2E-05 1.0E-04 
Clostridium_citroniae -27.80 6.58 2.4E-05 1.1E-04 
Bacteroides_faecis -27.66 6.58 2.7E-05 1.1E-04 
Eggerthella_lenta -27.33 5.19 1.4E-07 1.5E-06 
Coprobacter_fastidiosus -27.31 6.58 3.4E-05 1.3E-04 
Desulfovibrio_desulfuricans  -27.17 6.58 3.7E-05 1.4E-04 
Mitsuokella_unclassified -26.76 6.58 4.8E-05 1.7E-04 
Megasphaera_unclassified -26.76 6.58 4.8E-05 1.7E-04 
Bifidobacterium_animalis  -26.51 6.33 2.8E-05 1.2E-04 
Ruminococcaceae_bacterium_D16 -26.09 6.58 7.4E-05 2.6E-04 
Flavonifractor_plautii -25.73 5.19 7.0E-07 5.9E-06 
Bacteroides_clarus -25.14 6.58 1.3E-04 4.6E-04 
Olsenella_unclassified -24.90 6.59 1.6E-04 5.2E-04 
Pseudoflavonifractor_capillosus  -24.86 6.58 1.6E-04 5.2E-04 
Parabacteroides_distasonis  -6.88 2.62 8.7E-03 2.7E-02 
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Oscillibacter_unclassified -5.29 1.99 7.8E-03 2.4E-02 
Clostridium_nexile 28.34 6.45 1.1E-05 5.8E-05 
Collinsella_intestinalis  42.22 5.73 1.8E-13 7.0E-12 
     
AS & Control T0     
Desulfovibrio_piger -30.00 3.35 3.7E-19 4.5E-17 
Mitsuokella_multacida -27.09 3.54 2.1E-14 4.7E-13 
Odoribacter_unclassified -27.03 3.54 2.4E-14 4.7E-13 
Clostridium_citroniae -26.25 3.54 1.3E-13 2.2E-12 
Acidaminococcus_unclassified -26.09 3.54 1.8E-13 2.6E-12 
Clostridium_symbiosum -26.04 3.54 2.0E-13 2.6E-12 
Mitsuokella_unclassified -25.00 3.54 1.7E-12 2.1E-11 
Bacteroides_clarus -24.80 3.54 2.6E-12 2.8E-11 
Desulfovibrio_desulfuricans  -23.56 3.54 3.0E-11 3.0E-10 
Olsenella_unclassified -22.09 3.54 4.6E-10 4.2E-09 
Clostridium_hathewayi -19.35 2.28 2.0E-17 6.1E-16 
Anaerotruncus_colihominis  30.00 3.52 1.7E-17 6.1E-16 
Clostridium_nexile 30.00 3.52 1.7E-17 6.1E-16 
     
AS T3 & AS T0     
Alistipes_unclassified -32.11 7.53 2.0E-05 2.2E-04 
Lachnospiraceae_bacterium_2_1_58FAA -31.16 6.22 5.5E-07 1.3E-05 
Odoribacter_splanchnicus  -30.14 7.53 6.3E-05 6.2E-04 
Ruminococcus_bromii -29.80 4.83 6.7E-10 2.7E-08 
Paraprevotella_clara -29.66 6.60 6.9E-06 8.2E-05 
Paraprevotella_unclassified -29.64 6.06 1.0E-06 1.6E-05 
Alistipes_indistinctus  -29.57 4.93 1.9E-09 5.8E-08 
Bacteroides_cellulosilyticus  -29.55 6.05 1.1E-06 1.6E-05 
Flavonifractor_plautii -29.28 5.91 7.2E-07 1.4E-05 
Bilophila_wadsworthia -29.02 4.00 3.8E-13 2.3E-11 
Odoribacter_unclassified -28.95 7.53 1.2E-04 1.0E-03 
Clostridium_citroniae -28.63 7.53 1.4E-04 1.1E-03 
Eubacterium_ventriosum -28.22 3.43 2.0E-16 2.3E-14 
Eggerthella_lenta -28.15 5.91 1.9E-06 2.5E-05 
Pseudoflavonifractor_capillosus  -27.94 7.53 2.1E-04 1.4E-03 
Anaerotruncus_colihominis  -27.79 7.53 2.2E-04 1.4E-03 
Burkholderiales_bacterium_1_1_47 -27.74 7.51 2.2E-04 1.4E-03 
Bifidobacterium_animalis -26.37 7.24 2.7E-04 1.6E-03 
Bacteroides_stercoris  -22.08 5.99 2.3E-04 1.4E-03 
Ruminococcaceae_bacterium_D16 -21.69 7.53 4.0E-03 2.3E-02 
Lactococcus_lactis  29.03 7.39 8.5E-05 7.8E-04 
     
AS T2 & AS T0     
Odoribacter_unclassified -29.85 6.12 1.1E-06 6.4E-05 
Bifidobacterium_animalis  -26.37 5.88 7.3E-06 2.9E-04 
Ruminococcaceae_bacterium_D16 -23.17 6.12 1.5E-04 3.7E-03 
Eubacterium_biforme 24.87 5.75 1.5E-05 4.5E-04 
Coprobacter_fastidiosus 31.45 6.12 2.8E-07 3.3E-05 
     
AS T3 & AS T2     
Bacteroides_cellulosilyticus  -32.28 6.05 9.7E-08 2.3E-06 
Alistipes_unclassified -32.23 7.53 1.9E-05 1.9E-04 
Odoribacter_splanchnicus  -31.61 7.53 2.7E-05 2.5E-04 
Paraprevotella_unclassified -30.96 6.06 3.3E-07 6.5E-06 
Paraprevotella_clara -30.82 6.60 3.0E-06 3.5E-05 
Alistipes_indistinctus  -30.38 4.93 7.0E-10 2.8E-08 
Clostridium_citroniae -30.28 7.53 5.8E-05 4.9E-04 
Eggerthella_lenta -29.89 5.91 4.2E-07 7.0E-06 
Lachnospiraceae_bacterium_2_1_58FAA -29.83 6.22 1.6E-06 2.2E-05 
Flavonifractor_plautii -29.77 5.91 4.7E-07 7.0E-06 
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Bilophila_wadsworthia -28.48 4.00 1.0E-12 6.1E-11 
Coprobacter_fastidiosus -28.24 7.53 1.8E-04 1.3E-03 
Pseudoflavonifractor_capillosus  -27.82 7.53 2.2E-04 1.5E-03 
Anaerotruncus_colihominis  -27.77 7.53 2.3E-04 1.5E-03 
Ruminococcus_bromii -27.63 4.83 1.0E-08 3.1E-07 
Bacteroides_stercoris  -27.54 5.99 4.3E-06 4.6E-05 
Burkholderiales_bacterium_1_1_47 -27.42 7.51 2.6E-04 1.6E-03 
Eubacterium_ventriosum -27.21 3.43 2.2E-15 2.6E-13 
Eubacterium_biforme -24.87 7.07 4.4E-04 2.6E-03 
Oscillibacter_unclassified -6.50 2.29 4.5E-03 2.5E-02 
Lactococcus_lactis  29.17 7.39 7.9E-05 6.3E-04 
     
AS T0 & AS     
Bacteroides_coprocola -30.00 5.15 5.8E-09 8.4E-08 
Bacteroides_massiliensis  -30.00 4.23 1.2E-12 7.4E-11 
Bifidobacterium_bifidum -30.00 5.12 4.6E-09 8.4E-08 
Eubacterium_biforme -30.00 4.84 5.7E-10 1.7E-08 
Megasphaera_unclassified -30.00 5.15 5.8E-09 8.4E-08 
Bacteroides_faecis -30.00 5.15 5.8E-09 8.4E-08 
Coprobacter_fastidiosus -29.91 5.15 6.4E-09 8.4E-08 
Bacteroides_finegoldii -29.77 5.15 7.5E-09 9.0E-08 
Lactococcus_lactis  -28.44 5.10 2.5E-08 2.7E-07 
Bacteroides_salyersiae -22.85 5.15 9.2E-06 7.3E-05 
Odoribacter_unclassified 26.09 5.09 3.0E-07 2.5E-06 
Clostridium_citroniae 27.08 5.09 1.0E-07 9.5E-07 
Clostridium_hathewayi 27.69 3.23 9.9E-18 1.2E-15 
Clostridium_symbiosum 28.15 5.09 3.2E-08 3.2E-07 
Collinsella_intestinalis  30.00 4.53 3.6E-11 1.4E-09 
     
AS T2 & AS     
Bacteroides_coprocola -30.00 5.15 5.8E-09 1.0E-07 
Bacteroides_massiliensis  -30.00 4.23 1.2E-12 7.4E-11 
Bifidobacterium_animalis  -30.00 4.95 1.4E-09 5.5E-08 
Bifidobacterium_bifidum -30.00 5.12 4.6E-09 1.0E-07 
Megasphaera_unclassified -30.00 5.15 5.8E-09 1.0E-07 
Bacteroides_faecis -29.95 5.15 6.1E-09 1.0E-07 
Bacteroides_finegoldii -29.83 5.15 7.0E-09 1.0E-07 
Ruminococcaceae_bacterium_D16 -28.96 5.15 1.9E-08 2.2E-07 
Lactococcus_lactis  -28.58 5.10 2.1E-08 2.3E-07 
Bacteroides_salyersiae -23.05 5.15 7.7E-06 6.5E-05 
Collinsella_intestinalis  24.85 4.53 4.2E-08 4.2E-07 
Clostridium_symbiosum 27.49 5.09 6.6E-08 6.1E-07 
Clostridium_citroniae 28.73 5.09 1.7E-08 2.2E-07 
Clostridium_hathewayi 29.71 3.23 3.6E-20 4.3E-18 
     
AS T3 & AS     
Alistipes_unclassified -30.00 6.77 9.3E-06 5.3E-05 
Bacteroides_cellulosilyticus  -30.00 5.45 3.8E-08 5.2E-07 
Bacteroides_coprocola -30.00 6.77 9.3E-06 5.3E-05 
Bacteroides_massiliensis  -30.00 5.56 6.8E-08 8.1E-07 
Bacteroides_stercoris  -30.00 5.39 2.7E-08 5.0E-07 
Bifidobacterium_animalis  -30.00 6.51 4.0E-06 3.0E-05 
Bifidobacterium_bifidum -30.00 6.72 8.2E-06 5.3E-05 
Eubacterium_biforme -30.00 6.36 2.4E-06 2.0E-05 
Eubacterium_ventriosum -30.00 3.14 1.1E-21 1.3E-19 
Lachnospiraceae_bacterium_2_1_58FAA -30.00 5.60 8.6E-08 9.3E-07 
Megasphaera_unclassified -30.00 6.77 9.3E-06 5.3E-05 
Odoribacter_splanchnicus  -30.00 6.77 9.3E-06 5.3E-05 
Paraprevotella_clara -30.00 5.93 4.3E-07 4.3E-06 
Paraprevotella_unclassified -30.00 5.46 3.9E-08 5.2E-07 
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Ruminococcus_bromii -30.00 4.37 6.4E-12 2.5E-10 
Anaerotruncus_colihominis  -29.80 6.77 1.1E-05 5.8E-05 
Eggerthella_lenta -29.53 5.33 2.9E-08 5.0E-07 
Bacteroides_faecis -29.45 6.77 1.4E-05 7.0E-05 
Alistipes_indistinctus  -28.91 4.45 8.5E-11 2.5E-09 
Bilophila_wadsworthia -27.55 3.63 3.3E-14 2.0E-12 
Ruminococcaceae_bacterium_D16 -27.48 6.77 4.9E-05 2.3E-04 
Coprobacter_fastidiosus -26.70 6.77 8.0E-05 3.6E-04 
Bacteroides_finegoldii -26.44 6.77 9.3E-05 4.1E-04 
Burkholderiales_bacterium_1_1_47 -26.09 6.75 1.1E-04 4.7E-04 
Flavonifractor_plautii -25.05 5.32 2.5E-06 2.0E-05 
Bacteroides_salyersiae -24.92 6.77 2.3E-04 9.5E-04 
Pseudoflavonifractor_capillosus -24.01 6.77 3.9E-04 1.5E-03 
Parabacteroides_distasonis  -7.37 2.70 6.3E-03 2.4E-02 
Clostridium_hathewayi 26.70 4.19 1.9E-10 4.5E-09 
Clostridium_symbiosum 27.05 6.64 4.6E-05 2.3E-04 
Collinsella_intestinalis  28.63 5.91 1.3E-06 1.2E-05 
Significance is defined by P-adjusted ≤ 0.05. Red indicates species with reduced 
abundance while green represents species with increased abundance in that pairwise 
comparison. 
 
C) Significant pairwise comparisons of psoriatic arthritis (PSA) time-point, 
established samples and controls T0 
PSA T0 & Control T0 log2FoldChange lfcSE pvalue padj 
Bacteroides_finegoldii -30.00 4.59 6.6E-11 2.6E-09 
Bacteroides_salyersiae -30.00 4.59 6.6E-11 2.6E-09 
Lactococcus_lactis  -29.84 4.04 1.5E-13 1.8E-11 
Acidaminococcus_unclassified -29.74 4.59 9.7E-11 2.6E-09 
Mitsuokella_unclassified -29.65 4.59 1.1E-10 2.6E-09 
Mitsuokella_multacida -27.40 4.59 2.5E-09 4.9E-08 
Turicibacter_unclassified -26.34 4.59 9.9E-09 1.7E-07 
Oxalobacter_formigenes -24.09 4.59 1.6E-07 2.0E-06 
Bacteroides_clarus -24.04 4.59 1.7E-07 2.0E-06 
Ruminococcus_torques  2.44 0.62 8.2E-05 8.8E-04 
Clostridium_asparagiforme 13.32 4.22 1.6E-03 1.6E-02 
Erysipelotrichaceae_bacterium_21_3 24.77 4.56 5.5E-08 8.1E-07 
     
PSA T2 & Control T0     
Bacteroides_salyersiae -30.00 5.68 1.3E-07 2.3E-06 
Desulfovibrio_piger -30.00 5.02 2.2E-09 2.6E-07 
Megamonas_unclassified -30.00 5.68 1.3E-07 2.3E-06 
Phascolarctobacterium_succinatutens  -30.00 5.68 1.3E-07 2.3E-06 
Megamonas_hypermegale -30.00 5.68 1.3E-07 2.3E-06 
Alistipes_unclassified -29.93 5.68 1.4E-07 2.3E-06 
Bacteroides_finegoldii -29.80 5.68 1.5E-07 2.3E-06 
Mitsuokella_unclassified -28.84 5.68 3.8E-07 4.5E-06 
Mitsuokella_multacida -26.97 5.68 2.1E-06 1.9E-05 
Bacteroides_faecis -26.92 5.64 1.8E-06 1.8E-05 
Lactococcus_lactis -26.29 5.00 1.4E-07 2.3E-06 
Streptococcus_vestibularis  -26.17 5.68 4.1E-06 3.0E-05 
Acidaminococcus_unclassified -24.04 5.68 2.3E-05 1.6E-04 
Lachnospiraceae_bacterium_1_4_56FAA -23.87 5.13 3.3E-06 2.6E-05 
Bacteroides_clarus -23.20 5.68 4.4E-05 2.9E-04 
Oxalobacter_formigenes -22.08 5.68 1.0E-04 6.3E-04 
Clostridium_asparagiforme 14.76 5.19 4.4E-03 2.6E-02 
Erysipelotrichaceae_bacterium_21_3 26.40 5.61 2.5E-06 2.1E-05 
Anaerotruncus_colihominis  27.75 5.61 7.6E-07 8.1E-06 
Turicibacter_sanguinis 28.74 5.61 3.0E-07 4.0E-06 
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PSA T3 & Control T0     
Bacteroides_stercoris  -30.00 4.54 3.8E-11 2.2E-09 
Phascolarctobacterium_succinatutens  -30.00 6.40 2.7E-06 4.0E-05 
Roseburia_intestinalis  -30.00 3.10 3.5E-22 4.1E-20 
Megamonas_unclassified -29.72 6.40 3.4E-06 4.5E-05 
Bacteroides_salyersiae -29.20 6.40 5.0E-06 5.9E-05 
Desulfovibrio_piger -29.04 5.65 2.8E-07 8.2E-06 
Megamonas_hypermegale -28.46 6.40 8.6E-06 9.3E-05 
Bacteroides_finegoldii -28.16 6.40 1.1E-05 1.1E-04 
Alistipes_unclassified -27.96 6.40 1.2E-05 1.1E-04 
Paraprevotella_xylaniphila -27.84 5.30 1.5E-07 6.0E-06 
Mitsuokella_unclassified -27.22 6.40 2.1E-05 1.8E-04 
Lactococcus_lactis  -27.01 5.63 1.6E-06 3.2E-05 
Bacteroides_faecis -25.90 6.35 4.6E-05 3.6E-04 
Mitsuokella_multacida -25.66 6.40 6.0E-05 4.5E-04 
Bacteroides_clarus -24.76 6.40 1.1E-04 6.9E-04 
Desulfovibrio_desulfuricans  -24.73 6.40 1.1E-04 6.9E-04 
Acidaminococcus_unclassified -24.46 6.40 1.3E-04 7.8E-04 
Bacteroides_fragilis  -23.59 6.09 1.1E-04 6.9E-04 
Flavonifractor_plautii -22.57 4.46 4.1E-07 9.6E-06 
Turicibacter_unclassified -22.49 6.40 4.4E-04 2.4E-03 
Streptococcus_vestibularis  -21.43 6.40 8.1E-04 4.2E-03 
Lachnospiraceae_bacterium_1_4_56FAA -20.87 5.78 3.0E-04 1.7E-03 
Oxalobacter_formigenes -20.28 6.40 1.5E-03 7.5E-03 
Erysipelotrichaceae_bacterium_21_3 30.00 6.31 2.0E-06 3.3E-05 
     
PSA & Control T0     
Mitsuokella_unclassified -30.00 3.47 5.1E-18 2.4E-16 
Mitsuokella_multacida -29.95 3.47 5.8E-18 2.4E-16 
Bacteroides_clarus -29.93 3.47 6.0E-18 2.4E-16 
Veillonella_dispar -26.44 3.47 2.4E-14 4.8E-13 
Desulfovibrio_piger -14.10 3.04 3.4E-06 4.0E-05 
Clostridium_asparagiforme 13.60 3.21 2.3E-05 2.4E-04 
Erysipelotrichaceae_bacterium_21_3 22.65 3.47 6.8E-11 8.9E-10 
Actinomyces_graevenitzii 25.33 3.47 3.0E-13 4.4E-12 
Eubacterium_cylindroides  25.65 3.47 1.5E-13 2.5E-12 
Turicibacter_sanguinis  27.81 3.47 1.1E-15 2.7E-14 
Anaerotruncus_colihominis  29.33 3.47 3.0E-17 8.8E-16 
     
PSA T3 & PSA T0     
Roseburia_intestinalis  -31.41 3.36 7.9E-21 9.3E-19 
Megamonas_unclassified -31.28 7.00 7.8E-06 1.8E-04 
Alistipes_unclassified -30.26 7.00 1.5E-05 2.6E-04 
Phascolarctobacterium_succinatutens  -29.79 7.00 2.1E-05 2.7E-04 
Megamonas_hypermegale -29.65 7.00 2.3E-05 2.7E-04 
Bacteroides_fragilis  -28.65 6.66 1.7E-05 2.6E-04 
Bacteroides_stercoris  -28.57 4.95 7.7E-09 4.6E-07 
Bacteroides_faecis -27.88 6.95 6.0E-05 6.4E-04 
Clostridium_asparagiforme -27.85 6.49 1.8E-05 2.6E-04 
Desulfovibrio_piger -27.82 6.18 6.7E-06 1.8E-04 
Streptococcus_vestibularis  -26.66 7.00 1.4E-04 1.4E-03 
Flavonifractor_plautii -25.08 4.86 2.4E-07 9.6E-06 
Desulfovibrio_desulfuricans  -24.60 7.00 4.4E-04 3.7E-03 
Lachnospiraceae_bacterium_1_4_56FAA -23.28 6.32 2.3E-04 2.1E-03 
Paraprevotella_xylaniphila -18.53 5.80 1.4E-03 1.1E-02 
     
PSA T2 & PSA T0     
Alistipes_unclassified -32.23 6.35 3.8E-07 1.1E-05 
Megamonas_unclassified -31.57 6.35 6.6E-07 1.5E-05 
Streptococcus_vestibularis  -31.40 6.35 7.5E-07 1.5E-05 
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Megamonas_hypermegale -31.19 6.35 8.9E-07 1.5E-05 
Phascolarctobacterium_succinatutens  -29.79 6.35 2.7E-06 4.0E-05 
Bacteroides_faecis -28.90 6.30 4.5E-06 5.4E-05 
Desulfovibrio_piger -28.78 5.60 2.8E-07 1.1E-05 
Lachnospiraceae_bacterium_1_4_56FAA -26.27 5.73 4.5E-06 5.4E-05 
Turicibacter_unclassified 28.77 6.31 5.2E-06 5.5E-05 
Anaerotruncus_colihominis 34.25 6.31 5.8E-08 3.4E-06 
Turicibacter_sanguinis  38.30 6.31 1.3E-09 1.5E-07 
     
PSA T3 & PSA T2     
Turicibacter_sanguinis  -31.84 7.72 3.8E-05 9.1E-04 
Bacteroides_fragilis  -31.59 7.35 1.7E-05 6.8E-04 
Anaerotruncus_colihominis  -31.47 7.72 4.6E-05 9.1E-04 
Roseburia_intestinalis  -30.80 3.67 5.0E-17 5.9E-15 
Clostridium_asparagiforme -29.29 7.16 4.3E-05 9.1E-04 
Flavonifractor_plautii -26.99 5.35 4.5E-07 2.7E-05 
Desulfovibrio_desulfuricans  -26.75 7.72 5.3E-04 7.9E-03 
Turicibacter_unclassified -24.92 7.72 1.3E-03 1.6E-02 
Bacteroides_stercoris  -21.56 5.45 7.6E-05 1.3E-03 
Paraprevotella_xylaniphila -20.47 6.39 1.4E-03 1.6E-02 
     
PSA T0 & PSA     
Turicibacter_sanguinis  -37.37 4.52 1.3E-16 1.6E-14 
Anaerotruncus_colihominis  -35.82 4.52 2.2E-15 1.3E-13 
Acidaminococcus_unclassified -33.82 4.52 7.2E-14 2.1E-12 
Eubacterium_cylindroides  -32.31 4.52 8.6E-13 2.0E-11 
Actinomyces_graevenitzii -30.54 4.52 1.4E-11 2.7E-10 
Turicibacter_unclassified -30.00 4.52 3.1E-11 5.3E-10 
Lactococcus_lactis -29.90 3.97 5.3E-14 2.1E-12 
Bacteroides_finegoldii -29.06 4.52 1.3E-10 1.9E-09 
Oxalobacter_formigenes -27.95 4.52 6.2E-10 8.1E-09 
Bacteroides_salyersiae -25.01 4.52 3.1E-08 3.3E-07 
Desulfovibrio_piger 12.87 3.93 1.0E-03 1.0E-02 
Veillonella_dispar 26.20 4.48 4.9E-09 5.8E-08 
     
PSA T2 & PSA     
Megamonas_unclassified -32.57 5.62 6.7E-09 4.0E-07 
Megamonas_hypermegale -32.09 5.62 1.1E-08 4.4E-07 
Lachnospiraceae_bacterium_1_4_56FAA -31.16 5.08 8.3E-10 9.8E-08 
Bacteroides_faecis -31.08 5.58 2.5E-08 7.4E-07 
Alistipes_unclassified -30.14 5.62 8.1E-08 1.7E-06 
Phascolarctobacterium_succinatutens  -29.22 5.62 2.0E-07 2.9E-06 
Bacteroides_finegoldii -28.86 5.62 2.8E-07 3.7E-06 
Streptococcus_vestibularis  -28.62 5.62 3.5E-07 4.1E-06 
Acidaminococcus_unclassified -28.12 5.62 5.6E-07 6.0E-06 
Eubacterium_cylindroides  -27.55 5.62 9.4E-07 9.3E-06 
Lactococcus_lactis  -26.34 4.94 9.9E-08 1.7E-06 
Actinomyces_graevenitzii -26.26 5.62 3.0E-06 2.7E-05 
Oxalobacter_formigenes -25.95 5.62 3.9E-06 3.3E-05 
Bacteroides_salyersiae -25.01 5.62 8.5E-06 6.7E-05 
Desulfovibrio_piger -15.90 4.97 1.4E-03 1.0E-02 
Veillonella_dispar 29.60 5.55 9.4E-08 1.7E-06 
     
PSA T3 & PSA     
Anaerotruncus_colihominis  -33.04 6.34 1.9E-07 5.6E-06 
Megamonas_unclassified -32.29 6.34 3.6E-07 8.5E-06 
Turicibacter_sanguinis  -30.91 6.34 1.1E-06 1.6E-05 
Megamonas_hypermegale -30.55 6.34 1.5E-06 1.7E-05 
Bacteroides_faecis -30.06 6.30 1.8E-06 1.8E-05 
Roseburia_intestinalis  -29.71 3.07 4.2E-22 5.0E-20 
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Bacteroides_fragilis  -29.46 6.04 1.1E-06 1.6E-05 
Phascolarctobacterium_succinatutens  -29.22 6.34 4.1E-06 3.5E-05 
Bacteroides_stercoris  -29.07 4.50 1.0E-10 6.1E-09 
Acidaminococcus_unclassified -28.54 6.34 6.8E-06 5.4E-05 
Alistipes_unclassified -28.18 6.34 8.9E-06 6.2E-05 
Lachnospiraceae_bacterium_1_4_56FAA -28.16 5.73 8.9E-07 1.6E-05 
Clostridium_asparagiforme -28.13 5.88 1.7E-06 1.8E-05 
Flavonifractor_plautii -27.62 4.42 4.1E-10 1.6E-08 
Eubacterium_cylindroides  -27.41 6.34 1.5E-05 1.0E-04 
Bacteroides_finegoldii -27.22 6.34 1.8E-05 1.1E-04 
Lactococcus_lactis  -27.06 5.58 1.3E-06 1.6E-05 
Actinomyces_graevenitzii -26.25 6.34 3.5E-05 2.1E-04 
Turicibacter_unclassified -26.15 6.34 3.7E-05 2.1E-04 
Desulfovibrio_desulfuricans  -26.10 6.34 3.9E-05 2.1E-04 
Bacteroides_salyersiae -24.21 6.34 1.4E-04 7.0E-04 
Oxalobacter_formigenes -24.14 6.34 1.4E-04 7.0E-04 
Streptococcus_vestibularis  -23.88 6.34 1.7E-04 7.9E-04 
Paraprevotella_xylaniphila -23.47 5.26 8.1E-06 6.0E-05 
Desulfovibrio_piger -14.94 5.61 7.8E-03 3.5E-02 
Veillonella_dispar 29.57 6.25 2.2E-06 2.0E-05 
Significance is defined by P-adjusted ≤ 0.05. Red colour indicates species with 
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D) Significant pairwise comparisons of Inflammatory bowel diseases (IBD) time-
point, established samples and controls T0 
IBD T0 & Control T0 log2FoldChange lfcSE pvalue padj 
Adlercreutzia_equolifaciens  -30.00 2.73 4.4E-28 2.5E-26 
Akkermansia_muciniphila -30.00 3.22 1.2E-20 2.0E-19 
Alistipes_finegoldii -30.00 3.12 7.9E-22 1.5E-20 
Alistipes_onderdonkii -30.00 3.49 8.0E-18 7.0E-17 
Alistipes_senegalensis  -30.00 4.01 6.9E-14 4.4E-13 
Bacteroidales_bacterium_ph8 -30.00 3.07 1.5E-22 3.5E-21 
Bacteroides_caccae -30.00 3.53 1.8E-17 1.5E-16 
Bacteroides_cellulosilyticus -30.00 4.26 2.0E-12 5.5E-12 
Bacteroides_coprocola -30.00 4.26 2.0E-12 5.5E-12 
Bacteroides_dorei -30.00 3.46 4.6E-18 4.4E-17 
Bacteroides_finegoldii -30.00 4.26 2.0E-12 5.5E-12 
Bacteroides_massiliensis  -30.00 3.74 1.0E-15 6.7E-15 
Bacteroides_plebeius -30.00 4.26 2.0E-12 5.5E-12 
Bacteroides_salyersiae -30.00 4.26 2.0E-12 5.5E-12 
Bifidobacterium_catenulatum -30.00 4.26 2.0E-12 5.5E-12 
Clostridium_leptum -30.00 3.28 5.2E-20 5.9E-19 
Coprococcus_sp_ART55_1 -30.00 4.26 2.0E-12 5.5E-12 
Desulfovibrio_piger -30.00 4.26 2.0E-12 5.5E-12 
Eubacterium_biforme -30.00 4.26 2.0E-12 5.5E-12 
Eubacterium_siraeum -30.00 3.02 3.1E-23 8.9E-22 
Odoribacter_splanchnicus  -30.00 4.26 2.0E-12 5.5E-12 
Parabacteroides_unclassified -30.00 4.26 2.0E-12 5.5E-12 
Paraprevotella_clara -30.00 4.26 2.0E-12 5.5E-12 
Paraprevotella_unclassified -30.00 4.12 3.2E-13 1.7E-12 
Prevotella_copri -30.00 4.26 2.0E-12 5.5E-12 
Roseburia_inulinivorans -30.00 2.60 1.1E-30 1.2E-28 
Roseburia_unclassified -30.00 4.26 2.0E-12 5.5E-12 
Ruminococcus_bromii -30.00 3.27 4.4E-20 5.9E-19 
Ruminococcus_lactaris  -30.00 4.04 1.1E-13 6.6E-13 
Coprobacter_fastidiosus -29.95 4.26 2.2E-12 5.9E-12 
Bilophila_wadsworthia -29.80 2.95 4.5E-24 1.7E-22 
Mitsuokella_unclassified -29.36 4.26 5.8E-12 1.5E-11 
Acidaminococcus_unclassified -28.96 4.26 1.1E-11 2.8E-11 
Odoribacter_unclassified -28.77 4.26 1.5E-11 3.8E-11 
Ruminococcus_callidus  -28.75 4.26 1.6E-11 3.9E-11 
Mitsuokella_multacida -27.64 4.26 9.0E-11 2.2E-10 
Bacteroides_eggerthii -27.35 4.26 1.4E-10 3.4E-10 
Bacteroides_clarus -25.83 4.26 1.4E-09 3.1E-09 
Paraprevotella_xylaniphila -25.72 4.26 1.6E-09 3.6E-09 
Megamonas_unclassified -24.91 4.26 5.1E-09 1.1E-08 
Desulfovibrio_desulfuricans  -24.71 4.26 6.8E-09 1.5E-08 
Bacteroides_faecis -23.68 4.26 2.8E-08 5.8E-08 
Lachnospiraceae_bacterium_3_1_57FAA_CT1 -22.98 4.26 7.0E-08 1.4E-07 
Pseudoflavonifractor_capillosus  -22.62 4.26 1.1E-07 2.3E-07 
Olsenella_unclassified -21.93 4.27 2.7E-07 5.4E-07 
Roseburia_hominis -18.16 1.98 4.7E-20 5.9E-19 
Alistipes_indistinctus -15.13 2.62 7.9E-09 1.7E-08 
Barnesiella_intestinihominis  -10.82 2.81 1.2E-04 2.3E-04 
Bilophila_unclassified -8.08 2.26 3.5E-04 6.7E-04 
Bacteroides_thetaiotaomicron -7.63 3.14 1.5E-02 2.6E-02 
Eubacterium_rectale -5.54 2.42 2.2E-02 3.8E-02 
Alistipes_shahii -5.45 2.40 2.3E-02 4.0E-02 
Subdoligranulum_unclassified -5.38 1.69 1.5E-03 2.7E-03 
Ruminococcus_gnavus 8.55 2.52 6.8E-04 1.2E-03 
Veillonella_parvula 8.63 3.88 2.6E-02 4.3E-02 
Enterococcus_faecalis  9.33 4.14 2.4E-02 4.1E-02 
Veillonella_unclassified 10.00 2.98 7.8E-04 1.4E-03 
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Bacteroides_fragilis  14.11 4.14 6.5E-04 1.2E-03 
Lachnospiraceae_bacterium_4_1_37FAA 25.48 4.17 1.0E-09 2.4E-09 
Clostridium_nexile 29.94 3.45 4.0E-18 4.2E-17 
Anaerostipes_unclassified 30.00 4.17 6.5E-13 2.8E-12 
Blautia_hansenii 30.00 4.17 6.5E-13 2.8E-12 
Blautia_producta 30.00 4.06 1.5E-13 8.8E-13 
Clostridiales_bacterium_1_7_47FAA 30.00 4.17 6.5E-13 2.8E-12 
Dorea_unclassified 30.00 4.17 6.5E-13 2.8E-12 
Lachnospiraceae_bacterium_6_1_63FAA 30.00 3.58 5.5E-17 4.2E-16 
Lachnospiraceae_bacterium_9_1_43BFAA 30.00 3.63 1.3E-16 9.2E-16 
Morganella_morganii 30.00 4.17 6.5E-13 2.8E-12 
Streptococcus_gordonii 30.00 4.17 6.5E-13 2.8E-12 
     
IBD T2 & Control T0     
Akkermansia_muciniphila -30.00 3.22 1.2E-20 1.8E-19 
Alistipes_finegoldii -30.00 3.12 7.9E-22 1.3E-20 
Alistipes_onderdonkii -30.00 3.49 8.0E-18 1.0E-16 
Alistipes_senegalensis  -30.00 4.01 6.9E-14 5.6E-13 
Alistipes_shahii -30.00 2.61 1.4E-30 5.5E-29 
Bacteroidales_bacterium_ph8 -30.00 3.07 1.5E-22 2.9E-21 
Bacteroides_caccae -30.00 3.53 1.8E-17 2.0E-16 
Bacteroides_cellulosilyticus  -30.00 4.26 2.0E-12 6.4E-12 
Bacteroides_coprocola -30.00 4.26 2.0E-12 6.4E-12 
Bacteroides_faecis -30.00 4.26 2.0E-12 6.4E-12 
Bacteroides_finegoldii -30.00 4.26 2.0E-12 6.4E-12 
Bacteroides_massiliensis -30.00 3.74 1.0E-15 9.6E-15 
Bacteroides_plebeius -30.00 4.26 2.0E-12 6.4E-12 
Bacteroides_salyersiae -30.00 4.26 2.0E-12 6.4E-12 
Bifidobacterium_catenulatum -30.00 4.26 2.0E-12 6.4E-12 
Coprobacter_fastidiosus -30.00 4.26 2.0E-12 6.4E-12 
Coprococcus_sp_ART55_1 -30.00 4.26 2.0E-12 6.4E-12 
Desulfovibrio_piger -30.00 4.26 2.0E-12 6.4E-12 
Eubacterium_biforme -30.00 4.26 2.0E-12 6.4E-12 
Eubacterium_eligens -30.00 2.56 1.2E-31 1.4E-29 
Eubacterium_siraeum -30.00 3.02 3.1E-23 7.6E-22 
Odoribacter_splanchnicus -30.00 4.26 2.0E-12 6.4E-12 
Odoribacter_unclassified -30.00 4.26 2.0E-12 6.4E-12 
Parabacteroides_unclassified -30.00 4.26 2.0E-12 6.4E-12 
Paraprevotella_clara -30.00 4.26 2.0E-12 6.4E-12 
Paraprevotella_unclassified -30.00 4.12 3.2E-13 2.3E-12 
Prevotella_copri -30.00 4.26 2.0E-12 6.4E-12 
Roseburia_inulinivorans -30.00 2.60 1.1E-30 5.5E-29 
Roseburia_unclassified -30.00 4.26 2.0E-12 6.4E-12 
Ruminococcus_lactaris  -30.00 4.04 1.1E-13 8.3E-13 
Mitsuokella_unclassified -29.51 4.26 4.5E-12 1.4E-11 
Ruminococcus_callidus  -29.14 4.26 8.2E-12 2.4E-11 
Mitsuokella_multacida -28.04 4.26 4.8E-11 1.3E-10 
Bacteroides_eggerthii -27.65 4.26 8.9E-11 2.3E-10 
Paraprevotella_xylaniphila -26.81 4.26 3.2E-10 7.8E-10 
Bacteroides_clarus -26.40 4.26 6.0E-10 1.4E-09 
Desulfovibrio_desulfuricans  -25.72 4.26 1.6E-09 3.7E-09 
Megamonas_unclassified -25.22 4.26 3.3E-09 7.4E-09 
Olsenella_unclassified -24.94 4.27 5.0E-09 1.1E-08 
Pseudoflavonifractor_capillosus  -23.43 4.26 3.9E-08 8.2E-08 
Lachnospiraceae_bacterium_3_1_57FAA_CT1 -23.27 4.26 4.8E-08 1.0E-07 
Roseburia_hominis -20.25 2.04 3.3E-23 7.6E-22 
Alistipes_indistinctus  -17.29 2.67 8.8E-11 2.3E-10 
Alistipes_putredinis  -7.54 3.22 1.9E-02 3.8E-02 
Ruminococcus_gnavus 8.45 2.52 7.8E-04 1.6E-03 
Bacteroides_fragilis 11.50 4.14 5.5E-03 1.1E-02 
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Lachnospiraceae_bacterium_4_1_37FAA 23.52 4.17 1.7E-08 3.7E-08 
Lachnospiraceae_bacterium_6_1_63FAA 23.71 3.58 3.6E-11 1.0E-10 
Blautia_producta 25.31 4.06 4.7E-10 1.1E-09 
Clostridiales_bacterium_1_7_47FAA 26.92 4.17 1.1E-10 2.7E-10 
Blautia_hansenii 27.14 4.17 7.9E-11 2.1E-10 
Clostridium_nexile 27.93 3.45 5.8E-16 6.0E-15 
Anaerostipes_unclassified 28.32 4.17 1.1E-11 3.3E-11 
Streptococcus_gordonii 28.81 4.17 5.0E-12 1.5E-11 
Morganella_morganii 28.82 4.17 5.0E-12 1.5E-11 
Lachnospiraceae_bacterium_9_1_43BFAA 28.91 3.63 1.6E-15 1.4E-14 
Dorea_unclassified 29.38 4.17 1.9E-12 6.4E-12 
Lachnospiraceae_bacterium_5_1_57FAA 30.00 4.17 6.5E-13 4.4E-12 
IBD T3 & Control T0     
Akkermansia_muciniphila -30.00 3.63 1.4E-16 4.0E-15 
Bacteroidales_bacterium_ph8 -30.00 3.46 4.5E-18 1.8E-16 
Bacteroides_caccae -30.00 3.97 4.3E-14 7.0E-13 
Bacteroides_cellulosilyticus  -30.00 4.80 4.1E-10 1.9E-09 
Bacteroides_coprocola -30.00 4.80 4.1E-10 1.9E-09 
Bacteroides_finegoldii -30.00 4.80 4.1E-10 1.9E-09 
Bacteroides_massiliensis  -30.00 4.21 1.0E-12 1.3E-11 
Bacteroides_plebeius -30.00 4.80 4.1E-10 1.9E-09 
Bacteroides_salyersiae -30.00 4.80 4.1E-10 1.9E-09 
Clostridium_leptum -30.00 3.69 4.4E-16 9.9E-15 
Coprococcus_sp_ART55_1 -30.00 4.80 4.1E-10 1.9E-09 
Desulfovibrio_piger -30.00 4.80 4.1E-10 1.9E-09 
Eubacterium_biforme -30.00 4.80 4.1E-10 1.9E-09 
Eubacterium_siraeum -30.00 3.41 1.3E-18 1.5E-16 
Parabacteroides_unclassified -30.00 4.80 4.1E-10 1.9E-09 
Paraprevotella_clara -30.00 4.80 4.1E-10 1.9E-09 
Paraprevotella_unclassified -30.00 4.63 9.6E-11 1.0E-09 
Prevotella_copri -30.00 4.80 4.1E-10 1.9E-09 
Roseburia_unclassified -30.00 4.80 4.1E-10 1.9E-09 
Ruminococcus_lactaris  -30.00 4.55 4.2E-11 4.7E-10 
Ruminococcus_callidus  -28.77 4.80 2.0E-09 8.6E-09 
Alistipes_senegalensis  -28.64 4.51 2.2E-10 1.9E-09 
Bifidobacterium_catenulatum -28.47 4.80 3.0E-09 1.2E-08 
Mitsuokella_unclassified -27.92 4.80 6.0E-09 2.1E-08 
Mitsuokella_multacida -27.74 4.80 7.4E-09 2.6E-08 
Bacteroides_eggerthii -27.19 4.80 1.5E-08 4.6E-08 
Paraprevotella_xylaniphila -25.93 4.80 6.6E-08 2.0E-07 
Bacteroides_clarus -25.80 4.80 7.6E-08 2.3E-07 
Coprobacter_fastidiosus -25.60 4.80 9.6E-08 2.7E-07 
Bacteroides_faecis -25.05 4.80 1.8E-07 4.9E-07 
Megamonas_unclassified -24.89 4.80 2.2E-07 5.7E-07 
Desulfovibrio_desulfuricans  -23.47 4.80 1.0E-06 2.5E-06 
Odoribacter_unclassified -23.12 4.80 1.4E-06 3.6E-06 
Pseudoflavonifractor_capillosus  -22.97 4.80 1.7E-06 4.1E-06 
Lachnospiraceae_bacterium_3_1_57FAA_CT1 -22.83 4.80 2.0E-06 4.7E-06 
Roseburia_hominis -20.01 2.31 4.7E-18 1.8E-16 
Olsenella_unclassified -19.25 4.80 6.1E-05 1.4E-04 
Alistipes_indistinctus  -17.04 3.01 1.5E-08 4.6E-08 
Alistipes_onderdonkii -10.72 3.75 4.3E-03 9.3E-03 
Eubacterium_rectale -7.44 2.71 6.1E-03 1.3E-02 
Streptococcus_thermophilus  -7.10 3.04 2.0E-02 4.0E-02 
Subdoligranulum_unclassified -5.36 1.90 4.9E-03 1.1E-02 
Ruminococcus_gnavus 9.04 2.83 1.4E-03 3.2E-03 
Bacteroides_fragilis  11.04 4.65 1.8E-02 3.7E-02 
Enterococcus_faecalis  13.31 4.65 4.2E-03 9.3E-03 
Lachnospiraceae_bacterium_6_1_63FAA 20.31 4.02 4.3E-07 1.1E-06 
Blautia_producta 24.45 4.56 8.2E-08 2.4E-07 
 
291 | P a g e  
 
Clostridiales_bacterium_1_7_47FAA 24.57 4.68 1.5E-07 4.3E-07 
Blautia_hansenii 26.69 4.68 1.2E-08 4.0E-08 
Lachnospiraceae_bacterium_5_1_57FAA 27.26 4.68 5.8E-09 2.1E-08 
Dorea_unclassified 27.54 4.68 4.0E-09 1.5E-08 
Morganella_morganii 27.71 4.68 3.3E-09 1.3E-08 
Anaerostipes_unclassified 28.50 4.68 1.2E-09 5.1E-09 
Lachnospiraceae_bacterium_9_1_43BFAA 29.69 4.07 2.8E-13 4.1E-12 
Clostridium_nexile 30.00 3.87 8.9E-15 1.7E-13 
Lachnospiraceae_bacterium_4_1_37FAA 30.00 4.68 1.5E-10 1.4E-09 
     
IBD T3 & IBD T0     
Streptococcus_gordonii -35.57 5.74 5.8E-10 9.4E-09 
Alistipes_onderdonkii 19.28 4.64 3.3E-05 3.4E-04 
Alistipes_finegoldii 23.42 4.14 1.5E-08 1.9E-07 
Roseburia_inulinivorans 25.46 3.41 8.0E-14 4.6E-12 
Adlercreutzia_equolifaciens  25.58 3.59 9.8E-13 3.7E-11 
Bacteroides_dorei 26.81 4.61 5.8E-09 8.3E-08 
Ruminococcus_bromii 28.61 4.34 4.2E-11 9.6E-10 
Odoribacter_splanchnicus  29.18 5.71 3.2E-07 3.7E-06 
Bilophila_wadsworthia 29.37 3.89 4.1E-14 4.6E-12 
Acidaminococcus_unclassified 35.96 5.71 3.0E-10 5.7E-09 
Lachnospiraceae_bacterium_5_1_57FAA 38.70 5.71 1.2E-11 3.5E-10 
     
IBD T2 & IBD T0     
Eubacterium_eligens -27.25 3.13 2.9E-18 3.3E-16 
Alistipes_shahii -24.55 3.19 1.3E-14 3.8E-13 
Bacteroides_dorei 26.12 4.28 1.1E-09 1.4E-08 
Bilophila_wadsworthia 26.96 3.62 9.3E-14 2.1E-12 
Clostridium_leptum 27.02 4.04 2.3E-11 3.3E-10 
Adlercreutzia_equolifaciens  27.68 3.34 1.2E-16 6.9E-15 
Ruminococcus_bromii 29.37 4.03 3.3E-13 6.3E-12 
Acidaminococcus_unclassified 35.98 5.30 1.1E-11 1.9E-10 
Lachnospiraceae_bacterium_5_1_57FAA 41.44 5.30 5.4E-15 2.0E-13 
     
IBD T3 & IBD T2     
Streptococcus_gordonii -34.38 5.74 2.1E-09 4.8E-08 
Clostridium_leptum -27.02 4.39 7.2E-10 2.1E-08 
Alistipes_onderdonkii 19.28 4.64 3.3E-05 4.7E-04 
Alistipes_finegoldii 23.42 4.14 1.5E-08 2.8E-07 
Roseburia_inulinivorans 25.46 3.41 8.0E-14 3.0E-12 
Eubacterium_eligens 26.76 3.35 1.4E-15 1.6E-13 
Alistipes_shahii 26.78 3.42 4.7E-15 2.7E-13 
Odoribacter_splanchnicus  29.18 5.71 3.2E-07 5.2E-06 
Significance is defined by P-adjusted ≤ 0.05. Red colour indicates species with 
reduced abundance while green represents species with increased abundance in that 












Supplementary table 11 Comparison of significant pathways in IBD dataset 
A) Mean, standard deviation, and Kruskal-Wallis significance 
Significant pathways in IBD Control T0 IBD T0 IBD T2 IBD T3 p-value p-adjusted 
ARGDEG-III-PW Y: L-arginine degradation IV (arginine 
decarboxylase/agmatine deiminase pathway) 
9.9E-05 ± 2.8E-05 4.1E-05 ± 3.3E-05 2.6E-05 ± 6.3E-06 3.1E-05 ± 1.2E-05 5.4E-04 3.2E-02 
PWY-43: putrescine biosynthesis II 9.9E-05 ± 2.8E-05 4.1E-05 ± 3.3E-05 2.6E-05 ± 6.3E-06 3.1E-05 ± 1.2E-05 5.4E-04 3.2E-02 
PWY-7226: guanosine deoxyribonucleotides de novo 
biosynthesis I 
1.3E-04 ± 3.9E-05 3.5E-04 ± 1.0E-04 3.0E-04 ± 4.1E-05 2.7E-04 ± 5.1E-05 3.6E-04 3.2E-02 
PWY-7227: adenosine deoxyribonucleotides de novo 
biosynthesis 
1.3E-04 ± 3.9E-05 3.5E-04 ± 1.0E-04 3.0E-04 ± 4.1E-05 2.7E-04 ± 5.1E-05 3.6E-04 3.2E-02 
PWY0-1299: arginine dependent acid resistance 1.1E-04 ± 3.1E-05 2.5E-05 ± 1.6E-05 2.1E-05 ± 5.0E-06 2.5E-05 ± 1.3E-05 2.8E-04 3.2E-02 
ASPARAGINE-DEG1-PW Y: L-asparagine degradation I 2.4E-04 ± 5.1E-05 3.5E-04 ± 5.0E-05 4.1E-04 ± 7.5E-05 3.3E-04 ± 5.5E-05 7.2E-04 3.6E-02 
Mean and Standard deviation (SD) is defined as mean ± SD. Significance is defined by P-adjusted ≤ 0.05 
 
B) Significance of pairwise comparison from Dunn’s test 
Significant pathways in IBD control_T0 vs IBD_T0 control_T0 vs IBD_T2 control_T0 vs IBD_T3 IBD_T0 vs IBD_T2 IBD_T0 vs IBD_T3 IBD_T2 vs IBD_T3 
ARGDEG-III-PW Y: L-arginine 
degradation IV (arginine 
decarboxylase/agmatine deiminase 
pathway) 
1.3E-02 3.3E-03 1.2E-02 4.0E-01 4.3E-01 4.2E-01 
PWY-43: putrescine biosynthesis II 1.3E-02 3.3E-03 1.2E-02 4.0E-01 4.3E-01 4.2E-01 
PWY-7226: guanosine 
deoxyribonucleotides de novo 
biosynthesis I 
2.9E-03 3.2E-03 3.2E-02 4.3E-01 3.9E-01 3.8E-01 
PWY-7227: adenosine 
deoxyribonucleotides de novo 
biosynthesis 
2.9E-03 3.2E-03 3.2E-02 4.3E-01 3.9E-01 3.8E-01 
PWY0-1299: arginine dependent acid 
resistance 
6.1E-03 4.0E-03 6.9E-03 5.9E-01 4.5E-01 5.4E-01 
ASPARAGINE-DEG1-PW Y: L-
asparagine degradation I 
1.2E-02 1.7E-03 6.0E-02 3.2E-01 3.5E-01 2.5E-01 
Significance is defined by P-adjusted ≤ 0.05 for all pairwise comparisons 
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Chapter 4 IPCO: Inference of Pathways from Co-variance analysis 
4.1 Abstract 
Background Key aspects of microbiome research are the accurate identification of 
taxa and the profiling of their functionality. Amplicon profiling based on the 16S 
ribosomal DNA sequence is a ubiquitous technique to identify and profile the 
abundance of the various taxa. However, it does not provide information on their 
encoded functionality. Predictive tools that can accurately extrapolate the functiona l 
information of a microbiome based on taxonomic profile composition are essential. At 
present, the applicability of these tools is limited due to requirement of reference 
genomes from known species.  We present IPCO (Inference of Pathways from Co-
variance analysis), a new method of inferring functionality for 16S-based microbiome 
profiles independent of reference genomes. IPCO utilises the biological co-variance 
observed between paired taxonomic and functional profiles and co-varies it with the 
queried dataset.  
Results IPCO outperforms other established methods both in terms of sample and 
feature profile prediction. Validation results confirmed that IPCO can replicate 
observed biological associations between shotgun and metabolite profiles. 
Comparative analysis of predicted functionality profiles with other popular 16S-based 
functional prediction tools showed that the established tools had significantly lower 
performances with predicted functionality showing little to no correlation with paired 
shotgun features across samples.  
Conclusions IPCO can infer functionality from 16S datasets and significantly 
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4.2 Introduction 
Microbiome research has expanded exponentially over the last decade and has shown 
that microbiota communities have significant roles in health maintenance, as well as 
being key inputs into food and industrial processes (Hadrich, 2018;Team, 2019). The 
study of microbiome communities fundamentally falls under two strategies: the 
taxonomic composition is determined by either amplicon sequencing (16S marker 
gene) or metagenomic whole genome shotgun sequencing (mWGS) with the latter 
providing additional information on the functional capabilities which allows the 
identification of genes and pathways. Despite the availability of mWGS, amplicon 
sequencing still remains popular due to its relatively low cost, quicker computation 
time, lower disk space requirements, and ability to detect a diverse set of taxa, 
including those with a low abundance based only on the marker gene. Comparisons of 
these two approaches have discussed both the advantages and disadvantages of these 
methods (Clooney et al., 2016;Jovel et al., 2016).  
Amplicon sequencing is limited to providing only taxonomic information of 
the microbial communities. A number of tools can be used to predict the functiona l 
potential of the microbial communities obtained from 16S sequencing, the most cited 
being PICRUSt which was published as early as 2013 (Langille et al., 2013). Other 
widely used tools that were developed later are Tax4Fun (2015) (Asshauer et al., 
2015), and Piphillin (2016) (Iwai et al., 2016). All of these tools rely on functiona lly 
annotated reference genomes. The difference between them is the methodology used 
to map the amplicon data to these references and the approach used to assign 
functional annotation when suitable reference genomes are not available. PICRUSt 
works by considering the phylogenetic tree and the distance to the closest functiona lly 
annotated reference microbe (Langille et al., 2013). It relies on the GreenGenes 
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database (DeSantis et al., 2006) for matching the references to the queried amplicon 
data. The major limitation of PICRUSt comes forth in the case of 16S sequences, 
which do not have sequenced/annotated genomes of phylogenetically close relatives 
in the reference database. Tax4Fun and Piphillin implement BLAST and global 
alignment respectively between the amplicon data and the reference genomes obtained 
from different databases (Asshauer et al., 2015;Iwai et al., 2016). All of these tools 
use KEGG orthologs (KOs) (Kanehisa and Goto, 2000) annotation from reference 
genomes which is combined with amplicon abundance to predict the functionality. 
The limitation of all these methods is the requirement of sequenced/annota ted 
reference genomes. 
To overcome constraints of limited reference taxa, an alternative approach 
would be to use pairs of 16S amplicon and metagenomic datasets which show co-
variance between the samples based on taxonomic abundance and functiona lity 
respectively. The identified co-variance trends can then be combined with the 
taxonomic abundance of the queried dataset for whom the functionality will be 
predicted. In this paper, we present IPCO, a tool based on this novel approach for 
inferring functionality of a 16S amplicon dataset. The primary advantage of this new 
method is that it does not depend on the presence of sequenced and annotated genomes 
directly. IPCO is an application where values are assigned as the functional profiles 
for the samples of a 16S amplicon dataset based in a double co-inertia analys is 
involving the RLQ method (R-mode; Q-mode; and L-link between R and Q) (Dolédec 
et al., 1996;Dray and Legendre, 2008) between a paired taxonomic and functiona l 
dataset and a queried 16S amplicon dataset for which functionality will be inferred. 
Co-inertia analysis measures the concordance between two datasets, and maximises 
the squared covariance projected by two datasets (Dolédec and Chessel, 1994;Dray et 
 
299 | P a g e  
 
al., 2003). In paired taxonomic and functional profile datasets one would expect that 
alterations in the taxonomic profiles naturally should also reflect changes in its 
functional potential. Co-inertia can be further extended by application of the RLQ 
method, which integrates a third dataset (amplicon dataset in this case) and therefore 
analyses the co-inertia of the three datasets simultaneously. This methodology can 
provide a set of scores for the functional dataset and the amplicon dataset weighted by 
the paired taxonomic dataset.  
IPCO’s performance is compared with PICRUSt, Tax4Fun and Piphillin in 
terms of both sample and feature correlation with KEGG pathways from experimenta l 
datasets. IPCO also predicts MetaCyc pathway profiles and these predictions are 
validated against a paired mWGS dataset. Correlation of mWGS functional profiles 
against paired bile acids and short chain fatty acids (SCFAs) metabolite profile s 
confirmed the metabolomic associations with the observed metagenomic pathways. 
IPCOs ability to reproduce these biological associations is validated against these 
observed biological associations.  
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4.3 Methods 
4.3.1 IPCO algorithm 
IPCO is an implementation of the RLQ analysis which is also known as fourth corner 
analysis. It requires a reference taxonomic and functional paired dataset along with a 
third dataset, which is the 16S dataset for which the functional potential will be 
inferred. RLQ analysis is a double co-inertia method which explores two datasets (R 
and Q) through a mediator dataset (L). IPCO implements RLQ to associate the 
functional profiles (R) with a 16S profile dataset (Q) which is the 16S dataset for which 
functions need to be inferred through a mediator taxonomic profile dataset (L). R and 
L datasets are related as they have the same samples (paired) and are used as reference 
datasets. Q and L datasets are related as they have the same taxa identifiers. Functiona l 
profiles of R and taxonomic profiles of Q are standardised and scaled through the 
weighted average where the weights of the samples and taxa are obtained from L 
dataset. Through RLQ methodology, we obtain a R’LQ product table, which an 
association matrix of R and Q mediated through L abundance. In IPCO, we re-
standardise the R’LQ products by adding the weighted average of the functiona l 
potential back to the association matrix to obtain inferred functional profiles for the 
samples of Q dataset. 
In summary, IPCO implements the following steps: 
L = Matrix from correspondence analysis of reference taxa table (L table) 
R = Matrix from PCA of reference functional table (R table) weighted by samples 
from L 
Q = Matrix from PCA of query taxa table (Q table) weighted by taxa from L 
RLQ product = RLQ analysis (R, L, Q) (as described in the original paper) 
rw = row weights from correspondence analysis of L 
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waR = Weighted average of R table given by (∑R[ , j] * rw) / ∑rw (note: removed 
from RLQ product in RLQ calculation) 
where j represents 1 to nth sample   
Inferred profiles = RLQ product [i, ] + waR 
where i represents 1 to nth feature 
 
4.3.2 Data collection 
In the current study, human microbiome taxonomic and functional profile datasets 
were obtained from the HMP project (Human Microbiome Project, 2012a;b) using the 
curatedMetagenomicData R library (v.1.10.0) (Pasolli et al., 2017). mWGS functiona l 
(UniRef genefamilies) and taxonomic profiles datasets were obtained using the R 
library curatedMetagenomicData and paired V3-V5 16S rRNA OTU table was 
obtained from 16SHMPData R library (v.1.2.1) (Schiffer et al., 2019). Paired datasets 
were obtained for nasal, oral (buccal cavity), skin and stool samples. Representative 
OTUs of V3-V5 regions were downloaded from the HMP website (Human 
Microbiome Project, 2012a;b).  
A larger reference dataset consisting of functional and taxonomic profiles 
generated from only mWGS data were also obtained from the 
curatadMetagenomicData. This set is comprised of 1180 healthy samples from various 
cohorts as described in Ghosh et al. (Ghosh et al., 2020). 
Paired 16S and mWGS of an environmental dataset (Brazilian river water) 
used in this study are described in Tessler et al. (Tessler et al., 2017) and downloaded 
from the NCBI SRA (PRJNA389803, PRJNA310230). This cohort comprised of 
paired 16S rRNA and mWGS data obtained from four major rivers in Brazil: Amazon, 
Araguaia, Paraná, and Pantanal. The 16S rRNA and mWGS sequences was quality 
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filtered using Trimmomatic (v.0.38) (Bolger et al., 2014). Using USEARCH (v8.1), 
the quality filtered 16S rRNA sequences were dereplicated, clustered at 97% identity 
and chimera filtered (de-novo and using ChimeraSlayer) to obtain representative OTU 
sequences. Quality filtered reads were mapped to these OTUs to obtain the OTU table. 
The quality filtered mWGS data was processed using HUMAnN2 (v. 0.7.1) (Franzosa 
et al., 2018) to obtain mWGS derived taxonomic and functional profiles.  
MetaCyc and KEGG pathway mapping files as provided with HUMAnN2 and 
HUMAnN1 were filtered to remove all known eukaryotic pathways. All samples from 
all datasets (UniRef gene profiles) were processed against the filtered MetaCyc 
mapping file to obtain the MetaCyc pathway abundance and coverage datasets. 
The UniRef genefamilies dataset for all the samples were regrouped to KEGG 
Orthologs (KOs) IDs using humann2_regroup_table.py script and the KEGG to 
UniRef mapping provided in HUMAnN2 utilities. The regrouped KOs were processed 
using HUMAnN2 using the filtered HUMAnN1 KEGG pathways legacy database to 
obtain KEGG pathway profiles for the mWGS dataset. 
All OTU datasets were filtered to remove samples with a sequencing depth of 
less than 1000 reads. Samples removed from OTU datasets were omitted from their 
paired mWGS datasets also. Normalised unstratified functional information was used 
in the implementation after the removal of UNMAPPED, UNGROUPED and 
UNINTEGRATED variables. 
 
4.3.3 Data normalisation and transformations 
Taxonomic and functional abundance datasets were transformed using the following 
transformations: Z-scaling, proportion normalisation, log10 on rarefied and log10 on 
proportional data with 1e10-5 added as minimum count value, Hellinger 
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transformation (Legendre and Gallagher, 2001) and centred log ratio (clr) 
transformation (Aitchison, 1982). These transformations were investigated to identify 
the transformation best suited for IPCO.  
 
4.3.4 Validation of IPCO predictions 
IPCO is dependent on reference paired functional and taxonomic datasets. To validate 
the methodology, a bootstrap strategy was implemented to evaluate its predictions 
(Figure 1). A subset of the samples from the 16S table were randomly selected and 
considered as table Q. The samples omitted in Q formed the taxonomic table L and 
were matched with its pathway abundance dataset to obtain a paired functional (R) 
and taxonomy (L) datasets thus removing pathway information for the samples present 
in table Q. Using IPCO on R, L and Q table, pathway profiles were obtained for the 
samples from Q. Both inferred sample and feature (pathways) values were correlated 
using Spearman correlation with the actual mWGS pathway dataset for those samples 
present in Q. The bootstrapping analysis was repeated with 100 iterations to randomly 
subsample the reference datasets. An average was taken for both inferred sample to 
actual sample and inferred pathway to actual pathway correlation values from the 100 
iterations. 
To ensure that the predictions are not due to presences of homogenous samples 
and/or overfitting, the predicted profiles at each bootstrap were compared against 
shuffled mWGS sample profiles also. This was carried out using the HMP stool KEGG 
and MetaCyc pathways and its paired OTU level taxonomic dataset at all reference/test 
split described above. 
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Figure 1 Implementation of IPCO and bootstrap iterations   
The datasets were randomly subsampled into query and reference dataset. Reference 
dataset consist of taxonomic and functional profiles for the same samples. Reference 
taxonomic and queried dataset consist of different samples but are mapped to same 
taxa. The inferred profiles are correlated against the mWGS functional profiles for the 
query dataset to obtain the degree of associations. 100 bootstrap iteration were carried 
out to randomly generate different subsamples and measure the degree of association 
for each iteration. 
 
4.3.5 Effect of reference dataset size and taxonomic dataset  
IPCO is based on covariance between the datasets.  The size of the reference dataset 
and the taxonomy used will both affect the covariance between the taxonomic and 
functional datasets. IPCO was implemented at various taxonomic levels and various 
reference dataset sizes by subsampling the reference (10%, 30%, 50%, 70% and 80%).  
Taxonomy was assigned to the representative sequences using the RDP 
database (v.11.4) (Cole et al., 2014) implemented in mothur (v.1.34.4) (Schloss et al., 
2009). In addition, SPINGO (Allard et al., 2015) was used for species assignment 
using the RDP database (v.11.2). All levels of taxonomic classification were classified 
to a threshold of ≥ 80% confidence. At any level, if the classified threshold was below 
80%, it was set as unclassified. 
To ensure that the predictions are not due to the presence of homogenous 
samples and/or overfitting, the predicted profiles at each bootstrap were compared 
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against shuffled wMGS sample profiles also (Labels on the R and L reference datasets 
were shuffled). This was carried out using the HMP stool KEGG and MetaCyc 
pathways and its paired OTU level taxonomic dataset at all reference/test split 
described above. 
 
4.3.6 Functional prediction with published methodology 
For PICRUSt, the representative 16S rRNA sequences (OTUs) were mapped to 
Greengenes v13.5 to obtain closed representative OTU tables and processed through 
the PICRUSt pipeline to obtain KO profiles.  
For Tax4Fun, the taxonomic information for the OTUs were obtained from the 
SILVA123 reference downloaded from Tax4Fun website. The OTU table with 
taxonomic profiles were processed through Tax4Fun R library to obtain KO profiles. 
All processing was carried out with default settings. 
For Piphillin, OTU dataset and the representative OTU sequences were 
formatted as per requirement for Piphillin and all files were uploaded to the Piphillin 
website. An identity threshold of 90% was used and the KEGG database October 2018 
version was used. The threshold of 90% was used as the default of 97% returned 
insufficient hits to reference genomes. 
The KEGG pathway abundances were obtained using HUMAnN2 by 
processing the predicted KO profiles using the filtered HUMAnN1 KEGG legacy 
database. This allowed consistency in pathway calculation across different methods. 
Sample-to-sample and feature-to-feature (KOs and KEGG pathways) 
abundance correlations were calculated by comparing the predicted values obtained 
from the various tools against the mWGS generated profiles using Spearman 
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correlation. KOs and KEGG pathways present in both predicted and its paired mWGS 
datasets were considered.  
 
4.3.7 Comparison between IPCO at KO and KEGG level with published tools 
The Sample-to-sample and feature-to-feature correlations observed using the 
published tools for all the sites were compared against the correlation observed for 
IPCO inferred KO and KEGG pathways using reference:test split of 50:50 at all sites. 
Further, the IPCO inferred KO profiles (faecal site, reference:test 50:50) at each 
bootstrap were processed using HUMAnN2 to obtain inferred-KO KEGG pathways 
which were correlated against its paired mWGS KEGG pathway profiles. This was 
done to investigate the accuracy of using the IPCO inferred KO profiles to determine 
functional abundance at KEGG pathway level. 
 
4.3.8 Comparison of inference capability from mWGS species and 16S species 
level as reference taxonomy on an external query dataset 
It was investigated whether using mWGS species level dataset is sufficient as a 
reference set (table L) to generate inferred functionality for the independent dataset. 
The independent dataset used was the ELDERMET community dataset (Claesson et 
al., 2012). If this generated comparable results as 16S taxonomic reference, then it 
would allow generation of a larger reference R and L table by adding more samples 
from curatedMetagenomicData hub which would incorporate more functionality else 
would have to use HMP or similar 16S dataset as table L limiting the reference dataset 
size.  Species level dataset were obtained for the 16S ELDERMET and HMP 16S as 
described earlier. IPCO was implemented with the R table as HMP pathways dataset, 
L table as HMP closed OTU or 16S species or HMP mWGS species dataset and Q 
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table as ELDERMET 16S closed OTU or species dataset. Samples and common 
features from inferred table were correlated with the paired elder mWGS functiona l 
dataset.  
The species and functional dataset for the 1180 healthy samples were obtained 
from curatedMetagenomicData. The selection of healthy samples is described in 
Ghosh et al. (Ghosh et al., 2020). This dataset is referred as reference healthy in the 
results. IPCO was implemented with R table as reference pathways, L table as species 
mWGS dataset and Q table as ELDERMET species 16S dataset. The inferred 
functionality dataset for the ELDERMET dataset was correlated with mWGS 
functionality dataset to obtain sample and feature correlations. Correlations obtained 
from using this healthy reference were compared with the correlation values from 
using HMP as reference. 
 
4.3.9 Validation with independent datasets 
Validations of the IPCO’s prediction was carried out with the following 
assumptions: The healthy functional and taxonomic references from a particular site 
can be used to predict diseased samples also obtained from the same site without 
requiring diseased sample profiles as reference. This would confirm the 
appropriateness of using provided references. The second assumption is that the 
biological agreement between measured metabolite levels and mWGS functiona l 
profiles is reflected in the inferred functional profiles. To validate the results on 
external independent datasets, analyses were carried out on two cohorts: a colorectal 
cancer (CRC) publicly available data (Zeller et al., 2014) and an in-house elderly 
community data  (Claesson et al., 2012). The CRC dataset was used to validate the 
first assumption. The CRC cohort contains paired 16S and mWGS sequences obtained 
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from faecal samples of healthy and CRC individuals. The mWGS taxonomic and 
functional profiles were obtained from curatedMetagenomicData for the healthy 
(n=50) and CRC samples (n=41) based on the disease stratification provided. The 
forward reads from the 16S dataset were quality filtered using Trimmomatic. The 
quality filtered reads were processed using USEARCH and taxonomically annotated 
as described earlier. Predicted functional profiles (KEGG pathways) of the 16S CRC 
samples were also obtained for PICRUSt, Tax4Fun and Piphillin as described earlier.  
First, we assessed whether IPCO can be applied to infer the functional potential 
from the 16S microbiota profiles of diseased samples or not using the CRC cohort. 
The 16S genus level and mWGS pathways (KEGG and MetaCyc) profiles of the CRC 
samples were used as reference in IPCO for inferring functionality of the queried 16S 
CRC samples. This was carried out using the bootstrap approach (100 iterations) 
described earlier to ensure the reference and test datasets (reference/test split 50:50) 
did not contain the same CRC samples. This would serve as the baseline for all other 
comparisons where the applicability of the healthy samples as reference would be 
determined. Next, using the taxonomic and paired functional datasets of the healthy 
samples from the same cohort as reference for IPCO, functionalities were inferred for 
the 16S genus profiles of the CRC samples. The genus level reference dataset was 
used as a mediator as most 16S datasets are usually classified down to genus level. 
Both 16S and mWGS genus dataset from the in-cohort healthy were used as reference. 
Finally, the external healthy taxonomic and functional profiles provided in IPCO were 
used as reference to infer the functionality of the 16S CRC samples. The healthy 
samples from the CRC samples were also present in the IPCO healthy reference and 
were removed before implementing IPCO. Using multiple reference datasets with 
IPCO methodology allowed comparing the differences in predictive capacity observed 
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with using different reference datasets (that includes in-cohort and external data). 
Further, functionalities predicted for 16S CRC samples using PICRUSt, Tax4Fun and 
Piphillin were also included to compare the differences in prediction observed in 
different tools. Correlation observed (Sample-to-sample and feature-to-feature) using 
the CRC samples as reference vs healthy samples as reference were compared for 
IPCO to determine the appropriateness of IPCO’s reference. Correlation observed 
(Sample-to-sample and feature-to-feature) between predicted functional profiles 
obtained using 16S CRC samples and mWGS CRC samples using published tools 
were also compared with IPCO to evaluate the performance of all the tools. 
The elderly cohort contains mWGS, 16S, and metabolome datasets for the 
same samples. This was used to validate the second assumption: biological agreement 
between metabolite profile and mWGS functional potential (KEGG and MetaCyc 
pathways) is replicated in inferred functional profiles also. To investigate the 
biological signal in the predicted functionalities, functional profiles were obtained 
from all tools. 
For IPCO, paired functionality (KEGG pathway and MetaCyc) and taxonomy 
at species level from the reference healthy datasets provided in IPCO was used to infer 
functionalities for the 16S elderly samples. Functional profiles (KEGG pathways) 
were obtained using PICRUSt, Tax4Fun and Piphillin using the same approach as 
described earlier for the elderly community 16S dataset. Two types of metabolites : 
bile acids and short chain fatty acids (SCFAs) which are widely studied in microbiome 
research were considered for investigation. The metabolite dataset was log10 
transformed on the measured metabolite level after adding 1e-05 as minimum count 
value. The mWGS functional profiles were correlated with the metabolite profiles and 
the directionality, degree of association and significance was noted. Significance of 
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mWGS profile correlation was determined by p-adjusted ≤ 0.05 unless stated 
otherwise. The inferred functions obtained from all the tools including IPCO were then 
correlated with the same metabolites and the results were compared with mWGS 
results to investigate the direction, correlation, and significance (p-value ≤ 0.1). Only 
key pathways responsible for these metabolites were considered and agreement with 
mWGS results in terms of directionality and significance were considered to be 
correct, with a change in directionality or non-significance being considered as false 
positives. 
 
4.3.10 Statistical analysis 
All analysis was carried out in R (v.3.5.1) (Team, 2018). All correlations measured 
were carried out using Spearman correlation. Kruskal-Wallis test was used as 
applicable. Dunn’s test using dunn.test library (v.1.3.5) (Dinno, 2017) was used for 
pairwise comparison at different taxa and sample threshold levels. P-value adjustment 
was carried out using Benjamini-Hochberg procedure. Covariance between paired 
taxonomic and functional dataset was investigated with co-inertia analysis using ade4 
(v.1.7.13) library (Dray and Dufour, 2007). Significance of co-inertia was determined 
with the ade4 randtest function. Plots were created using ggplot2 (v.3.1.0) (Wickham, 
2009), RColorBrewer (v.1.1.2) (Neuwirth, 2014) and gridExtra (v.2.2.1) (Auguie, 
2016) R libraries.  
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4.4 Results 
4.4.1 Description of the study cohort 
Table 1 describes the cohort retained after removing samples with low sequencing 
depths and stratified functional features for the initial analysis. The samples retained 
were investigated using the IPCO, PICRUSt (Langille et al., 2013), Piphillin (Iwai et 
al., 2016) and Tax4Fun (Asshauer et al., 2015) to evaluate the performance of the 
tools.  
 
Table 1 Number of mWGS features and samples retained in the initial analysis 
 Samples KOs KEGG pathways MetaCyc OTUs 
HMP nasal 61 5971 129 659 7464 
HMP oral 71 5829 133 625 13696 
HMP skin 8 4886 132 593 3492 
HMP stool 87 6356 128 712 9966 
Water (Brazilian rivers) 37 2724 114 497 1185 
Total number of samples and features across the five reference datasets. 
 
IPCO was initially implemented in the HMP (Human Microbiome Project, 
2012a) stool cohort to investigate the effects of different data transformation, 
taxonomic levels and sample size thresholds.  
 
4.4.2 Data transformation of the reference datasets affects IPCO results  
In IPCO, the covariance between the three datasets (R, L and Q) vary depending on 
the transformation and normalisation method used. Investigation with the 
transformation/normalisation mentioned in the methods is shown in supplementary 
figure 1 and supplementary table 1. The Hellinger transformation was best suited as 
it had a higher RV coefficient for both samples and features and similar correlation 
values compared to other methods. Observed RV coefficients were significant (p-
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value ≤ 0.05) for all cases. Hence, this transformation is implemented as default for 
all further analysis. 
 
4.4.3 Lowest taxonomic levels and high samples size provides best results with 
IPCO 
Implementation of IPCO with 100 bootstraps for each subsampling at different 
reference sample sizes on both KEGG and MetaCyc pathway abundance datasets 
showed that the best sample and feature correlations were observed with the lowest 
taxonomic levels and highest sample size (Figure 2A-B, supplementary figure 2A-
B). No significant difference was observed in the sample correlation for any reference 
dataset size except for between 10% and other reference sizes at family level in the 
MetaCyc dataset (supplementary table 2). However, the feature correlation increased 
with increased sample size and at the lowest taxonomy levels. No significant 
differences were observed for feature correlation using a reference size of at least 30% 
or larger in the KEGG pathway analysis and 50% or more for MetaCyc at the different 
taxonomic levels investigated (supplementary table 2). 
The outlier observed in figure 1 and supplementary figure is due to increased 
abundances of pathways in that sample which are observed to be decreased in other 
samples. Looking at the KEGG pathways for the outlier samples, it was observed that 
the most abundant pathways also had a low coverage (maximum coverage = 1e-04). 
The randomisation of mWGS samples through shuffling during evaluation at 
each iteration resulted in a complete lack of feature-to-feature correlation 
(supplementary figure 3). Although a high sample-to-sample correlation was 
observed due to the functional redundancy across samples, the pattern associated with 
 
313 | P a g e  
 
different thresholds and with the unshuffled predictions seen in figure 1 and 
supplementary figure 2 were lost.  
 
 
Figure 2 Sample and feature correlation using KEGG pathway abundance at 
different taxonomic levels and reference dataset size   
Boxplots showing the variation of A) Sample to sample correlations B) Feature to 
feature correlations obtained between the inferred KEGG pathway abundances and the 
mWGS functional profiles at all different reference sizes and taxonomic levels. 
 
The shuffling of mWGS query samples during evaluation at each iteration 
resulted in completed lack of feature-to-feature correlation (supplementary figure 3). 
Although a high sample-to-sample correlation was observed, the pattern associated 
with different threshold and with the unshuffled predictions seen in figure 2 and 
supplementary figure 2 were lost. This suggests that the homogeneity between 
reference and query and overfitting in reference may not be associated with the 
reference threshold splits. 
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4.4.4 IPCO outperforms PICRUSt, Tax4Fun and Piphillin in terms of both 
sample and feature correlations 
To evaluate the functional inference of IPCO, we applied PICRUSt, Tax4Fun and 
Piphillin to the same datasets (Table 1) and KEGG pathway profiles were inferred. 
Spearman correlation was calculated for the inferred pathway profiles against its 
mWGS abundance both in terms of sample and feature correlation. IPCO 
outperformed PICRUSt, Tax4Fun and Piphillin in terms of sample correlation across 
all datasets (Figure 3A, supplementary table 3). IPCO showed highest sample 
correlation with a narrow IQR range for stool and oral samples. Skin and nasal dataset 
showed lower sample correlations compared to stool and oral samples, however it was 
observed to be higher than what was observed using the other tools. The lowest sample 
correlation was observed using the Brazilian river water dataset, but it was also higher 
than other tools for that site (supplementary table 3).  
Upon investigating the feature-to-feature correlations, it was observed that 
IPCO outperforms PICRUSt and Tax4Fun in stool and Brazilian river water datasets 
(Figure 3B). Nasal, oral and skin dataset revealed a lack of correlation using IPCO. It 
was noted that across all datasets, the median feature correlation for PICRUSt, 
Tax4Fun and Piphillin was close to zero. 
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Figure 3 Sample and feature correlations between inferred KEGG pathways and 
mWGS KEGG pathways profiles at different sites and using different methods  
Boxplots showing the comparison of A) Sample to sample correlations and B) Feature 
to feature correlations obtained between the inferred KEGG pathway abundance and 
the mWGS functional profiles at different sites using different methods. 
 
Sample-to-sample and feature-to-feature correlations based on KO abundances 
obtained from IPCO, PICRUSt, Tax4Fun and Piphillin were also calculated. IPCO 
was observed to outperformed other methods in terms of correlation values between 
both inferred sample and feature profiles against the observed mWGS sample and 
feature profiles (Figure 4, supplementary table 4) for faecal and Brazilian river water 
datasets. Feature-to-feature correlations for the remaining sites (nasal, oral and skin) 
were poor with the median correlation being close to zero for all tools including IPCO.    
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Figure 4 Sample and feature correlations between inferred KO and mWGS KO 
profiles at different sites and using different methods   
Boxplots showing the comparison of A) Sample to sample correlations and B) Feature 
to feature correlations obtained between the inferred KOs and the mWGS KO profiles 
at different sites using different methods. 
 
The IPCO inferred KO profiles obtained from HMP stool dataset using the 
equal reference to test split (50:50) threshold was further processed to obtain the 
inferred-KO KEGG pathway profiles at each iteration. Interestingly, these profiles at 
pathways levels showed a higher feature-to-feature correlation (1st quartile: 0.31, 
median: 0.49, 3rd quartile: 0.67, supplementary figure 4) when compared to other 
published tools but lower than the default IPCO methodology as observed in figure 3. 
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4.4.5 Lack of significant covariance between taxonomy and functional datasets 
results in a lack of feature correlation in nasal, oral, skin, and Brazilian river 
water datasets  
To investigate the poor performance by IPCO on the other sites excluding stool, the 
co-variance between the taxonomic and functional dataset was calculated. Co-inertia 
analysis of the taxonomic profiles with its paired functional datasets across all sites 
revealed a lack of significant covariance between taxonomy and functional profiles in 
the nasal, oral and skin datasets (supplementary table 5). The Brazilian river water 
dataset showed significant covariance when the mWGS derived taxonomy was used 
(while the 16S dataset did not co-vary significantly) (supplementary table 5). This 
may in part explain the poor performance of IPCO on these datasets. The taxonomic 
abundance of the reference dataset is not reflected in its paired functional dataset 
which resulted in a lack of significant covariance. It was observed that the functiona l 
diversity determined by the observed number of pathways had a narrow range 
compared the paired taxonomic diversity which showed more variation for all body 
sites excluding the stool dataset. This functional redundancy and the lack of detection 
of unique functionality suggests that the functional heterogeneity of species was not 
accurately reflected in these datasets. Given the lack of covariance in these datasets, 
further analysis was carried out using the stool dataset. 
 
4.4.6 Higher pathway coverage improves functional inference 
Investigation of the effect of pathway coverage on the correlation values between the 
observed pathway abundance and the inferred pathways obtained using IPCO showed 
that coverage correlated well with functional pathway prediction (Figure 5A). Based 
on this, the KEGG pathways were binned based on thresholds such that pathways 
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below the mean coverage of 0.01 were considered low correlation predictions and 
pathways with a mean coverage over 0.1% were considered high correlation 
predictions with the remaining pathways with a mean coverage between 0.01 and 0.1 
being considered medium correlated predictions. These predictions showed  
correlation values between 0.25 - 0.6 whereas the high correlated predictions had 
correlation values between 0.6 - 0.7 (Figure 5A). In case of MetaCyc pathways, we 
observed similar results where pathways with coverage less than 0.41 (1st quartile of 
mean coverage across samples) were low correlated predictions. Pathways whose 
mean coverage was between the 1st quartile (0.41) and the median value (0.99) showed 
improved feature correlation for the inferred pathways whereas the best feature 
correlation (0.37 - 0.62) was observed for those pathways whose average pathway 
coverage was greater than its median value (Figure 5B). For both KEGG and 
MetaCyc, we were able to get high correlation values for more than 50% of the 
pathways based on the coverage filtering. The number of pathways binned into each 
of the coverage thresholds for both KEGG and MetaCyc are described in table 2. All 
reported observations were carried out on HMP stool functional dataset. 
 
Table 2 Pathways retained at different coverage thresholds 
KEGG coverage threshold Total <0.01 0.01-0.1 >0.1 
Number of KEGG pathways 118 19 30 69 
MetaCyc coverage threshold Total <0.43 0.43-0.99 >0.99 
Number of MetaCyc pathways 693 173 166 354 
Number of KEGG and MetaCyc pathways identified at different coverage thresholds. 
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Figure 5 Comparison of feature-to-feature correlations at different pathway 
coverage thresholds for the KEGG and MetaCyc  
Boxplot showing the functional feature-to-feature correlations obtained using different 
coverage thresholds for the A) KEGG pathways and B) MetaCyc pathways. 
 
 
The mean coverage for the predicted KEGG pathways from PICRUSt, 
Tax4Fun and Piphillin modelled against its feature correlation values showed no 
positive association between coverage and feature correlation (supplementary figure  
5). This indicates that the coverage filter was not applicable for these tools as opposed 
to IPCO. All subsequent analyses were carried out using all the functionalities without 
filtering for coverage. 
 
4.4.7 IPCO can accurately infer sample and feature profiles using taxonomy from 
mWGS or 16S amplicon datasets 
An alternative approach to using a reference 16S dataset and paired mWGS functiona l 
is to derive the taxonomic information from the reference mWGS dataset itself. 
Investigation of using taxonomic information derived from mWGS showed a 
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comparable performance to using a 16S species or closed OTU level dataset when 
inferring the functionality of an external 16S dataset (supplementary figure 6). Table  
3 describes the sample characteristics considered for this analysis. The reference 
dataset in this case consists of a large cohort of healthy samples as detailed in the 
methods (Ghosh et al., 2020). The validation dataset used is the ELDERMET dataset 
(Claesson et al., 2012).  
 
Table 3 Number of samples, pathways, and species in the validation datasets 








Validation 79 123 776 NA 201 842 
Reference 
healthy 
1180 143 833 772 NA NA 
HMP 87 128 712 353 282 1341 
The number of samples and features present in the reference healthy and validat ion 
(ELDERMET) datasets, which were used when inferring functional profiles and 
comparing with observed functional profiles of the validation dataset. NA; Not 
applicable. 
 
It was observed that the use of species levels datasets obtained from the same 
mWGS data that was used to compute metagenomic functional profiles was suffic ient 
to infer functionality for 16S datasets (supplementary figure 6). Further validat ion 
involving the replication of biological pathway to metabolite associations was carried 
out using the reference healthy functional and paired mWGS species profiles as 
reference in IPCO to infer the functionality of the ELDERMET 16S dataset.  
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4.4.8 Healthy references implemented with IPCO shows better inferences for 
diseased samples 
IPCO was implemented with both in-cohort and the external healthy references on the 
CRC samples (16S genus level profiles) from the Zeller et al. The predicted pathways 
from the CRC dataset highlighted that the healthy references can be used to predict 
the diseased samples as determined by the high sample and feature correlation (Figure  
6, supplementary figure 7, supplementary table 6). The healthy IPCO reference and 
in-cohort healthy reference samples resulted in higher predicted feature correlation 
(KEGG predicted CRC vs mWGS CRC) compared to using CRC dataset as reference 
itself. Repeating the analysis using MetaCyc, the healthy reference (in-cohort 16S 
genus profiles) showed higher feature correlation compared to using CRC as reference 
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Figure 6 Comparison of sample and feature correlation observed when using 
different reference datasets to predict CRC sample functionality (KEGG 
pathways) 
Boxplot showing A) Sample-to-sample correlation observed with the use of only CRC 
samples as reference, healthy samples from same cohort as reference where the 
reference taxonomic dataset is 16S genus profiles, healthy samples from the same 
cohort with mWGS genus profiles as reference taxonomy, IPCO reference healthy at 
genus level (taxonomy reference), PICRUSt, Piphillin and Tax4Fun. B) represents 
feature-to-feature correlation observed with the use of different references as 
described for figure 6A.  
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4.4.9 Inferred profiles from IPCO replicate mWGS functional pathway to 
metabolite profile associations 
Correlation of the mWGS derived functionality (KEGG and MetaCyc) from 
ELDERMET samples to paired bile acid and SCFA profiles identified associations 
between key pathways and biologically relevant metabolites. 
Investigation of the bile acid profiles showed that KEGG pathway “ko00121: 
Secondary bile acid biosynthesis” pathways significantly negatively correlated with 
primary bile acids (cholic acid and chenodeoxycholic acid) while “ko00790: Folate 
biosynthesis” known to promote bile acid levels (Delgado-Villa et al., 2009) is 
observed to be significantly positively correlated with primary bile acids in 
ELDERMET mWGS data.  
With the secondary bile acids (lithocholic acid, dehydrocholic acid, 12-
ketolithocholic acid, dehydrolithocholic acid, hyodeoxycholic acid and isolithocho lic 
acid), it was observed that “ko00121: Secondary bile acid biosynthesis”, “ko00430: 
Taurine and hypotaurine metabolism”, “ko03070: Bacterial secretion system”, 
“ko05100: Bacterial invasion of epithelial cells” were all significantly positive ly 
correlated with secondary bile acid levels. This validates the concordance between the 
measured bile acid profiles and the ELDERMENT mWGS functional profiles thereby 
with the functional activity of the microbiota. This concordance between the measured 
bile acid profiles and the ELDERMET mWGS functional profiles thereby validates 
the link between the functional activity of the microbiota and the biochemica l 
characteristics of the gut environment.  
The results of the inferred functional profiles obtained from all the tools 
showed that IPCO provides the best estimation of the observed associations between 
the mWGS dataset and bile acid profiles (Figure 7, supplementary table 7). It was 
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observed that for primary bile acids only PICRUSt showed significant correlation with 
“ko00121: Secondary bile acid biosynthesis”, however the directionality was reversed. 
Neither Tax4Fun nor Piphillin showed significant associations for “ko00121: 
Secondary bile acid biosynthesis” abundance and primary bile acids. Looking at the 
secondary bile acids, we observed that 12-ketolithocholic acid did not show any 
significance with the inferred profiles obtained from all tools. Lithocholic acid and 
KEGG pathways obtained from IPCO agreed with mWGS results. Tax4Fun was 
significant but showed the opposite directionality to the observed association. 
Dehydrolithocholic acid was significantly associated with KEGG pathways in 
PICRUSt and Piphillin. All associations, directionality and significance from all tools 
compared to mWGS results are highlighted in figure 7. Overall, while correlating 
measured bile acids levels to predicted KEGG pathway profiles, IPCO was successful 
62% of time, whereas PICRUSt, Tax4Fun and Piphillin were correct only 12%, 31% 
and 38% of time respectively. 
Similar results were observed when the MetaCyc pathway abundance dataset 
was used as reference. Correlation of the ELDERMET mWGS MetaCyc pathways 
with bile acid profiles show significant correlation with “PWY-6518: glycocho la te 
metabolism (bacteria)” and “1CMET2-PWY: N10-formyl-tetrahydrofo la te 
biosynthesis”. These results were replicated with the inferred MetaCyc pathway 
profiles obtained from IPCO (supplementary table 8).   
 
325 | P a g e  
 
 
Figure 7 Correlation of the bile acids metabolite profiles with inferred KEGG 
pathway abundances from various methods  
Correlation of the inferred bile acid metabolite profile to paired mWGS KEGG 
pathways shows significant association (p-adjusted ≤ 0.1) with known pathways as 
shown in 1st column. Directionality of association is shown by correlation values 
colour intensity. Pathways inferred from IPCO shows same directionality and 
significance (p-value ≤ 0.1) as observed with mWGS profiles for most cases. “NS” 
inside the cell represent non-significant (p-value > 0.1) associations. 
 
 
The correlation between ELDERMET KEGG pathway abundance and SCFA 
(butyrate and propionate) profiles were observed to be not significant which included 
butanoate and propanoate metabolism, protein and amino acid metabolism (Lysine, 
Glumatine) pathways. This lack of association is consistent with the literature (Sze et 
al., 2019) and was replicated in the inferred profiles obtained from IPCO and PICRUSt 
(supplementary table 9). However, Tax4Fun and Piphillin showed significant 
associations for the inferred KEGG pathways obtained using those two tools for both 
butyrate and propionate levels. These significant associations are considered false  
positives, as they were not observed with the mWGS data. Piphillin reported the 
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highest number of false positive pathways for butanoate. In the case of propionate, 
IPCO also predicted two false positive pathways. 
Investigation of the SCFAs (butyrate and propionate) levels with ELDERMET 
mWGS MetaCyc pathways replicated the KEGG analysis and again showed that 
butyrate shows no significant association with key butyrate MetaCyc pathways after 
adjustment which is consistent with the literature (Sze et al., 2019). This observation 
was replicated in the IPCO inferred functional profiles (supplementary table 10). 
Propionate also showed no significant association with mWGS pathways and this 
observation was replicated with IPCO inferred pathways (supplementary table 10). 
As other tools do not report MetaCyc pathway profiles, this investigation could not be 
carried out with other tools.   
 
327 | P a g e  
 
4.5 Discussion 
We have developed IPCO, a novel tool which predicts functionality for 16S amplicon 
datasets but is not dependent on the direct mapping of 16S sequences to known 
reference genomes. Instead, it utilises paired mWGS functional and taxonomic 
datasets as references that are built from annotated genomes but do not assume that 
the functional potential of the taxa is the same as the reference genome.  
Alterations at taxonomic level will affect the overall functional potential at 
community level (Eng and Borenstein, 2018). The robustness of the association 
between functionality and taxonomy is dependent on both the abundance of the 
various taxa and the distribution of function across these taxa. Using this concept, 
IPCO is able to utilise the biologically and statistically significant covariance observed 
between the reference taxonomic and functional datasets and infer the functiona l 
capabilities of an external 16S amplicon dataset. The IPCO implementation is also 
unique in that it provides a distinction between high quality predictions and lower 
quality predictions based on pathway coverage for both KEGG and MetaCyc 
pathways.  
IPCO is reliant on the availability of reference datasets from the environment 
being studied. This raises the question of the appropriateness of using a set of defined 
samples (e.g. healthy reference) to infer samples that are dissimilar in some aspect 
(e.g. diseased) even within the same environment. By using different types of 
reference samples, it is observed that the healthy samples are better at predic ting 
diseased samples as long as they are obtained from the same environment. In fact, in 
this analysis, the functional inference capability of IPCO for both KEGG and MetaCyc 
was better with the use of healthy samples from the same site (Figure 6, 
Supplementary figure 7).. 
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One weakness of available functional prediction tools is that using a reference 
set of known functions from only a set of known taxa limits the prediction of 
functionality for the amplicon dataset. This limitation results in a lack of feature-to-
feature correlation i.e. KEGG pathway abundance calculated from 16S datasets do not 
correlate well across samples that are obtained from similar environments when 
compared with a paired mWGS dataset for the same samples. This is of concern as 
this potentially creates false positive results and/or reversed directionality when 
investigating functional profiles inferred from 16S datasets. By studying the IPCO 
inferred functionality and associations with biologically relevant metabolites, we have 
shown that the inferred functional capabilities obtained using IPCO, mimics the results 
of the mWGS functional profiles and outperform other predictive tools.  
The filtering criteria in IPCO allows the users to select a set of functiona l 
pathways with sufficient coverage to be inferred. This removes functional pathways 
which may have been spuriously assigned due to the presence of only a small subset 
of genes/reactions. It is noteworthy that despite using a uniform method to tabulate the 
pathway level information for all the tools, the pathway coverage information could 
not be used for filtering out low-coverage pathways for any tools except IPCO. The 
lack of association between feature coverage and correlation observed in other tools 
may be due to the assumption made when mapping to functionally annotated 
references by the published tools.  The reproducibility of results observed from both 
KEGG and MetaCyc shows that our method is independent of the functiona l 
annotation and can be implemented with any taxonomic level information and the 
taxonomic assignment can be done with any reference database as long as the taxa are 
present in the reference which acts as a mediator to co-vary the functional profiles 
with the 16S dataset. This may allow alternative implementations of the IPCO 
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methodology such as extrapolating of functional information for a set of samples 
obtained from shallow sequencing by using a subset of samples with deeper 
sequencing depth. 
Overall, IPCO had a superior performance compared to other tools using both 
KOs and KEGG pathways, even when inferred KO-KEGG pathways was used. The 
feature correlation observed across all tools including IPCO were lower using KEGG 
pathway level predictions. This could be potentially due to increased sparseness at KO 
level compared to pathway levels. The processing time also increases drastically due 
to the increased size of functional reference dataset (Number of KEGG pathways in 
HMP stool (n=87) dataset is 128 whereas the number of KOs for the same dataset is 
6356) which would be a limitation when using on a personal laptops or system with 
low computational and memory capacity. Similarly, the use of UniRef gene profile 
datasets is not feasible currently as nearly 2 million UniRef genefamilies are detected 
for the HMP stool samples alone which would require long processing times would 
require a high performance computation system to process such a large dataset.. 
IPCO performs better than the other established tools but it is not without its 
limitations. IPCO is reliant on a paired mWGS functional and taxonomic reference 
datasets which relay on functionally annotated genomes. As with other tools, sample 
profile predictions will appear to be highly correlated to the actual sample profiles due 
to functional redundancy at the pathway level where highly abundant pathways are 
shared across multiple taxa. Therefore, care should be taken when interpreting the 
predicted sample profiles. IPCO assigns a small pseudo value to each functiona lity 
due to the way the R’LQ algorithm calculates double co-inertia, which makes the 
resulting inferred functionality a non-zero abundance. To overcome this limitation, the 
low abundant functionality can easily be filtered by removing those functions whose 
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average inferred abundance across samples is below a certain quantile determined by 
the user. Although other tools predicted the features poorly across all sites, IPCO also 
performed poorly on the non-gut samples. Our analysis showed that this was due to a 
lack of suitable reference datasets (lacking significant co-variance between reference 
taxa and functions), but IPCO can be easily tuned to work at other body sites or 
environments as suitable mWGS data from these different environments become 
available. This is noteworthy as inferring functionality using amplicon-based 
approaches rely on its concordance with the functional profile, which is not possible  
if the functional- level distribution is discordant with the taxonomy. Why this would 
be the case is beyond the scope of this manuscript. The use of IPCO is also limited to 
potentially only those environments, for which as a reliable reference (i.e. signif icant 
covariance between taxonomic and functional profiles) is available. Samples from 
environments (e.g. low biomass) that may lack mWGS dataset limits the use of IPCO.  
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4.6 Conclusion 
IPCO provides a novel approach for functional inference, which is not directly 
dependent on the availability of functionally annotated reference genomes. The IPCO 
inferred functionality profiles reflect the true observed biological functionality. IPCO 
can be easily implemented with the default datasets or with in-house reference datasets 
without relying on the external reference datasets. Overall, IPCO provides a reliable 
inference of functional potential and can be easily implemented in the R statistica l 
software.   
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4.9 Supplementary Information 
4.9.1 Supplementary Figures 
 
Supplementary figure 1 Sample-to-sample and feature-to-feature correlations between inferred and mWGS functional profiles obtained 
for MetaCyc pathway schemes using different transformations  
The effect of transformation/normalisation methodologies on preliminary analysis of IPCO predictions using the MetaCyc functional profile 
datasets, in terms of A) sample to sample correlations and B) the feature to feature correlations for IPCO inferred sample and functional profiles 













Supplementary figure 2 Comparison of sample-to-sample and feature-to-feature correlations obtained between the inferred and the  
mWGS MetaCyc pathway abundances at different taxonomic levels and reference dataset size  
IPCO’s prediction of MetaCyc pathways abundance using different reference dataset size and at different taxonomic levels shows A) high sample 
to sample correlation at all different reference size and taxonomic levels and B) shows the correlation values of features improve with larger 
reference and lowest taxonomic level 
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Supplementary figure 3 Comparison of shuffling mWGS samples from query 
data against inferred profile (KEGG and MetaCyc) 
Boxplots showing the correlation values for inferred samples and features against 
mWGS pathway profiles. Figure 3A-B shows the sample and feature correlation 
observed with the KEGG pathways profiles when the query sample labels are shuffled. 
In figure 3C-D, the sample and feature correlation observed between predicted and 
mWGS MetaCyc profiles 
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Supplementary figure 4 Evaluating the correlation between IPCO inferred-KO 
KEGG pathways against the mWGS KEGG pathways  
Spearman correlation of KEGG pathways calculated using HUMAnN2 from the IPCO 
inferred KO profiles compared to mWGS KEGG pathways. A) shows the sample-to-
sample correlation observed and B) shows feature-to-feature correlation observed. 
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Supplementary figure 5 Feature correlation vs Mean coverage obtained from 
published tools  
A scatter plot of correlation values obtained from feature-to-feature correlation 
(KEGG pathways) vs mean coverage obtained from the published tools. The 













Supplementary figure 6 Comparison of using 16S and mWGS taxonomic dataset as table L when inferring for external dataset  
Supplementary figure 6 shows sample and feature correlation of inferred MetaCyc pathways of elderly 16S dataset obtained from using HMP 16S 
species and closed OTU, HMP mWGS species and healthy reference mWGS species as reference taxonomic dataset (table L). No significant 
change in observed sample (A) and feature (B) correlation for the external dataset when using the closed OTU level or species level dataset derived 
from either 16S representative sequences or mWGS taxonomy (table L). The external dataset (table Q) is collapsed to closed OTU level or species 













Supplementary figure 7 Accuracy of using different references to predict MetaCyc profiles for CRC samples 
Supplementary figure 7 highlights the sample (A) and feature (B) correlation obtained when using different samples types as reference taxonomy 
and functional datasets to predict MetaCyc profiles from 16S genus level of only CRC samples.  
CRC samples (ref): Using the CRC samples as references, In-cohort (ref) Healthy samples (16S Genus): Using the healthy samples from the same 
cohort with 16S Genus profiles as reference taxonomy, In-cohort (ref) Healthy samples (Shotgun Genus): Reference is healthy samples from the 
same cohort with refernce mWGS Genus profiles, IPCO Healthy (ref): The healthy samples provided with IPCO as references after exclud ing 
Zeller et al. samples  
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4.9.2 Supplementary Tables 
Supplementary table 1 Sample-to-sample and feature-to-feature covariance observed 
between mWGS and IPCO inferred functional profiles using different 
normalisation/transformation 
Normalisation/transformation 
Sample-to-sample covariance Feature-to-feature covariance 
RV P-value RV P-value 
Hellinger 0.89 0.001 0.54 0.007 
Log10 on rarefied counts 0.84 0.001 0.33 0.003 
Log10 on proportion 0.84 0.001 0.31 0.002 
Proportion 0.97 0.001 0.36 0.086 
z-scaling 0.24 0.001 0.20 0.079 
clr transformation 0.28 0.011 0.55 0.001 
Comparison of the effect of different normalisation/transformation on the sample to sample 
and feature to feature co-inertia between IPCO inferred and mWGS MetaCyc pathways 
abundance datasets. Co-variance is determined by RV coefficient. All observed co-
variance were significant at nominal p-value ≤ 0.05 except for proportional and z-scaled 
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Supplementary table 2 Pairwise comparison of correlations observed using reference 
datasets of different size and taxonomic level 
A) Significance (P-values) of the correlations between mWGS and IPCO-inferred KEGG 
pathway abundance profiles 
Samples 
Reference size Phylum Class Order Family Genus OTU  
10 - 30 2.6E-01 1.8E-01 3.1E-01 3.9E-01 3.0E-01 4.1E-01 
10 - 50 2.1E-01 1.4E-01 2.1E-01 2.6E-01 2.6E-01 2.6E-01 
10 - 70 2.2E-01 2.9E-01 5.0E-01 3.5E-01 6.7E-01 6.1E-01 
10 - 80 4.1E-01 1.8E-01 2.5E-01 6.8E-01 3.6E-01 3.6E-01 
30 - 50 5.6E-01 5.5E-01 5.0E-01 4.9E-01 5.7E-01 4.8E-01 
30 - 70 5.5E-01 6.6E-01 6.2E-01 5.3E-01 7.4E-01 5.7E-01 
30 - 80 6.3E-01 6.1E-01 5.1E-01 6.3E-01 6.5E-01 5.2E-01 
50 - 70 4.8E-01 5.5E-01 5.7E-01 5.3E-01 5.9E-01 5.6E-01 
50 - 80 5.2E-01 4.8E-01 5.1E-01 5.9E-01 4.9E-01 4.8E-01 
70 - 80 4.9E-01 5.1E-01 5.0E-01 4.9E-01 5.4E-01 5.2E-01 
Features 
Reference size Phylum Class Order Family Genus OTU  
10 - 30 1.2E-02 8.3E-04 7.2E-04 1.2E-02 3.4E-02 1.3E-05 
10 - 50 3.7E-03 3.4E-05 2.3E-06 2.5E-03 2.6E-03 1.7E-08 
10 - 70 2.9E-03 1.1E-04 6.2E-07 1.4E-03 3.1E-03 3.8E-09 
10 - 80 4.2E-03 9.7E-05 3.0E-07 1.7E-02 1.3E-02 1.2E-09 
30 - 50 4.7E-01 2.7E-01 1.2E-01 3.1E-01 2.1E-01 1.3E-01 
30 - 70 4.3E-01 4.1E-01 7.2E-02 2.8E-01 2.6E-01 8.5E-02 
30 - 80 4.6E-01 3.8E-01 4.8E-02 4.6E-01 3.6E-01 5.4E-02 
50 - 70 4.8E-01 3.7E-01 4.1E-01 4.8E-01 4.0E-01 4.2E-01 
50 - 80 4.8E-01 3.9E-01 3.5E-01 3.1E-01 3.0E-01 3.4E-01 
70 - 80 5.2E-01 4.8E-01 4.0E-01 2.8E-01 3.6E-01 3.8E-01 
Significance of correlation values of IPCO inferred samples and features obtained through 
pairwise comparison between different KEGG reference datasets size. Significance is 
determined by P-adjusted ≤ 0.05 and highlighted in red and bold  
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B) Significance (P-values) of the correlations between mWGS and IPCO-inferred 
MetaCyc pathway abundance profiles 
Samples 
Reference size Phylum Class Order Family Genus OTU  
10 - 30 3.8E-01 2.9E-01 4.8E-01 8.1E-02 2.2E-01 1.6E-01 
10 - 50 4.4E-01 1.4E-01 4.2E-01 2.5E-02 7.4E-02 1.5E-01 
10 - 70 4.4E-01 1.2E-01 4.0E-01 1.9E-02 4.9E-02 8.6E-02 
10 - 80 4.1E-01 1.4E-01 4.0E-01 1.9E-02 5.9E-02 1.2E-01 
30 - 50 3.8E-01 4.2E-01 4.4E-01 4.0E-01 3.7E-01 4.9E-01 
30 - 70 3.8E-01 3.6E-01 4.2E-01 3.4E-01 2.7E-01 4.7E-01 
30 - 80 4.4E-01 3.2E-01 3.8E-01 2.9E-01 2.5E-01 4.6E-01 
50 - 70 4.2E-01 4.5E-01 4.0E-01 4.1E-01 4.1E-01 4.2E-01 
50 - 80 4.2E-01 4.0E-01 4.5E-01 4.0E-01 3.8E-01 4.0E-01 
70 - 80 3.9E-01 4.2E-01 4.6E-01 4.5E-01 4.3E-01 4.4E-01 
Features 
Reference size Phylum Class Order Family Genus OTU  
10 - 30 2.2E-03 2.9E-05 2.3E-05 4.7E-05 3.3E-05 2.6E-08 
10 - 50 1.9E-02 1.1E-06 5.9E-08 7.6E-09 3.9E-11 6.0E-16 
10 - 70 1.7E-02 2.5E-07 9.6E-06 2.8E-11 4.0E-13 1.7E-16 
10 - 80 7.1E-02 4.7E-06 5.8E-08 2.8E-11 3.3E-13 3.2E-17 
30 - 50 2.8E-01 3.4E-01 1.6E-01 5.9E-02 9.4E-03 7.7E-03 
30 - 70 2.9E-01 2.2E-01 4.5E-01 6.4E-03 1.2E-03 5.0E-03 
30 - 80 1.1E-01 4.1E-01 1.6E-01 5.7E-03 1.0E-03 2.5E-03 
50 - 70 4.6E-01 3.8E-01 1.8E-01 2.0E-01 2.7E-01 4.2E-01 
50 - 80 2.8E-01 3.6E-01 4.5E-01 1.9E-01 2.6E-01 4.0E-01 
70 - 80 2.8E-01 3.2E-01 1.7E-01 4.6E-01 4.5E-01 4.3E-01 
Significance of correlation values of IPCO inferred samples and features obtained through 
pairwise comparison between different MetaCyc reference datasets size. Significance is 
determined by P-adjusted ≤ 0.05 and highlighted in red and bold 
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Supplementary table 3 Comparison of sample-to-sample and feature-to-feature 
correlations between the inferred and the mWGS pathway profiles (KEGG pathways) 
obtained using different methodologies for different sites 
  Samples 
  Water (Brazilian river) nasal oral skin stool 
IPCO - PICRUSt 5.5E-10 4.4E-11 3.0E-13 7.8E-03 9.2E-16 
IPCO - Piphillin 1.7E-10 8.2E-10 3.0E-13 7.8E-03 9.2E-16 
IPCO - Tax4Fun 5.5E-10 2.3E-11 3.0E-13 7.8E-03 9.2E-16 
PICRUSt - Piphillin 2.5E-07 3.4E-09 4.1E-03 7.8E-03 1.3E-03 
PICRUSt - Tax4Fun 7.3E-01 2.3E-11 3.0E-13 7.8E-03 9.2E-16 
Piphillin - Tax4Fun 3.8E-07 2.3E-11 3.0E-13 7.8E-03 3.5E-15 
  Features 
  Water (Brazilian river) nasal oral skin stool 
IPCO - PICRUSt 2.0E-08 1.4E-05 3.7E-06 1.4E-05 2.6E-16 
IPCO - Piphillin 3.5E-10 2.4E-07 8.0E-09 7.9E-09 2.6E-17 
IPCO - Tax4Fun 4.3E-08 2.9E-07 5.7E-08 1.5E-09 1.8E-17 
PICRUSt - Piphillin 7.1E-01 8.2E-01 4.1E-01 3.3E-02 1.2E-01 
PICRUSt - Tax4Fun 6.4E-01 4.2E-01 6.3E-01 1.1E-05 4.6E-02 
Piphillin - Tax4Fun 7.1E-01 8.6E-01 6.3E-01 7.0E-03 3.6E-01 
Pairwise comparison of sample-to-sample and feature-to-feature correlation values 
(KEGG pathways) from different methodology. Significance is determined by P-adjusted 
≤ 0.05 and highlighted in red and bold. 
 
Supplementary table 4 Comparison of sample-to-sample and feature-to-feature 
correlations between the inferred and the mWGS KEGG Orthologs (KO) profiles obtained 
using different tools for different sites 
Pairwise comparison of sample-to-sample and feature-to-feature correlation values using 
KO profiles from different methodology. Significance is determined by P-adjusted ≤ 0.05 
and highlighted in red and bold. 
  
  Samples 
  Water (Brazilian river) nasal oral skin stool 
IPCO - PICRUSt 8.1E-08 2.3E-09 7.8E-03 8.6E-16 3.2E-13 
IPCO - Piphillin 4.4E-10 8.7E-08 7.8E-03 8.6E-16 3.2E-13 
IPCO - Tax4Fun 2.6E-09 7.1E-11 7.8E-03 8.6E-16 3.2E-13 
PICRUSt - Piphillin 7.3E-06 6.8E-10 7.8E-03 2.8E-15 3.2E-13 
PICRUSt - Tax4Fun 8.7E-11 3.4E-11 7.8E-03 8.6E-16 3.2E-13 
Piphillin - Tax4Fun 7.5E-02 3.4E-11 7.8E-03 9.6E-01 3.2E-13 
  Features 
  Water (Brazilian river) nasal oral skin stool 
IPCO - PICRUSt 8.0E-24 3.2E-01 5.5E-107 2.0E-04 1.4E-52 
IPCO - Piphillin 1.5E-96 9.7E-03 2.1E-97 6.0E-02 3.7E-57 
IPCO - Tax4Fun 1.9E-38 1.4E-04 2.2E-90 2.5E-01 9.8E-260 
PICRUSt - Piphillin 3.5E-48 2.8E-04 1.0E-05 3.2E-27 7.8E-03 
PICRUSt - Tax4Fun 1.5E-06 3.3E-06 1.8E-03 3.8E-04 1.4E-96 
Piphillin - Tax4Fun 6.7E-32 4.0E-02 3.1E-02 2.3E-05 1.8E-49 
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Supplementary table 5 Co-variance observed between taxonomic and functional datasets 
from different sites 
KEGG 
  OTU & Pathway abundance mWGS species & Pathway abundance 
site RV pvalue RV pvalue 
nasal 0.08 0.892 0.07 0.404 
oral 0.14 0.845 0.12 0.366 
skin 0.47 0.795 0.43 0.390 
stool 0.35 0.001 0.35 0.001 
Water (Brazilian river) 0.17 0.188 0.23 0.009 
MetaCyc 
site RV pvalue RV pvalue 
nasal 0.11 0.945 0.07 0.745 
oral 0.14 0.911 0.13 0.233 
skin 0.43 0.929 0.36 0.630 
stool 0.41 0.001 0.47 0.001 
Water (Brazilian river) 0.19 0.146 0.22 0.012 
Co-inertia of samples and pathways between the inferred KEGG/MetaCyc profiles with its 
paired mWGS pathways abundance. Degree of co-variance is determined by RV 
coefficient and significance is determined by nominal p-value ≤ 0.05 and highlighted in 




Supplementary table 6 Comparison of inferred vs mWGS profiles of CRC samples  
A) Pairwise comparison between inferred and mWGS KEGG pathway profiles obtained 
using various references implemented in IPCO and by using published tools 
Pairwise comparisons P-values (Sample-to-sample) P-values (Feature-to-feature) 
CRC samples (ref) 
vs 
In-cohort (ref) Healthy samples (16S Genus) 
3.2E-02 2.7E-08 
CRC samples (ref) 
vs 
In-cohort (ref) Healthy samples (Shotgun Genus) 
2.3E-02 4.6E-02 
CRC samples (ref) 
vs 
IPCO Healthy (ref) 
7.2E-01 1.1E-08 












In-cohort (ref) Healthy samples (16S Genus) 
vs 
In-cohort (ref) Healthy samples (Shotgun Genus) 
1.3E-04 2.3E-14 
In-cohort (ref) Healthy samples (16S Genus) 
vs 
IPCO Healthy (ref) 
6.0E-01 3.6E-01 
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In-cohort (ref) Healthy samples (Shotgun Genus) 
vs 
IPCO Healthy (ref) 
6.0E-01 1.4E-12 




































Significance of all pairwise comparisons when inferring KEGG pathways functionality of 
colorectal cancer (CRC) samples using various references implemented in IPCO along 
with predictions from PICRUSt, Piphillin and Tax4Fun. Significant p-values (P-adjusted 
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B) Pairwise comparison between inferred and mWGS KEGG pathway profiles obtained 






In-cohort (ref) Healthy samples (16S 
Genus) 
vs 
CRC samples (ref) 
5.0E-01 3.8E-45 
In-cohort (ref) Healthy samples (Shotgun 
Genus) 
vs 
CRC samples (ref) 
5.0E-01 1.9E-14 
IPCO Healthy (ref) 
vs 
CRC samples (ref) 
5.0E-01 3.8E-14 
In-cohort (ref) Healthy samples (Shotgun 
Genus) 
vs 
In-cohort (ref) Healthy samples (16S 
Genus) 
5.0E-01 3.8E-75 
IPCO Healthy (ref) 
vs 
In-cohort (ref) Healthy samples (16S 
Genus) 
5.0E-01 2.2E-45 
IPCO Healthy (ref) 
vs 
In-cohort (ref) Healthy samples (Shotgun 
Genus) 
5.0E-01 3.2E-04 
Significance of all pairwise comparisons when inferring MetaCyc pathways functionality 
of colorectal cancer (CRC) samples using various references implemented in IPCO. 
Significant p-values (P-adjusted ≤ 0.05) is highlighted in red and bold. 
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Supplementary table 7 Correlation between the paired bile acid profiles and the different 
KEGG pathways obtained using mWGS and those inferred using different methods 
Spearman correlation values 
Bile acids  KEGG pathways Shotgun IPCO PICRUSt Tax4Fun Piphillin 
cholic acid  ko00121: Secondary bile acid biosynthesis -0.34 -0.21 0.37 -0.08 0.00 
cholic acid  ko00790: Folate biosynthesis 0.48 0.36 0.02 0.34 0.36 
Chenodeoxycholic acid  ko00121: Secondary bile acid biosynthesis -0.27 -0.22 0.31 -0.07 -0.05 
Chenodeoxycholic acid  ko00790: Folate biosynthesis 0.43 0.31 0.06 0.36 0.35 
Lithocholic acid  ko00430: Taurine and hypotaurine metabolism 0.35 0.22 0.11 0.22 0.3 
Lithocholic acid  ko03070: Bacterial secretion system 0.37 0.2 -0.15 -0.23 -0.01 
Dehydrocholic acid  ko05100: Bacterial invasion of epithelial cells -0.27 -0.21 -0.30 -0.20 -0.42 
12-Ketolithocholic acid  ko00121: Secondary bile acid biosynthesis 0.24 -0.12 0.08 -0.05 0.06 
12-Ketolithocholic acid  ko00430: Taurine and hypotaurine metabolism 0.24 0.03 -0.08 0.05 0.07 
dehydrolithocholic acid  ko00121: Secondary bile acid biosynthesis 0.25 0.13 -0.11 -0.01 0.19 
dehydrolithocholic acid  ko00430: Taurine and hypotaurine metabolism 0.28 -0.08 0.22 -0.02 0.14 
7-ketolithocholic acid  ko00790: Folate biosynthesis 0.003 0.006 -0.05 0.001 0.021 
Hyodeoxycholic acid  ko00430: Taurine and hypotaurine metabolism -0.27 -0.19 0.04 -0.10 -0.08 
Ursodeoxycholic acid  ko00790: Folate biosynthesis 0.49 0.42 0.01 0.38 0.36 
Dioxolithocholic acid  ko00790: Folate biosynthesis 0.32 0.18 0.15 0.19 0.15 
Isolithocholic acid  ko00430: Taurine and hypotaurine metabolism 0.27 0.04 0.17 0.17 0.25 
P-values of Spearman correlation 
cholic acid  ko00121: Secondary bile acid biosynthesis 0.014 0.064 0.001 0.497 0.971 
cholic acid  ko00790: Folate biosynthesis 0.001 0.001 0.865 0.002 0.001 
Chenodeoxycholic acid  ko00121: Secondary bile acid biosynthesis 0.052 0.049 0.005 0.521 0.638 
Chenodeoxycholic acid  ko00790: Folate biosynthesis 0.002 0.006 0.605 0.001 0.001 
Lithocholic acid  ko00430: Taurine and hypotaurine metabolism 0.013 0.049 0.340 0.051 0.007 
Lithocholic acid  ko03070: Bacterial secretion system 0.008 0.08 0.180 0.04 0.927 
Dehydrocholic acid  ko05100: Bacterial invasion of epithelial cells 0.053 0.059 0.006 0.084 0.000 
12-Ketolithocholic acid  ko00121: Secondary bile acid biosynthesis 0.099 0.293 0.492 0.68 0.573 
12-Ketolithocholic acid  ko00430: Taurine and hypotaurine metabolism 0.085 0.809 0.472 0.647 0.541 
dehydrolithocholic acid  ko00121: Secondary bile acid biosynthesis 0.072 0.251 0.326 0.897 0.089 
dehydrolithocholic acid  ko00430: Taurine and hypotaurine metabolism 0.048 0.462 0.056 0.842 0.207 
7-ketolithocholic acid  ko00790: Folate biosynthesis 0.003 0.006 0.673 0.001 0.021 
Hyodeoxycholic acid  ko00430: Taurine and hypotaurine metabolism 0.051 0.089 0.739 0.360 0.479 
Ursodeoxycholic acid  ko00790: Folate biosynthesis 0.001 0.0001 0.943 0.001 0.001 
Dioxolithocholic acid  ko00790: Folate biosynthesis 0.02 0.123 0.191 0.098 0.178 
Isolithocholic acid  ko00430: Taurine and hypotaurine metabolism 0.055 0.757 0.131 0.138 0.025 
Correlation between mWGS key KEGG pathways profiles with its paired bile acid 
metabolites levels and replication of correlations with inferred profiles from different 
methodology with bile acids levels. Significance for the mWGS profile is determined by 
p-adjusted ≤ 0.1 and for the different methodology by nominal p-value ≤ 0.1 and 
highlighted in red and bold. Directionality and strength of correlation is determined by 













Supplementary table 8 Correlation between mWGS and inferred MetaCyc pathway pathway abundance and their paired bile acid profiles 
    Shotgun IPCO 
Bile_acids  MetaCyc pathways cor value pvalue padj cor value pval 
cholic acid 1CMET2-PWY: N10-formyl-tetrahydrofolate biosynthesis 0.30 0.007 0.029 0.30 0.008 
cholic acid PWY-6518: glycocholate metabolism (bacteria) 0.32 0.005 0.019 0.37 0.001 
Chenodeoxycholic acid 1CMET2-PWY: N10-formyl-tetrahydrofolate biosynthesis 0.28 0.013 0.051 0.25 0.028 
Chenodeoxycholic acid PWY-6518: glycocholate metabolism (bacteria) 0.28 0.012 0.048 0.33 0.003 
Deoxycholic acid PWY-6518: glycocholate metabolism (bacteria) 0.33 0.003 0.030 0.26 0.022 
Lithocholic acid 1CMET2-PWY: N10-formyl-tetrahydrofolate biosynthesis 0.31 0.006 0.201 0.22 0.048 
Lithocholic acid PWY-6518: glycocholate metabolism (bacteria) 0.27 0.018 0.234 0.27 0.017 
7-ketolithocholic acid 1CMET2-PWY: N10-formyl-tetrahydrofolate biosynthesis 0.30 0.008 0.052 0.24 0.036 
7-ketolithocholic acid PWY-6518: glycocholate metabolism (bacteria) 0.26 0.020 0.086 0.33 0.003 
Ursodeoxycholic acid 1CMET2-PWY: N10-formyl-tetrahydrofolate biosynthesis 0.31 0.006 0.021 0.40 0.0002 
Ursodeoxycholic acid PWY-6518: glycocholate metabolism (bacteria) 0.27 0.017 0.053 0.38 0.001 
Dioxolithocholic acid 1CMET2-PWY: N10-formyl-tetrahydrofolate biosynthesis 0.24 0.032 0.115 0.19 0.099 
Isolithocholic acid 1CMET2-PWY: N10-formyl-tetrahydrofolate biosynthesis 0.23 0.046 0.990 0.06 0.600 
Correlation between mWGS key MetaCyc pathways profiles with its paired bile acid metabolites levels and replication of correlations between 
IPCO inferred profiles with bile acids levels. Significance for the mWGS profile is determined by nominal p-value ≤ 0.1 and for IPCO profiles by 
nominal p-value ≤ 0.1. The p-adj values (≤ 0.1) are also noted for the mWGS results. All significances are highlighted in red and bold. Directiona lity 
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Supplementary table 9 Correlation of mWGS and inferred KEGG pathways to its paired 
butyrate and propionate levels 
Spearman correlation values 
 shotgun IPCO PICRUSt Tax4Fun Piphillin 
Butyrate 
ko00250: Alanine, aspartate and glutamate metabolism 0.06 0.02 0.06 0.06 -0.22 
ko00300: Lysine biosynthesis 0.17 0.03 0.06 -0.03 -0.24 
ko00310: Lysine degradation -0.09 -0.13 0.03 0.04 -0.10 
ko00471: D-Glutamine and D-glutamate metabolism 0.08 -0.02 0.02 0.22 -0.12 
ko00650: Butanoate metabolism 0.12 -0.11 0.08 -0.05 -0.19 
ko04974: Protein digestion and absorption -0.07 -0.02 0.03 0.09 0.04 
Propionate 
ko00250: Alanine, aspartate and glutamate metabolism 0.07 0.01 0.07 0.10 -0.15 
ko00260: Glycine, serine and threonine metabolism 0.11 0.01 -0.01 0.08 -0.17 
ko00270: Cysteine and methionine metabolism 0.12 -0.18 -0.03 -0.14 -0.06 
ko00340: Histidine metabolism 0.10 0.02 -0.14 0.00 -0.30 
ko00471: D-Glutamine and D-glutamate metabolism 0.08 -0.09 0.00 0.30 -0.05 
ko00473: D-Alanine metabolism 0.04 -0.31 0.01 -0.14 0.01 
ko00640: Propanoate metabolism -0.11 -0.20 -0.11 -0.17 -0.14 
ko04974: Protein digestion and absorption -0.05 0.00 0.10 0.17 0.17 
P-values of Spearman correlation 
Butyrate 
ko00250: Alanine, aspartate and glutamate metabolism 0.59 0.83 0.58 0.57 0.06 
ko00300: Lysine biosynthesis 0.13 0.76 0.59 0.79 0.04 
ko00310: Lysine degradation 0.44 0.24 0.76 0.74 0.39 
ko00471: D-Glutamine and D-glutamate metabolism 0.48 0.83 0.86 0.05 0.31 
ko00650: Butanoate metabolism 0.29 0.32 0.46 0.68 0.09 
ko04974: Protein digestion and absorption 
0.56 0.87 0.80 0.43 0.70 
Propionate 
ko00250: Alanine, aspartate and glutamate metabolism 0.52 0.90 0.55 0.37 0.19 
ko00260: Glycine, serine and threonine metabolism 0.35 0.95 0.93 0.50 0.14 
ko00270: Cysteine and methionine metabolism 0.31 0.12 0.77 0.23 0.57 
ko00340: Histidine metabolism 0.39 0.89 0.21 0.99 0.01 
ko00471: D-Glutamine and D-glutamate metabolism 0.47 0.43 0.97 0.01 0.64 
ko00473: D-Alanine metabolism 0.72 0.01 0.96 0.22 0.93 
ko00640: Propanoate metabolism 0.35 0.07 0.32 0.13 0.23 
ko04974: Protein digestion and absorption 
0.68 1.00 0.39 0.13 0.14 
Correlation between mWGS key KEGG pathways profiles with its paired butyrate and 
propionate metabolites levels and replication of correlations between inferred profiles from 
different methodology with butyrate and propionate levels. Significance for the mWGS 
profile and for the different methodology by nominal p-value ≤ 0.1, highlighted in red, and 
bold. mWGS profiles were not significantly correlated with butyrate and propionate levels. 












Supplementary table 10 Estimates and p-values of correlation from key mWGS and inferred MetaCyc pathways to its paired butyrate and 
propionate levels 
  shotgun IPCO 
SCFAs MetaCyc pathways cor value pval padj cor value pval 
Butyrate 
ARGDEG-PW Y: superpathway of L-arginine, putrescine, and 4-aminobutanoate degradation 0.041 0.721 0.963 0.036 0.751 
CENTFERM-PW Y: pyruvate fermentation to butanoate 0.052 0.650 0.936 -0.118 0.298 
DAPLYSINESYN-PW Y: L-lysine biosynthesis I -0.030 0.791 0.963 -0.149 0.190 
P163-PWY: L-lysine fermentation to acetate and butanoate -0.079 0.487 0.883 -0.206 0.069 
P4-PWY: superpathway of L-lysine, L-threonine and L-methionine biosynthesis I -0.168 0.139 0.526 -0.146 0.200 
PWY-2941: L-lysine biosynthesis II -0.018 0.873 0.979 -0.053 0.643 
PWY-2942: L-lysine biosynthesis III 0.248 0.028 0.230 0.070 0.540 
PWY-5022: 4-aminobutanoate degradation V -0.043 0.704 0.963 -0.187 0.098 
PWY-5097: L-lysine biosynthesis VI 0.350 0.002 0.125 0.149 0.191 
PWY-5100: pyruvate fermentation to acetate and lactate II 0.017 0.882 0.979 -0.079 0.488 
PWY-5505: L-glutamate and L-glutamine biosynthesis  0.097 0.395 0.820 -0.147 0.197 
PWY-5676: acetyl-CoA fermentation to butanoate II -0.082 0.473 0.867 -0.016 0.889 
PWY-6590: superpathway of Clostridium acetobutylicum acidogenic fermentation  0.054 0.638 0.931 -0.111 0.330 
Propionate 
ASPASN-PWY: superpathway of L-aspartate and L-asparagine biosynthesis  0.191 0.092 0.384 0.106 0.351 
HISDEG-PW Y: L-histidine degradation I -0.056 0.621 0.996 -0.081 0.476 
HOMOSER-METSYN-PW Y: L-methionine biosynthesis I -0.004 0.972 0.951 -0.049 0.669 
HSERMETANA-PW Y: L-methionine biosynthesis III 0.042 0.711 0.747 -0.059 0.604 
MET-SAM-PWY: superpathway of S-adenosyl-L-methionine biosynthesis  -0.034 0.768 0.919 -0.081 0.475 
METSYN-PW Y: L-homoserine and L-methionine biosynthesis  -0.021 0.857 0.976 -0.062 0.585 
P108-PWY: pyruvate fermentation to propanoate I -0.088 0.442 0.661 0.065 0.570 












PWY-5028: L-histidine degradation II 0.127 0.267 0.689 -0.108 0.344 
PWY-5100: pyruvate fermentation to acetate and lactate II -0.329 0.003 0.979 -0.122 0.283 
PWY-5345: superpathway of L-methionine biosynthesis (by sulfhydrylation) -0.003 0.977 0.891 -0.025 0.829 
PWY-5347: superpathway of L-methionine biosynthesis (transsulfuration) -0.014 0.899 0.979 -0.061 0.594 
PWY-5505: L-glutamate and L-glutamine biosynthesis  -0.202 0.075 0.747 -0.076 0.505 
PWY-6151: S-adenosyl-L-methionine cycle I -0.183 0.107 0.976 -0.107 0.349 
PWY-6628: superpathway of L-phenylalanine biosynthesis  0.223 0.048 0.591 0.115 0.313 
PWY0-1061: superpathway of L-alanine biosynthesis  -0.042 0.711 0.591 -0.103 0.364 
PWY0-781: aspartate superpathway 0.077 0.502 0.730 -0.055 0.632 
SER-GLYSYN-PW Y: superpathway of L-serine and glycine biosynthesis I 0.322 0.004 0.979 0.118 0.302 
THRESYN-PW Y: superpathway of L-threonine biosynthesis  -0.032 0.782 0.839 -0.109 0.338 
Correlation between mWGS key MetaCyc pathways profiles with its paired butyrate and propionate metabolites levels and replication of correlations 
between IPCO inferred profiles with butyrate and propionate levels. Significance for the mWGS profile and IPCO profiles is determined by nomina l 
p-value ≤ 0.1 or p-adjusted ≤ 0.1 and highlighted in red and bold. mWGS profiles were not significantly correlated with butyrate and only three 
pathways with propionate levels. Directionality and strength of correlation is determined by spearman correlation estimate. 
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Chapter 5 Gut microbiota dynamics in patients with Multiple Sclerosis  
5.1 Abstract 
Background Multiple sclerosis (MS) is an immune-associated disorder of the neurons 
characterised by demyelination and inflammation. Microbiota alterations have been 
identified as a risk factor in various inflammatory conditions. However, age-related 
microbiota alterations related to biological and premature ageing have not been 
previously considered as a confounder. 
Aim To investigate the gut microbiota compositional changes associated with the 
different phenotypes of MS. 
Method This study consists of 32 MS patients stratified into 21 relapse-remitting MS 
(RRMS), 8 secondary progressive MS (SPMS) and 3 primary progressive MS (PPMS) 
phenotypes. These samples are compared against 9 young healthy and 96 elderly 
healthy samples. Whole genome shotgun (mWGS) sequencing of the faecal samples 
was carried out and analysed to identify taxonomic and functional changes associated 
with MS phenotypes.  
Results We identified significant separation in the β-diversity associated with the 
group stratification. Increased abundances of taxa including Clostridium species, 
Eggerthella and Escherichia coli were observed in MS patients, whereas 
Lachnospiracea, Eubacterium and Ruminococcus that are previously associated with 
high fibre diet and improved health were less abundant. Functional profiles associated 
with fermentation and secondary metabolites were reduced in MS patients. 
Conclusion We identified taxonomic and functional alterations associated with MS 
that are distinct from age-related phenotypes. These changes reflect the depletion and 
loss of health associated taxa. 
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5.2 Introduction 
Multiple sclerosis (MS) is a neurodegenerative disorder of the central nervous system 
(CNS) involving autoimmune responses and premature cellular aging (Nicaise et al., 
2019). This results in lesions due to demyelination in the nerve cells in optic nerves, 
white and grey matter (Filippi et al., 2018). The aetiology of the disease is multi-
factorial and includes environmental stressors but not ageing. MS is more prevalent in 
western countries with European ancestry compared to Asian, African or Native 
American population (Rosati, 2001) and is commonly reported in adults aged 20-40 
years (Ghasemi et al., 2017).  
MS is classified into different subtypes depending on the onset, progression, 
and assessment of the disease. These subtypes include clinically isolated syndrome 
(CIS) defined by initial onset of the disease. Relapsing-remitting MS (RRMS) is 
characterised by reversible relapse of the lesions. Primary progressive MS (PPMS) is 
diagnosed with disease progression continuing from the beginning without relapses. 
Once MS progression results in permanent defects, it is considered as secondary 
progressive MS (SPMS) (Filippi et al., 2018). Polymorphism in various immune 
associated genes like HLA class I and II, and Interleukin (IL) genes have been 
identified as risk factors (Cotsapas and Mitrovic, 2018). Production of pro-
inflammatory cytokines, influx of immune cells, ineffective functioning of the T-
regulatory cells are reported to cause neuro-axonal damage (Filippi et al., 2018). 
The gut microbiota is associated with various immune functions of the host 
that involve T-cells mediated immune homeostasis (Pandiyan et al., 2019). 
Experimental autoimmune encephalomyelitis (EAE) animal models are used for 
studying MS and they highlight T-cell mediated immune response resulting in 
demyelination of neurons (Berer et al., 2011;Lee et al., 2011). Germ-free EAE models 
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or antibiotics treatment of animal models were observed to have reduced disease 
activity and increased immune tolerance (Yokote et al., 2008;Lee et al., 2011). 
Alternatively, certain bacterial metabolites (short chain fatty acids) were shown to 
have protective activity against EAE (Haghikia et al., 2015). A reduction in disease 
severity is observed in animal models upon colonisation of certain species from 
Lactococcus, Bifidobacterium and Prevotella (Ezendam et al., 2008;Rezende et al., 
2013;Mangalam et al., 2017).  
Microbial alterations have been associated with EAE susceptibility in animal 
models and as well as in MS patients. In human studies, patients with MS were shown 
to have a reduced abundance of taxa associated with short-chain fatty acid production, 
microglia and T-regulatory cells interactions (Mirza and Mao-Draayer, 2017). Despite 
identification of taxonomic association with MS, a recent study observed that the 
predictive power of the taxonomic features was very low with high false negative rates 
across multiple methods (Bang et al., 2019).  
 In the current study, we hypothesised that the gut microbiota profiles might 
be distinct in MS patients with different unique and shared signature between 
subtypes, but that signature might be confounded by alterations associated with 
premature cellular aging. Therefore, the MS signature is compared against young 
healthy and an elderly healthy population to understand the changes in microbio ta 
dynamics that is altered in the disease and associated subgroups.  
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5.3 Method 
5.3.1 Sample collection 
Recruitment of samples was carried out in Cork University Hospital, Cork. Subjects 
diagnosed with RRMS, PPMS and SPMS were recruited along with healthy 
volunteers. Written consent was obtained from all recruited subjects. Exclus ion 
criteria were defined as antibiotic usage in 3 months prior sampling, history of alcohol 
abuse or participation in drug trials 1 month prior.  
 
5.3.2 DNA Extraction 
Genomic DNA was extracted from faecal samples (0.25 g) using the Repeat Bead 
Beating (RBB) method of Yu and Morrison (Yu and Morrison, 2004) with the 
following modifications. Sterile zirconia beads (0.5 g) collection comprising of one 
3.0 mm bead, 0.1 g of 0.5 mm beads, and 0.3 g of 0.1 mm beads were used. Faecal 
samples were homogenised via bead beating for 90 seconds (Mini-Beadbeater™, 
BioSpec Products, Bartlesville, OK, USA), with the samples cooled on ice for 60 
seconds before another 90 seconds bead beating. Pooled supernatants were incubated 
with 350 ml of 7.5 M ammonium acetate (Sigma). The extraction then proceeded as 
per the RBB extraction protocol. Genomic DNA was visualised on 1% agarose gel 
and quantified using the Nanodrop 1000 (Thermo Scientific, Ireland). Extracted 
genomic DNA was stored at -20°C until sent for metagenomic whole genome shotgun 
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5.3.3 Bioinformatics analysis 
Quality filtering and trimming of mWGS sequence data was carried out as described 
in HMP project (Lloyd-Price et al., 2017). Human reads were removed using 
BMTagger (v.3.1) by indexing it against human reference genome (hg19). Low quality 
sequences and reads shorter than 60 bases were removed using trimBWAstyle.p l. 
Taxonomic and functional profiles were obtained using MetaPhlAn2 (Truong et al., 
2015) and HUMAnN2 (Franzosa et al., 2018) respectively with default parameters. 
UniRef90 database was used in HUMAnN2 pipeline. Counts per million (CPM) 
normalisation was carried out on pathway abundances output. Community samples 
from the ELDERMET cohort were included into the study for comparison against an 
aging population (Claesson et al., 2012). Species-level taxonomic dataset and pathway 
dataset stratified with taxonomic information was used for all analysis. 
 
5.3.4 Statistical Analysis 
All analyses were carried out in R (v.3.3.1) (Team, 2016). Using a threshold of P-
adjusted ≤ 0.05 (Benjamini-Hochberg method), statistical significance was defined. 
Alpha diversity was measured using observed species index. Alterations in global 
microbiota profile was investigated using redundancy analysis (RDA) from vegan 
library (v. 2.4.3) (Oksanen et al., 2017) on log10-transformed data modelled against 
the group stratification and visualised using s.class functionality from the ade4 (v. 
1.7.6) library (Dray and Dufour, 2007). A minimum value of 1e-05 was added to the 
taxonomic data before log transformation. Significance of the RDA model and effect 
size was calculated using analysis of variance (ANOVA) with 1000 permutations. 
Species level taxonomic data and pathways abundance profiles were filtered 
to retain only those features that were present in at least 50% samples in at least one 
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group. Differentially abundant taxa and pathways were determined using Kruskal-
Wallis test and Dunn’s test post-hoc analysis. P-values from Kruskal-Wallis were 
adjusted and pairwise analysis was carried out only on those features that passed the 
p-adjusted threshold from Kruskal-Wallis test.  
Binary dataset was generated from the pairwise comparison carried out in the 
taxonomic and functional datasets. Taxonomic and functional features that were 
significant (P-adjusted ≤ 0.05) were defined as 1 and non-significant features were 
denoted as 0. Binary distance for the features was calculated and clustered with Ward’s 
linkage (ward.D2 method; R statistical software). The binary dataset and clustered 
dendrogram was visualised as a heatmap from gplots (v. 3.0.1) (Warnes et al., 2019) 
to identify clusters associated with different group stratification. Identification of 
clusters was carried out by visual observation. Enrichment/depletion of significant 
pathways in each cluster was carried out using Fisher’s exact test by comparing the 
pathway representation within the cluster versus across the whole dataset excluding 
the cluster. Nominal P-value (≤ 0.05) was used to define statistical significance from 
the Fisher’s exact test. Bar plots were created using ggplot2 (v. 2.2.1) (Wickham, 
2009).  
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5.4 Results 
5.4.1 Sample characteristics 
A total of 32 MS samples were considered for the study. The controls samples 
comprised of 7 young healthy and 96 ELDERMET community samples. Overall, the 
study included 96 community dwelling elderly, 7 healthy, 21 RRMS, 8 SPMS and 3 
PPMS samples. From the MS samples plus 7 young healthy samples, a total of 174 
gigabases of quality filtered sequencing data with 25,050,928±1,228,109 reads per 
sample was obtained.  
 
5.4.2 Gut microbiota profiles of the cohort 
From the mWGS sequencing run, including community samples, a total of 399 species 
belonging to 66 different families were profiled. The α-diversity defined by number 
of observed species showed no significant differences between groups (Figure 1A, 
Table 1). The RDA analysis on the global microbiota composition identified 
significant differences (p-value ≤ 0.05) in the microbiota structure based on group 
stratification with an effect size of 6.64% (Figure 1B). The separation between 
different subtypes of MS and young healthy was observed along the Y-axis explaining 
1.42 % of variance whereas the X-axis identified separation between the community 
samples and MS subtypes with 3.69 % of variance. The SPMS and RRMS did not 
show prominent separation between themselves on the 1st two redundancy axes. The 
young healthy and the elderly community samples also separated along the Y-axis. 
Based on the relative abundance at Phylum level, Bacteroides and Firmicutes 
dominated, followed by Proteobacteria and Actinobacteria across all samples (Figure  
2).   
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Figure 1 Taxonomic diversity within and between Groups 
 
A) Represents the observed species count within each group. Non-significant (P-value 
≤ 0.05) difference is observed between the groups. B) Ordination based on 
redundancy analysis on the log10 transformed taxonomic species-level dataset. 
Significant separation is observed between MS phenotypes on the Y-axis and with the 
community elderly samples on the X-axis. 
 
Figure 2 Mean relative abundance at Phylum level 
 
The average relative abundance of each phyla observed across the whole dataset 
stratified by group status. 
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Table 1 Observed taxonomic and functional diversity 
Groups Observed species Observed gene count 
Community 89.1 ± 14.2 286589.8 ± 56489.9 
Healthy 86.1 ± 7.9 321115.3 ± 23505.4 
PPMS 67 ± 28.2 205051 ± 163008.9 
RRMS 91.1 ± 13.8 313949.3 ± 45406.6 
SPMS 85.3 ± 9.4 274191 ± 40564.2 
The values reported are the average values ± standard deviation for each group. 
 
5.4.3 Taxonomic abundance was significantly altered in MS groups 
The identification of significantly differentially (P-adjusted ≤ 0.05) abundant species 
was carried out on a filtered taxonomic dataset containing abundance information for 
117 species. Based on Kruskal-Wallis test, we identified 42 taxa in total to be 
significantly different in at least one group. These significant taxa were further 
investigated using pairwise comparisons, as represented in Figure 3A. PPMS and 
SPMS partly shared similar significance results, hence despite being defined as 
different MS subtypes medically, were merged together as an artificial group 
represented by PP_SP. Based on this new grouping we identified 44 species to be 
significantly different in at least one group. Post-hoc analysis revealed significant 
taxonomic signature associated with the groups Figure 3B. The mean and standard 
deviation of the relative abundances of the significant taxa per groups are represented 
in Table 2. In summary, the MS phenotype groups identified different Clostridium 
species to be significantly different from elderly samples. Most species were observed 
to be more abundant in MS compared to elderly samples. In the RRMS groups, 
Clostridium and Eggerthella species were more abundant whereas Lachnospiracea, 
Ruminococcus and Hemophilus parainfluenzae were depleted in comparison to elderly 
samples. Similar trends were observed in PPMS and SPMS merged group, which also 
included reduced abundance of Bacteroides ovatus. Compared to young healthy 
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samples, very few species were significantly different in different MS phenotypes. 
This included increased abundance of Escherichia coli, Clostridium bolteae and 
decreased abundance of Ruminococcus callidus, Lachnospiraceae bacterium and 
Eubacterium ramulus in MS groups. The elderly samples were distinguished from the 
healthy with reduced abundances of Clostridium bolteae, Ruminococcus callidus, 
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Figure 3 Taxonomic alteration associated with aging and MS stratification. 
 
A) Heatmap of the significantly differently abundant species which highlights the 
significant taxa across pairwise comparisons. Clustering is based on binary distance 
using Ward’s linkage. B) Heatmap representing significantly different species based 
on merged PPMS and SPMS groups (PP_SP). Clustering is based on binary distance 
and Ward’s linkage. 
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Table 2 Taxonomic abundance across the control and MS stratifications. 
Significant species Community Healthy PP_SP RRMS 
Anaerostipes hadrus 0.06 ± 0.16 0.23 ± 0.32 0 ± 0.01 0.01 ± 0.02 
Anaerotruncus colihominis 0 ± 0.01 0.02 ± 0.03 0.05 ± 0.09 0.08 ± 0.13 
Bacteroides intestinalis 0.66 ± 2.17 2.23 ± 4.26 0.92 ± 3.05 1.14 ± 2.98 
Bacteroides ovatus 2.62 ± 3.73 1.18 ± 1.36 0.45 ± 0.56 1.24 ± 1.9 
Bifidobacterium longum 0.21 ± 0.49 0.3 ± 0.36 2.44 ± 5.02 1.49 ± 3.95 
Bilophila unclassified 0.18 ± 0.24 0.53 ± 0.3 0.35 ± 0.36 0.79 ± 0.84 
Bilophila wadsworthia 0.02 ± 0.03 0.09 ± 0.05 0.05 ± 0.06 0.11 ± 0.15 
Clostridiales bacterium_1_7_47FAA 0 ± 0 0.01 ± 0.01 0.01 ± 0.03 0.01 ± 0.02 
Clostridium asparagiforme 0 ± 0.01 0.02 ± 0.02 0.04 ± 0.06 0.06 ± 0.08 
Clostridium bolteae 0.02 ± 0.06 0.11 ± 0.23 0.58 ± 0.96 0.25 ± 0.78 
Clostridium citroniae 0 ± 0.01 0.02 ± 0.02 0.02 ± 0.03 0.03 ± 0.04 
Clostridium clostridioforme 0 ± 0 0.01 ± 0.02 0.02 ± 0.06 0.19 ± 0.51 
Clostridium hathewayi 0.07 ± 0.68 0 ± 0.01 0.22 ± 0.28 0.03 ± 0.03 
Clostridium leptum 0.02 ± 0.05 0.11 ± 0.14 0.04 ± 0.05 0.06 ± 0.07 
Clostridium ramosum 0 ± 0.01 0 ± 0 0.03 ± 0.04 0 ± 0.01 
Clostridium symbiosum 0 ± 0.01 0.01 ± 0.02 0.23 ± 0.39 0.06 ± 0.09 
Coprobacillus unclassified 0.01 ± 0.08 0 ± 0 0.06 ± 0.09 0.01 ± 0.02 
Eggerthella lenta 0 ± 0.01 0 ± 0 0.07 ± 0.22 0.01 ± 0.02 
Eggerthella unclassified 0.01 ± 0.02 0.02 ± 0.03 0.88 ± 2.54 0.13 ± 0.3 
Erysipelotrichaceae bacterium_2_2_44A 0 ± 0.02 0 ± 0 0.03 ± 0.04 0.01 ± 0.02 
Erysipelotrichaceae bacterium_21_3 0 ± 0.01 0 ± 0 0.01 ± 0.01 0.01 ± 0.02 
Erysipelotrichaceae bacterium_6_1_45 0 ± 0.01 0 ± 0 0.01 ± 0.01 0.01 ± 0.01 
Escherichia coli 1.35 ± 5.03 0.05 ± 0.1 0.52 ± 0.92 2.32 ± 3.94 
Eubacterium ramulus 0.06 ± 0.08 0.52 ± 0.7 0.06 ± 0.11 0.09 ± 0.16 
Eubacterium ventriosum 0.12 ± 0.18 0.19 ± 0.3 0.01 ± 0.02 0.07 ± 0.1 
Flavonifractor plautii 0.01 ± 0.01 0.01 ± 0.02 0.03 ± 0.08 0.04 ± 0.08 
Gordonibacter pamelaeae 0 ± 0 0.01 ± 0.02 0.02 ± 0.04 0.02 ± 0.03 
Haemophilus parainfluenzae 0.59 ± 1.54 0.11 ± 0.2 0.03 ± 0.06 0.03 ± 0.06 
Holdemania filiformis 0.01 ± 0.03 0.01 ± 0.01 0.03 ± 0.04 0.04 ± 0.04 
Holdemania unclassified 0 ± 0.01 0.03 ± 0.05 0 ± 0.01 0.02 ± 0.03 
Lachnospiraceae bacterium_1_1_57FAA 0.07 ± 0.21 0.16 ± 0.22 2.04 ± 5.87 0.1 ± 0.24 
Lachnospiraceae bacterium_3_1_57FAA_CT1 0.02 ± 0.05 0 ± 0 0.51 ± 1.25 0.03 ± 0.08 
Lachnospiraceae bacterium_5_1_63FAA 0.04 ± 0.11 0.05 ± 0.05 0.01 ± 0.03 0.02 ± 0.03 
Lachnospiraceae bacterium_7_1_58FAA 0.03 ± 0.09 0.04 ± 0.06 0.13 ± 0.16 0.08 ± 0.09 
Leuconostoc citreum 0.01 ± 0.01 0 ± 0 0 ± 0 0 ± 0 
Odoribacter splanchnicus 1.71 ± 1.23 0.94 ± 0.64 0.75 ± 0.94 0.88 ± 0.74 
Oscillibacter unclassified 0.19 ± 0.23 0.39 ± 0.41 0.76 ± 0.66 0.85 ± 0.77 
Pseudoflavonifractor capillosus 0 ± 0.01 0 ± 0 0.01 ± 0.02 0.01 ± 0.02 
Ruminococcus callidus 0.12 ± 0.27 0.56 ± 0.88 0.01 ± 0.02 0.01 ± 0.03 
Ruminococcus lactaris 0.27 ± 0.5 0.35 ± 0.47 0 ± 0 0.12 ± 0.23 
Solobacterium moorei 0 ± 0 0 ± 0 0.02 ± 0.07 0 ± 0 
Subdoligranulum sp_4_3_54A2FAA 0.01 ± 0.07 0.19 ± 0.21 1.04 ± 2.59 0.47 ± 1.2 
Subdoligranulum unclassified 5.41 ± 5.5 12.82 ± 9.88 11.41 ± 10.62 7.59 ± 5.98 
Veillonella parvula 0.12 ± 0.33 0.01 ± 0.01 0.01 ± 0.02 0.04 ± 0.07 




370 | P a g e  
 
5.4.4 Differential functionality associated with control and MS stratifications 
The functional diversity defined by the number of genes identified is described in 
Table 1. There was a trend towards significance in the difference in gene counts 
between the groups (P-value: 0.1). The identified UniRef genefamilies corresponded 
to 439 MetaCyc pathways belonging to 280 species. After filtering, 330 pathways 
were retained that belonged to 84 species. Differential abundance analysis with 
Kruskal-Wallis test identified 275 pathways from 38 species as significantly (P-
adjusted ≤ 0.05) different in at least one group. Post-hoc analysis from the significant 
outcome of Kruskal-Wallis test identified 198 pathways that showed significance in 
pairwise comparisons. Binary clustering of the significant (P-adjusted ≤ 0.05) 
pathways identified unique species-specific pathways signature associated with 
different groups amongst which PPMS and SPMS showed shared signature (Figure  
4A).  
Merging the two groups: PPMS and SPMS as PP_SP and reanalysing the 
pathway abundance identified 283 pathways from 36 species as significantly different 
amongst the groups. Binary clustering on the regrouped data identified prominent 
clusters (Figure 4B). All MS phenotypes cluster (cluster blue) was associated with 
132 pathways from 8 species. RRMS cluster (cluster red) contains 144 pathways from 
8 species. The merged PPMS and SPMS cluster (cluster orange) has 32 pathways from 
9 species. The healthy cluster (cluster magenta) is associated with 82 pathways from 
9 species. The elderly cluster (cluster cyan) has 59 pathways from 14 species. The 
elderly vs MS cluster (cluster brown) is associated with 65 pathways from 16 species. 
Cluster green contains 82 pathways that were identified in the multigroup analysis but 
showed no pairwise significance. 
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Figure 4 Functional species-specific pathways are differentially altered across 




















Heatmap representing significantly (P-adjusted ≤ 0.05) different pathways with 

























Heatmap representing significantly (P-adjusted ≤ 0.05) different pathways with 
species stratification based on merged PPMS and SPMS groups (PP_SP). Clustering 
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Each cluster was further evaluated for enriched/depleted pathways. 
Identification of significantly (P-value ≤ 0.05) enriched/depleted pathways from each 
cluster is detailed in Table 3. Interestingly cluster blue which is associated with all 
MS phenotype did not identify any significantly enriched/depleted pathways. In 
RRMS associated cluster, only two pathways were significantly different. The two 
pathways “PWY-5083: NAD/NADH phosphorylation and dephosphorylation” and 
“PWY-6892: thiazole biosynthesis I (E. coli)” both belongs to superclass of cofactors, 
electron carrier and vitamin biosynthesis. These two pathways were more abundant in 
RRMS compared to healthy. In the elderly associated cluster, the pathways identified 
were primarily associated with different Clostridium species. Three of the pathways 
were nucleic acid biosynthesis, L-profile biosynthesis, and nitrate reduction. All of 
these pathways have decreased abundance in elderly samples compared to young 
healthy and MS samples. The brown cluster that is associated with difference between 
elderly and MS phenotypes has pathways associated with secondary metabolite 
production (methylerythritol phosphate pathway I) and fermentation process 
(Bifidobacterium shunt) which are more abundant in the elderly samples. The healthy 
associated cluster retained maximum number of enriched/depleted pathways. The 
mixed SPMS and PPMS cluster identified a significantly different archaeal pathway 
(Flavin biosynthesis) that was more abundant in the MS samples compared to 
community and healthy samples. Valine biosynthesis and peptidoglycan biosynthes is 
pathways were less abundant in SPMS-PPMS merged group compared to healthy and 












Table 3 List of pathways that are significantly enriched/depleted in each cluster 





Escherichia coli, Haemophilus parainfluenzae 6.99 ± 14.98 1.05 ± 1.4 5.06 ± 8.76 12.27 ± 20.74 3.0E-03 
PWY-6892: thiazole 
biosynthesis I (E. coli) 
Escherichia coli, unclassified 8.51 ± 11.8 3.29 ± 3.27 5.31 ± 7.88 7.95 ± 8.99 2.7E-02 
black 
PWY-181: photorespiration unclassified 0.47 ± 1.22 1.73 ± 1.73 0.88 ± 1.71 1.29 ± 2.67 1.9E-02 
PWY-6737: starch degradation 
V 
Clostridium citroniae, Clostridium leptum, 
Clostridium symbiosum 
0.09 ± 0.27 0.91 ± 1.05 0.92 ± 1.68 0.87 ± 1.03 3.4E-02 
cyan 
PWY-4981: L-proline 
biosynthesis II (from arginine) 
Clostridium asparagiforme, Clostridium 
citroniae 
0 ± 0.03 0.24 ± 0.24 0.6 ± 0.91 0.33 ± 0.31 4.2E-02 
PWY-7219: adenosine 
ribonucleotides de novo 
biosynthesis 
Anaerotruncus colihominis, Bifidobacterium 
longum, Clostridium asparagiforme, 
Clostridium leptum, Holdemania filiformis, 
Lachnospiraceae bacterium_1_1_57FAA, 
Subdoligranulum sp_4_3_54A2FAA 
1.08 ± 1.67 6.4 ± 5.82 29.33 ± 50.16 13.38 ± 26.99 4.4E-02 
PWY-7220: adenosine 
deoxyribonucleotides de novo 
biosynthesis II 
Clostridium asparagiforme, Clostridium 
leptum, Subdoligranulum sp_4_3_54A2FAA 
0.09 ± 0.29 1.53 ± 1.36 3.66 ± 6.71 1.52 ± 2.05 1.5E-02 
PWY-7222: guanosine 
deoxyribonucleotides de novo 
biosynthesis II 
Clostridium asparagiforme, Clostridium 
leptum, Subdoligranulum sp_4_3_54A2FAA 
0.09 ± 0.29 1.53 ± 1.36 3.66 ± 6.71 1.52 ± 2.05 1.5E-02 
PWY490-3: nitrate reduction 
VI (assimilatory) 
unclassified 0.3 ± 0.63 1.55 ± 1.5 0.27 ± 0.46 1.21 ± 1.95 4.2E-02 
magenta 
CRNFORCAT-PWY: 
creatinine degradation I 






Escherichia coli 1.79 ± 5.53 0 ± 0 1.88 ± 3.46 6.88 ± 14.89 4.4E-02 
PWY-5022: 4-aminobutanoate 
degradation V 












PWY-5918: superpathay of 
heme biosynthesis from 
glutamate 
Escherichia coli 2.66 ± 8.48 0.15 ± 0.4 3.21 ± 5.9 7.58 ± 12.44 4.4E-02 
PWY-6690: cinnamate and 3-
hydroxycinnamate degradation 
to 2-oxopent-4-enoate 









Escherichia coli 3.05 ± 10.08 0 ± 0 3.53 ± 6.83 10.57 ± 20.94 4.4E-02 









Alistipes indistinctus, Bifidobacterium longum, 
Odoribacter splanchnicus 
5.92 ± 3.98 4.54 ± 2.5 5.62 ± 3.04 4.7 ± 4.4 4.9E-02 
P124-PWY: Bifidobacterium 
shunt 
unclassified 1.22 ± 1.25 0.3 ± 0.8 0.62 ± 1.15 0.54 ± 1.17 3.3E-02 
orange 
PWY-6167: flavin biosynthesis 
II (archaea) 




Bacteroides ovatus, Faecalibacterium 
prausnitzii 
33.13 ± 30.8 51.89 ± 43.27 22.71 ± 28.49 22.41 ± 23.22 1.4E-02 
VALSYN-PWY: L-valine 
biosynthesis 
Clostridium leptum, Dorea formicigenerans, 
Ruminococcus lactaris 
1.78 ± 2.26 4.3 ± 2.87 0.68 ± 0.63 1.59 ± 1.59 4.9E-02 
The values reported are the average abundance values ± standard deviation for each group. Significance is defined by nominal P-value ≤ 0.05. 
The species column reports the species for which each significant pathway was stratified with.  
 




The importance of gut microbiota in immune homeostasis and immune-media ted 
disorders is well established. Amongst all the MS phenotypes, RRMS is the most 
commonly identified form (Doshi and Chataway, 2016). The environmental influence 
defined by microbiota and its metabolites in MS is established using EAE animal 
models (Yokote et al., 2008;Lee et al., 2011). This study explores the taxonomic 
signature and potential functionality associated with different MS phenotypes and its 
deviation from a healthy ageing microbiota signature. It identified dissimilarity in 
global taxonomic composition between different MS phenotypes compared to both 
young and elderly healthy samples. This was reflected through differential abundances 
of both taxonomic and functional markers which are associated with the different MS 
phenotypes. 
 Diversity plays a key role in maintenance of the immune system. Studies have 
shown that presence or depletion of certain taxa can trigger or supress inflammation 
(Forbes et al., 2016). In the current study, we observed that the dissimilarity between 
the samples was distinct despite small effect size.  
Further exploration of the taxa associated with the different groups have 
identified increased abundances of certain Clostridium species in the MS samples. 
Various studies have identified different species of this genus to be associated with 
pro- or anti-inflammatory properties depending on the species (Lopetuso et al., 2013). 
Similarly, Eggerthella is also reported to be higher in cases where T-cell functiona lity 
is partly compromised (Jin et al., 2015). Certain species from Lachnospiracea, 
Eubacterium and Ruminococcus are associated with health beneficial activities like T-
regulatory cell modulation and are observed in healthy controls across different studies 
(Kang et al., 2010). These species are known producers of short-chain fatty acids, 
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which is linked with high-fibre diet and improved health. The altered abundances of 
these species in the current study could be related to potentially improper immune 
modulation in the gut. Similarly, polysaccharides from different species of 
Bacteroides have been identified to have different effect in immune modulat ion 
(Wexler, 2007). In this regards, Bacteroides ovatus is identified with increased levels 
of immunoglobulin A (IgA) and IgG antibodies in inflammatory bowel disease 
patients however, their exact role in pathogenesis is unclear (Saitoh et al., 2002). This 
species interestingly is reduced in our study in the MS phenotype groups. Prevalence 
of Escherichia coli and Clostridium bolteae in the MS samples could be associated 
with infection in MS (Kaper et al., 2004;Song et al., 2004). The young healthy and 
elderly samples also showed a difference in abundances of SCFA producers and 
Bacteroides intestinalis (Shortt et al., 2018). These changes may be associated with 
ageing, dietary habits, medications, and lifestyle changes. 
The potential functionality of the microbiota in this study have highlighted 
different functional clusters associated with different groups. The MS associated 
clusters that showed difference against healthy young or elderly samples contains 
superclasses of pathways associated with secondary metabolism, fermentation, and 
cofactors biosynthesis.  The contributing taxa to these functionalities are also observed 
to be the significantly different. Despite uncovering different functionality, their role 
in the pathogenesis of MS remains unclear. 
This study undertook robust and rigorous statistical measures to investigate the 
microbiota from the MS cohort. Despite uncovering microbiota alterations, which are 
independently established in different studies, the study is limited by the sample size 
representation per group and a lack of clinical data. The merging of PPMS and SPMS 
due to statistically significance and similar signature would require further 
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investigation into the similarity and dissimilarity of the disease onset in these two sub 
phenotypes accounting for microbiota profiles. The functional potential identified in 
the study is not a representation of the actual activity of the microorganism and must 
be carefully considered. In conclusion, we report taxonomic and functional alterations 
that are associated with differences in the abundances of different species. These 
differences may be linked with immune modulation but appear to be independent of 
any age-related microbiota alterations associated with premature ageing. Further 
exploration may identify possible links with disease onset and progression of MS. 
These taxa may also serve as diagnostic measure to identify disease risk.   
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Chapter 6 Discussion and future perspectives 
The microbiota field has expanded exponentially over the last decade. With reducing 
cost of sequencing, improvement in sequencing technologies and development of new 
tools that can not only process large volumes of data but also function computationa lly 
faster, various studies have been carried out across the world to understand the 
relationship of the gut microbiota with the host. Large consortiums such as MetaHIT 
(Qin et al., 2010) and the Human Microbiome Project (HMP) (Human Microbiome 
Project, 2012) have obtained valuable information on the microbiota and their 
functionality. Independent studies and meta-analyses of multiple publicly availab le 
datasets have shown how the microbiota is shaped across ethnicity, genetics, age-
demographics, diseases, clinical factors, lifestyle, diet and other social and economic 
factors (Duvallet et al., 2017;Jackson et al., 2018;Almeida et al., 2019;Pasolli et al., 
2019). These large studies shed light into the malleable nature of the gut microbio ta 
which is important for not only uncovering confounders but also ensuring proper 
microbiota study design and discovering biologically relevant signatures. This lays the 
foundation for future clinical research that may involve studies of probiotics, faecal 
microbiota transplant, or investigation of the mechanistic role of disease associated 
marker taxa. Understanding these links along with the effect of various covariates will 
allow researchers to address the issues with reproducibility of results also. The 
reproducibility concerns have led to the establishment of Microbiome Quality Control 
project (Sinha et al., 2015) which provides guidelines for microbiota data analysis and 
researches effectors of microbiota alterations.  
 A key aspect of microbiota studies is to identify taxa and microbial products 
which may contribute as risk factors for immune-associated diseases. Such 
characteristic features would have the potential as markers for predicting onset or 
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diagnosis of immune-associated conditions. The changes in the microbiota profiles 
may also be associated with treatment and disease activity which would serve as 
indicators for remission and efficacy of treatment. Insights from various microb io ta 
research has established their prominent role in immune-homeostasis, production of 
nutrients and metabolites crucial for the health of the host (Cianci et al., 2018;Valdes 
et al., 2018). Numerous studies have identified various gut microbes with pro- and 
anti-inflammatory activities (Cianci et al., 2018). Presence or absence of commensa l 
microbiota has been linked with metabolic abnormality in the host, increased 
abundance of pathobionts or development of immune-associated disorders (Stecher, 
2015). However, microbiota-based human studies with conditions like osteoporosis 
and different types of arthritis that include the investigation of the effect of immune -
modulatory and disease modifying non-antibiotic medications are limited. This is 
discussed thoroughly in the thesis where the respective chapters explore the 
relationship between the gut microbes and various immune-associated diseases. It 
generates a knowledge base of the microbiota as a risk factor and acknowledges the 
therapeutic potential of the microbiota in modulating the immune diseases. 
Chapter 2 of the thesis is an observational study that explores the gut-bone 
axis. This study is the first and one of the largest human study that identifies the 
changes in the gut microbial community in medically classified osteopenia and 
osteoporosis subjects in comparison to age- and gender-match healthy subjects. The 
study also includes extensive analysis of dietary, clinical, and anthropometr ic 
measures and accounts for the association of various covariates with microbiota. These 
various covariates showed similar trends and effect size as reported in literature. After 
identifying and adjusting for various confounders, the study identified a specific set of 
genera that were associated with bone mineral density (BMD) measure and remained 
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significantly associated with BMD even after removing the effect of various 
medications and BMI. However, it was noted the Clostridium XIVa and Veillonella 
remained associated with both BMI and BMD. The identified taxa have been reported 
individually to be associated in various bone and immune-associated studies, thus 
supporting the results of the study. This study benefits from large comparable sample 
size per group, use of robust and rigorous statistical approaches and extensive meta-
data investigation. The study has been published in Rheumatology in which an 
editorial has also been written on the manuscript which is a recognition of the study 
(Aurora, 2019). 
Our results are divergent from a recent study by Li et al. on a Chinese cohort 
of 102 samples that reported various taxonomic and functional alterations to be 
associated with BMD measures. However, that study segregated their data based on 
median BMD value and not clinically defined criteria. It also lacked adjustment for 
multiple testing except for the functional analysis (Li et al., 2019). Wang et al. 
published a preprint recently that investigated the relationship between BMD and gut 
microbiota using shotgun whole genome metagenomics (mWGS) sequence data on a 
large cohort of 361 elderly Chinese women. The associated species identified in this 
study belonged to the significant genera identified in our study validating the results 
of our research (Wang et al., 2019b). Overall, the current study from chapter 2 
improves the understanding of gut-bone axis which could lead to development of 
microbiota-based diagnostic/therapeutic approach. This would have tremendous 
applications in early detection and/or in providing intervention to the at-risk elderly 
population through microbiota modulation, thereby improving the quality of life and 
reducing economic burden. 
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 Chapter 3 of the thesis investigates the changes in the gut microbiota dynamics 
in three different arthritic conditions: ankylosing spondylitis (AS), rheumatoid arthrit is 
(RA) and psoriatic arthritis (PSA). This is studied by sampling the subjects across 
three time-points during the course of biologics treatment. As these conditions are 
extraintestinal, to evaluate the degree of the gut microbiota association with 
inflammation, IBD samples were also included as an outgroup. The study also benefits 
with the inclusion of established long-term biologics treated groups comprising of 
different samples with same arthritic conditions. This study is unique as it is the first 
explore the link between biologics treatment and microbiota from arthritis and 
Inflammatory Bowel disease (IBD) along with extensive clinical, dietary, serum and 
anthropometric information. Unlike the previous chapter, this study was carried out 
with mWGS sequence data allowing investigation of species level taxonomic and the 
functional profiles. The time-point sampling and the inclusion of established treated 
samples allowed us to track the changes in the gut microbiota during the course of 
treatment and control for various covariates associated with inter-individua l 
differences like dietary habits, lifestyle etc. The study observed that the long- term 
biologics treated arthritic groups did not show significant difference in diversity from 
healthy controls which could be an indicator of similar gut microbiota composition. 
Interestingly, it was observed that samples from RA and PSA individuals at baseline 
(T0) were not significantly different from controls which might be partly due to 
methotrexate treatment that was absent is AS group. This suggest that the microbio ta 
alterations are associated with immuno-suppressive treatments. IBD, in agreement 
with previous literature, showed significantly reduced α-diversity and altered β-
diversity (Halfvarson et al., 2017). Various healthy controls associated taxa were also 
depleted in the IBD samples. The presence of both control and disease associated taxa 
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in different established arthritic groups and their absence in T0 samples may indicate 
partial restoration. The validation with independent RA dataset where similar signa ls 
were observed further confirms our results (Zhang et al., 2015). The correlation 
between different taxonomic signatures and clinical data were also consistent with 
literature (Wexler, 2007;Lopetuso et al., 2013). The lack of distinct functiona l 
signature may be indicator of redundancy in functional potential. Despite the sample 
size limitation in the study, the identification of established signatures and the presence 
of healthy associated taxa in the long-term biologics treated samples justifies the 
hypothesis that the altered gut microbiota composition is partially restored during 
remission upon treatment with immunosuppressants.  
Understanding the dynamics of gut microbes in immune-mediated disorders 
involves uncovering taxonomic markers and bacterial metabolites that can trigger or 
suppress immune responses in the intestine. Various immune-associated inflammato ry 
conditions such as different types of arthritis, IBD and multiple sclerosis (MS) have 
identified gut microbiota as an external risk factor (Clemente et al., 2018). The 
relationship between the gut microbiota and immune cells can be bi-directional where 
the immune cells modulate the bacterial population in the gut and the microbio ta 
influences immune cell activities. This also raises the question of how non-antibiot ic 
medications such as immunosuppressants affects this relationship between gut 
microbiota and inflammation (Busquets et al., 2015;Zhang et al., 2015;Bazin et al., 
2018). This is important as it may shed light into the dynamics of gut microbiota in 
different immune disorders as studies have shown a partial restoration of the gut 
microbiota towards healthy controls during remission stage. 
Similarly, Chapter V of the thesis studied the gut microbiota signature in 
different multiple sclerosis (MS) phenotypes. The findings in this chapter also reflect 
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the depletion of healthy associated bacterial species and presence of potential pro-
inflammatory associated and pathogenic taxa. It also indicates that different subtypes 
of MS may share similar microbiota signature as evident from primary-progress ive 
(PPMS) and secondary progressive (SPMS) samples. While the immune-associa ted 
characteristic taxonomic signatures were observed, the low number of MS samples in 
the study is a limitation to the robustness of the signature. The lack of meta-data also 
limits the understanding of the microbiota-host interactions in this case as microbio ta 
is affected by various covariates. Despite the limitation, the microbiota profiles show 
an altered composition, which is distinct from both young and elderly healthy 
population. Reproduction of taxonomic alterations as published in various 
independent studies reaffirms our study validating the biological association of the gut 
microbiota in MS which is distinct from healthy ageing. These altered microbio ta 
profiles can be potentially exploited for development of early detection and disease 
activity monitoring system. Furthermore, there is potential for development of 
microbiota based live biotherapeutics from key taxonomic markers with disease 
modulatory properties. 
Chapter 4 of the thesis was focused on development of a novel methodology 
for functional inference from amplicon dataset. The functional potential of the gut 
microbiota was necessary for understanding the microbiota interaction with the 
immune system. Data generated from bacterial transcripts, proteins and metabolites 
can allow assessment of the activity of the microbes in the gut. However, the 
generation of such data can be limited by various technical challenges. Alternative ly, 
the identification of the microbial genes and estimation of the functional potential is 
achieved with mWGS sequencing. The use of amplicon sequencing remains popular 
due to its low cost and computational necessity but lacks functional information. To 
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extrapolate the functional capabilities from amplicon data, inference tools have been 
developed (Langille et al., 2013;Asshauer et al., 2015;Iwai et al., 2016). However, 
these tools are limited due to their reliance on functionally annotated taxa.  
Our methodology: Inference of Pathways from Co-Variance analysis (IPCO), 
implements a double co-inertia approach for inferring functionality of an amplicon 
dataset. The advantage of IPCO is that it is not limited to the use of one particular type 
of annotation or reliance on specific databases. We have shown that IPCO works well 
with both KEGG and MetaCyc annotation. IPCO can also be easily implemented using 
an in-house reference dataset instead of the provided references. This translates to the 
flexibility of IPCO, which allows better comparison with other datasets avoiding the 
requirement of re-processing the data towards a specific type of annotation. Another 
highlight of IPCO is that the predicted values of IPCO shows the same directiona lity 
for various features (pathways) as observed in mWGS dataset which is assumed to 
reflect of the actual biological signals. This signal is reproduced to the greatest extent 
using IPCO. This signature is not observed using any of the other publicly availab le 
methods. This highlights the lack of predicted pathways to mWGS pathways 
abundance correlation across various samples in the available methods. This would 
result is spurious identification of significantly differential functionality, incorrect 
assumption of the directionality of abundance, thus leading to further inconclus ive 
observations. The study also highlighted that concordance between functional and 
taxonomic profiles obtained from different sites is different. This is partially reflect ive 
of the level of unannotated information which requires further investigation. IPCO is 
implemented in R, which is widely used for statistical analyses. Various other tools 
such as DADA2 (Callahan et al., 2016), phyloseq (McMurdie and Holmes, 2013) that 
allows processing 16S data are completely implemented in R.  IPCO is made availab le 
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as a preprint, which has been viewed nearly 300 times as full text as of November 
2019. 
Future improvements of IPCO would include better inference from other 
environments and body sites besides stool samples, assigning a confidence value to 
the prediction, and identification of the taxonomic contribution similar to MelonnPan 
(Mallick et al., 2019). The current version of IPCO is also limited to the KEGG version 
of HUMAnN1 (Abubucker et al., 2012) and could be updated in future. Superclass 
information for the MetaCyc pathways would also be provided in the future. To 
improve the usability of IPCO, scripts/tutorials for processing the output of IPCO and 
downstream analysis can be added to help naive users. PICRUSt2 (Douglas et al., 
2019) and Tax4Fun2 (Wemheuer et al., 2018) have also been made available as 
preprint version. IPCO would also benefit from benchmarking against these tools once 
published. 
Overall, research carried out as part of the thesis improves the understand ing 
of the gut microbiota in immune diseases. Amplicon and mWGS sequencing provided 
the necessary information for the current research. Despite this, there is a need for 
different multi-omics profiles to further elucidate the microbiota-host interact ions 
(Wang et al., 2019a). Schirmer et al. investigated a IBD cohort with 
metatranscriptomics data and have shown the strengths of analysing the functiona l 
activity (Schirmer et al., 2018). The group identified different taxa which showed 
differential abundance in IBD samples but lacked any functional activity. It also 
highlighted that despite the similar abundances of certain taxa their functiona l 
activities were different in the patients through the duration of the disease. Similar ly 
shifts in biochemical and functional properties was also noted by Lloyd-Price et al. 
(Lloyd-Price et al., 2019). Bacterial transcripts can have a short life span which could 
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be challenge if there is a long time gap due to transport, storage, extraction and 
sequencing (Allaband et al., 2019). Bacterial metabolites profiles are also very 
informative as metabolites such as short chain fatty acids (SCFAs) are associated with 
healthy fibre associated microbiota and gut-immune homeostasis (Makki et al., 2018). 
Secondary bile acids have also been linked with colon cancer which further highlights 
the necessary for evaluating the metabolite profiles (Ocvirk and O'Keefe, 2017). 
Recently AGORA has been published which provides metabolite capacity for 773 gut 
bacteria (Magnusdottir et al., 2017). Although, such resources are helpful in inferr ing 
metabolite profiles, these may not be reflective of the actual profiles as many unknown 
species are also present in the gut. 
The importance of various clinical, biochemical, dietary, and other meta-data 
cannot be overstated. This is observed in Chapter 5 of the thesis where lack of clinica l 
information is a limitation in the study. Chapter 2 and 3 in the thesis reflects a better 
comprehensive study due to the availability of various meta-data. The relationship 
between microbiota and various covariates is stressed in the publications by 
Zhernakova et al. and Falony et al. (Falony et al., 2016;Zhernakova et al., 2016). The 
use of amplicon sequencing to generate 16S datasets are mostly reported down to 
genus level. With newer tools such as DADA2, Deblur (Amir et al., 2017) and species 
level classifiers like SPINGO (Allard et al., 2015), working with sub-genus level 
datasets would allow better understanding of the gut microbiota as different species 
from the same genus can harbour different genes or may have pro- or anti-
inflammatory functions. E.g. Clostridium and Bacteroides (Wexler, 2007;Lopetuso et 
al., 2013). Increased taxonomic resolution down to strain levels is also necessary as 
different strains of the same species can harbour different functional capacity like 
pathogenic capability e.g. Escherichia coli (Tenaillon et al., 2010).  
 
392 | P a g e  
 
 
 The work carried out as part of thesis provides evidences of microbiota-hos t 
association in relation to immune-associated conditions. Nevertheless, the studies are 
not without limitations. In chapter 2, the study identifies confounding effect of obesity 
measures that are linked with BMD. This makes it difficult to isolate the signature 
between microbiota and BMD due to the co-variance between BMD and BMI. The 
large differences in microbiota profiles seen when comparing below weight, normal 
BMI and obese individuals makes addressing this confounder a particularly important 
concern. Although statistical modelling was utilised to remove this effect, the 
possibility remains that these differences may be due in part to non-BMD differences 
between groups. To fully account for BMI, it would be necessary to confront this 
confounder at the recruitment stage of the study and match the groups for BMI as well 
as the other confounders such as gender, age and frailty. This should be the goal of 
any future observational study looking at the microbiota and BMD. 
Also, from chapter 2, 3, and 5, which investigates the association between the 
microbiota and various diseases, it is evident that an experimental design that follows 
the subjects over the time would be beneficial. This would allow a better 
understanding of how habitual, diet, clinical and medication factors and other changes 
in the subjects will influence and be influenced by the microbiota. A longitudinal study 
would allow better accounting for the stability and variations in the microbio ta 
population structure during disease pathogenesis. In a clinical setting, accounting for 
medications is necessary when investigating the microbiota signature across and 
during disease activity and treatment duration. When testing for the effect of disease 
modifying medications with respect to microbiota, it would be statistically beneficia l 
to include a placebo group. The placebo group would allow us to investigate the effect 
disease pathogenesis on the microbiota in absence of medications. This would allow 
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better understanding of specific microbiota signatures associated with disease 
pathogenesis and the effect of medications on the microbiota. However, a number of 
ethical considerations would need to be explored before such a study could proceed.  
While investigating the microbiota population from the human gut, most 
studies focus on the bacterial component as archaea species are sparsely populated 
(usually below detection threshold). Similarly, due to lack of universally common 
region in viruses; bacteriophages, which dominates the viral component in the human 
gut (Sutton and Hill, 2019), cannot be captured using amplicon sequencing. Although 
mWGS approaches can capture all the genomic content, lysogenic stage (viral genome 
integrated into host genome without killing the host) of the bacteriophages makes it 
complicated to separate the viral and bacterial genome. Hence, a separate phage 
isolation and sequencing protocol is followed for studying bacteriophages.  
The focus on the bacterial content of the microbiota overlook the presence of 
an organism(s) that perform key functions in health and disease. For instance, species 
of archaea are able of metabolise TMA preventing its absorption in the intestine 
(Nkamga et al., 2017). Archaea utilises hydrogen from the gut and converts it into 
methane. Removal of hydrogen indirectly allows more ATP production by the gut 
bacteria promoting their growth (Nkamga et al., 2017). Certain archaeal species can 
convert heavy metal into methylated products which exhibits toxic effect towards gut 
bacteria and host (Nkamga et al., 2017). These capabilities of archaea show that they 
are critical members of the gut microflora and their metabolic activities have a direct 
and/or indirect impact on bacterial population and the host.  
Similarly, bacteriophages also play an important role in regulating bacterial 
population. Without accounting for bacteriophages, the understanding of microbio ta 
population dynamics would remain incomplete. The bacteriophages are responsible 
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for horizontal gene transfer, infection and predation of bacterial host, which also 
results in evolutionary pressure on the bacterial host (Sutton and Hill, 2019). 
Bacteriophages are highly specific and predation of susceptible bacterial strains allows 
selection of phage resistant strains. Such changes result in mutation of viral genome s 
and selection of bacteriophages with infectivity leading to a continuous cycle of 
changes in population dynamics between bacteriophages and its host (Weinbauer, 
2004; Scanlan, 2017). Recently Clooney et al. reported that the bacteriophage 
population showed concordance with the bacterial community and accounting for both 
bacteriophage and bacterial composition allowed better predictive power between IBD 
and control samples thereby highlighting the importance and necessity of accounting 
for phage population while studying the microbiota (Clooney et al., 2019).  
In conclusion, the research on understanding the relationship of gut microbio ta 
in various immune disorders carried out as part of this thesis contributes significantly 
towards the microbiota knowledge and the development of necessary methodology for 
microbiota studies. From chapters 2, 3 and 5, the novel findings add significantly to 
the biological understanding to the role of microbiota in inflammation and vice-versa. 
The research further reaffirms the relationship with various meta-data such as 
medication, biochemical properties, and dietary factors. The replication of previous ly 
reported signature not only validates the biological signal reported in this thesis but 
also stresses the importance of gut microbiota as a risk factor in different disorders. 
The reduced abundance of the health associated taxa such as those involved in SCFA 
production, modulation of T-regulatory cells is an indicator that these taxa are 
necessary for gut homeostasis and their depletion can trigger altered immune 
responses. The presence of commensal taxa is also necessary for controlling the 
abundances of pathobionts, which may further aggravate inflammation if allowed to 
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proliferate. The observations from the various studies carried out as part of the thesis 
provides evidence for various taxonomic markers that may have the potential for 
diagnostic tool and/or predicting remission in immune conditions. The research 
carried out in this thesis provides many conclusive answers but also raises new 
challenges for future studies. Such studies could involve investigation of the identified 
microbiota alterations for their mechanistic role in immune-disorder and the effect of 
immunosuppressive medications. The study can be further expanded to investigate the 
potential health-promoting capabilities of the taxa that are associated with beneficia l 
properties. These would hopefully guide the field towards a better understanding of 
the mechanistic link between gut microbiota and the host and may lead to development 
of novel therapeutics.  
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